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Abstract 
Trachoma is a chronic keratoconjunctivitis caused by recurrent episodes of infection with the 
gram negative bacterium Chlamydia trachomatis. It is the most common infectious cause of 
blindness with at least 1.3 million estimated to be blind from the disease, 8 million to have 
trichiasis and 40 million to have active disease. Trachoma is now predominantly found in poor, 
rural areas in developing countries and it is classified by the World Health Organization as a 
Neglected Tropical Disease. Ocular infection with C. trachomatis is usually found in children 
and causes a marked inflammatory response with a follicular conjunctivitis and papillary 
hypertrophy. After suffering recurrent episodes of infection and inflammation these children are 
at risk of developing conjunctival scarring which can progress to entropion, trichiasis, corneal 
opacity and blindness in later life. The pathogenesis of the scarring process is believed to be 
immune mediated but is poorly understood. The aim of this work was to further our 
understanding of the pathogenesis of scarring trachoma. 
 
Two case-control studies were undertaken. The Trachomatous Scarring (TS) study included 
363 cases with mild-moderate conjunctival scarring and 363 control subjects. Participants 
underwent a clinical examination, digital photography, in vivo confocal microscopy (IVCM) and 
had conjunctival swabs taken for quantitative gene expression, C. trachomatis detection and 
bacteriological culture. The Trachomatous Trichiasis (TT) study included 34 cases with 
trachomatous trichiasis who had severe conjunctival scarring and 33 control subjects. 
Participants underwent similar examination and sample collection procedures as those in the 
TS study, but in addition had conjunctival biopsy samples taken for histology and 
immunohistochemistry. 
 
Scarring was associated with evidence of an innate immune response with increased 
expression of antimicrobial peptides and pro-inflammatory mediators. Confirmation of an 
innate response was seen with immunohistochemistry with an increased infiltrate of Natural 
Killer cells seen in scarred tissue. Immunohistochemistry also showed an infiltrate of 
unidentified CD45 negative cells in cases. Scarring was associated with differential regulation 
of various modifiers of the extra-cellular matrix. There was no evidence of a Th2 response in 
scarred cases, but rather a Th1 response was detected. Non-chlamydial bacterial infection 
was more frequently found in cases than controls and was also associated with upregulation of 
innate and pro-inflammatory mediators. C. trachomatis was very rarely detected, but when 
seen was associated with a characteristic Th1 response seen in children.  
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Connective tissue scarring could be seen morphologically with masked grading of IVCM and 
histological sections. An increased inflammatory cell infiltrate could also be seen with both 
examination techniques. Gene expression changes in relation to IVCM scarring generally 
showed good agreement with corresponding changes by clinical scarring. IVCM appeared to 
be able to detect subclinical scarring and also identified dendritifrom cells which were strongly 
associated with the presence of scarring.  
 
This work confirms other studies highlighting the importance of innate immune responses in 
the pathogenesis of trachomatous scarring. Non-chlamydial bacterial infection may be an 
important factor in driving this innate response with resulting tissue damage and fibrosis. 
Tissue changes could be objectively assessed with IVCM for various parameters, especially 
connective tissue scarring, and allowed some novel observations about the scarring process to 
be made. 
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 Format of the thesis 
 
The thesis for this PhD utilises the “research/review papers” format, recently introduced by 
the London School of Hygiene and Tropical Medicine. It therefore includes a number of 
papers which have either been published in, accepted by, or are formatted for submission to, 
peer-reviewed journals. The chapters listed in italics in the Contents are in this 
research/review paper format and include publication details in a cover sheet, including 
acknowledgement of the contributions of other people. The other chapters of the thesis are 
composed of “linking material” which includes information/data not covered in the papers 
and helps to make the thesis a coherent body. The linking material was written by Victor Hu. 
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Systematic Review
Epidemiology and control of trachoma: systematic review
Victor H. Hu1,2, Emma M. Harding-Esch1, Matthew J. Burton1,2, Robin L. Bailey1, Julbert Kadimpeul3 and David C.
W. Mabey1
1 London School of Hygiene and Tropical Medicine, UK
2 Kilimanjaro Centre for Community Ophthalmology, Moshi, Tanzania
3 Unite´ d’Ophtalmologie, Programme de Lutte Contre la Ce´cite´, Re´gion me´dicale de Zinguinchor, Senegal
Summary Trachoma is the commonest infectious cause of blindness. Recurrent episodes of infection with serovars
A–C of Chlamydia trachomatis cause conjunctival inflammation in children who go on to develop
scarring and blindness as adults. It was estimated that in 2002 at least 1.3 million people were blind from
trachoma, and currently 40 million people are thought to have active disease and 8.2 million to have
trichiasis. The disease is largely found in poor, rural communities in developing countries, particularly in
sub-Saharan Africa. The WHO promotes trachoma control through a multifaceted approach involving
surgery, mass antibiotic distribution, encouraging facial cleanliness and environmental improvements.
This has been associated with significant reductions in the prevalence of active disease over the past
20 years, but there remain a large number of people with trichiasis who are at risk of blindness.
keywords trachoma, review, Chlamydia trachomatis, epidemiology, control
Introduction
Trachoma is the leading infectious cause of blindness
worldwide. It is caused by infection with Chlamydia
trachomatis and is characterised by inflammatory changes
in the conjunctiva in children with subsequent scarring,
corneal opacity and blindness in adults. The World Health
Organization (WHO) estimated in 2002 that 1.3 million
people were blind from trachoma (Resnikoff et al. 2004)
and it is likely that a further 1.8 million were suffering
from low vision (Frick et al. 2003a). Many of the
additional 1.9 million cases of blindness from ‘corneal
opacities’ were also likely to be because of trachoma in
areas where it is endemic (Resnikoff et al. 2004). The
number of people with active disease is estimated to be 40
million, and the number with trichiasis, 8.2 million
(Mariotti et al. 2009). Trachoma is an ancient disease and
has previously been a significant public health problem in
many areas of the world including parts of Europe and
North America. Today, however, trachoma is largely
found in poor, rural communities in low-income countries,
particularly in sub-Saharan Africa. In 1998, the WHO
established the Alliance for the Global Elimination of
Blinding Trachoma by 2020 (GET2020). This promotes
trachoma control through the SAFE Strategy: surgery for
trichiasis, antibiotics for C. trachomatis infection, facial
cleanliness and environmental improvement. Where con-
trol measures have been implemented encouraging reduc-
tions in the prevalence of trachoma have been found.
Historical perspective
The earliest references to trachoma come from China in the
27th century BC (Al-Rifai 1988). Features of trachoma
were also described in the Ebers papyrus from Egypt, 15th
century BC, and epilation forceps discovered in tombs from
the 19th century BC (Maccallan 1931, Hirschberg 1982).
Trachoma became a major public health problem in
Europe at the beginning of the 19th century, when the
disease was believed to have been brought back by troops
returning from the Napoleonic wars in Egypt. So great was
the burden of the disease at that time that many of the
major ophthalmic hospitals founded in the 19th century
were established to treat trachoma, including Moorfields
Eye Hospital and Massachusetts Eye and Ear Infirmary. By
the end of the 19th century, immigrants to the United
Tropical Medicine and International Health doi:10.1111/j.1365-3156.2010.02521.x
volume 15 no 6 pp 673–691 june 2010
ª 2010 Blackwell Publishing Ltd 673
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States were routinely screened for trachoma and sent home
if they had signs of the disease. Trachoma has now
disappeared from developed countries (with the exception
of Aboriginal communities in outback Australia (Tellis
et al. 2007), probably as a result of general improvements
in living and hygiene standards.
Clinical features and natural history
Trachoma is a chronic keratoconjunctivitis caused by
recurrent infection with serovars A, B, Ba and C of
C. trachomatis. Infection is most commonly found in
children. With repeated reinfection, some people go on to
develop scarring complications and blindness in later life.
The clinical manifestations of trachoma are subdivided
into those associated with ‘active’ disease, usually seen in
childhood, and those associated the cicatricial or scarring
complications, seen in late childhood and adults (Figure 1).
Active disease is characterised by recurrent episodes of
chronic, follicular conjunctivitis. Follicles are subepithelial
collections of lymphoid cells and appear as small, yellow-
white elevations on the conjunctiva of the everted upper
lid. Papillary hypertrophy (engorgement of small vessels
with surrounding oedema) also occurs and can obscure the
deep tarsal vessels if severe enough. Vascular infiltration of
the upper cornea (pannus) may also develop in active
disease, but this rarely affects vision. Individuals are
frequently asymptomatic or have only mild symptoms even
if marked signs of inflammation are evident. If present,
symptoms are similar to those associated with any chronic
conjunctivitis: redness, discomfort, tearing, photophobia
and scant muco-purulent discharge. Conjunctival follicles
at the upper margin of the cornea leave shallow depres-
sions after they resolve known as ‘Herbert’s pits’ which,
unlike follicles and papillae, are a pathognomonic sign of
trachoma.
Repeated and prolonged episodes of infection and
inflammation can result in the scarring complications of
trachoma. Initially, conjunctival scarring is seen in the
subtarsal conjunctiva, which can range from a few linear or
stellate scars to thick, distorting bands of fibrosis. Con-
traction of this scar tissue causes entropion (in-turning of
the eyelids) and trichiasis (eyelashes touching the eyeball)
which is often painful. Eventually, corneal opacification
develops the blinding end-stage of the disease. This is
probably a result of multiple insults to the cornea:
mechanical trauma from lashes, secondary bacterial or
fungal infection and a dry ocular surface.
Over the years, various grading systems for trachoma
have been proposed. The one which is currently used by
trachoma control programmes is the 1987 WHO simplified
grading system (Table 1) (Thylefors et al. 1987).
The prevalence of active disease is highest in pre-school
children and declines to low levels in adulthood (Dawson
et al. 1976; West et al. 1991b; Dolin et al. 1998). This
parallels the distribution of C. trachomatis infection, with
up to half of the community bacterial load being found in
children under the age of 1 year in some studies (Solomon
et al. 2003; Melese et al. 2004b). Adult bacterial loads are
usually lower than those of children, and the duration of
infection and disease also declines with age, presumably as
the result of an acquired immune response (Bailey et al.
1999; Grassly et al. 2008). This is in contrast to the
scarring features of trachoma, the prevalence of which
(a)
(c)
(b)
(d)
Figure 1 Clinical features of trachoma.
(a) Active trachoma in a child, characterised
by a mixed papillary (TI) and follicular
response (TF). (b) Tarsal conjunctival
scarring (TS). (c) Entropion and trichiasis
(TT). (d) Blinding corneal opacification
(CO) with entropion and trichiasis (TT).
Tropical Medicine and International Health volume 15 no 6 pp 673–691 june 2010
V. H. Hu et al. Epidemiology and control of trachoma
674 ª 2010 Blackwell Publishing Ltd
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increase with age, reflecting the cumulative nature of the
damage. Where the prevalence of active disease is very
high, cicatricial complications may be seen at an early age;
trichiasis was reported in 2–3% of children under the age
of 15 years in southern Sudan where the prevalence of
active disease was 70–80% (Ngondi et al. 2006a; King
et al. 2008).
Cohort studies in trachoma-endemic communities in The
Gambia and Tanzania have looked at the progression of
the scarring process:
• Worsening of conjunctival scarring was seen in nearly
50% of scarred subjects over 5 years (Tanzania)
(Wolle et al. 2009).
• Progression from conjunctival scarring to trichiasis
was seen in 10% after 7 years and 6% after 12 years
(Tanzania and The Gambia) (Munoz et al. 1999;
Bowman et al. 2001).
• Minor trichiasis (<5 lashes touching the eye) pro-
gressed to major trichiasis (five or more lashes
touching the eye) in 33% after 1 year and in 37%
after 4 years; and unilateral progressed to bilateral
trichiasis in 46% after 1 year (The Gambia) (Bowman
et al. 2002b; Burton et al. 2006).
• Trichiasis is associated with the development of
corneal scarring: 8% of people with trichiasis devel-
oped incident corneal scarring after 4 years, and there
was worsening of established corneal scarring in 34%
after 1 year (The Gambia) (Bowman et al. 2002b;
Burton et al. 2006).
The first study from Tanzania had a standardised,
prospective design but the others did not. There is
considerable variation in the reported rates of progression,
which may reflect both variation in progression rates in
different populations and methodology. A key determinant
of the rate of disease progression is probably the burden of
C. trachomatis infection in a community over time,
although the direct evidence for this is limited. Several
studies found that the risk of developing scarring compli-
cations is greater in those with recurrent or persistent
severe inflammatory trachoma (Dawson et al. 1990;
Munoz et al. 1999; West et al. 2001; Burton et al. 2006).
Infection vs. disease
There is little doubt that C. trachomatis is the cause of
trachoma; Koch’s postulates were largely fulfilled shortly
after the first isolation of C. trachomatis in 1957 (Tang
et al. 1957; Collier et al. 1958). However, C. trachomatis
cannot be detected in all cases of active disease, even using
highly sensitive nucleic acid amplification tests (NAAT)
(Baral et al. 1999; Lietman et al. 2000; Burton et al. 2003;
Miller et al. 2004b). In low prevalence communities,
especially those that have received mass antibiotic treat-
ment, C. trachomatis is only found in a minority of those
with active disease. Those with intense trachomatous
inflammation are more likely to be infected and have
higher bacterial loads than those with follicular disease
(Burton et al. 2003; Solomon et al. 2004b; Wright &
Taylor 2005). In endemic communities infection is some-
times detected in those who do not fulfil the WHO criteria
for active disease. Part of the explanation for this poor
correlation is likely to be the kinetics of the disease with a
short latent phase (infection before clinical signs with the
incubation period for disease), a patent phase (infection
and clinical signs) and a recovery phase (infection cleared
but clinical signs persist, which can last for many months)
(Bailey et al. 1994; Wright et al. 2008). The mismatch
between the presence of infection and clinical findings is
also partly explained by use of the simplified WHO grading
system, which excludes those with fewer than five follicles
in the subtarsal conjunctiva (Ward et al. 1990).
Transmission of Chlamydia trachomatis infection
Chlamydia trachomatis is probably transmitted between
individuals by a variety of mechanisms, including:
• Direct spread from eye to eye during close contact
such as during play or sleep.
• Spread of infected ocular or nasal secretions on
fingers.
• Indirect spread by fomites such as infected face-
cloths.
Table 1 1987 WHO simplified trachoma grading (Thylefors et al.
1987)
Grade Description
Trachomatous
inflammation – Follicular
TF The presence of five or more
follicles (each >0.5 mm in
diameter) in the upper tarsal
conjunctiva
Trachomatous
inflammation – Intense
TI Pronounced inflammatory
thickening of the tarsal
conjunctiva that obscures
more than half of the deep
normal vessels
Trachomatous scarring TS The presence of scarring in the
tarsal conjunctiva
Trachomatous trichiasis TT At least one lash rubs on the
eyeball
Corneal opacity CO Easily visible corneal opacity
over the pupil
Tropical Medicine and International Health volume 15 no 6 pp 673–691 june 2010
V. H. Hu et al. Epidemiology and control of trachoma
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• Transmission by eye-seeking flies.
• Possible spread from nasopharyngeal infection by
aerosol.
A combination of these and other transmission mecha-
nisms probably operates in most environments, although
their relative importance may vary. For example, in some
environments eye-seeking flies probably contribute to the
transmission of infection. Chlamydia trachomatis has been
detected by polymerase chain reaction in around 20% of
Musca sorbens caught on the faces of children in Ethiopia
(Jones 1975; Miller et al. 2004a; Lee et al. 2007) and
intervention trials to reduce fly density have been associ-
ated with a reduction in active trachoma in The Gambia
(Emerson et al. 1999, 2004). However, in other locations,
the density of eye-seeking flies is insignificant and does not
appear to contribute towards transmission (Taylor et al.
1985). Genital strains of C. trachomatis do not cause
endemic trachoma, although occasionally they cause a self-
limiting conjunctivitis (Brunham et al. 1990).
Trachoma is a focal disease and has been found to
cluster at the level of the community, the household and
within bedrooms, reflecting the infectious nature of the
disease and suggesting that prolonged intimate contact is
necessary for the transmission of infection (Dawson et al.
1976; Katz et al. 1988; Bailey et al. 1989; West et al.
1991b; Burton et al. 2003). This is particularly important
for trachoma control programmes, as it significantly
increases the sample size necessary for estimating the
prevalence within a region (Katz et al. 1988). Most
transmission events occur within the household, and a
failure to treat all infected household members during mass
antibiotic distribution may result in rapid re-infection of
that family followed by more gradual spread across the
community (Blake et al. 2009).
No non-human reservoir of infection has been found,
with flies only acting as passive vectors. The importance of
extra-ocular sites of infection has been debated. Chlamydia
trachomatis can be detected in secretions from the naso-
pharynx, and a recent study also showed that infected
nasal discharge in children at baseline was associated with
an increased risk of active disease and conjunctival
infection 2 months after systemic treatment (Malaty et al.
1981; West et al. 1993; Gower et al. 2006). However,
nasal swabs were taken only from children with visible
discharge and were of the discharge rather than from nasal
epithelium. Positive results may simply have been a
reflection of severe ocular infection which was not cleared
with one dose of antibiotic, with infected secretions passing
through the nasolacrimal ducts. An earlier study using
nasal swabs on all children showed that new ocular
infection after treatment was not related to a positive or
negative nasal specimen at baseline (West et al. 1993). In
addition, genotyping of conjunctival and nasal samples
from individuals with concurrent infection showed differ-
ent genotypes to be present, suggesting that auto-infection
was not an important factor (Andreasen et al. 2008).
Prevalence and geographical distribution
Trachoma is a major cause of blindness in many less-
developed countries, especially in poor, rural areas.
Blinding trachoma is believed to be endemic in over 50
countries, with the highest prevalence of active disease and
trichiasis in Africa, predominantly in the savannah areas of
East and Central Africa and the Sahel of West Africa
(Figure 2). It is also endemic in a number of countries in
the Middle East, Asia, Latin America and the Western
Pacific (Polack et al. 2005). Current WHO estimates for
the prevalence of active disease, trichiasis and blindness are
significantly lower than previous ones and declines in the
prevalence have been noted in several countries, but there
is considerable uncertainty around these estimates, as little
recent information is available from India and China.
About half of the global burden of active trachoma is
concentrated in five countries: Ethiopia, India, Nigeria,
Sudan and Guinea; while half of the global burden of
trichiasis is concentrated in three countries: China, Ethio-
pia and Sudan (Mariotti et al. 2009). Recent studies from
southern Sudan, previously inaccessible during the civil
war, have shown very high levels of trachoma: up to 80%
of children had active disease and one-fifth of adults had
trichiasis (Ngondi et al. 2006a; King et al. 2008). Tra-
choma was shown to account for 35% of blindness, with
5% of the entire population (including children) suffering
from low vision or blindness associated with trachoma
(Ngondi et al. 2006b, 2007).
Some caution is required in the interpretation of global
estimates of trachoma prevalence (Burton & Mabey 2009).
These have generally been produced with models that have
relied on the results of a limited number of surveys
conducted in a few endemic countries. Various assump-
tions and extrapolations are then made, which have
considerable potential for error, such as extrapolating data
from a single survey within a district to give the district-
level prevalence, and national averages being generated
from available district prevalence data. The six million
people estimated by the WHO to be blind from trachoma
in the 1990s was probably a substantial overestimate as
results were based on questionnaires reporting numbers of
people who might become blind without treatment
(Thylefors et al. 1995). More recent estimates have used
more reliable survey data.
Tropical Medicine and International Health volume 15 no 6 pp 673–691 june 2010
V. H. Hu et al. Epidemiology and control of trachoma
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Notwithstanding the aforementioned limitations of the
available data, there does appear to be a downward
trend in the number of people affected by trachoma.
Improved living standards in many countries probably
account for at least part of this trend, as was the case
with the disappearance of trachoma from industrialised
countries a century ago (Dolin et al. 1997; Hoechsmann
et al. 2001). The establishment of trachoma control
programmes has probably played a major role, although
this is difficult to quantify. Worryingly, the number of
people estimated to have trichiasis has shown little
decline since 1991, with a slight increase estimated
between 2003 and 2008. This suggests that progressive
conjunctival scarring can occur even when there has been
a marked reduction in active disease and C. trachomatis
infection, which has long-term implications for control
programmes.
The most recent estimate from the WHO places the
burden of trachoma at 1.3 million disability-adjusted life
years. This measures the gap between a normal, healthy
population and the ‘cost’ of a disease from premature
mortality and disability (WHO 2008). The economic cost
of trachoma has been estimated at between US$ 3 billion –
8 billion in lost productivity (Frick et al. 2003a,b).
Estimates of the global burden of trachoma, however, are
faced with several problems including a lack of robust
prevalence data and the decision over inclusion of different
disease manifestations (Burton & Mabey 2009). Trichiasis
without visual impairment, for example, causes a level of
disability comparable to that caused by visual impairment
from non-trachomatous causes, yet it has not always been
included in disease burden calculations (Frick et al.
2001b).
Risk factors for trachoma
Many studies have examined potential risk factors for
trachoma, which have been previously reviewed (Emerson
et al. 2000; West 2004; Haylor 2008). Studies examining
the relationship between trachoma and various environ-
mental, socio-economic and behavioural factors are diffi-
cult to interpret as they often lack adequate controls and
are potentially confounded with many factors being closely
interrelated. For example, establishing what contribution a
dirty face makes to trachoma, or vice versa, is difficult, as
active disease may cause ocular ⁄nasal discharge, but
discharge may be an important route for transmission. In
addition, variability in survey methodology and question-
naires may not allow reliable comparisons between studies
(Emerson et al. 2000).
Trachoma is currently more common in dry areas, and
the relationship between water and trachoma has been
studied in several settings, with some conflicting results.
It is plausible that better access to water would improve
hygiene levels and reduce the transmission of infection.
Several studies have indeed found an association between
increased distance to water and the prevalence of active
disease (Mathur & Sharma 1970; Tielsch et al. 1988;
Taylor et al. 1989; West et al. 1989; Schemann et al.
2002). However, other studies have not supported this
and the association appears to be absent when the
distance to water is small (West et al. 1991b; Zerihun
1997; Kuper et al. 2003). This may be explained by the
presence of a ‘water use plateau’ in which per capita
water consumption between households often seems to
be constant when the round trip to collect water is
below a threshold of around 30 min (Cairncross &
Feachem 1993). The quantity of water brought into a
household may be more important than the distance to
water. Indeed, one study found the quantity to be
independent of distance and that children from house-
holds with a greater quantity of water had less active
disease (Kupka et al. 1968). However, other studies have
shown that after controlling for distance the total
quantity of water used had no effect on the prevalence of
disease (West et al. 1989; Bailey et al. 1991). The second
Trachoma Endemic Contries (known)
2009
Figure 2 Map of trachoma endemic
countries in 2009. Reproduced with
permission from Dr Silvio P. Mariotti,
WHO ⁄NMH ⁄ .
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of these two studies may unlock the key issue with
regard to water and trachoma: the authors actually
measured how much water was brought into the house
and also observed how the water was used. After
controlling for family size, distance to water and other
socio-economic factors, families with trachoma used less
water for washing children than did control families
without trachoma, regardless of the amount of water
available for consumption (Bailey et al. 1991).
The association between frequent face washing and
reduced trachoma has been reported in some, but not all,
studies (Taylor et al. 1985; Tielsch et al. 1988; Bailey
et al. 1991; Luna et al. 1992). Self-reporting may have
compromised the results, as washing may be perceived as
a desirable activity and hence over-reported. A
large-scale randomised trial of an intensive educational
intervention to encourage face washing in Tanzania
showed that children with a clean face were less likely to
have severe inflammatory trachoma (TI). However, there
was no reduction in the overall prevalence of active
trachoma and intensive behavioural intervention was
required (West et al. 1991a, 1995; Schemann et al.
2002).
As discussed previously, flies are also a risk factor for
trachoma by facilitating transmission. M. sorbens, the fly
most commonly found in contact with eyes, preferen-
tially breeds in human faeces. Latrine access is associated
with a lower risk of trachoma. This has been attributed
to the removal of faecal material from the environment
leading to a smaller fly population (Emerson et al. 2004).
Crowding is probably a risk factor for trachoma,
especially living in close proximity to children with active
disease (Bailey et al. 1989; Sahlu & Larson 1992). Women
tend to have a higher rate of the scarring complications
of trachoma and this is generally considered to be a
result of their increased contact with young children, the
main reservoir of infection (Turner et al. 1993).
Migration between communities may also be important in
the re-introduction of C. trachomatis (Burton et al.
2005b).
Assessing the burden of trachoma
Trachoma as a public health problem is defined by the
WHO as a prevalence of TF of at least 10% in children
aged 1–9, or a prevalence of TT of at least 1% in those
aged 15 or more. Trachoma is no longer considered a
public health problem when the TF prevalence in children
falls below 5% and the prevalence of TT is <0.1% (WHO,
1997; Kuper et al. 2003). No specific guidelines are
provided for areas where the prevalence falls between these
thresholds.
Population-based prevalence surveys (PBPS)
To determine where trachoma is a public health problem,
WHO recommends cluster random sampling (Ngondi
et al. 2009b). Districts likely to be trachoma-endemic are
identified using information from previous surveys, written
reports, hospital eye surgery records and interviewing
people with local experience. A list of all clusters within the
districts identified is made. Clusters are preferably areas of
approximately the same population size, so that the cluster
selection is with probability of selection proportional to
size. A random sample of clusters is then selected, which is
sufficiently large such that the sample prevalence of TF in
1–9 year olds, or TT in those aged 15 or more, reflects the
prevalence in the whole population (WHO, 2006). A two-
stage design can be employed, whereby villages (clusters)
are selected in the first stage, and households are selected in
the second. If household lists are not available, other
methods for selecting households are by random walk and
compact segment sampling. Reports should present stan-
dardisation of the examiners’ grading, the sample size
parameters, confidence intervals of the estimate, and
adjustment for clustering (Ngondi et al. 2009b). As well as
obtaining accurate estimates of TF and TT prevalence,
surveys should collect data on the number of public access
and surface water points in the district, and the proportion
of households that have access to latrines and that are
within 15 min walk of the nearest water source available
during the dry season. These data allow planning, moni-
toring and evaluation of control interventions (WHO,
2006).
Population-based prevalence surveys provide compre-
hensive prevalence data and are rightly considered the
‘gold standard’ for trachoma surveys (Wright et al. 2005).
Although they can be designed to provide precise preva-
lence estimates over wide areas, they generally do not give
accurate estimates at the cluster level, and the sampling
needs to incorporate large design effects (four or more)
arising from the focal nature of active trachoma and use
large numbers of clusters if they are not to overlook
hyperendemic clusters of disease (WHO-ITI, 2004).
Moreover, they are time consuming and expensive because
of the large sample sizes needed. Two alternative methods
have been proposed: trachoma rapid assessment (TRA) and
acceptance sampling TRA (ASTRA).
Trachoma rapid assessment
Trachoma rapid assessment was designed to allow simple,
fast and cost-effective assessment of active disease,
trichiasis and environmental risk factors. Existing data
are first used to identify areas that are likely to be
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trachoma-endemic. The burden of trichiasis, active disease
and associated risk factors is then assessed in these areas
(Negrel & Mariotti 1999). At least three, but no more than
seven, villages are selected per district, with priority given
to those areas ‘deemed most socio-economically disad-
vantaged’ (Wright et al. 2005). In these communities,
individuals with TT are identified, leading to a crude
estimate of TT prevalence. Fifty children aged 1–9 from at
least 15 households that ‘appear to have the lowest socio-
economic status’ are then assessed for TF and ⁄or TI.
Finally, a survey is performed to determine household level
trachoma risk factors.
Trachoma rapid assessment provides rankings rather
than prevalence estimates, and the method of selection of
areas, communities and households outlined previously
will generally be subjective. This may lead to overestimated
and ⁄or inconsistent prevalence data, with the possible
extrapolation of biased data to the whole village and
district (Negrel et al. 2001; Myatt et al. 2003; Solomon
et al. 2004b). Evaluations of TRA rankings in comparison
to PBPS in Tanzania and China found comparable ranking
of communities, but TRA performed worse in low prev-
alence settings (Paxton 2001; Liu et al. 2002). However,
PBPS does not itself provide reliable estimates or rankings
for individual clusters, so these comparisons are flawed
(Ngondi et al. 2009b). In The Gambia, a study comparing
two TRA surveys found that active disease prevalence
estimates and rankings were inconsistent, indicating that it
is not a reliable method (Limburg et al. 2001).
Acceptance sampling TRA (ASTRA)
Acceptance sampling TRA, based on the principle of
sequential sampling methods, such as lot quality assurance
sampling (LQAS), has been proposed as an alternative to
TRA. A maximum sample size and an acceptable number
of TF cases are set and sampling stops when one of these is
met. Villages are classified as high prevalence if sampling is
stopped because the set number of TF cases was exceeded,
or as low prevalence where sampling is stopped because the
maximum sample size was reached (Myatt et al. 2003).
Thus, there is no fixed sample size. ASTRA was evaluated
in Malawi (Myatt et al. 2003) and Vietnam (Myatt et al.
2005) and found to be more reliable than TRA for the
prioritisation of communities with active disease.
The advantages of ASTRA are its speed and low cost as a
result of smaller sample sizes than are required for PBPS.
Sample sizes may, however, become large if the option of
continuing sampling in a lot until the maximum sample
size is met is taken, rather than stopping when the expected
number of TF cases is met (Ngondi et al. 2009b). ASTRA
may provide reliable TF prevalence estimates in individual
communities so long as the sample size is not too small
and, if combined with Centric Systematic Area Sampling,
may provide prevalence estimates over wide areas and
basic mapping of TF prevalence (WHO-ITI, 2004). How-
ever, LQAS sampling works best when the distribution of
cases is homogeneous (Anker et al. 1998), and when village
populations do not vary too much. Because trachoma
clusters both within communities and districts, an optimal
rapid and affordable strategy to take clustering into
account when choosing households and communities to
sample is still a challenge. In the mean time, PBPS remain
the only reliable source of prevalence data for trachoma,
and have generally been used to prepare national control
plans, and to forecast ultimate intervention goals for
surgery and antibiotic treatment.
Clinical signs versus infection
An additional concern with all of these survey methods is
their reliance on clinical signs as a measure of trachoma
prevalence. As mentioned previously, clinical signs are
sometimes poorly correlated with ocular C. trachomatis
infection, especially in low prevalence communities and
those that have received mass treatment. As three of the
four components of the WHO endorsed SAFE strategy for
the control of trachoma aim to interrupt transmission of
the bacteria, logic dictates that control measures should be
directed to areas with most infection. It has been suggested
that NAAT testing should be used to assess the prevalence
of ocular C. trachomatis infection in areas where the
prevalence of TF is <10% or between 10% and 20%
(Lansingh & Carter 2007). NAAT testing is not considered
necessary in higher prevalence areas as the correlation
between disease and infection is more reliable (Lansingh &
Carter 2007). However, NAAT testing is beyond the
budget of most trachoma control programmes, although
cost savings can be made by pooling samples from low
prevalence communities (Diamant et al. 2001). A simple
point of care test for C. trachomatis showed promise when
evaluated in trachoma-endemic communities in Tanzania
(Michel et al. 2006) but it is not yet commercially
available. Its sensitivity and specificity were lower when
evaluated in subsequent, larger studies in The Gambia and
Senegal (article in preparation).
Controlling trachoma: the SAFE strategy
Blindness from trachoma is essentially irreversible, but it
can be prevented. The Alliance for the Global Elimination
of Blinding Trachoma by the year 2020 (GET 2020) was
established by the WHO in 1997 and recommends the
SAFE strategy for trachoma control: Surgery for trichiasis;
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Antibiotics to treat C. trachomatis infection; Facial clean-
liness through personal hygiene; Environmental improve-
ment with education and improved local economy.
Surgery for trichiasis
The aim of surgery for trichiasis is to reduce the progres-
sion to corneal opacity and blindness as a result of lashes
abrading the cornea. Surgery has been shown to improve
comfort, reduce ocular discharge and improve visual acuity
in major trichiasis cases (Reacher et al. 1992; Bowman
et al. 2000a; Burton et al. 2005a). While trichiasis surgery
has not been directly shown to reduce the progression to
corneal opacity (Bowman et al. 2001, 2002b), the con-
sensus view is that there is some protective effect. The
WHO recommends regular surgical sessions at fixed sites
once a week, with periodic outreach stations held in
trachoma-endemic communities, and should be offered to
anyone with trichiasis, regardless of the number of
in-turned eyelashes (WHO, 2006).
What type of surgery?
Several procedures are in routine use by trachoma control
programmes. These generally involve a full thickness
incision through the tarsal plate combined with several
everting sutures to turn the distal part of the eyelid
outwards (Yorston et al. 2006). In a randomised controlled
trial, the bilamellar tarsal rotation (BLTR), which also
includes incision of the skin, was found to give the best
results of the procedures that were compared and therefore
WHO recommends this method (Reacher et al. 1992,
1993). The main alternatives in regular use are variations
of the posterior lamellar tarsal rotation (PLTR), including
the Trabut procedure. In the only study comparing
recurrence rates, no significant difference between BLTR or
PLTR was found (Adamu & Alemayehu 2002).
What are the challenges for surgery?
One of the major problems is high post-surgery trichiasis
recurrence rates, ranging from about 20% in the first
2 years (Reacher et al. 1992; Bog et al. 1993; Zhang et al.
2004a; Merbs et al. 2005; El Toukhy et al. 2006) to 60%
after 3 years (Reacher et al. 1993; Bowman et al. 2000a).
Several factors may contribute to recurrent trichiasis such
as the type of procedure used, the surgeon’s experience, the
severity of pre-operative disease (severe scarring and
entropion are associated with increased recurrence), suture
type and infection status (Reacher et al. 1992; Alemayehu
et al. 2004; Burton et al. 2005c; Merbs et al. 2005; El
Toukhy et al. 2006). The presence of conjunctival
inflammation, which may reflect ongoing inflammatory-
cicatricial responses, has been observed in patients with
trichiasis and conjunctival scarring and may be important
in the process of recurrent trichiasis. It is unclear what is
driving this process as infection with C. trachomatis is
relatively uncommon and has not been associated with
recurrent trichiasis (Burton et al. 2005c; West et al.
2006c). Other bacteria (non-chlamydial) are commonly
associated with trichiasis and so may contribute to
inflammation in the late stages of the disease (Burton et al.
2005c). To explore whether controlling infection improved
results, three randomised trials of post-operative azithro-
mycin have been conducted. These have given different
results. No effect was found in a low-prevalence Gambian
setting (Burton et al. 2005c), reduced recurrence was
observed in a high-prevalence Ethiopian settings (West
et al. 2007a), and reduced recurrence was observed for
major trichiasis, but increased recurrence for minor
trichiasis, in a medium-prevalence area of Nepal (Zhang
et al. 2006).
In many settings, the up-take of surgical services by
patients has been relatively low. Patient barriers include
cost, fear of surgery, transport difficulties, need for an
escort, lack of awareness about the need for treatment or
how to access care (Courtright 1994; West et al. 1994;
Bowman et al. 2002a; Melese et al. 2004a; Habte et al.
2008). It has been shown that community-based surgery
has greater attendance rates (66%) than health centre-
based surgery (44%) (Bowman et al. 2000c). Surgery is
therefore most successful when performed within the
community by a trained nurse, with little or no cost to the
patient (Mabey et al. 2003). Provider-level barriers include
lack of training, auditing, availability of sterilised equip-
ment and supplies and surgeons. To increase the number of
surgeons, ophthalmic nurses can be successfully trained
(Alemayehu et al. 2004). Case finding is of crucial impor-
tance and is facilitated by having individuals living in
endemic communities trained to recognise trichiasis and
refer cases (WHO, 2006).
Non-surgical alternatives
In many trachoma-endemic regions, epilation of the
eyelashes is commonly practised with home-made equip-
ment. For mild trichiasis with a few peripheral lashes in the
absence of significant entropion, this may be a reasonable
alternative to surgery; however, this has not yet been
formally tested. In a cross-sectional analysis before surgery,
epilation was associated with a reduced risk of corneal
opacification in people with more severe entropion but
made no difference for mild disease (West et al. 2006a).
A retrospective study showed that epilation neither helped
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nor hindered the progression process, although when
combined with hot ash there was more corneal damage
(Bowman et al. 2002b). Eyelid-taping has also been
proposed as a non-surgical intervention, but this is
generally a short-term measure prior to surgery (Yorston
et al. 2006). Nevertheless, eyelid-taping alone is more
effective than a single episode of epilation at keeping lashes
off the eye at 3 months (Graz et al. 1999).
Antibiotics
The demonstration that a single oral dose of azithromycin
was as effective as 6 weeks of daily tetracycline ointment
in the treatment of active disease was a major advance
(Bailey et al. 1993) and led directly to the launching of the
global elimination initiative. Mass treatment of whole
districts or communities is recommended, as this is more
effective in preventing reinfection than the treatment of
individual cases (Schachter et al. 1999). The WHO criteria
for deciding whether or not to treat are shown in Table 2.
A district is defined as a geographical area containing
between 100 000 and 150 000 people.
Which antibiotic?
The WHO recommends two antibiotic treatment regimes:
either 1% tetracycline eye ointment twice daily for 6 weeks
or a single oral dose of azithromycin. Randomised
controlled trials comparing these two treatments demon-
strated that they are equally efficacious (Bailey et al. 1993;
Tabbara et al. 1996; Dawson et al. 1997; Schachter et al.
1999) but that azithromycin is more effective in opera-
tional use (Bowman et al. 2000b). Tetracycline is almost
universally available but suffers from poor compliance
because of the length of administration, being difficult and
unpleasant to apply, and side-effects such as stinging and
blurred vision (West 1999; Kuper et al. 2003). Azithro-
mycin is well tolerated by both adults and children, has
good compliance, and has fewer side-effects than tetracy-
cline (Schachter et al. 1999; West 1999). It is also active
against extra-ocular C. trachomatis. A recent cluster-
randomised trial in Ethiopia showed that at 12 months,
there was a 50% reduction in childhood mortality in
communities where children had been treated with oral
azithromycin compared to those where they had not (Porco
et al. 2009). Pfizer has donated 135 million doses of
azithromycin for use in control programmes, distributed by
the ITI. The ITI is active in 18 trachoma-endemic coun-
tries. Azithromycin dosage is based on weight for children
(20 mg ⁄kg body weight), with adults receiving 1 g. As
weighing scales need daily calibration, are cumbersome to
carry, and the cooperation of young children can be hard
to obtain, height as a surrogate for weight has been
suggested and proved successful for dosing (Munoz et al.
2003).
Azithromycin for trachoma control is not currently
recommended for children under 6 months or pregnant
women, and therefore tetracycline ointment is the treat-
ment of choice for these groups. However, azithromycin is
recommended by the Centre for Disease Control in infants
under 1 month for pertussis prophylaxis (Tiwari et al.
2005) and is also recommended for the treatment of genital
chlamydial infection in pregnant women (Gray et al. 2001;
Pitsouni et al. 2007). The treatment of infants is important
as infants under 1 year have the highest bacterial load, as
discussed previously.
While oral azithromycin would seem to be a safe option,
a potential alternative is azithromycin eye drops. A clinical
trial of short duration azithromycin eye drops found that at
2 months, the cure rate and safety of topical 1.5%
azithromycin was non-inferior to oral azithromycin
(Cochereau et al. 2007), and mass treatment with the eye
drops of a district in Cameroon saw the prevalence of
active disease fall from 31.5% before treatment to 6.3%
1 year after treatment (Huguet et al. 2010).
As with any antibiotic, there are concerns that wide-
spread use might lead to drug resistance. Azithromycin
resistance has not yet been observed in C. trachomatis
(Solomon et al. 2005; Hong et al. 2009), but resistance in
other bacteria, such as Streptococcus pneumoniae, has
been documented, especially after multiple rounds of mass
treatment (Leach et al. 1997; Chern et al. 1999; Gaynor
et al. 2005) although this disappeared within 12 months of
treatment (Fry et al. 2002; Gaynor et al. 2003a). The
clinical relevance of this resistance has yet to be deter-
mined. It has been argued that in communities where
Table 2 WHO criteria for mass antibiotic treatment distribu-
tion(WHO-ITI 2004)
Prevalence of
TF in children
1–9 years Recommendation
District level
‡10% Mass treat whole district annually
for 3 years, then re-assess the
prevalence in the district
<10% Do community-level assessment
Community level
‡10% Mass treat whole community annually
for 3 years, then re-assess the
prevalence in the community
‡5% but <10% Target treatment to affected children
and the household they live in
<5% Antibiotic treatment not recommended
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macrolide resistance is rare, mass treatment with azithro-
mycin is unlikely to increase the prevalence of resistant
S. pneumoniae (Batt et al. 2003). Nasopharyngeal
S. pneumoniae resistance to topical tetracycline has also
been detected (Gaynor et al. 2005). The risk of drug
resistance highlights the need for sensitive diagnostic tests,
where treatment can be targeted to limit the over-use of
antibiotics within the mass treatment policy (Mabey et al.
2003).
To whom should treatment be given?
The optimal strategy of mass antibiotic treatment is subject
to some debate and probably varies depending on the
prevalence. Alternative treatment target groups have been
proposed:
• All children under 10 years old, because children are
the main reservoir of infection (Holm et al. 2001;
Solomon et al. 2003, 2004a). Frequent mass treat-
ment of all children under 11 years has shown herd
protection in the entire community in high-prevalence
settings (House et al. 2009).
• All people living in a household containing an
individual with active disease (Holm et al. 2001;
Burton et al. 2003; Blake et al. 2009).
• All people living in a community (e.g. village), where
the prevalence of active disease rises above a specific
threshold (Burton et al. 2003).
• Children with active disease and other children
residing with the TF ⁄TI child more than 50% of the
time (Laming et al. 2000).
• All TI individuals, as they have the highest number of
chlamydial DNA copies per swab (Solomon et al.
2003).
• Only infected individuals, as this would remove the
source of infection from the community, but this
requires the means to detect infection in the field
(Lietman et al. 1999).
In a study from a low-prevalence setting in The Gambia
in which the residents of 14 villages were examined and
tested for C. trachomatis infection, the theoretical effec-
tiveness of several strategies in delivering antibiotic to
infected individuals was compared (Burton et al. 2003). If
only the individuals with active trachoma were treated,
then only 24% of infected people would receive antibi-
otic. If treatment was targeted to all the residents of a
household where at least one case of active trachoma was
found, then 96% of infections would be treated. How-
ever, the number of people needed to be treated for each
infection case was 9.6. Finally, if all villages with more
than 15% active disease in children were treated, then
90% of infections would have been treated and the
number needed to treat was 5.4. Thus, for a low-to-
medium prevalence setting, community level treatment,
determined by the prevalence of active disease in the
children, appears to be a relatively efficient approach.
In a high-prevalence village in Tanzania, it was estimated
that if only children under 10 years were treated, only 69%
of those with high loads would be treated. If all members of
households with children aged <10 years were treated,
90% of the entire population would be treated because
most people live in households with children. Treating only
those with clinical signs would miss 23% of those with
high loads. The authors concluded that it is therefore more
practical and effective to treat the entire community, so
long as coverage is high enough (West et al. 2005a).
Mass treatment is considered the most cost-effective
strategy, especially in high-prevalence areas (Frick et al.
2001a; Holm et al. 2001). Targeted treatment strategies
require all children to be examined, which can be expensive
and time consuming. In addition, re-infection is more likely
to occur, as those treated may be re-infected by untreated
individuals (West et al. 1993). Mass treatment has the
advantage that all infected individuals are captured
(Schachter et al. 1999; Solomon et al. 2004a; West et al.
2005a). This is important, as clinical signs are not reliable
as a basis for targeted treatment (Baral et al. 1999),
asymptomatic individuals act as a reservoir of infection
(Burton et al. 2003; West et al. 2005a) and adults can also
act as an important reservoir of high load infection (West
et al. 2005a).
What treatment coverage should be achieved?
WHO recommends that treatment coverage should be
between 80% and 90% (WHO, 2004). Mathematical
modelling assuming 80% treatment coverage and 3 years of
annual treatment demonstrated elimination of infection in
95% of communities (Ray et al. 2009). In contrast, data
from Tanzania demonstrated that despite overall treatment
coverage of 86%, ocular C. trachomatis infection remained
in the community for up to 18 months after treatment,
albeit at a low level (Burton et al. 2005b). Much of the near
elimination of ocular C. trachomatis infection at 2 years
after a single round of azithromycin mass treatment in a
Tanzanian community has been attributed to the 97.8%
treatment coverage (Solomon et al. 2004a), However,
treatment coverage is not the sole key to success. In a
low-prevalence setting in The Gambia, significant
re-infection in two villages post-treatment was observed,
despite treatment coverage being 86% and 92%. This was
attributed to a mass migration event where virtually the
entire population of these two communities attended a
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religious festival in Senegal shortly after being treated
(Burton et al. 2005b). In one Ethiopian study, an overall
treatment coverage of 91.9% was achieved, but was
followed by a 12.3% exponential rate of return of infection
(Melese et al. 2004b). Also in Ethiopia, it was demon-
strated that although treatment coverage was important in
determining the prevalence of ocular C. trachomatis infec-
tion at 2 months post-treatment, coverage was no longer a
predictor of infection at 6 months (Lakew et al. 2009a).
Factors found to affect the acceptability of azithromycin
are local prevention norms (for example, believing that
injections are better than oral medicine), perceptions of the
distribution team’s expertise, witnessing adverse effects
in others, and the timing, quality and quantity of infor-
mation provided. Therefore, to maximise coverage, it is
important to understand the community’s perceptions,
conduct a pre-distribution assessment and community
education, provide advance notice of the distribution,
build a good relationship with the community, create and
follow standardised distribution guidelines, and improve
distributor training (Desmond et al. 2005).
How often should mass treatment be given?
It has been argued that a single round of mass treatment,
with high coverage, may reduce the prevalence of infection
to below a threshold at which it cannot persist, and from
which it cannot return. This is known as the Allee effect
(Chidambaram et al. 2005). Alternatively, mass treatment
may eliminate some strains of C. trachomatis from the
community, reducing the antigenic diversity which may
enable the bacteria to evade the human immune system,
and this less diverse population may never re-attain a high
prevalence (Zhang et al. 2004b; Burton et al. 2005b;
Chidambaram et al. 2006; Andreasen et al. 2008). Factors
affecting the success of a single round of mass treatment
are the baseline prevalence, treatment coverage, treatment
efficacy in the individual, whether ‘F’ and ‘E’ component
measures are in place, and the amount of in- and out-
migration (Lietman et al. 1999; Gaynor et al. 2003b;
Burton et al. 2005b; Chidambaram et al. 2006).
A single round of mass azithromycin treatment was
successful in reducing the prevalence of ocular C. tracho-
matis infection from 9.5% at baseline to 0.1% at 2 years in
a Tanzanian community (Solomon et al. 2004a). After a
second round of mass treatment at 2 years, infection was
eliminated by 5 years post-baseline (Solomon et al. 2008).
This demonstrates that antibiotic treatment alone can
result in elimination, as no ‘F’ or ‘E’ interventions were
introduced. However, the baseline treatment coverage of
97.8% far exceeds that which would normally be achieved
under operational conditions. The decline in trachoma
prevalence may not have been a result solely of the mass
azithromycin treatment as tetracycline eye ointment was
distributed at the 6, 12 and 18 month follow-ups to
individuals with active disease. However, 15–100% of the
community ocular C. trachomatis load at each of the final
three follow-ups was found in participants who had
received tetracycline in the previous follow-up, indicating
tetracycline treatment did not play a major role in the
observed prevalence decline. Alternatively, random fluctu-
ation, seasonal effects, secular trend and regression to the
mean may have contributed to the outcome. In contrast,
two rounds of mass azithromycin treatment (at baseline
and 18 months) in a different Tanzanian village did not
eliminate active disease or C. trachomatis infection 5 years
post-baseline (West et al. 2007b). In fact, although the
infection rate declined between baseline and 18 months,
the prevalence of infection was higher at the 5-year follow-
up than at 18 months in all age groups.
Several studies have reported moderate success of one
round of antibiotic treatment, with infection initially
falling immediately post-treatment, but increasing (albeit
to a lower prevalence than at baseline) within 12 months
of treatment. In Egypt, The Gambia and Tanzania, it was
observed that the prevalence of infection at 1 year after
mass treatment was substantially lower than at baseline,
but was higher than the prevalence at the 3-month follow-
up (Schachter et al. 1999). Similar results of an initial
reduction in infection with re-emergence approximately
1 year after treatment, but which does not return to pre-
treatment levels by 2 years, have been reported by others in
high-prevalence settings (Melese et al. 2004b; West et al.
2005b; Chidambaram et al. 2006; Lakew et al. 2009b).
A study of 14 Gambian villages demonstrated that in low
or medium prevalence areas, a single round of mass
azithromycin treatment could lead to long-term control of
infection, but that monitoring is required because of
re-infection (Burton et al. 2003, 2005b). To help overcome
the risk of re-infection from migration, it has been
recommended that broader geographical areas should be
treated, and people who have immigrated into the village
should be treated after the initial mass treatment (Schach-
ter et al. 1999; Burton et al. 2005b).
The aforementioned studies demonstrate that the effect
of a single round of mass azithromycin treatment is
heterogeneous, with some communities experiencing
elimination of infection whereas others observe rapid
re-emergence. In fact, more frequent treatment distribu-
tions could be beneficial in high-prevalence settings.
Mathematical modelling has shown that where the prev-
alence of active disease is >50% in children, bi-annual
treatment could eliminate disease (Lietman et al. 1999).
Where disease prevalence is <35%, treatment annually or
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every 2 years would suffice. Mathematical simulations
for elimination of infection in Ethiopia suggest that 5 years
of biannual treatment would lead to elimination in 95% of
all villages (Ray et al. 2007). Data from Ethiopia demon-
strated that the prevalence of infection at 24 months was
significantly lower in villages treated biannually than in
villages treated annually (Melese et al. 2008).
As a result of the re-emergence of infection in these
studies, there is empirical evidence to support the need for
repeated antibiotic treatment. Mathematical modelling has
suggested that treatment could be stopped once the
prevalence of infection has fallen below 5% (Ray et al.
2009). Socio-economic improvements may then allow the
disease to be permanently eliminated without the need for
further treatment. This is the rationale adopted by the
WHO in their advocacy of the SAFE strategy. However, if
the ‘F’ and ‘E’ components of the SAFE strategy do not
have a strong enough effect, the prevalence of infection
may return to pre-intervention level (Gaynor et al. 2002).
Facial cleanliness
Improving facial cleanliness (the absence of ocular and
nasal discharge) (Negrel & Mariotti 1999) aims to reduce
auto-transmission and transmission to others by removing
a potential source of infection (Kuper et al. 2003). It is
promoted through health education and improved water
supply, but the evidence-base for this control strategy is
limited. As discussed previously, gaining information on
face washing is difficult, as the validity of self-reporting is
questionable, measures of a clean face are subjective and
certain indicators (discharge and flies) are more reliable
than others (dust and food on the face) (Harding-Esch
et al. 2008; Zack et al. 2008). Observational data indicate
there is an association between having a clean face and not
having trachoma but, as already mentioned, this does not
establish a causal relationship.
A cross-sectional study in Mexico reported that the
frequency of face washing (>7 times a week) was negatively
correlated with the likelihood of children having active
disease (Taylor et al. 1985). Peach et al. conducted a
randomised trial comparing four groups: a control group
(no intervention), eye washing only, tetracycline eye
ointment only and tetracycline combined with eye wash-
ing. At 3 months, there was no significant benefit to eye
washing, either alone or in combination with treatment
(Peach et al. 1987). In Tanzania, an educational interven-
tion to keep children’s faces clean was implemented, and
the number of clean pre-school children’s faces was
recorded. There was an increase in the percentage of clean
faces from 9% at baseline to 33% at 1 year (Lynch et al.
1994). Subsequently, the only randomised controlled trial
of face washing compared mass tetracycline treatment with
mass tetracycline treatment combined with a face-washing
programme (West et al. 1995). Screening was performed at
baseline, 6 and 12 months post-baseline. Children who
received both the face-washing programme and treatment
were more likely to have sustained clean faces than those
who only received treatment, although the difference was
not significant (OR 1.61, 95% CI 0.94–2.74). However,
65% of children in the intervention group still had a dirty
face at two or more follow-ups. The risk of having severe
trachoma (defined as the presence of ‡15 follicles or the
presence of inflammation that obscured all tarsal plate
vessels) in the face-washing group after 1 year was signif-
icantly lower than the treatment-only group (OR 0.62,
0.40–0.94), as mentioned previously. However, there was
no difference in the overall prevalence of active disease
between the two arms. The programme was labour
intensive and expensive.
Environmental improvement
The ‘E’ component of the SAFE strategy aims to reduce
transmission of C. trachomatis by promoting better per-
sonal and environmental hygiene. The elimination of
trachoma from Europe and North America in the 19th
century in the absence of any specific intervention, dem-
onstrates the importance of environmental improvement
components of the SAFE strategy (Mabey et al. 2003).
Through increasing water supply and quality, improving
access to latrines, decreasing fly density, reduced crowding
and providing health education, transmission of trachoma
should be interrupted (Kuper et al. 2003).
Resnikoff et al. compared health education alone, mass
tetracycline treatment alone, health education combined
with tetracycline treatment, and a control group (no
intervention), assigning only one village to each arm
(Resnikoff et al. 1995). They found that at 6 months, the
incidence of active disease was lower in the health education
only group compared with the control group. However,
there was no value in the addition of health education to
mass treatment, with mass treatment alone producing the
best results in terms of cure rate and lower incidence.
There was little evidence for the fly control component
of the SAFE strategy until Emerson et al. demonstrated
that insecticide spraying in The Gambia led to an overall
and significant 61% lower community prevalence of active
disease, a reduction of 75% in the M. sorbens fly popu-
lation, and a 96% reduction in fly-eye contacts in the
intervention villages at 3 months (Emerson et al. 1999).
However, the study only compared two pairs of villages
and was open to bias. In 2004, Emerson et al.compared
seven clusters that received spraying with seven that did
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not. Insecticide spraying led to an 88% decrease in fly-eye
contacts and a significant 55.8% reduction in the preva-
lence of active disease in the intervention clusters (Emerson
et al. 2004). West et al. randomised 16 Tanzanian com-
munities to receive a single round of mass azithromycin
treatment (control group) or to receive azithromycin and
frequent rounds of insecticide spraying (intervention
group) (West et al. 2006b). In contrast to the previous
studies, they found no difference in the prevalence of active
disease at either 6 or 12 months post-baseline, or of
C. trachomatis infection at 6 months, between interven-
tion and control communities, despite the mean prevalence
of flies being significantly lower in the intervention group.
Furthermore, spraying is labour intensive, expensive and
not sustainable (Rabiu et al. 2007).
Only one randomised controlled trial examining latrine
use exists. Emerson et al. compared seven clusters that
received latrines, with seven that did not (Emerson et al.
2004). Latrine provision resulted in a 30% decrease in
M. sorbens-eye contacts, and an associated 29.5% reduc-
tion in trachoma prevalence, which did not reach statistical
significance, despite latrine use reported to be 98%.
Latrines will only improve environmental sanitation if they
are used consistently by a large proportion of the
community. Therefore, latrine provision should be in
accordance with what already exists and what is acceptable
in the community (WHO, 2006).
The SAFE Strategy: putting the pieces together
Although the individual components of the SAFE strategy
have demonstrated success in controlling trachoma, it is
through the implementation of all four elements together
that this control strategy is expected to have most success.
Some studies have evaluated the combined effect of
multiple components of the SAFE strategy. A cross-
sectional analysis of implementation of the A, F and E
components in Ethiopia demonstrated that receiving three
rounds of azithromycin treatment, having a clean face, and
increased face-washing frequency, were independently
associated with a reduced prevalence of active disease in
children (Ngondi et al. 2008). Thus, implementation of the
different SAFE components would have an additive effect
in trachoma control.
Implementation of the entire SAFE strategy in five
Ethiopian districts showed that uptake of all components
was high by the 3-year evaluation time-point (Ngondi et al.
2009a). The declines in TF, TI and unclean face prevalence
in children aged 1–9 were statistically significant, and the
prevalence of TT significantly decreased in three of the
districts. The overall prevalence of ocular C. trachomatis
infection at 3 years was 3.1%, but was higher in districts
last treated over a year ago (4.3%) and lower in those
treated recently (1.4%), suggesting on-going transmission.
In Zambia, introduction of SAFE measures led to a
reduction in the prevalence of total trachoma in children
under 10 years from 55% at baseline to 10.6% at 2 years.
The prevalence of TF fell from 24.9% to 4.5% in children,
and the prevalence of TT in adults fell from 0.6% to 0.3%
(Astle et al. 2006). However, in the absence of control
groups, secular trend cannot be excluded as an explana-
tion. In addition, without investigating these interventions
through a randomised controlled trial, the relative impact
of each component cannot be elucidated.
In Sudan, a control area was included with which to
compare four areas in which the SAFE strategy had been
implemented. The evaluation at 3 years showed heteroge-
neous uptake of interventions and results. All four inter-
vention areas experienced declines in the prevalence of TF,
TI and unclean faces. This was substantial in two of the
areas, moderate in one, and non-significant in one, com-
pared with the control. The decline in active disease was
most likely attributable to antibiotic treatment and
improved facial cleanliness was a result of hygiene health
education combined with water provision, as the greatest
trachoma declines were achieved where uptake of these
activities was highest (Ngondi et al. 2006c). In Ethiopia,
Cumberland et al. conducted a trial where 40 communities
were randomised to either health promotion by national
radio only (control); mass azithromycin treatment and
radio; mass treatment, radio and information, education
and communication (IEC) materials; or mass treatment,
radio, IEC and community video and drama shows
(Cumberland et al. 2008). The exact allocation schedule
was unable to be followed, but the 3 year evaluation
demonstrated a significantly reduced risk of active disease
in communities given antibiotics combined with IEC (OR
0.35, 95% CI 0.13–0.89), and in communities additionally
receiving video health messages (OR 0.31, 0.11–0.89).
Similarly, the risk of having ocular C. trachomatis infec-
tion was significantly lower in these two intervention
groups. Although antibiotic treatment was identified as
being the most active component for all outcomes, the
addition of health education was beneficial.
Conclusion
Blinding trachoma disappeared from Western Europe and
North America at the beginning of the 20th century, yet it
continues to cause an enormous burden of disease in poor
rural communities in the developing world. There have
been encouraging reductions in the prevalence of active
disease in many countries in the past 20 years. However, a
large backlog of unoperated trichiasis cases which remains
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in many countries will have to be addressed by national eye
care programmes if blinding trachoma is to be eliminated
by 2020.
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Trachoma: an update
Various grading systems for trachoma have been pro-
posed, most of which recognise that the disease has an ini-
tial active/inflammatory stage, which is most commonly
found in children, and a cicatricial stage, which is usually
seen in adults. Trachoma control programmes currently use
the 1987 WHO simplified grading system (Table 1 and
Figure 1).  
PREVALENCE AND GEOGRAPHICAL DISTRIBUTION
Trachoma is endemic in over 50 countries, with the high-
est burden of active disease and trichiasis in parts of Africa.
It is also found in the Middle East, Asia, Latin America and
the Western Pacific (Figure 2). Australia is the only high-
income country in which trachoma is still a problem, where
it is found in the Aboriginal community.5 While trachoma
was a major public health problem in Europe and North
America a century ago, it has now disappeared from these
areas with improvements in living and hygiene standards. 
It was estimated that in 2002 there were 1.3 million peo-
ple blind from trachoma.2 However, this number may be
much higher when considering those categorised as being
blind from ‘corneal opacities’ in trachoma endemic coun-
tries, and there is a further large number suffering from tra-
chomatous low vision.6,7 There are currently estimated to
be 40 million people with active trachoma, and 8.2 million
with trichiasis.8 These numbers are significantly lower than
previous estimates, probably partly because of previous
poor data collection and unwarranted extrapolations
between populations. However, there are probably also sig-
nificantly fewer people now affected by the disease.9 This
reduction mirrors improvements in living standards, as was
the case in industrialised countries, and trachoma control
programmes are also likely to have played a role. Good
prevalence data from India and China is lacking, however,
and small changes in these countries could have a large effect
on global data. Of note, there has been little reduction in
the number of people with trichiasis, with a slight increase
estimated between 2003 and 2008.10 This suggests that con-
junctival scarring can progress even when active disease and
C. trachomatis infection has been successfully combated,
Trachoma is the most common infectious cause of blindness
worldwide. There are currently estimated to be 40 million peo-
ple with active disease, 8 million with trachomatous trichiasis
and 6 million blind or visually impaired from trachoma. The
disease is mainly found in poor, rural areas in developing
countries, especially in isolated communities with little infras-
tructural support. Conjunctival infection with Chlamydia tra-
chomatis causes inflammation in children who are at risk of
developing scarring and blindness as adults. Trachoma control
measures utilise surgery for trichiasis along with ways of
reducing the prevalence and transmission of infection includ-
ing mass antibiotic treatment, promoting facial cleanliness and
environmental improvements. Recent decades have seen
encouraging reductions in the levels of active disease, but not
of trichiasis. Much work remains if blindness from trachoma is
to be eliminated in the next decade, the target of Vision 2020.
Trachoma is a chronic keratoconjunctivitis caused byserovars A–C of Chlamydia trachomatis. It is anancient disease with references to it having been made
many centuries BC, but is still the most common infectious
cause of blindness worldwide. The World Health
Organisation (WHO) currently estimates there to be 6 mil-
lion blind or visually impaired from trachoma.1 Trachoma
is found in poor, rural areas in developing countries, typi-
cally in isolated communities with poor water access. It has
been identified as a priority by the WHO both within the
Neglected Tropical Diseases Programme and Vision 2020.
This review outlines the main features of the disease with
attention to recently published findings.
CLINICAL FEATURES AND NATURAL HISTORY
Infection with C. trachomatis is mostly found in children
who develop a chronic, follicular conjunctivitis and/or pap-
illary hypertrophy, which, if severe enough, can obscure
visualisation of the deep blood vessels (Figure 1). Pannus
of the upper cornea may also occur. Follicles at the limbus,
after resolving, may leave shallow depressions (‘Herbert’s
pits’), which are a pathognomonic sign of trachoma.
Symptoms are generally mild, with infection often going
unnoticed by the patient. All children in an endemic area
will usually be infected at some point, with recurrent
episodes of infection being common. It is believed that
recurrent episodes of infection drive the scarring compli-
cations of trachoma including entropion, trichiasis, corneal
opacity and blindness. Unlike the blindness resulting from
cataract, which is painless and treatable, trachomatous
blindness is painful and, in practice, irreversible.
Chlamydial infection and signs of active disease are most
commonly found in young children and decline with age.
The duration of infection and disease and the level of bac-
terial loads all decrease with age, probably as the result of
an acquired immune response.2 However, the scarring
complications are cumulative and increase with age so that
trichiasis and corneal opacity are more common in the older
members of a community. Where there is a very high preva-
lence of active disease, up to 80% of children in southern
Sudan, for example, trichiasis has been seen in those less
than 15 years of age.3,4
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Table 1. The simplified World Health Organisation trachoma grading system
Grade Description
Trachomatous Inflammation – Follicular (TF)
Trachomatous Inflammation – Intense (TI)
Trachomatous Scarring (TS)
Trachomatous Trichiasis (TT)
Corneal Opacity (CO)
The presence of five or more follicles, each at
least 0.5 mm in diameter, in the upper tarsal
conjunctiva
Pronounced inflammatory thickening of the
tarsal conjunctiva that obscures more than half
of the normal deep vessels
The presence of easily visible lines, bands or
sheets of scarring in the tarsal conjunctiva
At least one lash rubbing on the eyeball, or
evidence of recent epilation
Easily visible corneal opacity causing blurring of
the pupil margin and usually causing significant
visual impairment (<0.3)
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which has significant implications for future trachoma con-
trol planning.
THE BURDEN OF DISEASE
The WHO estimated that in 2004 the burden of disease was
around 1.3 million disability-adjusted life years (DALYs,
which measure the gap between an ‘ideal’ healthy popula-
tion and the premature mortality and morbidity caused by
a specific disease).11 There has been significant variation in
different estimates of the burden of disease. This is unsur-
prising as there have been differences in the prevalence data
used, the weightings given to disabilities and whether or not
trichiasis is included as causing disabling disease indepen-
dently of visual impairment.12 Most estimates have not
included trichiasis even though it may be as disabling as visu-
al impairment alone.13,14 The economic cost of trachoma has
been calculated as being as much as US$8 billion.14
DIAGNOSTIC TESTS: INFECTION VS. DISEASE
Various tests have been used to diagnose ocular infection
with C. trachomatis. The earliest, Giemsa staining and
microscopy of conjunctival scrapings, shows intracytoplas-
mic inclusions and helped to confirm the infectious nature
of trachoma. Tissue culture is expensive and time consum-
ing, but has excellent specificity. It also shows that viable
organism is present and has the potential to assess for
antimicrobial resistance.15 Serological or tear antibody
assays have been used in epidemiological research but are
not helpful in detecting current infection.16 Direct
immunofluorescent cytology and enzyme immunoassay
(EIA) have also been used to detect infection, but are less
sensitive than nucleic acid amplification tests (NAAT). 
NAAT tests are extremely sensitive for the presence of the
organism, and can theoretically detect one elementary body
in a sample. However, poor correlation has generally been
shown with clinical grading. Individuals with follicular
inflammation are more likely to be positive with NAAT tests
in hyperendemic regions than in hypoendemic, and those
with intense trachomatous inflammation are more likely to
be positive than those with follicular inflammation.17 Part
of the explanation for this poor correlation is likely to be
the kinetics of the disease, with a latent phase (infection
before clinical signs), a patent phase (infection and clinical
signs) and a recovery phase (infection cleared but clinical
signs persist).18 The mismatch between NAAT testing and
clinical findings is probably also partly explained by the use
of grading systems such as the simplified WHO system in
which individuals with less than five follicles will be graded
as not having trachoma. NAAT testing has become accept-
ed as the gold standard for detecting infection in research,
but is unsuitable for use in trachoma control programmes,
being complex, expensive and time consuming.
A rapid test or ‘point of care’ assay, which was developed
to detect chlamydial lipopolysaccharide using EIA in the
field and was relatively cheap and easy to perform, showed
initial promise.19 However, when evaluated subsequently in
larger studies in the Gambia and Senegal, the sensitivity and
specificity were lower than previously thought.20
THE BIOLOGY OF CHLAMYDIA
Chlamydia are small, Gram-negative, obligate intracellular
bacteria. C. trachomatisonly naturally infects humans. It con-
tains the ocular serovars A, B, Ba and C, which are responsi-
ble for endemic trachoma, genital serovars D to K and the
Figure 1. Clinical
features/simplified grading
system for trachoma. Top:
Trachomatous Inflammation –
Follicular (TF); second top:
Trachomatous Inflammation –
Intense (TI); middle:
Trachomatous Scarring (TS);
second bottom: Trachomatous
Trichiasis (TT); bottom: Corneal
Opacity (CO).
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lymphogranuloma venereum serovars 1, 2 and 3. Serovars D
to K can also cause a follicular conjunctivitis, generally known
as ‘inclusion conjunctivitis’, which may appear similar to the
initial infection seen in trachoma, but is sporadic in nature
and not associated with the long-term sequelae.
Chlamydia have a unique developmental life cycle with
an extracellular, infectious form – the elementary body (EB)
– and an intracellular, replicative form – the reticulate body
(RB). The EB is typically 0.5 µm in diameter, metabolical-
ly inert and actively taken up by epithelial cells into intra-
cellular inclusions. EBs here transform into RBs, which are
up to 1.5 µm in diameter, and multiply by binary fission
until there are thousands of organisms within the host cell
cytoplasmic inclusion body. RBs then transform back into
EBs and are released on lysis of the host cell. The develop-
mental cycle typically takes 24–48 hours.
TRANSMISSION OF INFECTION
Ocular infection with C. trachomatis is probably spread in
a variety of ways, including direct contact, spread of infect-
ed secretions on fingers or fomites and transmission by eye-
seeking flies. Trachoma is a focal disease that clusters at the
level of the community and the household, reflecting the
infectious nature of the disease.21,22 During mass antibiot-
ic treatment it is important that all infected members of a
household are treated or re-infection within that family and
Figure 2. Map of trachoma
endemic countries in 2009.
Reproduced with permission of Dr
Silvio P. Mariotti, WHO/NMH/PBD. 
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subsequently across the community is likely to happen.
Non-human reservoirs of infection have not been identi-
fied and extra-ocular sites of infection do not appear to play
an important role in the transmission of infection.23
RISK FACTORS
Various environmental, socio-economic and behavioural
factors have been associated with trachoma. Determining
which of these have a causative relationship with the dis-
ease is more difficult as many of the studies have lacked ade-
quate controls and results may be confounded by factors
being closely related. For example, trachoma is associated
with poor access to water;24 however, the more important
factor seems to be how water is used in the household.
Families with trachoma use less water for washing children
than control families without trachoma after controlling for
various factors.25 There is some evidence that unclean faces
are associated with trachoma and that promoting face wash-
ing may reduce the prevalence of trachoma.26,27 Flies are a
risk factor for trachoma by facilitating transmission, and
reducing the fly density and latrine provision lowers the risk
of trachoma.28,29 The transmission of trachoma also occurs
in the absence of flies, however.30 Other risk factors for tra-
choma include crowding, female gender and migration
between communities.21,31,32
PROGRESSION OF SCARRING
Blindness from trachoma is thought to start with recurrent
episodes of infection with C. trachomatis in childhood, as
outlined above. These infectious episodes lead to the devel-
opment of conjunctival scarring, usually in late childhood
or adulthood. Progression of this scarring leads to defor-
mation of the eyelid, including the tarsal plate, with entro-
pion and trichiasis developing. Trauma from the trichiasis,
a dry ocular surface (from destruction of the Meibomian
glands and goblet cells, reduced lacrimal gland output and
defective lid closure) and secondary bacterial or fungal
infection result in corneal scarring and blindness. A num-
ber of epidemiological studies have looked at progression
of the scarring process and these have shown that TS (con-
junctival scarring) can progress to TT (trichiasis) in 10% of
cases over seven years and TT to CO (corneal opacity) in
8% over four years.33,34 Marked variation has been found
between these studies. These differences may be partly
because of a genuine difference between the study areas and
partly because of short follow-up times. 
PATHOGENESIS
Ocular inoculation with trachoma secretions in human vol-
unteer studies have shown that naive individuals almost
always developed infection, but that on rechallenge with the
same serovar only half became re-infected and the disease
was milder and more short-lived.35,36 More rapid disease
resolution with age has also been found in longitudinal stud-
ies.2 These findings suggest that some serovar-specific pro-
tective immune response can develop, and has a role in the
resolution of infection. However, it is also generally accept-
ed that the immune response to C. trachomatis is responsi-
ble for much of the damage found in the disease. The cellular
paradigm suggests that non-immune host cells, particular-
ly epithelial cells, release pro-inflammatory cytokines and
chemokines in response to chlamydial and other bacterial
infection, which induce an inflammatory response leading
to tissue damage. This is in contrast to the immunological
paradigm, which argues that the damage is driven by an
acquired immune cell response, which is important for
defence against infection but also leads to collateral tissue
damage.37
Histopathological studies show a mixed inflammatory
cell infiltrate with lymphoid follicles, which, in children, are
composed largely of B cells.38 Animal models and exami-
nation of peripheral blood samples suggest that an effective
cell-mediated immune response appears to be important in
the resolution of infection.39 A strong TH1 response seems
to be particularly important in clearing infection, while a
predominantly TH2 response may be associated with fail-
ure to clear infection.40,41 Gene expression analysis has
shown that the levels of various pro-/anti-inflammatory
cytokines and extra-cellular matrix modifiers are altered in
trachoma.42,43 An imbalance in this response may result in
immunopathological tissue damage.
SURVEY METHODS
The WHO defines trachoma as being a public health prob-
lem when the prevalence of follicular trachoma is at least
10% in 1–9-year-olds or the prevalence of trachomatous
trichiasis is at least 1% in over 14-year-olds. A population-
based prevalence survey (PBPS) is the gold standard for
determining where trachoma is a public health problem and
should yield good prevalence data on the level of active dis-
ease and trichiasis.44 However, it is an expensive and time-
consuming process. Alternative survey methods are
trachoma rapid assessment (TRA) and acceptance sampling
trachoma rapid acceptance (ASTRA). TRA provides rank-
ings rather than prevalence estimates, is quick to perform
and may have a role in prioritising areas for treatment or
ascertaining absence of disease. However, it has limited reli-
ability.45 ASTRA sampling continues until either a maxi-
mum sample size has been reached or a preset number of
TF cases have been found. It is also relatively quick and may
be able to provide TF prevalence estimates. However, it
works best when the distribution of cases is homogenous,
while trachoma is a disease which clusters. PBPS remains
the only way of providing trachoma prevalence data and is
the WHO recommended survey method.
MATHEMATICAL MODELS
Trachoma is a disease in which the disabling complications
– trichiasis and blindness – take decades to manifest, and
this presents challenges to epidemiological and interven-
tion studies of the disease. Various mathematical models of
trachoma have been proposed as an alternative means of
analysis.46 These have been used to suggest, for example,
that discontinuing antibiotic treatment when the preva-
lence of infection falls below 5% would be appropriate for
most areas and could significantly reduce the amount of
antibiotic distribution required.47
TRACHOMA CONTROL
In 1997 the WHO established the Global Alliance for the
Elimination of Blinding Trachoma by the year 2020 (GET
2020), which recommends the ‘SAFE’ strategy: S for surgery
for trichiasis; A for antibiotics to reduce the reservoir of
infection; F for facial cleanliness through personal hygiene;
and E for environmental improvement to reduce the trans-
mission of infection.48 A more comprehensive review of the
SAFE strategy than is outlined below has been presented
elsewhere.49,50
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Surgery for trichiasis
The WHO recommends the bilamellar tarsal rotation pro-
cedure (BTR) following the results of a randomised surgi-
cal trial in Oman.51 Recurrence rate at two years in this study
was 18%; however, recurrence rates after 2–3 years vary
greatly, from 20% to 60%.18 Various factors seem to be
involved, including surgeon variability, disease severity and
infection status. It should be borne in mind, however, that
recurrence may be defined as only a single lash touching the
globe and so-called surgical failure may still be a significant
improvement to the preoperative status of the patient. Poor
uptake of surgery amongst people with trachomatous
trichiasis is a major obstacle to be overcome. Barriers to
uptake include constraint by duties such as child care, lack
of time, perceived cost of surgery, lack of an escort, distance
to travel to surgery and fear of the operation.52
Antibiotics to reduce the community burden of C. tra-
chomatis infection
Mass antibiotic treatment of a community aims to reduce
the reservoir of chlamydial infection. If treatment is given
only to those individuals with clinically evident active dis-
ease, then reinfection will likely occur from those with clin-
ically unapparent infection. The WHO recommends mass
antibiotic treatment of all people over 6 months of age where
the prevalence of active trachoma in children aged 1–9 years
exceeds 10%. The macrolide antibiotic azithromycin (20
mg/kg up to 1 g) should be used, or, where this drug can-
not be used, topical tetracycline ointment can be used twice
daily for six weeks. Azithromycin has been generously
donated by Pfizer through the International Trachoma
Initiative, which has transformed the availability of treat-
ment. The WHO currently recommends that treatment
should be given annually for three years and then the preva-
lence reassessed. 
Studies have suggested that mass antibiotic treatment can
significantly reduce the level of infection, especially in areas
with a low/moderate level of disease.53 However, in the
absence of other interventions, reinfection tends to occur
in hyperendemic areas.54 Biannual treatment may be more
effective in this context.55 As with any mass antibiotic dis-
tribution, one of the major concerns is the potential devel-
opment of resistant organisms. To date, this has not been
an issue with Chlamydia spp.; however, azithromycin resis-
tance in pneumococci develops soon after mass treatment.
The prevalence of macrolide-resistant strains does appear
to decrease after 6–12 months, but if mass treatment were
given six-monthly then resistance may become more of an
issue.18
A recent cluster-randomised trial in Ethiopia showed that
at 12 months, there was a 50% reduction in childhood mor-
tality in communities where children had been treated with
oral azithromycin compared to those where they had not.56
This noteworthy finding needs to be validated in other stud-
ies, but may have important implications for mass antibi-
otic distribution.
Facial cleanliness to interrupt the transmission of
trachoma
Improved facial cleanliness may reduce ocular and nasal
secretions, which are potential sources of C. trachomatis
infection, thereby reducing transmission. Clean faces may
also be less of a target for flies, which can act as a vector.
Studies on facial cleanliness confront several problems
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including measuring cleanliness accurately, face washing
occurring only before examination by alert carers and
deciding whether dirty faces lead to trachoma or trachoma
leads to dirty faces. A Cochrane review on the promotion
of face washing for prevention of active trachoma conclud-
ed that there is some evidence that face washing, when com-
bined with topical tetracycline ointment, can be effective in
reducing severe trachoma (TI).57 However, a beneficial
effect was not found for face washing, either alone or in
combination with tetracycline ointment, in reducing the
overall prevalence of active trachoma (TF and/or TI). 
Environmental changes to interrupt the transmission
of trachoma
This is potentially the most important area in trachoma con-
trol – trachoma disappeared from Europe and North
America as a result of improved living conditions rather
than mass antibiotic distribution or surgical practice.
However, it is also the area with the least evidence to sup-
port it. Strategies generally involve components such as
increasing water supply, improving latrine access, reducing
the density of flies and health education. A Cochrane review
concluded that there is evidence that insecticide spray as a
fly control measure reduces trachoma significantly, that
latrine provision has not demonstrated significant tra-
choma reduction and that health education may be effec-
tive in reducing trachoma.58 While many trachoma control
measures currently being implemented may have some sup-
port from observational studies, there is a need for further
rigorous clinical trials.
The SAFE strategy as a whole
Implementation of the four components of the SAFE 
strategy is expected to have most success in eliminating 
ocular chlamydial infection and blindness from tra-
choma.59,60 Studies assessing the SAFE strategy with the use
of comparable control areas suggest that antibiotic treat-
ment has the greatest impact in reducing trachoma but that
provision of the other components does provide addition-
al benefit.61,62 
CONCLUSION
There have been considerable reductions in the prevalence
of trachoma over the last few decades, probably due to the
widespread implementation of the SAFE strategy and sec-
ular changes. Reductions in the level of disease in some
countries have meant that trachoma is no longer consid-
ered a public health threat there. However, it remains an
important cause of blindness in poor, rural communities in
many parts of the developing world. Major obstacles exist
in tackling trachoma in many areas, including scarce
resources or armed conflict, and these factors tend to be
found more commonly in those countries where trachoma
is still an important problem. The outcomes of operational
programmes in this context may be disappointing com-
pared to those of research studies, for example, in the antibi-
otic coverage achieved or the results of trichiasis surgery.
Even if ocular chlamydia infection were to be eliminated
tomorrow there would remain a large cohort of people with
a history of infection who are still at risk of developing pro-
gressive scarring complications and blindness. The GET
2020 has been instrumental in advancing control efforts but
trachoma cannot be forgotten about for the foreseeable
future.
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  Abstract 
 
Trachoma, caused by Chlamydia trachomatis (Ct), is the leading infectious blinding disease 
worldwide. Chronic conjunctival inflammation develops in childhood and leads to eyelid 
scarring and blindness in adulthood. The immune response to Ct provides only partial 
protection against re-infection, which is common, and causes scarring pathology through 
incompletely characterised mechanisms. We review the current literature on both protective 
and pathological immune responses in trachoma. The resolution of Ct infection is probably 
IFNγ-dependent, involving both Th1 and Natural Killer cells. However, an increasing number 
of studies indicate that innate immune responses, possibly arising from the epithelium, may 
be important in the development of tissue damage and scarring, which involves matrix 
metalloproteinase activity. Current trachoma control measures that are centred on repeated 
mass antibiotic treatment of populations are logistically challenging and have the potential to 
drive anti-microbial resistance. Development and introduction of a vaccine would offer 
significant benefits, but a clearer understanding of the mechanisms of immunopathology 
remain elusive and a barrier to vaccine progress.  
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  Introduction 
Trachoma results from infection of the conjunctiva with Chlamydia trachomatis (Ct) and is 
the commonest infectious cause of blindness worldwide. The World Health Organization 
(WHO) estimates that at least 1.3 million people are blind from trachoma and 40 million have 
active disease; it is included in the Neglected Tropical Diseases Programme.1, 2 The WHO 
recommends the SAFE Strategy for trachoma control: Surgery for trichiasis; mass Antibiotic 
distribution to treat infection; improved Facial hygiene and Environmental improvements to 
interrupt Ct transmission.3 
 
Trachoma is caused by Ct serovars A to C. Whereas genital tract Ct infection, the 
commonest bacterial sexually transmitted disease worldwide, infecting 90 million people 
each year, is caused by serovars D to K.4 The ocular and genital strains are strictly 
differentiated with ocular strains lacking a functional tryptophan synthase operon.5 Both 
ocular and genital infections produce inflammatory reactions, which are often asymptomatic, 
leading to scarring complications with significant morbidity in a subset of those infected.  
 
This article reviews the literature on immunity and immunopathogenesis in trachoma. We 
focus on results from human studies of ocular Ct infection, but also draw on relevant studies 
of genital tract infection and animal models. Human studies of the pathology, immune 
response and immunopathogenesis in trachoma are comprehensively summarised in 
Supplemental Tables S1 to S6.  
 
Clinical features, natural history and infection 
 
Infection with Ct causes a chronic conjunctivitis, “active trachoma”, which is characterised by 
follicles (sub-epithelial collections of lymphoid cells appearing as small, yellow-white 
elevations) and papillae (engorgement of small vessels with inflammatory conjunctival 
thickening). Infection may be detected in the absence of clinical disease and, conversely, 
active disease may be present without detectable current Ct infection.6 Children 
experiencing repeated episodes of infection are at increased risk of subsequent conjunctival 
scarring, which causes in turning of the eyelids (entropion) so that the eyelashes scratch the 
eye (trichiasis). Eventually sight is lost as irreversible corneal opacification develops from a 
combination of insults, which compromise the ocular surface (trichiasis, dryness, secondary 
bacterial or fungal infections). Clinical features are shown in Figure 1. The scarring 
complications of trachoma usually develop slowly over many years. Several longitudinal 
studies support this pathway to blindness, although there is considerable variation in 
reported disease progression rates, possibly reflecting differences in both the natural history 
in different populations and in study methodology (Table 1). 
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A key question is why only a minority of people living in trachoma endemic regions develop 
severe scarring complications. It is likely that the answer to this is a complex interaction 
between the individual’s lifetime burden of infection and their local immune response. 
Severe, persistent or recurrent conjunctival inflammation is strongly associated with the risk 
of scarring complications.7-11 Females are at increased risk of conjunctival scarring and 
trichiasis, possibly from greater lifetime Ct exposure through close contact with children. 
There is good evidence that the immune response to Ct is partly determined by host genetic 
variations. Several studies from different populations have identified genetic polymorphisms 
related to immune system function which are associated with trachomatous scarring, 
indicating the importance of host immuno-genetic variations in modifying the risk of 
developing blinding disease (Table S1).12-23  
 
Trachoma was initially thought to result from a single episode of infection. However, the 
importance of repeated re-infection in the pathogenesis of scarring disease is now supported 
by various lines of investigation: animal models require repeated inoculation to induce 
disease; absence of scarring following a single inoculation in human volunteer studies; and 
cohort studies from trachoma-endemic areas demonstrating repeated infection.11, 24-28 
However, in vitro studies have shown that persistent, non-replicating forms of Ct develop in 
response to various stress stimuli (penicillin, interferon-γ, iron or nutrient depletion).29 While 
the relevance of these findings to human infection is not known, it has been suggested that 
persistent infection may drive the disease. There is very limited in vivo evidence for 
persistent ocular infection.30 An important observation about Ct infection and ocular disease 
is that infection is infrequently detected in older adults, who are the group in which 
progressive scarring and blinding complications usually develop.10, 31-33 This is partly 
explained by the shorter duration of infection with increasing age.34 However, other factors 
may also be important in scarred conjunctiva, such as non-chlamydial bacterial infection 
(discussed below). 
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  Figure 1: Clinical features and grades of trachoma. N: normal. TF: Trachomatous 
inflammation - Follicular. TI: Trachomatous inflammation - Intense. TS: Trachomatous Scarring. 
TT: Trachomatous Trichiasis. CO: Corneal Opacity. 
 
 
 
Histopathology 
 
Active disease 
Histological studies of conjunctival biopsies from children with active trachoma found mild to 
moderate epithelial hyperplasia with a mixed inflammatory infiltrate consisting of many 
macrophages with some T cells and polymorphonuclear leucocytes (Table S2).35-37 Dendritic 
cells are seen in the deeper epithelium and underlying stroma. Plasma cells form a band 
directly beneath the epithelium and around accessory lacrimal glands. Lymphoid follicles, the 
clinical and pathological hallmark of active trachoma, are found in the stroma (Figure 2). In 
children these consist mainly of B cells with some macrophages and T-cells, and are 
surrounded with a lymphocytic mantle. Around the follicle a diffuse infiltrate consisting of a 
mixed population of leucocytes (T-cells, neutrophils, macrophages, mast cells and 
eosinophils) is seen. Schematic diagrams of normal conjunctiva and active disease shown in 
Figures 3 and 4. 
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  Figure 2:  Histological section of the conjunctiva from a child with active trachoma.  Kindly 
supplied by Professor Ahmed El-Asrar.  
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  Figure 3: Schema of the normal conjunctiva. 
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  Figure 4:  Schema of the conjunctiva in active disease. See Figure 3 for the key. 
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  Scarring disease 
Adults with conjunctival scarring have an epithelium which may show either squamous 
metaplasia or atrophy with focally denuded areas replaced by fibrinous exudate and cellular 
debris (Figure 5).37, 38 A chronic inflammatory cell infiltrate is found, most marked in the 
substantia propria with lymphocytes predominating.35, 39 CD4+ and CD8+ T-cells are present, 
and these generally outnumber B-cells. Follicles may be seen histologically in very inflamed 
subjects, even when absent clinically, and these contain monocytes, macrophages and 
plasma cells, but lack the germinal centres or centrally located B-cells seen in follicles of 
children. Underneath the epithelium the stroma is replaced by abnormal, compact, thick and 
mostly avascular scar tissue.38 This subepithelial fibrous membrane has vertically aligned 
fibres parallel to the surface epithelium and is firmly adherent to the tarsal plate (Figure 6).  
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  Figure 5:  Histological sections of healthy conjunctiva and trachomatous scarring. Top: 
healthy. Middle and bottom: scarred, note disruption of the normal epithelial cell morphology and 
loss of epithelial cells; an increased inflammatory cell infiltrate; and loss of the normal connective 
tissue architecture. 
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  Figure 6:  Schema of the conjunctiva with trachomatous scarring. See Figure 3 for the key. 
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  Resolution of C. trachomatis infection 
 
Epithelial cells mount a pro-inflammatory and chemotactic response 
Several in vitro studies of Ct infected epithelial cell lines have found that this infection 
provokes pro-inflammatory responses with epithelial cells producing pro-inflammatory and 
chemotactic cytokines such as interleukin-6 (IL-6), IL-8, growth regulated oncogene α 
(GROα) and granulocyte macrophage colony-stimulating factor (GM-CSF).40, 41 The 
secretion of these factors was prolonged and required synthesis of chlamydial proteins. In 
contrast, other bacterial species provoked a rapid but transient cytokine induction.40  
 
Human studies are consistent with the epithelium producing pro-inflammatory factors 
constituting an initial innate response to Ct. Immunohistochemistry of conjunctival epithelium 
from children with active trachoma has shown IL-1 expression.42 Gene expression studies on 
conjunctival surface swab samples find enriched expression of multiple pro-inflammatory / 
chemotactic factors, Table S3.28, 43-45 In active trachoma, the epithelium shows increased 
MHC class I expression and induction of MHC class II (not normally found at this site).36, 46 
There is evidence for natural killer (NK) cell and neutrophil recruitment and activation in 
active disease/infection, as part of an acute inflammatory responses.44, 47, 48  
 
 
Importance of cell-mediated immunity and IFNγ production 
The results of animal studies of genital chlamydial infection suggest that resolution of 
infection is dependent on a Type-1 T-helper lymphocyte (Th1) response mediated primarily 
through interferon-γ (IFNγ). Congenitally athymic (nude) mice are unable to clear C. 
muridarum genital tract infection.49 However, adoptive transfer to nude mice of CD4+ or 
CD8+ T-cells derived from normal mice previously infected with C. muridarum resolved the 
infection.50 The CD4+ enriched cell line was much more efficient at clearing infection. 
However, recent murine studies using Ct instead of C. muridarum as the infectious agent did 
not find the absence of CD4+ cells altered the course of infection; limitations of animal 
models of Ct infection need to be recognised.51 Although, CD8+ T-cells can help resolve 
infection, they seem less important in animal models, as they were not an absolute 
requirement for immunity.52  
 
IFNγ is produced by several cell types including Th1 lymphocytes, CD8+ cytotoxic T 
lymphocytes (CTL) and NK cells. The production of IFNγ characterises the Th1 response 
and has several anti-chlamydial actions, which probably play a central role in clearing 
infection. IFNγ induces indoleamine-2,3-dioxygenase (IDO) expression, which lowers the 
intracellular pool of the essential amino acid tryptophan, which is necessary for chlamydial 
 
 
Victor Hu   PhD thesis   52
	  metabolism.53 It can also up-regulate inducible nitric oxide synthase (iNOS), which may help 
control Ct and protect against chronic sequelae in murine models.54 Chlamydial growth can 
also be limited by IFNγ-mediated intracellular iron depletion.55  
 
Several human studies point to the importance of the cell-mediated immune (CMI) response 
to ocular Ct infection. Biopsies from children with active trachoma show heavy cellular 
infiltrates with both CD4+ and CD8+ lymphocytes.36 Children who resolved active disease 
(associated with infection) had stronger peripheral blood lymphoproliferative responses to Ct 
antigens compared to children with persistent disease, Table S4.56 Gene expression studies 
have shown increased expression of IFNγ, IL12p40, Perforin, IDO, IL4, IL10 and forkhead 
box p3 (FOXP3) in infection and/or disease, with levels generally being highest if both were 
present.28, 43, 44, 57 Increased expression of IFNγ, IL10 and FOXP3 has been associated with 
longer episodes of infection.58 A recent study using Ct elementary bodies (EB) to stimulate 
PBMC in individuals exposed to ocular infection showed that NK cells were a major source 
of IFNγ.48  
  
Protective immunity to C. trachomatis 
 
Human volunteer studies of trachoma have provided some evidence that a partial, protective 
immune response develops following ocular Ct infection.59-61 Conjunctival inoculation with Ct 
led to a characteristic follicular / papillary conjunctivitis in nearly all volunteers after 2-14 
days. However, when previously infected individuals were re-challenged with the same 
serovar there was an attenuated clinical response with reduced re-isolation rates. This 
apparent immunity to re-infection was serovar-specific: if a different serovar was used then 
disease and infection levels were similar to the primary infection. Presumed complete 
immunity after primary infection, in which no clinical signs developed and the organism was 
never detected, despite multiple re-challenge inoculations, was rare. Despite the concerns 
over the induction of presumed delayed type hypersensitivity (DTH), the trachoma vaccine 
trials in the 1960s did demonstrate short-term, serovar-specific immunity could be induced.62, 
63 Trachoma models in non-human primates also showed that, after recovery from a primary 
infection, on secondary challenge there was less severe disease which resolved more 
rapidly.25 With regular weekly re-inoculations it also became progressively more difficult to 
detect the organism, suggesting the development of protective immunity. 
 
A longitudinal study in which a cohort from a trachoma endemic population was regularly 
assessed for disease and infection, found the duration of both shortened considerably with 
increasing age.34 This could be a result of an increasingly effective protective immune 
response developing with repeated exposure to Ct. The clinical manifestations also 
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  appeared to be modulated: adults experienced short bursts of intense disease and children 
more prolonged episodes of follicular disease.34 
 
Acquired T-cell dependent cell-mediated immune responses, as outlined above, probably 
contribute to protection against or more rapid resolution of re-infection, although direct 
evidence for this from human trachoma studies is limited. Fading immunity in animal models 
is correlated with a reduction in CD4+ T-cells, which leave the genital tract following 
resolution of infection.64 A study of the incidence of genital tract infection amongst sex 
workers in Nairobi, Kenya, found that IFNγ production by PBMC stimulated with chlamydial 
heat shock protein 60 (cHsp60) was associated with reduced risk of re-infection compared to 
women without such responses.65 
 
The importance of humoral immunity to Ct is unclear. Several human studies have detected 
anti-chlamydial antibodies in tear fluid and serum (Table S5).66-69 However, in a longitudinal 
study, anti-chlamydial IgG in tears from clinically normal individuals was associated with an 
increased incidence of subsequently developing clinically active trachoma.70 In contrast, 
there was an opposite (non-significant) trend with anti-chlamydial IgA. Individuals with 
conjunctival scarring have been found to have significantly higher plasma titres of anti-
chlamydial IgG and lower titres of IgA compared with normal controls.71 However, a 
consistent picture has not emerged from these studies. The presence of antibodies may 
simply indicate previous infection and may not necessarily be protective. 
 
Various animal models of genital tract infection have yielded a mixed pattern of results on 
the relative importance of the humoral response. Some have shown that B-cell deficient 
mice can resolve a primary chlamydial infection and are only slightly delayed in clearing 
secondary infections, compared to control mice.72, 73 However, other studies found that B-cell 
deficient mice that also had their CD4+ cells depleted were completely unable to control 
secondary infection, whereas mice depleted of CD4+ cells alone only showed slight delay in 
clearing secondary infection.74, 75 In addition, transfer of monoclonal antibodies to Ct major 
outer membrane protein (MOMP) and LPS into B-cell deficient, CD4+ T-cell depleted mice 
restored the ability of these mice to control secondary infection.76 Antibodies to polymorphic 
membrane protein D (PmpD) have also been shown to be neutralising in vitro.77 However, 
whether similar protective effects occur in human ocular infection is unknown.  
 
Immunopathogenesis of trachoma 
 
In 1974 Silverstein proposed that tissue damage and scarring sequelae in trachoma are the 
result of a chronic, immunopathogenic response to an otherwise seemingly innocuous, 
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  superficial infection.78 He observed that Ct infection itself is limited to a small minority of 
epithelial cells and is not particularly cytopathic, with cells accommodating large chlamydial 
inclusion bodies. The infection can be quite prolonged suggesting that the immune response 
is relatively inefficient or that Ct is effective at avoiding immune responses. At the tissue 
level the inflammatory infiltrate and subsequent scarring is in the conjunctival stroma, below 
the level of the epithelium, where the infection is located.  
 
A key clinical observation pointing to the immunopathogenic nature of trachoma is that 
visible conjunctival inflammation is frequently found in the absence of detectable Ct.6, 24, 28, 43, 
79 In longitudinal studies discrete episodes of active disease persist long after the associated 
initiating infectious episode has resolved.34 In one trachoma vaccine trial the incidence of 
trachoma was higher in the vaccinated group and another reported a possible increase in 
disease severity.63, 80  
 
Monkey models of Ct infection support the importance of immunopathology in trachoma.25 
Treatment of infected animals with corticosteroids markedly reduced the inflammation and in 
monkey vaccine studies re-challenge was associated with more severe inflammatory 
disease and scarring complications.81, 82  
 
Several theories for the pathogenesis and scarring caused by chlamydial infection have 
been proposed, none of which entirely explain the observed data. These broadly divide into 
two paradigms: the “cellular” paradigm in which the response of the epithelial cell layer is 
central and sufficient to explain the pathology and the “immunological” paradigm in which 
cell mediated immunity causing either DTH or autoimmune mimicry explains disease 
pathology.41, 52, 78, 83 These processes are not mutually exclusive and may both contribute.  
 
The immunological paradigm 
 
The immunological paradigm suggests that tissue damage and fibrosis in chlamydia related 
disease results from CMI responses against specific chlamydial antigens. It argues that 
specific T-cell responses, which are important in clearing Ct infection, also cause collateral 
tissue damage. There are two major lines of investigation that have provided a degree of 
support for this hypothesis.  
 
Delayed-type hypersensitivity and cHsp60  
During early trachoma vaccine studies on non-human primates it was observed that the 
disease phenotype could be more severe on re-challenge. This led the investigators to 
propose that a DTH reaction to chlamydial antigens was responsible for the disease.26 
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  Subsequently, in a guinea pig model of ocular infection, a Ct antigen, extracted using the 
detergent triton X-100, was able to provoke an inflammatory reaction in animals previously 
infected with Ct.84 The active component was identified as the 57kDa protein, cHsp60.85 
Similar experiments were conducted in cynomolgus monkeys, with comparable results.86 
There was some concern that the conjunctival inflammatory response observed in these 
monkeys might have been partly provoked by the triton X-100 detergent itself, as repeated 
installation of the buffer alone also led to significant inflammation. However, when 
experiments were repeated with recombinant cHsp60, inflammation was provoked in guinea 
pig eyes and in the subcutaneous abdominal salpingitis pocket model in monkeys.85, 87, 88 
However, initial priming with the triton extract in monkey eyes or recombinant cHsp60 in a 
guinea pig model, rather than with viable Ct, does not result in inflammation following re-
challenge, suggesting that the antigen alone is insufficient to sensitise the animals.86, 89  
 
Human studies on cHsp60 have delivered equivocal results on its role in pathogenesis. 
Antibodies to cHsp60 are associated with trachomatous scarring, pelvic inflammatory 
disease and tubal infertility.90-92 It is unclear, however, whether these antibodies have a 
pathogenic role or are simply markers of previous infection. Other studies have suggested 
that immune responses to cHsp60 may even be protective; examination of PBMC 
proliferation responses to chlamydial antigens in trachoma endemic populations found that 
conjunctival scarring was associated with weaker responses to cHsp60, while the resolution 
of infection was associated with increased responses.56, 71 Also, as noted above, IFNγ 
production by PBMC stimulated with cHsp60 is associated with protection against 
subsequent genital tract re-infection.65  
 
Differential activity of CD4+ T-cell subsets	  
A Th2 dominated response has been linked to the development of scarring complications in 
some infectious diseases such as schistosomiasis.93 However, there is little evidence for a 
similar role in trachoma. Conjunctival gene expression profiling in children found an increase 
in both Th1 and Th2 cytokine expression including IFNγ, IL12B and IL4.28, 43 Adults with 
scarring, compared to controls, have reduced lymphoproliferative responses and IFNγ 
production in response to stimulation with Ct EB and some antigens, but an increased 
number of IL-4 producing cells in response to cHsp60.71, 94 This seems to support the 
hypothesis that individuals with scarring may have weaker Th1 cell-mediated responses to 
Ct, leading to prolonged infection and inflammation possibly as a result of Th2 responses 
with pro-fibrotic effects. However, two recent studies comparing the conjunctival gene 
expression transcriptome by microarray in subjects with scarring trachoma and matched 
controls found no evidence for Th2 responses and only indirect evidence of increased 
expression of genes associated with Th1 cells.45, 95 Furthermore, the expression of IL13 was 
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  lower in individuals with established conjunctival scarring and inflammation, compared to 
healthy controls. Additionally, Th2 cytokine levels in tear fluid were not increased in scarred 
individuals, Table S6.96  
 
The role other types of CD4+ T-cells play in trachoma pathogenesis has received little 
attention. One study showed that the expression of FOXP3, a marker of regulatory T-cell 
activity, was increased in children who had clinical signs of trachoma but in whom infection 
had resolved.57 However, whether this role is beneficial, by dampening the immune 
response and subsequent tissue damage once infection has been cleared, or detrimental, by 
impeding removal of infectious agent, is unknown. The expression of IL17A, suggestive of 
Th17 cell activity, has been found to be significantly increased in active trachoma (discussed 
below).44, 97, 98 
 
The cellular paradigm  
 
In the cellular paradigm tissue damage and scarring are driven by infected epithelial cells, 
which serve as early innate system responders. Pro-inflammatory chemokines, cytokines 
and growth factors produced by Ct infected epithelial cells initiate the recruitment of 
inflammatory immune cells (neutrophils, macrophages and NK cells). Infected epithelial cells 
express multiple factors, which also promote the CMI response and are chemotactic for 
lymphocytes. The cellular paradigm does not differentiate between damage resulting from 
professional innate immune cells, such as neutrophils and monocytes, and adaptive immune 
cells.41 However, it does propose that chronic inflammatory responses, tissue damage and 
fibrosis in Ct related disease is largely driven from the epithelium rather than by DTH. There 
is now increasing evidence that innate immune responses are a prominent feature of 
responses in trachoma and likely interact with the adaptive response. 
 
Animal studies have shown an influx of neutrophils into genital tract tissue following Ct 
inoculation.99 Neutrophils were not required to clear infection the intensity of the neutrophil 
infiltrate was related to subsequent fibrotic sequelae.100 A guinea pig model of trachoma 
examining neutrophil depletion showed no affect on the burden of infection, however, there 
was less clinical inflammation and fewer mucosal erosions histologically.47 In this study 
adaptive immune responses were also affected with reduced CD4+ and CD8+ cell 
recruitment and changes in the expression of various cytokines and chemokines such as 
decreased CCL5 (T-cell chemokine). This study only evaluated animals for up to 7 days and 
once again caution needs to be exercised in extrapolating results of animal models to 
humans. However, it does provide an insight into the role of innate immunity in trachoma 
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  pathogenesis, and how this might partly be mediated through its interaction with adaptive 
responses. 
 
The production of pro-inflammatory cytokines in response to Ct infection is mediated in part 
through recognition of pathogen-associated molecular patterns (PAMP) by Toll-like receptors 
(TLR) and other pattern recognition receptors (PRR).101 While TLR2 knockout (KO) mice 
were able to eradicate infection in a similar manner to control mice they had reduced TNFα 
and CXCL2.102 Of particular note is the observation that TLR2-KO mice also had a marked 
reduction in late oviduct pathology. Human genetic studies on TLR polymorphisms have yet 
to identify significant associations with chlamydial diseases.103-105 
 
In children with active trachoma IL-1 has been found in the surface epithelial cells of cases, 
but not controls.42 This might promote recruitment of innate immune cells, including 
neutrophils and macrophages, which are indeed seen in large numbers in the sub-epithelial 
substantia propria of children with active trachoma.35, 36 In vivo confocal microscopy of the 
conjunctival surface has shown that most of the cellular infiltrate in active and scarring 
trachoma is concentrated just below the epithelium, supporting the importance of the 
epithelial cell layer as a source of chemotactic factors.106  
 
For both active and scarring trachoma conjunctival transcriptome studies found prominent 
innate immune responses.44, 45 In children with active disease and / or Ct infection there was 
marked enrichment of neutrophil and NK cell related transcripts.44 In addition, several PRR 
and chemokines including the neutrophil chemotactic factor CXCL5 were increased.98 In 
adults with scarring and little Ct infection there was also strong evidence for an innate 
immune response, with some of the most abundant increases in gene expression found for 
pro-inflammatory mediators such as Psoriasin-1 (S100A7), IL1B and CXCL5.45 These 
factors induce neutrophil chemotaxis, and were particularly increased in inflamed cases. The 
importance of the chemokine response in trachoma is further supported by the finding that 
defined SNP-haplotypes in IL8 were associated with scarring.22 
 
TNFα, while not specific to innate immune processes, is a key cytokine in acute 
inflammation and has been associated with scarring trachoma in several studies: a SNP in 
the TNFA promoter region, elevated levels in tear fluid, and increased secretion from 
peripheral blood mononuclear cells (PBMC) from scarred subjects stimulated with EBs.14, 18, 
20, 96 Increased transcript levels of TNFA, as well as IL1B, have also been associated with 
active disease/infection.28, 43, 107  
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  There is increasing evidence that non-chlamydial bacterial infection could play a role in the 
pathogenesis of trachoma, and that this is likely to be through innate mechanisms. While 
infection with Ct is often found in children with active trachoma, it is only rarely identified in 
adults, as discussed above. Infection with bacteria other than Ct, however, is more common 
in individuals with conjunctival scarring, trichiasis or its recurrence after surgery, compared 
to controls, and it is also more common in active disease.31, 32, 108-110 This non-chlamydial 
bacterial infection is associated with elevated expression of IL1B and matrix 
metalloproteinases (MMP) 1 and 9 a year after trichiasis surgery, and with a number of pro-
inflammatory cytokines in children.98, 111  
 
A possible role for IL-17A  
 
Neither the immunological nor cellular paradigms completely accommodate the published 
data regarding trachoma pathogenesis. Initial studies suggest that IL17A may be important 
in trachoma pathogenesis.44, 98 IL17A is the signature cytokine of Th17 cells, a CD4+ T-cell 
population which act in an antigen-specific manner.112 However, it is also produced by 
several other cell types, notably innate immune cells (γδ T-cells, NK cells, macrophages, 
neutrophils) and it can contribute to innate inflammatory responses.113, 114 The IL-17A 
receptor is found on various cell types including dendritic cells, lymphocytes, epithelial cells 
and fibroblasts.115 IL17A is pro-inflammatory and plays an important role in host immunity to 
extracellular and some intracellular pathogens.116 Recently, it has become apparent that 
IL17A may contribute to fibrosis through several mechanisms including epithelial-
mesenchymal transition (EMT) and increased collagen production in a TGFβ1-dependant 
manner.117 Infection of mice with Mycobacterium tuberculosis followed by repeated BCG 
injections led to an IL17A dominated response, which was refractory to regulation by 
IFNγ.118 This led to extensive lung tissue damage by neutrophils that could be reduced by 
anti-IL17A antibody. This may have parallels with trachoma, which would have major 
implications for our understanding of the immunopathology and vaccine design. 
 
Tissue damage and fibrogenesis in trachoma 
 
Neutrophil infiltration appears important in causing tissue damage; they produce toxic 
reactive oxygen and nitrogen species and animal models of genital tract infection have 
suggested that these may result in damage to host tissue.119 Neutrophils may also mediate 
tissue damage through the production of MMPs. The MMPs constitute a group of more than 
25 endopeptidases which are capable of degrading extracellular matrix proteins and are 
important in ocular surface disease.120 Following tissue injury they degrade the basement 
membrane thereby aiding the recruitment of inflammatory cells.121 They have also been 
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  shown to have wide-ranging effects on inflammatory and immune processes such as 
modulating chemokine activity and activation of TGFβ, IL-1β and TNFα.122 While MMPs are 
required for normal tissue homeostasis some have also been associated with tissue damage 
in trachoma. MMP9 in particular has been implicated in the pathogenesis of Ct infections: it 
is part of the neutrophil lysosome and may mediate epithelial dissolution associated with 
infection through degradation of type IV collagen; MMP9 gene knockout mice had a reduced 
rate of scarring sequelae in a model of genital tract infection; elevated MMP9 is found in 
active and scarring trachoma; and scarring trachoma is associated with a coding SNP that is 
adjacent to the active binding site of the MMP9 enzyme 17, 43, 119, 123, 124 Scarring trachoma is 
also associated with elevated MMP7 and MMP12 expression,45, 95 and recurrence of 
trichiasis after surgery is associated with a reduced MMP1/TIMP1 transcript ratio.111  
 
Fibrosis develops when the normal tissue architecture is replaced by excessive connective 
tissue through the abnormal accumulation of extracellular-matrix components. Macrophages 
are key effecter cells in this process and studies on patients with trachoma have shown that 
they produce a number of pro-fibrogenic mediators including TGF-β, PDGF, CTGF (a 
profibrotic downstream mediator of TGF-β) and bFGF (stimulates fibroblasts and endothelial 
cells and is involved in tissue remodelling).42, 98, 125 Chemokines have been shown to act as 
fibrogenic mediators, in particular, the CC- and CXC-chemokine families, and various 
members of these families have been associated with scarring including the pro-fibrogenic 
CCL18.45, 93, 96-98, 121 This pro-fibrotic milieu results in the production and deposition of 
inappropriate ECM proteins, including collagen, by fibroblasts and the laying down of scar 
tissue. The role EMT may play in trachoma has so far not been examined, but this may 
prove to be an important area of research in the future. 
 
Programmatic implications 
 
Trachoma is still endemic in over 50 countries and current trachoma control strategies face 
major obstacles. With regards to mass antibiotic distribution the coverage levels in practice 
are often disappointing; there are concerns that mass distribution of azithromycin may lead 
to an increase in antibiotic resistance; and the “arrested immunity hypothesis” suggests that 
shortening the duration of chlamydial infection with treatment results in population-wide 
reductions in protective immunity.126-128 The number of people estimated to have sight-
threatening trichiasis has shown little reduction since 1991 and many countries have very 
large backlogs of people requiring corrective lid surgery.2 As well as being potentially the 
most effective way of reducing blindness from trachoma, a chlamydial vaccine could be very 
cost effective and have major benefits for genital tract disease caused by Ct.129, 130 
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  The human trachoma vaccine studies in the 1960s using inactivated whole EB tended to 
show only partial, short-term, serovar-specific protection which was little better than natural 
immunity and may even have resulted in more severe disease.62, 63, 80, 131-134 Understanding 
the immunobiology of trachoma, including both how infection is successfully cleared and its 
pathogenesis, is important in the rational design of an effective vaccine which avoids 
immunopathology. Understanding the immunology of trachoma could also facilitate the 
development of interventions that block scarring progression, which could be of benefit in 
other ocular surface scarring diseases.  
 
Conclusion 
 
The immunology and pathogenesis of trachoma is a challenging but fascinating area of 
study. Recent data has revealed the importance of the human innate immune response in 
both active disease and the pathogenesis of scarring. The role of IL17A in inflammatory 
pathology in trachoma requires further investigation. There is still a pressing need for further 
research to better understand this ancient blinding disease. The development of new 
interventions, especially a vaccine, would help to overcome the many obstacles that lie in 
the way of eliminating blinding trachoma. 
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Sa
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si
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ts
 
Lo
ca
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n 
K
ey
 fi
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m
en
ts
 
 
 
 
 
 
 
Th
e 
pa
th
ol
og
y 
of
 
tra
ch
om
a 
in
 a
 b
la
ck
 S
ou
th
 
A
fri
ca
n 
po
pu
la
tio
n3
5  
D
es
cr
ip
tiv
e 
ca
se
 s
er
ie
s 
of
 a
ct
iv
e 
an
d 
sc
ar
rin
g 
tra
ch
om
a.
 
33
 c
as
es
 o
f 
va
ry
in
g 
ag
es
. 
S
ou
th
 
A
fri
ca
 
A
 m
ix
ed
 in
fla
m
m
at
or
y 
ce
ll 
in
fil
tra
te
, e
sp
ec
ia
lly
 
in
 c
hi
ld
re
n.
 O
ld
er
 a
du
lts
 a
ls
o 
ha
d 
a 
m
ar
ke
d 
in
fil
tra
te
, m
ai
nl
y 
of
 p
la
sm
a 
ce
lls
.  
 
C
on
ju
nc
tiv
al
 ly
m
ph
oc
yt
e 
su
bs
et
s 
in
 tr
ac
ho
m
a1
35
 
C
as
e-
co
nt
ro
l s
tu
dy
 o
f a
du
lts
 w
ith
 T
T 
an
d 
(u
nm
at
ch
ed
) c
on
tro
ls
 m
ea
su
rin
g 
T 
ce
ll 
su
bt
yp
es
, B
 c
el
ls
 a
nd
 Ig
G
/Ig
M
/Ig
A
. 
21
 c
as
es
 (1
1 
w
ith
 
in
fla
m
m
at
io
n)
 
an
d 
3 
co
nt
ro
ls
. 
S
au
di
 
A
ra
bi
a 
C
as
es
 h
ad
 in
cr
ea
se
d 
T 
ce
lls
 o
f d
iff
er
en
t 
su
bt
yp
es
. I
nf
la
m
ed
 c
as
es
 h
ad
 in
cr
ea
se
d 
B
 
ce
lls
. A
nt
ib
od
ie
s 
w
er
e 
fo
un
d 
in
 a
ll 
ca
se
s 
(Ig
M
 
on
ly
 if
 in
fla
m
ed
), 
N
o 
de
m
og
ra
ph
ic
 d
et
ai
ls
. 
Im
m
un
op
at
ho
lo
gy
 o
f 
tra
ch
om
at
ou
s 
co
nj
un
ct
iv
iti
s3
6  
D
es
cr
ip
tiv
e 
ca
se
 s
er
ie
s 
of
 c
hi
ld
re
n 
w
ith
 
ac
tiv
e 
tra
ch
om
a.
 
8 
ca
se
s.
 
E
gy
pt
 
E
pi
th
el
ia
l h
yp
er
pl
as
ia
 a
nd
 H
LA
-D
R
 
ex
pr
es
si
on
. A
 m
ix
ed
 in
fla
m
m
at
or
y 
ce
ll 
in
fil
tra
te
 o
f t
he
 e
pi
th
el
iu
m
 a
nd
 s
tro
m
a.
 
Fo
lli
cl
es
 c
om
po
se
d 
la
rg
el
y 
of
 B
 c
el
ls
. P
la
sm
a 
ce
lls
 p
re
do
m
in
an
tly
 Ig
A
, s
om
e 
Ig
G
 a
ls
o.
 
 
T 
ce
lls
 a
nd
 tr
ac
ho
m
a.
 
Th
ei
r r
ol
e 
in
 c
ic
at
ric
ia
l 
di
se
as
e3
9  
C
as
e-
co
nt
ro
l s
tu
dy
 o
f a
du
lts
 w
ith
 T
T 
an
d 
(u
nm
at
ch
ed
) c
on
tro
ls
. 
14
 c
as
es
 (3
 w
ith
 
in
fla
m
m
at
io
n)
 
an
d 
3 
co
nt
ro
ls
. 
U
S
A
 
A
 c
hr
on
ic
 in
fla
m
m
at
or
y 
ce
ll 
in
fil
tra
te
 w
as
 s
ee
n 
in
 c
as
es
, m
ai
nl
y 
ly
m
ph
oc
yt
es
. T
 c
el
ls
 
(c
on
si
st
in
g 
of
 C
D
4+
 a
nd
 C
D
8+
) o
ut
nu
m
be
re
d 
B
 c
el
ls
. 
U
nc
le
ar
 w
he
th
er
 c
as
es
 a
nd
 
co
nt
ro
ls
 c
om
pa
ra
bl
e 
- n
o 
de
m
og
ra
ph
ic
 d
et
ai
ls
; c
on
tro
l 
su
bj
ec
ts
 a
ll 
ha
d 
fa
ta
l 
sy
st
em
ic
 d
is
ea
se
. 
Th
e 
hi
st
op
at
ho
lo
gy
 a
nd
 
m
ec
ha
ni
sm
 o
f e
nt
ro
pi
on
 
in
 p
at
ie
nt
s 
w
ith
 
tra
ch
om
a3
8  
D
es
cr
ip
tiv
e 
ca
se
 s
er
ie
s 
of
 a
du
lts
 w
ith
 
TT
. 
11
 c
as
es
 
(w
ith
ou
t 
in
fla
m
m
at
io
n)
. 
S
au
di
 
A
ra
bi
a 
A
tro
ph
ic
 e
pi
th
el
iu
m
; c
om
pa
ct
 s
ca
r t
is
su
e 
w
ith
 
pa
ra
lle
l f
ib
re
s;
 lo
ss
 o
f g
ob
le
t c
el
ls
.  
 
Im
m
un
op
at
ho
ge
ne
si
s 
of
 
co
nj
un
ct
iv
al
 s
ca
rr
in
g 
in
 
tra
ch
om
a4
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C
as
e-
co
nt
ro
l s
tu
dy
 o
f c
hi
ld
re
n 
w
ith
 
ac
tiv
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tra
ch
om
a 
an
d 
co
nt
ro
ls
 lo
ok
in
g 
fo
r 
IL
-1
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 IL
-1
β,
 T
N
F-
α 
an
d 
P
D
G
F.
  
9 
ca
se
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an
d 
4 
co
nt
ro
ls
. 
S
au
di
 
A
ra
bi
a 
E
pi
th
el
ia
l c
el
ls
 e
xp
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ed
 IL
-1
α 
an
d 
IL
-1
β.
 
M
ar
cr
op
ha
ge
s 
ex
pr
es
se
d 
IL
-1
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 IL
-1
β,
 T
N
F-
α 
an
d 
P
D
G
F.
 N
o 
cy
to
ki
ne
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de
te
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ed
 in
 c
on
tro
ls
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ol
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ge
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en
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ac
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at
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un
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iv
iti
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C
as
e-
co
nt
ro
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es
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f d
iff
er
en
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tiv
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ro
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ul
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ar
rin
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ro
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S
au
di
 
A
ra
bi
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A
ct
iv
e 
di
se
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sh
ow
ed
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cr
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se
d 
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pe
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IV
 c
ol
la
ge
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 a
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 s
om
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ty
pe
 V
 c
ol
la
ge
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ot
 s
ee
n 
in
 c
on
tro
ls
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S
ca
rin
g 
sh
ow
ed
 
m
ar
ke
d 
de
po
si
tio
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of
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pe
s 
IV
 a
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 V
 c
ol
la
ge
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O
ve
rla
p 
of
 p
at
ie
nt
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w
ith
 
pr
ev
io
us
 s
tu
dy
.42
 
A
 s
ur
ve
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 tr
ac
ho
m
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st
op
at
ho
lo
gy
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ha
ni
sm
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pr
og
re
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iv
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ci
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tio
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D
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cr
ip
tiv
e 
ca
se
 s
er
ie
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of
 d
iff
er
en
t 
st
ag
es
 o
f t
ra
ch
om
a.
 
5 
ch
ild
re
n 
w
ith
 
ac
tiv
e 
di
se
as
e;
 
21
 a
du
lts
 w
ith
 
TT
. 
Tu
rk
ey
 
A
ct
iv
e 
di
se
as
e 
sh
ow
ed
 ly
m
ph
oi
d 
fo
lli
cl
es
 w
ith
 
su
rr
ou
nd
in
g 
m
ix
ed
 in
fla
m
m
at
or
y 
ce
ll 
in
fil
tra
te
. 
S
ca
rr
in
g 
sh
ow
ed
 e
pi
th
el
ia
l s
qu
am
ou
s 
m
et
ap
la
si
a/
at
ro
ph
y 
an
d 
co
lla
ge
n 
sc
ar
 ti
ss
ue
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at
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at
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iv
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ro
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tu
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f c
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d 
C
D
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 a
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og
ra
ph
y 
fo
r M
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P
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6 
ac
tiv
e 
tra
ch
om
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ca
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an
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7 
co
nt
ro
ls
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S
au
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A
ra
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a 
M
M
P
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ro
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ca
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s 
bu
t 
no
 c
on
tro
ls
. C
as
es
 a
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o 
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M
P
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 w
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og
ra
ph
y.
 
 
E
xp
re
ss
io
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ro
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nj
un
ct
iv
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fro
m
 p
at
ie
nt
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w
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ct
iv
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tra
ch
om
a1
25
 
C
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e-
co
nt
ro
l s
tu
dy
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f c
hi
ld
re
n 
w
ith
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tiv
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tra
ch
om
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an
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ro
l c
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in
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po
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C
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E
G
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an
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in
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tiv
e 
tra
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om
a 
ca
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an
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6 
co
nt
ro
ls
 
S
au
di
 
A
ra
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Tr
ac
ho
m
at
ou
s 
ep
ith
el
iu
m
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ad
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at
ed
 
V
E
G
F,
 a
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 m
ac
ro
ph
ag
es
 h
ad
 in
cr
ea
se
d 
ex
pr
es
si
on
 o
f C
TG
F 
an
d 
bF
G
F.
 C
as
es
 a
ls
o 
ha
d 
in
cr
ea
se
d 
C
D
10
5 
an
d 
te
na
sc
in
. 
O
ve
rla
p 
of
 p
at
ie
nt
s 
w
ith
 
pr
ev
io
us
 s
tu
dy
.12
4   
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vi
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ro
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tio
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l s
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 m
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g 
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-1
β,
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-2
, I
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4,
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-5
, I
L-
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-1
0,
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-
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p4
0,
 T
G
F-
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, T
N
F-
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an
d 
C
D
3-
δ.
  
50
 p
eo
pl
e 
of
 
va
ry
in
g 
ag
es
 
an
d 
di
se
as
e 
st
at
us
. 
Ta
nz
an
ia
 
 
In
fe
ct
io
n 
w
as
 a
ss
oc
ia
te
d 
w
ith
 u
pr
eg
ul
at
ed
 
IN
F-
γ,
 IL
-1
β,
 IL
-2
, T
G
F-
β1
 a
nd
 T
N
F-
α.
 
A
ct
iv
e 
di
se
as
e 
w
as
 a
ss
oc
ia
te
d 
w
ith
 
up
re
gu
la
te
d 
IN
F-
γ,
 IL
-2
, I
L-
12
p4
0,
 T
G
F-
β1
 
an
d 
TN
F-
α.
 S
ca
rr
in
g 
w
as
 a
ss
oc
ia
te
d 
w
ith
 
up
re
gu
la
te
d 
TG
F-
β1
. 
β-
ac
tin
 u
se
d 
as
 
ho
us
ek
ee
pi
ng
 g
en
e.
 
TG
F-
β1
 is
 p
os
t-
tra
ns
cr
ip
tio
na
lly
 
re
gu
la
te
d 
an
d 
su
bs
eq
ue
nt
 s
tu
di
es
 
ha
ve
 n
ot
 fo
un
d 
it 
to
 b
e 
as
so
ci
at
ed
 w
ith
 d
is
ea
se
. 
C
yt
ok
in
e 
an
d 
fib
ro
ge
ni
c 
ge
ne
 e
xp
re
ss
io
n 
in
 th
e 
co
nj
un
ct
iv
as
 o
f s
ub
je
ct
s 
fro
m
 a
 G
am
bi
an
 
co
m
m
un
ity
 w
he
re
 
tra
ch
om
a 
is
 e
nd
em
ic
43
 
P
op
ul
at
io
n 
ba
se
d 
cr
os
s-
se
ct
io
na
l s
tu
dy
 
m
ea
su
rin
g 
IN
F-
γ,
 IL
-1
β,
 IL
-2
, I
L-
4,
 IL
-1
0,
 
IL
-1
2p
35
, I
L-
12
p4
0,
 T
G
F-
β2
, T
N
F-
α,
 
M
M
P
-1
, M
M
P
-9
, p
er
fo
rin
 a
nd
 C
ol
la
ge
n 
I. 
  
24
8 
pe
op
le
 o
f 
va
ry
in
g 
ag
es
, 4
2 
of
 w
ho
m
 h
ad
 
ac
tiv
e 
tra
ch
om
a,
 
17
 h
ad
 C
t 
in
fe
ct
io
n.
  
Th
e 
G
am
bi
a 
A
ct
iv
e 
di
se
as
e 
w
ith
ou
t C
t i
nf
ec
tio
n 
as
so
ci
at
ed
 w
ith
 u
pr
eg
ul
at
ed
 IL
-1
β,
 IL
-1
0,
 
TN
F-
α,
 a
nd
 M
M
P
-9
. C
t i
nf
ec
tio
n 
(w
ith
 o
r 
w
ith
ou
t d
is
ea
se
) w
as
 a
dd
iti
on
al
ly
 
as
so
ci
at
ed
 w
ith
 u
pr
eg
ul
at
ed
 IN
F-
γ,
 IL
-
12
p4
0,
 p
er
fo
rin
 a
nd
 IL
-4
. 
N
o 
co
m
m
en
t m
ad
e 
on
 
in
di
vi
du
al
s 
w
ith
 s
ca
rr
in
g.
 
TG
F-
β1
 le
ve
ls
 to
o 
lo
w
 to
 
m
ea
su
re
. T
G
F-
β2
 w
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co
ns
tit
ut
iv
el
y 
ex
pr
es
se
d 
ac
ro
ss
 a
ll 
cl
in
ic
al
 
ca
te
go
rie
s.
 
Te
m
po
ra
l c
yt
ok
in
e 
ge
ne
 
ex
pr
es
si
on
 p
at
te
rn
s 
in
 
su
bj
ec
ts
 w
ith
 tr
ac
ho
m
a 
id
en
tif
y 
di
st
in
ct
 
co
nj
un
ct
iv
al
 re
sp
on
se
s 
as
so
ci
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ed
 w
ith
 in
fe
ct
io
n2
8  
Lo
ng
itu
di
na
l s
tu
dy
 o
f c
hi
ld
re
n,
 w
ith
 
ex
am
in
at
io
n 
ev
er
y 
2 
w
ee
ks
 fo
r 2
4 
w
ee
ks
 
in
cl
ud
in
g 
sw
ab
s 
fo
r m
ea
su
rin
g 
IN
F-
γ,
 IL
-
1β
, I
L-
10
, I
L-
12
p4
0 
an
d 
TN
F-
α.
  
16
 c
hi
ld
re
n:
 a
t 
ba
se
lin
e 
9 
ha
d 
ac
tiv
e 
di
se
as
e,
 7
 
w
er
e 
cl
in
ic
al
ly
 
no
rm
al
. 
Th
e 
G
am
bi
a 
In
fe
ct
io
n 
w
ith
ou
t d
is
ea
se
 a
ss
oc
ia
te
d 
w
ith
 
up
re
gu
la
te
d 
IN
F-
γ,
 IL
-1
β,
 IL
-1
2p
40
. 
In
fe
ct
io
n 
w
ith
 d
is
ea
se
 a
ss
oc
ia
te
d 
w
ith
 
gr
ea
te
r u
pr
eg
ul
at
io
n 
of
 a
ll 
cy
to
ki
ne
s.
  
S
im
pl
ifi
ed
 W
H
O
 g
ra
di
ng
 
sy
st
em
 u
se
d 
de
sp
ite
 
sm
al
l s
am
pl
e 
si
ze
. 
C
on
ju
nc
tiv
al
 F
O
X
P
3 
ex
pr
es
si
on
 in
 tr
ac
ho
m
a:
 
do
 re
gu
la
to
ry
 T
 c
el
ls
 h
av
e 
a 
ro
le
 in
 h
um
an
 o
cu
la
r 
ch
la
m
yd
ia
 tr
ac
ho
m
at
is
 
in
fe
ct
io
n?
57
 
C
ro
ss
-s
ec
tio
na
l s
tu
dy
 o
f c
hi
ld
re
n 
m
ea
su
rin
g 
IN
F-
γ,
 ID
O
, I
L-
10
 a
nd
 
FO
X
P
3.
  
34
5 
ch
ild
re
n:
 7
4 
w
ith
 a
ct
iv
e 
di
se
as
e,
 2
0 
w
ith
 
sc
ar
rin
g,
 2
51
 
cl
in
ic
al
ly
 n
or
m
al
.  
Th
e 
G
am
bi
a 
In
fe
ct
io
n 
w
ith
ou
t d
is
ea
se
 a
ss
oc
ia
te
d 
w
ith
 
up
re
gu
la
te
d 
IN
F-
γ 
an
d 
ID
O
. F
O
X
P
3 
up
re
gu
la
te
d 
in
 d
is
ea
se
 w
ith
ou
t i
nf
ec
tio
n.
 
In
fe
ct
io
n 
w
ith
 d
is
ea
se
 w
as
 a
ss
oc
ia
te
d 
w
ith
 
gr
ea
te
r u
pr
eg
ul
at
io
n 
of
 IN
F-
γ,
 ID
O
, I
L-
10
 
an
d 
FO
X
P
3.
 
 
C
on
ju
nc
tiv
al
 e
xp
re
ss
io
n 
of
 M
M
P
 a
nd
 
pr
oi
nf
la
m
m
at
or
y 
cy
to
ki
ne
 
ge
ne
s 
af
te
r t
ric
hi
as
is
 
su
rg
er
y1
11
 
Lo
ng
itu
di
na
l s
tu
dy
 m
ea
su
rin
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IL
-
1β
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N
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 M
M
P
-1
, M
M
P
-2
, M
M
P
-9
, 
TI
M
P
-1
, a
nd
 T
IM
P
-2
 a
 y
ea
r a
fte
r T
T 
su
rg
er
y.
 
 2
40
 c
as
es
 
Th
e 
G
am
bi
a 
R
ec
ur
re
nt
 T
T 
as
so
ci
at
ed
 w
ith
 re
du
ce
d 
M
M
P
-1
/T
IM
P
-1
 ra
tio
. I
nf
la
m
m
at
io
n 
as
so
ci
at
ed
 w
ith
 u
pr
eg
ul
at
ed
 IL
-1
β,
 T
IM
P
-2
 
an
d,
 if
 n
on
-C
t b
ac
te
ria
l i
nf
ec
tio
n 
al
so
 
pr
es
en
t, 
w
ith
 T
N
F-
α 
an
d 
M
M
P
-9
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P
at
hw
ay
-fo
cu
se
d 
ar
ra
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ve
al
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cr
ea
se
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M
M
P
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tra
ns
cr
ip
tio
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tra
ch
om
at
ou
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tri
ch
ia
si
s9
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nt
ro
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f a
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 w
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 T
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an
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ex
pe
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d 
on
 E
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 a
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he
si
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 m
ol
ec
ul
es
 a
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an
 
Th
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Th
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Th
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ce
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. C
on
fir
m
at
or
y 
qP
C
R
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 c
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es
 a
nd
 1
1 
co
nt
ro
ls
. N
=9
4 
fo
r q
P
C
R
 s
tu
dy
. 
Th
e 
G
am
bi
a 
M
M
P
-7
 u
pr
eg
ul
at
io
n 
w
as
 th
e 
on
ly
 
co
ns
is
te
nt
 re
su
lt 
be
tw
ee
n 
ar
ra
y 
an
d 
qP
C
R
 
re
su
lts
. N
o 
ev
id
en
ce
 fo
r T
h1
/T
h2
/T
h3
 
po
la
riz
at
io
n 
w
as
 fo
un
d.
 
 
 
 
Victor Hu   PhD thesis   67
	  ge
ne
 e
xp
re
ss
io
n 
of
 s
el
ec
te
d 
ta
rg
et
s 
pe
rfo
rm
ed
 in
 a
n 
in
de
pe
nd
en
t c
as
e-
co
nt
ro
l s
tu
dy
. M
M
P
-7
 le
ve
l w
as
 
m
ea
su
re
d.
  
H
um
an
 c
on
ju
nc
tiv
al
 
tra
ns
cr
ip
to
m
e 
an
al
ys
is
 
re
ve
al
s 
th
e 
pr
om
in
en
ce
 o
f 
in
na
te
 d
ef
en
se
 in
 C
t 
in
fe
ct
io
n4
4  
C
as
e-
co
nt
ro
l s
tu
dy
 o
f c
hi
ld
re
n 
w
ith
 
ac
tiv
e 
di
se
as
e 
an
d 
co
nt
ro
ls
 in
vo
lv
in
g 
tra
ns
cr
ip
to
m
e-
w
id
e 
m
ic
ro
ar
ra
y 
ex
pe
rim
en
ts
. C
on
fir
m
at
or
y 
qP
C
R
 g
en
e 
ex
pr
es
si
on
 o
f s
el
ec
te
d 
ta
rg
et
s 
w
as
 
pe
rfo
rm
ed
 in
 a
n 
in
de
pe
nd
en
t c
as
e-
co
nt
ro
l s
tu
dy
.  
20
 c
as
es
 w
ith
 
ac
tiv
e 
di
se
as
e 
an
d 
in
fe
ct
io
n;
 2
0 
ca
se
s 
w
ith
 
ac
tiv
e 
di
se
as
e 
w
ith
ou
t i
nf
ec
tio
n;
 
20
 c
on
tro
ls
.  
Th
e 
G
am
bi
a 
G
en
e 
en
ric
hm
en
t s
ho
w
ed
 th
e 
to
p-
ra
nk
in
g 
ge
ne
 o
nt
ol
og
y 
te
rm
s 
fo
r d
is
ea
se
/in
fe
ct
io
n 
w
er
e 
ty
pi
ca
l o
f i
m
m
un
e 
sy
st
em
 a
ct
iv
at
io
n,
 
ep
ith
el
ia
l c
el
l i
nt
eg
rit
y,
 a
po
pt
os
is
, c
el
l 
de
at
h,
 le
uk
oc
yt
e 
m
ig
ra
tio
n 
an
d 
IL
-r
ec
ep
to
r 
ac
tiv
ity
. Q
ua
nt
ita
tiv
e 
P
C
R
 re
su
lts
 w
er
e 
co
ns
is
te
nt
 w
ith
 th
e 
ar
ra
y 
da
ta
. 
 
C
on
ju
nc
tiv
al
 
tra
ns
cr
ip
to
m
e 
in
 s
ca
rr
in
g 
tra
ch
om
a4
5  
C
as
e-
co
nt
ro
l s
tu
dy
 o
f a
du
lts
 w
ith
 T
T 
an
d 
co
nt
ro
l s
ub
je
ct
s 
in
vo
lv
in
g 
tra
ns
cr
ip
to
m
e-
w
id
e 
m
ic
ro
ar
ra
y 
ex
pe
rim
en
ts
. 
C
on
fir
m
at
or
y 
qP
C
R
 g
en
e 
ex
pr
es
si
on
 o
f 
se
le
ct
ed
 ta
rg
et
s 
w
as
 p
er
fo
rm
ed
 in
 a
n 
in
de
pe
nd
en
t c
as
e-
co
nt
ro
l s
tu
dy
.  
M
ic
ro
ar
ra
y 
an
al
ys
is
: 1
5 
TT
 
w
ith
ou
t 
in
fla
m
m
at
io
n;
 1
3 
TT
 w
ith
 
in
fla
m
m
at
io
n;
 1
4 
co
nt
ro
ls
. 
qP
C
R
 s
tu
dy
: 
38
6 
TT
 c
as
es
, 
38
6 
co
nt
ro
ls
 
E
th
io
pi
a 
G
en
e 
en
ric
hm
en
t r
es
ul
ts
 w
er
e 
co
ns
is
te
nt
 
w
ith
 s
qu
am
ou
s 
m
et
ap
la
si
a 
of
 th
e 
ep
ith
el
iu
m
, a
n 
ac
tiv
at
ed
 in
na
te
 im
m
un
e 
re
sp
on
se
 e
sp
ec
ia
lly
 w
he
n 
in
fla
m
m
at
io
n 
w
as
 p
re
se
nt
 (I
L1
B
, C
X
C
L5
, S
10
0A
7)
, 
cy
to
sk
el
et
al
 re
m
od
el
lin
g 
(M
M
P
7,
 M
M
P
9,
 
M
M
P
12
), 
lim
ite
d 
Th
1 
re
sp
on
se
 (I
N
D
O
, 
N
O
S
2A
), 
an
d 
no
 e
vi
de
nc
e 
fo
r a
 T
h2
 
re
sp
on
se
. Q
ua
nt
ita
tiv
e 
P
C
R
 re
su
lts
 w
er
e 
co
ns
is
te
nt
 w
ith
 th
e 
ar
ra
y 
da
ta
. 
 
A
ct
iv
e 
tra
ch
om
a 
is
 
as
so
ci
at
ed
 w
ith
 in
cr
ea
se
d 
co
nj
un
ct
iv
al
 e
xp
re
ss
io
n 
of
 
IL
17
A
 a
nd
 p
ro
-fi
br
ot
ic
 
cy
to
ki
ne
s9
8  
P
op
ul
at
io
n 
ba
se
d 
cr
os
s-
se
ct
io
na
l s
tu
dy
 
m
ea
su
rin
g 
S
10
0A
7,
 IL
1B
, I
L1
7A
, I
L2
3A
, 
C
X
C
L5
, C
C
L1
8,
 T
LR
2,
 N
LR
P
3,
 K
LR
D
1,
 
C
TG
F 
an
d 
M
M
P
9.
 
47
0 
ch
ill
dr
en
. 
Ta
nz
an
ia
 
A
ct
iv
e 
di
se
as
e 
w
as
 a
ss
oc
ia
te
d 
w
ith
 
up
re
gu
la
te
d 
S
10
0A
7,
 IL
17
A
, C
C
L1
8,
 
C
X
C
L5
 a
nd
 C
TG
F.
 N
on
-c
hl
am
yd
ia
l 
ba
ct
er
ia
l i
nf
ec
tio
n 
w
as
 a
ss
oc
ia
te
d 
w
ith
 
up
re
gu
la
te
d 
IL
17
A
, C
X
C
L5
, C
C
L1
8 
an
d 
K
LR
D
1.
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  Ta
bl
e 
S4
: L
ym
ph
op
ro
lif
er
at
iv
e 
an
d 
cy
to
ki
ne
 s
tu
di
es
 u
si
ng
 h
um
an
 P
B
M
C
s 
 
Ti
tle
 
St
ud
y 
su
m
m
ar
y 
Sa
m
pl
e 
si
ze
 / 
Pa
rt
ic
ip
an
ts
 
Lo
ca
tio
n 
K
ey
 fi
nd
in
gs
 
C
om
m
en
ts
 
 
 
 
 
 
 
C
on
ju
nc
tiv
al
 s
ca
rr
in
g 
in
 
tra
ch
om
a 
is
 a
ss
oc
ia
te
d 
w
ith
 d
ep
re
ss
ed
 c
el
l-
m
ed
ia
te
d 
im
m
un
e 
re
sp
on
se
s 
to
 c
hl
am
yd
ia
l 
an
tig
en
s7
1  
C
as
e-
co
nt
ro
l s
tu
dy
 o
f c
as
es
 w
ith
 s
ca
rr
in
g 
an
d 
co
nt
ro
ls
, m
ea
su
rin
g 
ly
m
ph
op
ro
lif
er
at
iv
e 
re
sp
on
se
s 
an
d 
IN
F-
γ 
pr
od
uc
tio
n 
in
 re
sp
on
se
 
to
 C
t E
B
, M
O
M
P
 a
nd
 c
H
sp
60
. C
t L
P
S
 w
as
 
de
te
ct
ed
 b
y 
E
LI
S
A
 a
nd
 C
t D
N
A
 d
et
ec
te
d 
by
 
P
C
R
. 
29
 T
S
 c
as
es
 
(u
ni
nf
la
m
ed
) a
nd
  
29
 c
on
tro
ls
 
Th
e 
G
am
bi
a 
C
as
es
 h
ad
 re
du
ce
d 
pr
ol
ife
ra
tiv
e 
re
sp
on
se
s 
to
 
al
l 3
 C
t a
nt
ig
en
s,
 a
 s
m
al
l r
ed
uc
tio
n 
in
 IN
F-
γ 
se
cr
et
io
n 
an
d 
m
or
e 
C
t i
nf
ec
tio
n.
 
. 
S
ub
je
ct
s 
re
co
ve
rin
g 
fro
m
 
hu
m
an
 o
cu
la
r c
hl
am
yd
ia
l 
in
fe
ct
io
n 
ha
ve
 e
nh
an
ce
d 
ly
m
ph
op
ro
lif
er
at
iv
e 
re
sp
on
se
s 
to
 c
hl
am
yd
ia
l 
an
tig
en
s 
co
m
pa
re
d 
w
ith
 
th
os
e 
of
 p
er
si
st
en
tly
 
di
se
as
ed
 c
on
tro
ls
56
 
Lo
ng
itu
di
na
l s
tu
dy
 fo
llo
w
in
g 
ch
ild
re
n 
w
ith
 
ac
tiv
e 
tra
ch
om
a 
fo
r 6
 m
on
th
s,
 e
xa
m
in
ed
 e
ve
ry
 
2-
4 
w
ee
ks
. L
ym
ph
op
ro
lif
er
at
iv
e 
re
sp
on
se
s 
an
d 
IN
F-
γ 
pr
od
uc
tio
n 
to
 C
t E
B
, M
O
M
P
 a
nd
 
cH
S
P
60
 m
ea
su
re
d 
af
te
r 4
-5
 m
on
th
s.
 C
t L
P
S
 
w
as
 d
et
ec
te
d 
by
 ID
E
IA
.  
47
 a
ct
iv
e 
tra
ch
om
a 
ca
se
s:
 
26
 h
ad
 p
er
si
st
en
t 
cl
in
ic
al
 d
is
ea
se
 
th
ro
ug
ho
ut
 th
e 
st
ud
y 
pe
rio
d;
 2
1 
re
so
lv
ed
 d
is
ea
se
. 
Th
e 
G
am
bi
a 
C
hi
ld
re
n 
w
ho
 re
so
lv
ed
 d
is
ea
se
 h
ad
 s
tro
ng
er
 
pr
ol
ife
ra
tiv
e 
re
sp
on
se
s 
to
 a
ll 
C
t a
nt
ig
en
s.
 N
o 
di
ffe
re
nc
e 
in
 IN
F-
γ 
pr
od
uc
tio
n.
 P
er
si
st
en
t 
di
se
as
e 
w
as
 a
ss
oc
ia
te
d 
w
ith
 C
t i
nf
ec
tio
n.
 
 
 
Th
1/
Th
2 
pr
of
ile
s 
of
 
pe
rip
he
ra
l b
lo
od
 
m
on
on
uc
le
ar
 c
el
ls
; 
re
sp
on
se
s 
to
 a
nt
ig
en
s 
of
 
C
t i
n 
su
bj
ec
ts
 w
ith
 s
ev
er
e 
tra
ch
om
at
ou
s 
sc
ar
rin
g9
4  
C
as
e-
co
nt
ro
l s
tu
dy
 o
f c
as
es
 w
ith
 s
ca
rr
in
g 
an
d 
co
nt
ro
ls
, m
ea
su
rin
g 
ly
m
ph
op
ro
lif
er
at
iv
e 
re
sp
on
se
s,
 IN
F-
γ 
pr
od
uc
tio
n 
an
d 
ge
ne
 
ex
pr
es
si
on
 (I
N
F-
γ,
 IL
-4
 a
nd
 IL
-1
0)
 in
 re
sp
on
se
 
to
 C
t E
B
s,
 M
O
M
P
 a
nd
 c
H
sp
60
. C
t L
P
S
 w
as
 
de
te
ct
ed
 b
y 
E
LI
S
A
. 
30
 T
S
 c
as
es
 
(u
ni
nf
la
m
ed
) a
nd
 
30
 c
on
tro
ls
. 
Th
e 
G
am
bi
a 
cH
sp
60
 c
au
se
d 
in
cr
ea
se
d 
IL
-4
 p
ro
du
ci
ng
 c
el
ls
 
in
 c
as
es
 a
nd
 in
cr
ea
se
d 
IN
F-
γ 
pr
od
uc
tio
n 
in
 
co
nt
ro
ls
. M
O
M
P
 c
au
se
d 
in
cr
ea
se
d 
IN
F-
γ 
pr
od
uc
in
g 
ce
lls
 in
 c
on
tro
ls
.  
 
S
ys
te
m
ic
 e
ffe
ct
or
 a
nd
 
re
gu
la
to
ry
 im
m
un
e 
re
sp
on
se
s 
to
 c
hl
am
yd
ia
l 
an
tig
en
s 
in
 tr
ac
ho
m
at
ou
s 
tri
ch
ia
si
s4
8  
C
as
e-
co
nt
ro
l s
tu
dy
 o
f c
as
es
 w
ith
 s
ca
rr
in
g 
an
d 
co
nt
ro
ls
, m
ea
su
rin
g 
ly
m
ph
op
ro
lif
er
at
iv
e 
re
sp
on
se
s 
an
d 
pr
od
uc
tio
n 
of
 IF
N
γ,
 T
N
Fα
, I
L5
, 
IL
10
, I
L1
2p
40
, a
nd
 IL
13
 a
nd
 a
ls
o 
ce
llu
la
r 
so
ur
ce
 o
f I
FN
γ,
 IL
10
, F
O
X
P
3,
 C
TL
A
4,
 G
IT
R
, 
in
 re
sp
on
se
 to
 C
t E
B
s,
 M
O
M
P
, P
m
pD
, P
m
pG
 
an
d 
O
m
p2
. 
42
 T
T 
ca
se
s 
an
d 
42
 c
on
tro
ls
 (1
7 
pa
irs
 a
na
ly
se
d 
fo
r 
ce
llu
la
r s
ou
rc
e;
 1
5 
pa
irs
 a
na
ly
se
d 
fo
r 
N
K
 c
el
l m
ar
ke
rs
). 
Th
e 
G
am
bi
a 
N
o 
si
gn
ifi
ca
nt
 d
iff
er
en
ce
s 
in
 
ly
m
ph
op
ro
lif
er
at
io
n,
 c
yt
ok
in
e 
le
ve
ls
 o
r c
el
l 
ty
pe
s 
be
tw
ee
n 
ca
se
s 
an
d 
co
nt
ro
ls
 d
et
ec
te
d.
 
N
K
 c
el
ls
 id
en
tif
ie
d 
to
 b
e 
a 
m
aj
or
, e
ar
ly
 s
ou
rc
e 
of
 IF
N
γ,
 w
hi
ch
 in
cr
ea
se
d 
w
ith
 a
ge
. 
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  Ta
bl
e 
S5
: A
nt
ib
od
y 
/ B
 c
el
l r
es
po
ns
es
 fr
om
 h
um
an
 s
er
um
, c
on
ju
nc
tiv
al
 a
nd
 te
ar
 s
am
pl
es
 
Ti
tle
 
St
ud
y 
su
m
m
ar
y 
Sa
m
pl
e 
si
ze
 / 
Pa
rt
ic
ip
an
ts
 
Lo
ca
tio
n 
K
ey
 fi
nd
in
gs
 
C
om
m
en
ts
 
 
 
 
 
 
 
Fl
uo
re
sc
en
t a
nt
ib
od
ie
s 
in
 
th
e 
flu
id
 o
f t
he
 
co
nj
un
ct
iv
al
 s
ac
 o
f 
tra
ch
om
a 
pa
tie
nt
s6
6  
C
as
e-
co
nt
ro
l s
tu
dy
 o
f c
hi
ld
re
n 
w
ith
 
ac
tiv
e 
di
se
as
e 
an
d 
co
nt
ro
ls
 m
ea
su
rin
g 
an
tib
od
ie
s 
to
 T
R
IC
 in
 c
on
ju
nc
tiv
al
 fl
ui
d 
an
d 
(in
 a
 s
ub
se
t o
nl
y)
 s
er
um
. 
21
 c
as
es
 a
nd
 2
2 
co
nt
ro
ls
. 
Is
ra
el
 
10
 c
as
es
 h
ad
 a
nt
ib
od
ie
s 
de
te
ct
ed
 
co
m
pa
re
d 
to
 n
on
e 
of
 th
e 
co
nt
ro
ls
. 
C
on
ju
nc
tiv
al
 ti
tre
s 
w
er
e 
hi
gh
er
 th
an
 s
er
um
 
tit
re
s 
in
 s
om
e 
pa
tie
nt
s.
 
M
et
ho
d 
of
 re
cr
ui
tm
en
t a
nd
 
de
m
og
ra
ph
ic
 d
et
ai
ls
 n
ot
 
gi
ve
n.
 M
ac
C
al
la
n 
gr
ad
in
g 
cl
as
si
fic
at
io
n 
us
ed
. 
A
nt
ib
od
ie
s 
to
 tr
ac
ho
m
a 
in
 
ey
e 
se
cr
et
io
ns
 o
f S
au
di
 
A
ra
b 
ch
ild
re
n6
7  
C
as
e-
co
nt
ro
l s
tu
dy
 o
f c
hi
ld
re
n 
m
ea
su
rin
g 
an
tib
od
ie
s 
to
 T
R
IC
 in
 
co
nj
un
ct
iv
al
 fl
ui
d 
an
d 
te
ar
s.
 C
hl
am
yd
ia
l 
cu
ltu
re
 a
nd
 d
et
ec
tio
n 
of
 in
cl
us
io
n 
bo
di
es
 
fro
m
 c
on
ju
nc
tiv
al
 s
w
ab
s 
al
so
 p
er
fo
rm
ed
. 
81
 S
au
di
 
A
ra
bi
an
 c
hi
ld
re
n 
(a
nd
 3
0 
C
au
ca
si
an
 
ch
ild
re
n.
  
S
au
di
 
A
ra
bi
a 
50
 S
au
di
 A
ra
bi
an
 c
hi
ld
re
n 
ha
d 
an
tib
od
ie
s 
co
m
pa
re
d 
to
 n
on
e 
of
 th
e 
C
au
ca
si
an
 
ch
ild
re
n.
 S
au
di
 A
ra
bi
an
 c
hi
ld
re
n 
w
ho
 w
er
e 
an
tib
od
y 
po
si
tiv
e 
w
er
e 
m
or
e 
lik
el
y 
to
 h
av
e 
ac
tiv
e 
tra
ch
om
a,
 to
 h
av
e 
in
cl
us
io
n 
bo
di
es
 
se
en
 a
nd
 to
 b
e 
cu
ltu
re
 p
os
iti
ve
. 
M
ac
C
al
la
n 
gr
ad
in
g 
cl
as
si
fic
at
io
n 
us
ed
. 
Th
e 
se
ru
m
 a
nd
 
co
nj
un
ct
iv
al
 a
nt
ib
od
y 
re
sp
on
se
 to
 tr
ac
ho
m
a 
in
 
G
am
bi
an
 c
hi
ld
re
n6
8  
Lo
ng
itu
di
na
l s
tu
dy
 m
ea
su
rin
g 
Ig
G
 a
nd
 
Ig
A
 a
nt
ib
od
ie
s 
to
 T
R
IC
 in
 te
ar
s 
an
d 
Ig
G
 
an
tib
od
ie
s 
in
 s
er
um
, o
n 
6 
oc
ca
si
on
s 
ov
er
 6
1 
w
ee
ks
. D
et
ec
tio
n 
of
 in
cl
us
io
n 
bo
di
es
 fr
om
 c
on
ju
nc
tiv
al
 s
w
ab
s 
al
so
 
pe
rfo
rm
ed
. 
99
 c
hi
ld
re
n,
 th
e 
m
aj
or
ity
 o
f 
w
ho
m
 h
ad
 
ac
tiv
e 
di
se
as
e 
at
 
so
m
e 
po
in
t. 
 
Th
e 
G
am
bi
a 
H
ig
he
r s
er
um
 a
nt
ib
od
y 
tit
re
s 
w
er
e 
st
ro
ng
ly
 a
ss
oc
ia
te
d 
w
ith
 c
lin
ic
al
 d
is
ea
se
. 
Te
ar
 Ig
G
 w
as
 le
ss
 s
tro
ng
ly
 a
ss
oc
ia
te
d,
 
an
d 
Ig
A
 e
ve
n 
le
ss
. S
er
um
 Ig
G
 ti
tre
s 
w
er
e 
hi
gh
er
 in
 d
is
ea
se
d 
ch
ild
re
n 
if 
in
cl
us
io
ns
 
w
er
e 
fo
un
d.
 
M
od
ifi
ed
 M
ac
C
al
la
n 
gr
ad
in
g 
cl
as
si
fic
at
io
n 
us
ed
. 
Lo
ca
l a
nd
 h
um
or
al
 
ch
la
m
yd
ia
l a
nt
ib
od
ie
s 
in
 
tra
ch
om
a 
pa
tie
nt
s 
of
 
di
ffe
re
nt
 a
ge
 g
ro
up
s1
38
 
C
ro
ss
-s
ec
tio
na
l s
tu
dy
 m
ea
su
rin
g 
an
tib
od
ie
s 
to
 T
R
IC
 in
 te
ar
s 
an
d 
se
ru
m
 in
 
ca
se
s 
w
ith
 tr
ac
ho
m
a.
 
19
4 
ca
se
s 
of
 
va
ry
in
g 
ag
es
 
w
ith
 d
iff
er
en
t 
st
ag
es
 o
f 
tra
ch
om
a.
 
Is
ra
el
 
A
ve
ra
ge
 a
nt
ib
od
y 
tit
re
s 
in
 te
ar
s 
te
nd
ed
 to
 
de
cr
ea
se
 w
ith
 a
ge
, a
nd
 in
 s
er
a 
to
 
in
cr
ea
se
 w
ith
 a
ge
. 
M
ac
C
al
la
n 
gr
ad
in
g 
cl
as
si
fic
at
io
n 
us
ed
. 
In
fe
ct
io
n 
st
at
us
 a
nd
 
co
m
pa
ris
on
 w
ith
 c
on
tro
ls
 
no
t s
ho
w
n,
  
A
nt
ic
hl
am
yd
ia
l a
nt
ib
od
y 
in
 
te
ar
s 
an
d 
se
ra
, a
nd
 
se
ro
ty
pe
s 
of
 C
t i
so
la
te
d 
fro
m
 s
ch
oo
lc
hi
ld
re
n 
in
 
S
ou
rth
er
n 
Tu
ni
sa
69
 
C
ro
ss
-s
ec
tio
na
l s
tu
dy
 m
ea
su
rin
g 
an
tib
od
ie
s 
to
 T
R
IC
 in
 te
ar
s 
an
d 
se
ru
m
. 
C
hl
am
yd
ia
l c
ul
tu
re
 w
as
 a
ls
o 
pe
rfo
rm
ed
. 
94
 s
ch
oo
l 
ch
ild
re
n 
ag
ed
 6
-
10
 y
ea
rs
 (t
ea
rs
 
co
lle
ct
ed
 in
 7
1 
ch
ild
re
n)
. 
Tu
ni
si
a 
A
nt
ib
od
y 
tit
re
s,
 e
sp
ec
ia
lly
 in
 te
ar
s,
 
sh
ow
ed
 s
om
e 
co
rr
el
at
io
n 
w
ith
 le
ve
l o
f 
co
nj
un
ct
iv
al
 in
fla
m
m
at
io
n.
 T
itr
es
 w
er
e 
hi
gh
er
 if
 c
ul
tu
re
 p
os
iti
ve
.  
 
 
C
on
ju
nc
tiv
al
 s
ca
rr
in
g 
in
 
tra
ch
om
a 
is
 a
ss
oc
ia
te
d 
w
ith
 d
ep
re
ss
ed
 c
el
l-
m
ed
ia
te
d 
im
m
un
e 
re
sp
on
se
s 
to
 c
hl
am
yd
ia
l 
an
tig
en
s7
1  
S
am
e 
st
ud
y 
as
 in
 s
ec
tio
n 
ab
ov
e:
 s
er
um
 
an
tib
od
y 
re
sp
on
se
s 
to
 C
t E
B
, M
O
M
P
 
an
d 
cH
sp
60
 a
ls
o 
m
ea
su
re
d.
 
29
 c
as
es
 a
nd
  
29
 c
on
tro
ls
 
Th
e 
G
am
bi
a 
S
ca
rr
in
g 
w
as
 a
ss
oc
ia
te
d 
w
ith
 in
cr
ea
se
d 
Ig
G
 a
nd
 d
ec
re
as
ed
 Ig
A
 to
 C
t E
B
. 
 
Th
e 
in
flu
en
ce
 o
f l
oc
al
 
an
tic
hl
am
yd
ia
l a
nt
ib
od
y 
on
 th
e 
ac
qu
is
iti
on
 a
nd
 
pe
rs
is
te
nc
e 
of
 h
um
an
 
oc
ul
ar
 c
hl
am
yd
ia
l 
Lo
ng
itu
di
na
l, 
co
m
m
un
ity
-w
id
e 
st
ud
y 
w
ith
 
ex
am
in
at
io
ns
 a
t 0
, 7
 a
nd
 2
0 
m
on
th
s 
in
cl
ud
in
g 
co
nj
un
ct
iv
al
 s
w
ab
s 
fo
r C
t 
an
tib
od
ie
s 
an
d 
in
fe
ct
io
n.
 S
er
um
 fo
r C
t 
an
tib
od
y 
re
sp
on
se
s 
ta
ke
n 
at
 b
as
el
in
e 
77
1 
w
ith
ou
t 
di
se
as
e 
at
 
ba
se
lin
e 
(3
7 
de
ve
lo
pe
d 
di
se
as
e)
; 1
84
 
Th
e 
G
am
bi
a 
H
ig
h 
le
ve
ls
 o
f I
gG
 fr
om
 s
w
ab
 s
am
pl
es
 
as
so
ci
at
ed
 w
ith
 a
n 
in
cr
ea
se
d 
ris
k 
of
 
de
ve
lo
pi
ng
 in
ci
de
nt
 a
ct
iv
e 
di
se
as
e,
 th
er
e 
w
as
 a
n 
op
po
si
te
 tr
en
d 
fo
r I
gA
 (p
=0
.1
3)
.  
S
er
um
 a
nt
ib
od
y 
re
sp
on
se
s 
no
t 
R
es
ul
ts
 w
er
e 
ad
ju
st
ed
 fo
r 
sh
ar
in
g 
a 
ro
om
 w
ith
 a
n 
ac
tiv
e 
ca
se
 a
s 
a 
m
ar
ke
r o
f 
ex
po
su
re
 to
 in
fe
ct
io
n.
 
U
nc
le
ar
 w
he
th
er
 re
su
lts
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  in
fe
ct
io
n:
 Ig
G
 a
nt
ib
od
ie
s 
ar
e 
no
t p
ro
te
ct
iv
e7
0  
an
d 
fro
m
 a
 s
ub
se
t a
t 7
 m
on
th
s.
  
w
ith
 d
is
ea
se
 a
t 
ba
se
lin
e 
(6
4 
w
ith
 p
er
si
st
en
t 
di
se
as
e)
. 
si
gn
ifi
ca
nt
ly
 d
iff
er
en
t. 
re
fe
r t
o 
ris
k 
of
 in
ci
de
nt
 
in
fe
ct
io
n 
or
 c
lin
ic
al
 d
is
ea
se
. 
C
ha
ra
ct
er
iz
at
io
n 
of
 B
-c
el
l 
re
sp
on
se
s 
to
 C
t a
nt
ig
en
s 
in
 h
um
an
s 
w
ith
 
tra
ch
om
a1
39
 
C
as
e-
co
nt
ro
l s
tu
dy
 u
si
ng
 th
e 
E
LI
S
P
O
T 
as
sa
y 
to
 m
ea
su
re
 c
el
ls
 a
ct
iv
el
y 
se
cr
et
in
g 
an
tib
od
y 
to
 C
t E
B
, M
O
M
P
 a
nd
 
cH
sp
60
 in
 th
e 
se
ru
m
. S
er
um
 Ig
G
 a
nd
 
Ig
A
 re
sp
on
se
s 
to
 M
O
M
P
 a
ls
o 
m
ea
su
re
d.
 
41
 c
hi
ld
re
n 
w
ith
 
ac
tiv
e 
di
se
as
e 
(3
6 
w
ith
 T
F,
 5
 
w
ith
 T
I) 
an
d 
19
 
co
nt
ro
ls
; 1
7 
ad
ul
ts
 w
ith
 
sc
ar
rin
g 
an
d 
17
 
co
nt
ro
ls
. 
Th
e 
G
am
bi
a 
C
hi
ld
re
n 
w
ith
 T
I h
ad
 a
n 
al
m
os
t a
bs
en
t B
 
ce
ll 
re
sp
on
se
 o
f a
ll 
is
ot
yp
es
 to
 a
ll 
C
t 
an
tig
en
s 
(lo
w
er
 th
an
 c
on
tro
ls
). 
C
hi
ld
re
n 
w
ith
 T
F 
ha
d 
in
cr
ea
se
d 
Ig
A
 s
ec
re
tin
g 
ce
lls
. 
A
du
lts
 h
ad
 s
im
ila
r n
um
be
rs
 o
f B
 c
el
ls
. 
A
nt
ib
od
y 
re
sp
on
se
s 
no
t s
ig
ni
fic
an
tly
 
di
ffe
re
nt
.  
C
on
tro
l c
hi
ld
re
n 
an
d 
ad
ul
ts
 
ha
d 
cl
ea
rly
 d
et
ec
ta
bl
e 
ac
tiv
el
y 
se
cr
et
in
g 
B
 c
el
ls
. 
In
fe
ct
io
n 
w
ith
 C
t n
ot
 
co
nf
irm
ed
. 
A
nt
ib
od
y 
re
sp
on
se
 to
 th
e 
60
-k
D
a 
cH
sp
 is
 
as
so
ci
at
ed
 w
ith
 s
ca
rr
in
g 
tra
ch
om
a9
0  
C
as
e-
co
nt
ro
l s
tu
dy
 o
f s
ca
rr
ed
 s
ub
je
ct
s 
an
d 
co
nt
ro
ls
, m
ea
su
rin
g 
se
ru
m
 Ig
G
 
re
sp
on
se
s 
to
 C
t E
B
 a
nd
 c
H
sp
60
. 
14
8 
ca
se
s 
an
d 
14
8 
co
nt
ro
ls
. 
Th
e 
G
am
bi
a 
S
er
op
re
va
le
nc
e 
of
 C
t i
nf
ec
tio
n 
ar
ou
nd
 
90
%
 in
 c
as
es
 a
nd
 c
on
tro
ls
. c
H
sp
60
 Ig
G
 
w
as
 d
et
ec
te
d 
in
 m
or
e 
ca
se
s 
th
an
 c
on
tro
ls
 
(3
2%
 v
s 
16
%
), 
ev
en
 a
fte
r s
tra
tif
yi
ng
 fo
r C
t 
tit
re
. 
A
lth
ou
gh
 m
or
e 
ca
se
s 
th
an
 
co
nt
ro
ls
 w
er
e 
se
ro
po
si
tiv
e 
fo
r c
H
sp
60
, t
he
 o
ve
ra
ll 
pr
op
or
tio
n 
po
si
tiv
e 
w
as
 
re
la
tiv
el
y 
lo
w
 c
om
pa
re
d 
to
 
ge
ni
ta
l t
ra
ct
 in
fe
ct
io
n.
 
Im
m
un
e 
re
sp
on
se
 to
 
ch
la
m
yd
ia
l 6
0-
ki
lo
da
lto
n 
he
at
 s
ho
ck
 p
ro
te
in
 in
 
te
ar
s 
fro
m
 N
ep
al
i 
tra
ch
om
a 
pa
tie
nt
s1
40
 
C
ro
ss
-s
ec
tio
na
l s
tu
dy
 m
ea
su
rin
g 
se
ru
m
 
an
d 
te
ar
 a
nt
ib
od
y 
re
sp
on
se
s 
to
 c
H
sp
60
, 
M
O
M
P
 a
nd
 c
H
sp
60
 fu
si
on
 p
ro
te
in
s.
 
C
hl
am
yd
ia
l a
nt
ib
od
y 
tit
re
s 
w
er
e 
m
ea
su
re
d 
us
in
g 
M
IF
 to
 E
B
s.
 
14
6 
pe
op
le
 o
f 
va
ry
in
g 
ag
es
: 4
0 
w
ith
 T
F,
 5
3 
w
ith
 
TI
, 3
7 
w
ith
 T
S
, 
16
 d
is
ea
se
-fr
ee
. 
N
ep
al
 
A
ct
iv
e 
an
d 
sc
ar
rin
g 
di
se
as
e 
w
er
e 
as
so
ci
at
ed
 w
ith
 te
ar
 c
H
sp
60
 Ig
G
. S
er
um
 
cH
sp
60
 Ig
G
 w
as
 a
ss
oc
ia
te
d 
w
ith
 T
I o
nl
y.
 
A
lm
os
t a
ll 
in
di
vi
du
al
s 
w
er
e 
se
ro
po
si
tiv
e 
by
 
M
IF
. 
 
C
ha
ra
ct
er
iz
at
io
n 
of
 
hu
m
or
al
 im
m
un
e 
re
sp
on
se
s 
to
 c
hl
am
yd
ia
l 
H
sp
60
, C
P
A
F 
an
d 
C
T7
95
 
in
 in
fla
m
m
at
or
y 
an
d 
se
ve
re
 tr
ac
ho
m
a1
41
 
C
as
e-
co
nt
ro
l s
tu
dy
 m
ea
su
rin
g 
te
ar
 
an
tib
od
y 
re
sp
on
se
s 
to
 c
H
sp
60
, C
P
A
F 
an
d 
C
T7
95
.  
65
 c
as
es
 w
ith
 
ac
tiv
e 
di
se
as
e 
an
d 
65
 c
on
tro
ls
; 
59
 c
as
es
 w
ith
 
TT
 a
nd
 5
9 
co
nt
ro
ls
. 
N
ep
al
 
A
ct
iv
e 
ca
se
s 
ha
d 
el
ev
at
ed
 Ig
G
 to
 a
ll 
an
tig
en
s 
(m
or
e 
so
 w
he
n 
in
fe
ct
io
n 
w
as
 
pr
es
en
t) 
an
d 
el
ev
at
ed
 Ig
A
 to
 c
H
sp
60
, 
co
m
pa
re
d 
to
 c
on
tro
ls
. T
T 
ca
se
s 
ha
d 
si
gn
ifi
ca
nt
ly
 e
le
va
te
d 
Ig
G
 to
 C
P
A
F 
an
d 
re
du
ce
d 
Ig
A
 to
 C
T7
95
. 
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  Ta
bl
e 
S6
: M
is
ce
lla
ne
ou
s 
hu
m
an
 tr
ac
ho
m
a 
st
ud
ie
s 
Ti
tle
 
St
ud
y 
su
m
m
ar
y 
Sa
m
pl
e 
si
ze
 / 
Pa
rt
ic
ip
an
ts
 
Lo
ca
tio
n 
K
ey
 fi
nd
in
gs
 
C
om
m
en
ts
 
 
 
 
 
 
 
E
xp
re
ss
io
n 
of
 M
H
C
 c
la
ss
 
II 
an
tig
en
s 
by
 c
on
ju
nc
tiv
al
 
ep
ith
el
ia
l c
el
ls
 in
 
tra
ch
om
a:
 im
pl
ic
at
io
ns
 
co
nc
er
ni
ng
 th
e 
pa
th
og
en
es
is
 o
f b
lin
di
ng
 
di
se
as
e4
6  
C
as
e-
co
nt
ro
l s
tu
dy
 o
f c
hi
ld
re
n 
w
ith
 
ac
tiv
e 
di
se
as
e 
an
d 
co
nt
ro
ls
, a
ss
es
si
ng
 
M
H
C
 c
la
ss
 II
 e
xp
re
ss
io
n 
on
 c
on
ju
nc
tiv
al
 
ep
ith
el
ia
l c
el
ls
 fr
om
 s
w
ab
 s
am
pl
es
. C
t 
an
tig
en
 w
as
 d
et
ec
te
d 
by
 ID
E
IA
. 
40
 c
as
es
 a
nd
 3
8 
co
nt
ro
ls
. 
Th
e 
G
am
bi
a 
M
H
C
 c
la
ss
 II
 e
xp
re
ss
io
n 
fo
un
d 
an
d 
w
as
 
as
so
ci
at
ed
 w
ith
 p
ap
ill
ar
y 
in
fla
m
m
at
io
n.
 
 
C
el
l-m
ed
ia
te
d 
im
m
un
ity
 in
 
tra
ch
om
at
ou
s 
sc
ar
rin
g1
42
 
C
om
pa
ra
tiv
e 
st
ud
y 
of
 s
ub
je
ct
s 
w
ith
 
le
pr
os
y 
co
m
pa
re
d 
to
 s
ib
lin
gs
 w
ith
ou
t 
le
pr
os
y,
 in
 w
ho
m
 th
e 
gr
ad
e 
of
 
tra
ch
om
at
ou
s 
co
nj
un
ct
iv
al
 s
ca
rr
in
g 
w
as
 
di
sc
or
da
nt
. 
50
 s
ib
lin
g 
pa
irs
 
in
vo
lv
in
g 
pa
uc
ib
ac
ill
ar
y 
an
d 
12
 in
vo
lv
in
g 
m
ul
tib
ac
ill
ar
y 
le
pr
os
y.
  
E
th
io
pi
a 
M
ul
tib
ac
ill
ar
y 
le
pr
os
y 
(ta
ke
n 
to
 in
di
ca
te
 
su
pp
re
ss
ed
 c
el
l-m
ed
ia
te
d 
im
m
un
ity
) w
as
 
as
so
ci
at
ed
 w
ith
 re
du
ce
d 
co
nj
un
ct
iv
al
 
sc
ar
rin
g.
 P
au
ci
ba
ci
lla
ry
 le
pr
os
y 
(ta
ke
n 
to
 
in
di
ca
te
 e
nh
an
ce
d 
ce
ll-
m
ed
ia
te
d 
im
m
un
ity
) 
w
as
 a
ss
oc
ia
te
d 
w
ith
 in
cr
ea
se
d 
sc
ar
rin
g.
 
 
S
yn
th
et
ic
 p
ep
tid
es
 b
as
ed
 
on
 C
t a
nt
ig
en
s 
id
en
tif
y 
cy
to
to
xi
c 
T 
ly
m
ph
oc
yt
es
 
in
 s
ub
je
ct
s 
fro
m
 a
 
tra
ch
om
a-
en
de
m
ic
 
po
pu
la
tio
n1
43
 
C
as
e-
co
nt
ro
l s
tu
dy
 o
f a
du
lts
 w
ith
 
co
nj
un
ct
iv
al
 s
ca
rr
in
g,
 c
on
tro
l a
du
lts
 a
nd
 
ch
ild
re
n 
w
ith
 a
ct
iv
e 
tra
ch
om
a 
bu
t n
o 
in
fe
ct
io
n.
 C
TL
 re
sp
on
se
s 
to
 s
yn
th
et
ic
 
pe
pt
id
es
 b
as
ed
 o
n 
M
O
M
P
 a
nd
 c
H
hs
p6
0 
w
er
e 
m
ea
su
re
d 
in
 a
pp
ro
pr
ia
te
 H
LA
 
in
di
vi
du
al
s.
 
12
 a
du
lt 
ca
se
s,
 
10
 a
du
lt 
co
nt
ro
ls
 
an
d 
4 
ch
ild
re
n.
 
Th
e 
G
am
bi
a 
C
TL
 re
sp
on
se
s 
w
er
e 
fo
un
d 
in
 6
 s
ub
je
ct
s 
(3
 
to
 M
O
M
P
 a
nd
 3
 to
 c
H
sp
60
), 
al
l o
f w
ho
m
 
w
er
e 
ei
th
er
 a
du
lt 
co
nt
ro
ls
 o
r c
hi
ld
re
n.
  
M
et
ho
d 
fo
r d
et
ec
tin
g 
C
t 
in
fe
ct
io
n 
no
t s
ho
w
n.
 
S
er
um
 c
om
pl
em
en
t 
co
m
po
ne
nt
s 
in
 p
at
ie
nt
s 
w
ith
 tr
ac
ho
m
a1
44
 
C
as
e-
co
nt
ro
l s
tu
dy
 m
ea
su
rin
g 
se
ru
m
 
C
1q
, C
3,
 C
4 
an
d 
C
5 
le
ve
ls
.  
98
 c
as
es
 a
nd
 5
6 
co
nt
ro
ls
, o
f 
va
ry
in
g 
ag
es
. 
In
di
a 
S
er
um
 C
1q
 a
nd
 C
3 
w
er
e 
lo
w
er
 in
 a
ct
iv
e 
di
se
as
e 
an
d 
re
tu
rn
ed
 to
 n
or
m
al
 a
fte
r 
tre
at
m
en
t. 
C
on
tro
ls
 p
ro
ba
bl
y 
no
t 
m
at
ch
ed
 fo
r r
is
k 
of
 
tra
ch
om
a.
 M
ac
C
al
la
n 
gr
ad
in
g 
cl
as
si
fic
at
io
n 
us
ed
. 
Fa
ilu
re
 to
 d
et
ec
t H
LA
-
A
*6
80
2-
re
st
ric
te
d 
T 
ce
lls
 
sp
ec
ifi
c 
fo
r C
t a
nt
ig
en
s 
in
 
su
bj
ec
ts
 fr
om
 tr
ac
ho
m
a-
en
de
m
ic
 c
om
m
un
iti
es
14
5  
C
as
e-
co
nt
ro
l s
tu
dy
 o
f s
ub
je
ct
s 
w
ith
 
co
nj
un
ct
iv
al
 s
ca
rr
in
g 
an
d 
co
nt
ro
ls
. C
D
8+
 
T 
ce
ll 
re
sp
on
se
s 
w
er
e 
m
ea
su
re
d 
to
 
sy
nt
he
tic
 H
LA
-A
*6
80
2 
pr
ed
ic
te
d 
pe
pt
id
es
 b
as
ed
 o
n 
M
O
M
P
, M
IP
 a
nd
 
cH
sp
70
. 
10
 c
as
es
 w
ith
 
sc
ar
rin
g 
an
d 
10
 
co
nt
ro
ls
 
(c
hi
ld
re
n 
an
d 
ad
ul
ts
). 
Th
e 
G
am
bi
a 
N
o 
si
gn
ifi
ca
nt
 re
sp
on
se
s 
w
er
e 
ob
se
rv
ed
. 
 
Th
e 
fre
qu
en
cy
 o
f C
t m
aj
or
 
ou
te
r m
em
br
an
e 
pr
ot
ei
n-
sp
ec
ifi
c 
C
D
8+
 T
 
ly
m
ph
oc
yt
es
 in
 a
ct
iv
e 
tra
ch
om
a 
is
 a
ss
oc
ia
te
d 
w
ith
 c
ur
re
nt
 o
cu
la
r 
Lo
ng
itu
di
na
l s
tu
dy
 w
ith
 e
xa
m
in
at
io
ns
 
ev
er
y 
2 
w
ee
ks
 fo
r 2
8 
w
ee
ks
. P
ep
tid
e 
te
tra
m
er
s 
to
 M
O
M
P
 w
er
e 
us
ed
 to
 d
et
ec
t 
C
D
8+
 c
el
ls
 in
 a
pp
ro
pr
ia
te
 H
LA
 
in
di
vi
du
al
s.
 P
C
R
 w
as
 u
se
d 
to
 d
et
ec
t C
t 
D
N
A
. 
86
 c
hi
ld
re
n,
 
ar
ou
nd
 2
0%
 o
f 
w
ho
m
 h
ad
 
in
fe
ct
io
n 
an
d/
or
 
di
se
as
e 
at
 th
e 
ou
ts
et
. 
Th
e 
G
am
bi
a 
C
t-s
pe
ci
fic
 c
el
ls
 w
er
e 
fo
un
d 
re
la
tiv
el
y 
in
fre
qu
en
tly
, b
ut
 th
er
e 
w
as
 s
om
e 
as
so
ci
at
io
n 
w
ith
 C
t i
nf
ec
tio
n.
 S
uc
h 
ce
lls
 
w
er
e 
no
t a
ss
oc
ia
te
d 
w
ith
 d
is
ea
se
. 
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  in
fe
ct
io
n1
46
 
R
ol
e 
of
 s
ec
re
te
d 
co
nj
un
ct
iv
al
 m
uc
os
al
 
cy
to
ki
ne
 a
nd
 c
he
m
ok
in
es
 
pr
ot
ei
ns
 in
 d
iff
er
en
t 
st
ag
es
 o
f t
ra
ch
om
at
ou
s 
di
se
as
e9
6  
C
ro
ss
-s
ec
tio
na
l s
tu
dy
 w
ith
 m
at
ch
ed
 
co
nt
ro
ls
 u
si
ng
 m
ul
tip
le
x 
be
ad
 a
na
ly
si
s 
to
  
m
ea
su
re
 le
ve
ls
 o
f I
FN
-α
, I
FN
-γ
,  
IL
-1
β,
 
IL
-1
R
a,
 IL
-2
, I
L-
2R
, I
L-
4,
 IL
-5
, I
L-
6,
 IL
-7
, 
IL
-8
, I
L-
10
, I
L-
12
p4
0,
 IL
-1
3,
 IL
-1
5,
 IL
-1
7,
 
TN
F-
α,
 G
M
-C
S
F,
 C
C
L2
, C
C
L3
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 Chapter 4 
A review of in vivo confocal 
microscopy of the ocular surface 
 
 
 
 
Introductory linking material on types of ocular in vivo 
confocal microscopy and studies which have been applied 
to the ocular surface 
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Principles of in vivo confocal microscopy (IVCM) 
 
IVCM is based on the optical principle of confocality of the examined object with the light 
source and the detector plane.1-3 Light is focused through a pinhole onto a single point on 
the object of interest. The light is reflected back through a second confocal pinhole and onto 
a light sensitive detector. The illumination (condenser) and observation (objective) systems 
are therefore focused on the same focal point, hence the term confocal. Any light originating 
from outside the focal plane is highly suppressed by the pinholes and only the layer of the 
object located at the focal plane contributes to the image. This suppression of light outside of 
the focal plane allows a greater resolution to be gained, but this is at the expense of the field 
of view which is very small. It is necessary to rapidly scan the focal point across the sample 
and for the image to be reconstructed to allow a real-time view. An image is gained which is 
en face or parallel to the surface being examined. By moving the position of the focal plane 
to different depths further optical sections can be acquired allowing imaging in three 
dimensions. 
 
Figure 1: Diagrammatic representation of the optical principles of confocal microscopy. The 
broken lines show light reflected from behind the focal plane which is limited by the pinholes 
from reaching the observer. (Reproduced from Brit J Ophthalmol, Jalbert et al, 87:225-236, 
2003, with permission from BMJ Publishing Group Ltd). 
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Light biomicroscopy, for example with the use of a slit-lamp, uses an optical section which is 
perpendicular or oblique to the surface being seen with a high proportion of scattered light. 
Resolution is decreased by interference from light reflected from structures in front of and 
behind the plane of examination. The slit-lamp microscope gives a maximum magnification 
of about 40 times, or a lateral resolution of approximately 20-30µm.3 Increasing the 
magnification only results in blurring as the light reflected on adjacent structures obscures 
the image being observed.  
 
Types of ocular surface confocal microscopes 
Tandem scanning confocal microscopes 
These utilise a Nipkow disc which consists of a metal plate with multiple pinhole apertures 
arranged in an archimedian spiral and a white light source.3-7 The focal plane is exposed to 
multiple spots of illumination and rotation of the disc allows the whole sample to be scanned. 
Each pinhole has a conjugate pinhole diametrically opposite to it on the disc. The small 
pinhole diameters (around 30µm) limit light transmission and visualisation of structures less 
than 5µm is difficult. A bright illuminating light source is necessary and appears very bright to 
the subject being scanned. The Tandem Scanning Corporation (Reston, USA), subsequently 
purchased by Advanced Scanning Corporation (New Orleans, USA), produced the first 
commercially available ophthalmic confocal microscope, but it is no longer in production. 
 
 Slit-scanning confocal microscopes 
These use two optically conjugate vertical slit apertures for illumination and observation of 
the field of interest and so are only truly confocal in the axis perpendicular to the slit height.3-
7 White light form a halogen bulb is used as the light source. A rapidly oscillating two-sided 
mirror scans the confocal image across the field. A wide slit aperture (300µm for the  Nidek 
ConfoScan 4) allows improved field brightness and contrast, and is also quicker, compared 
to the tandem scanning microscope, but this is partly at the expense of an increased depth 
of field and partial lack of confocalilty. The most commonly used slit-scanning confocal 
microscope is the ConfoScan produced by Nidek Technologies (Gamagori, Japan). This can 
be used either in a non-contact mode, or with a contact probe which gives great 
magnification. The manufacturer states the magnification with the contact probe to be 500×, 
the lateral resolution to be 0.6µm per pixel and the scan size to be 640×345µm.8 
 
Laser scanning confocal microscopes 
The Heidelberg Retina Tomograph (HRT) uses a diode laser with a wavelength of 670 nm 
(Class I laser) to acquire images.3-7 This machine was originally developed to scan the 
posterior pole of the eye, in particular the optic nerve head for use in glaucoma.  A 
microscope lens, the Rostock Cornea Module (RCM), is used to image anterior segment 
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structures using a contact technique with a polymethyl methacrylate cap contacting the 
ocular surface. Two scanning mirrors split the laser bean in two perpendicular directions in 
order to scan the image. The manufacturer states the lateral resolution to be ~1µm per pixel, 
and the image size to be 400×400µm, the magnification is not stated.9 
 
Human ocular surface studies using IVCM 
There have been a large number of publications which have used IVCM to study the ocular 
surface. Different types of studies are summarised below, with a focus on larger studies with 
more quantitative data. However, much of what has been published has included only 
descriptive case reports/series and there is a relative paucity of robust studies with a well-
defined, repeatable methodology and rigorous data analysis. 
 
Normal ocular surface 
A number of studies have characterised the IVCM appearance of the normal cornea 
including epithelial cell density, nerve density and diameter, keratocyte density, endothelial 
cell density, corneal thickness and changes with ageing.5-7 The tear film and corneoscleral 
limbus have also been imaged.10-12 Studies on the conjunctiva have looked at epithelial cell 
density, dendritiform cell density and changes with ageing.10, 13-21  
 
Inflammatory-fibrotic diseases of the conjunctiva 
Measurement of an apparent IVCM inflammatory cell infiltrate in the palpebral conjunctiva of 
patients with atopic keratoconjunctivitis has been shown to be significantly lower in control 
subjects and in patients on cyclosporine compared to patients on standard treatment.22 The 
infiltrate was also found to have a positive association with clinical inflammation and 
fluorescein and Rose Bengal staining scores and a negative association with corneal 
sensitivity and tear film break-up time. A similar publication found the infiltrate to be 
positively correlated with the inflammatory cell density on brush cytology specimens.23 A 
study of vernal keratoconjunctivitis found an increased inflammatory cell infiltrate and 
dendritiform cells compared to controls.24 In these studies the IVCM scans are stated to be 
analysed by masked observers with the “three best focused scans” selected for cell counts. 
However, it is not completely clear exactly how the scans for the cell counts were chosen 
from all of the scans initially taken.  
 
A number of studies have been done on Sjogren’s syndrome. The inflammatory cell density 
has been found to be higher in Sjorgren’s and non-Sjorgren’s dry eye compared to controls, 
and to show a positive association with vital staining scores and a negative association with 
tear stability and quantity.25 Another study calculated the mean individual epithelial cell area 
and epithelial nuclear/cytoplasmic ratio using scans from the bulbar conjunctiva and found 
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these to be increased and decreased respectively in patients diagnosed with Sjogrens’ 
syndrome.26 Theses measurements also significantly correlated with corresponding 
measurements from impression cytology specimens. Similar findings were found in a study 
by the same group on patients with superior limbic keratoconjunctivitis.27  
 
Microbial keratitis 
One of the most common clinical applications of IVCM is in the diagnosis and monitoring of 
microbial keratitis.6, 7, 28, 29 Numerous studies have reported visualising the hyphae of  
filamentous fungi and possibly even Candida albicans pseudofilaments.30 The regression of 
fungal hyphae with treatment has also been reported.31, 32 Images of Acanthamoeba cysts 
have been published, sometimes with a double-walled appearance without which they may 
be difficult to differentiate from inflammatory cells.28 It may also be possible to see 
trophozoites and swollen corneal nerves, but this is not as widely accepted.6, 33 There have 
also been reports of IVCM showing sub-epithelial infiltrates in epidemic keratoconjunctivitis, 
alteration in the sub-basal nerve plexus in herpex simplex virus infection and needle-like 
deposits in infectious crystalline keratopathy.34-36 
 
IVCM has been reported to show good sensitivity and specificity in the diagnosis of 
acanthamoeba keratitis, but this was in the absence of masked grading.37 Two prospective 
studies of patients presenting with a clinical diagnosis of infectious keratitis reported good 
sensitivities and specificities for acanthamoeba and fungal infections.38 However, this was 
again in the absence of masked grading and little detail was presented on the protocol for 
taking the IVCM images or how standardised the protocols were. A more objective study 
using masked observers who selected a diagnosis of either acanthaoeba, fungal, 
Microsporidia, Nocardia or bacterial keratitis for culture-proven cases after viewing a 
representative IVCM scan.39 With this more objective methodology the highest sensitivity 
and specificity values found were 56% and 84% respectively. 
 
Ocular surface neoplasia 
The use of IVCM as a diagnostic aid for possible ocular surface neoplais is another in which 
IVCM could play an important clinical role. However, there have been relatively few studies 
in this area. Case reports have shown that abnormal cells and tissue in malignant lesions 
can apparently be clearly seen.40-46 A case series of ten patients with ocular surface 
squamous neoplasia found various characteristic cellular changes in high grade dysplasia.47 
A series of 28 pigmented tumours found that IVCM showed good sensitivity and specificity 
with histological analysis, although the observers were not masked to the clinical status.48 
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Corneal degenerations, dystrophies and ectasia 
There have been many reports into various corneal degenerations, dystrophies and ectasia 
including a reduction on keratocyte density in keratoconus and visualisation of guttae in 
Fuch’s endothelial dystrophy.6, 7, 49  
 
Other ocular surface studies 
IVCM studies in many other conditions have been reported including changes associated 
with contact lens wear, refractive and glaucoma surgery, topical medication, and also in 
numerous systemic diseases, especially corneal nerve changes in diabetic patients.3, 5-7, 49 
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 Chapter 5 
Clinical grading of trachomatous 
conjunctival scarring 
 
 
 
 
Linking material summarising existing trachoma grading 
systems and describing a new grading system for 
trachomatous conjunctival scarring 
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Trachoma grading systems 
 
It has generally been recognised that trachoma has two main stages: an initial active or 
inflammatory stage most commonly found in childhood, and a cicatricial stage usually found 
in adults. The various grading systems which have been developed over time generally 
show some reflection of these different phases. 
 
In the late 19th century, on the basis of histological studies, Raehlmann described trachoma 
as consisting of Acute Trachoma with follicles present as part of an acute conjunctivitis, 
which then progressed to Chronic Trachoma consisting of three further stages.1 2 The first of 
the chronic stages was characterised by an increase in the size and number of follicles, the 
development of papillae and superior corneal pannus. The second chronic stage showed 
early tarsal scarring and the final chronic stage the development of entropion and trichiasis. 
 
In 1908 MacCallan published his classification which was to become the world standard for 
over 60 years.3  
 
Table 1:  MacCallan’s Classification of Trachoma3 
Stage Description 
1 Small / immature follicles on the upper tarsal conjunctiva 
2a Large mature follicles 
2b Large mature follicles with papillary hypertrophy 
3 Conjunctival scarring with some of the conjunctival signs described in 
stages 1 and 2 
4 Advanced conjunctival scarring without any signs described in stages 1 
and 2 
 
 
However, this system does not include entropion or trichiasis or any mention of corneal 
disease. Those who have developed disease causing blindness, or who are at high risk of 
doing so, are therefore not recorded. 
 
The World Health Organization has produced various grading systems for trachoma. One of 
the first of these, in 1966, included 20 signs which needed to be graded, and required the 
use of a slit lamp.4 This system was very difficult to use in the field and complex to analyse. 
In 1981, after various modifications, the grading was simplified to the “FPC” (follicles, 
papillae, cicatrices) system with five signs: upper tarsal follicles, upper tarsal papillary 
hypertrophy and diffuse infiltration, conjunctival scarring, trichiasis and/or entropion and 
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corneal scarring.5 The everted lid is divided into three zones, Figure 1, with the inner zones 2 
and 3 only being used for grading. 
 
Figure 1: Division of the upper lid for trachoma grading.  Sketch of an everted upper eyelid 
showing the division into zones for the FPC system. The shaded area indictates the area to 
be examined for the simplified system (see below). Modified by Matthew Burton and 
reproduced with the permission of M. Burton and the World Health Organization. 
 
 
 
 
Table 2:  WHO Trachoma Grading, 1981, FPC System5 
Grade Description 
Upper Tarsal Follicles (F) 
F 0 No follicles. 
F 1 Follicles present, but no more than 5 in zones 2 and 3 together. 
F 2 More than 5 follicles in zones 2 and 3 together, but less than 5 in zone 3. 
F 3 Five or more follicles in each of the three zones. 
Upper tarsal papillary hypertrophy and diffuse inflammation (P) 
P 0 Absent: normal appearance 
P 1 Minimal: individual vascular tufts (papillae) prominent, but deep 
subconjunctival vessels on the tarsus not obscured.  
P 2 Moderate: more prominent papillae, and normal vessels appear hazy, 
even when seen by the naked eye. 
P 3 Pronounced: conjunctiva thickened and opaque, normal vessels on the 
tarsus are hidden over more than half of the surface. 
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Conjunctival scaring (C) 
C 0 No scarring on the conjunctiva 
C 1 Mild: fine scattered scars on the upper tarsal conjunctiva, or scars on 
other parts of the conjunctiva. 
C 2 Moderate: more severe scarring but without shortening or distortion of the 
upper tarsus. 
C 3 Severe: scarring with distortion of the upper tarsus. 
Trichiasis and/or entropion (T/E) 
T/E 0 No trichiasis and/or entropion. 
T/E 1 Lashes deviated towards the eye, but not touching the globe. 
T/E 2 Lashes touching the globe but not rubbing the cornea. 
T/E 3 Lashes constantly rubbing the cornea. 
Corneal scarring (CC) 
CC 0 Absent 
CC 1 Minimal scarring or opacity but not involving the visual axis, and with clear 
central cornea. 
CC 2 Moderate scarring or opacity involving the visual axis, with the papillary 
margin visible through the opacity. 
 
 
This classification has been useful in the research setting but is still too complicated for 
programmatic work. The WHO simplified grading for trachoma was subsequently developed 
in 1987.6 In this system the same five signs which are graded in the FPC system are 
assessed, but the grader simply decides on the presence or absence of the sign rather than 
the severity. This simplified system can be quickly learnt by ophthalmic health care workers, 
is suitable for use in field studies and shows good agreement between clinical grading and 
grading from photographs.7, 8  
 
Table 3:  WHO simplified grading for trachoma, 19876   
Grade and description Example photograph 
Normal tarsal conjunctiva 
 
The dotted lines indicate the area to 
be examined 
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Trachomatous Inflammation – 
Follicular (TF) 
 
Description: The presence of 5 or 
more follicles (>0.5mm) in the upper 
tarsal conjunctiva 
  
Trachomatous Inflammation – 
Intense (TI) 
 
Description: Pronounced 
inflammatory thickening of the tarsal 
conjunctiva that obscures more than 
half of the deep normal vessels  
Trachomatous Scarring (TS) 
 
Descripton: The presence of 
scarring in the tarsal conjunctiva 
 
 
 
Trachomatous Trichiasis (TT) 
 
Descripton: At least one lash rubs 
on the eyeball 
 
Corneal Opacity (CO) 
 
Description: Easily visible corneal 
opacity over the pupil 
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The FPC system can be easily converted to the Simplified one using the table below, 
allowing comparison of results from different areas. Active disease is defined as having 
either TF (F2 or F3) and/or TI (P3). 
 
Table 4:  Conversion of WHO FPC System to Simplified System 
 
Simplified System FPC System Implication 
TI P3 Severe intensity of inflammation 
TF F2 or F3 Presence of follicular trachoma 
TS C1, C2 or C3 Presence of cicatricial trachoma 
TT T/E 2 or T/E 3 Potentially disabling lesions 
CO CC 2 or CC 3 Visually disabling lesion 
 
 
Alternative grading systems previously published 
 
The WHO grading system for conjunctival scarring does not contain clear definitions of mild 
or moderate scarring and tarsal distortion is difficult to see on photographs. Alternative 
grading systems have therefore been used in two different studies9, 10 The first of these, 
published by Wolle et al, is shown in Table 5. 
 
Table 5: Grading of trachomatous conjunctival scarring by Wolle et al.9 
 
  
Grade Definition 
S1 A single line of scarring no more than 3mm in length and some stellate 
scars, but not as severe as S2. 
S2 
 
Multiple lines of scarring of more than 3mm in length with or without 
convergence that occupy approximately one eighth of the eyelid, but not 
as severe as S3. 
S3 A linear pattern of scarring occupying at least one third of the upper lid 
with clear conjunctiva between, but not as severe as S4. 
S4 More than 90% of the conjunctiva obliterated by scarring. 
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Figure 2: Reference images for trachomatous conjunctival scarring by Wolle et al9 
 
 
Grading was performed using photographs taken with a digital camera (990, Nikon, Tokyo) 
at 5× magnification. Interobserver agreement on grading of a set of 84 images gave a kappa 
score (unweighted) of 0.74. This grading system uses a combination of length of scars and 
proportion of the upper lid involved in scarring. However, the grades do not appear to be 
completely contiguous. For example, it is not clear what the grade would be if the scarring 
involved between one eighth and one third of the upper lid. 
 
Another scarring grading system has been published by Roper et al and shown in Table 6.10  
 
Table 6: Grading of trachomatous conjunctival scarring by Roper et al.10  
Grade Definition 
0 No visible scarring in the tarsal conjunctiva. 
1 Small amount of early scarring apparent, but not clearly visible. 
2 Moderate amount of early scarring apparent, but not clearly visible. 
3 The presence of clearly visible scarring in the tarsal conjunctiva 
(equivalent to WHO simplified grading of TS). 
4 Extensive clearly visible scarring involving most of the tarsal 
conjunctiva. 
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In this paper subjects were examined with 2.5× loupes and photographs were also taken 
with a digital camera (D40, Nikon, Tokyo). Between clinical and photographic grading of 
1254 subjects the weighted kappa score was 0.67. Unfortunately, this grading system, like 
the 1981 WHO system, does not contain very clear definitions of the different grades. 
 
A novel grading system for conjunctival scarring 
 
In view of the shortcomings of previously published grading systems for conjunctival scarring 
we developed a new grading system, shown in Table 7 and Figure 3. In this system the 
surface area of the upper tarsal conjunctiva (zones 2 and 3) is divided into whether less than 
one third, between one and two thirds, or more than two thirds is covered with scarring, 
which correspond to grades S1, S2 and S3. If less than one third is covered with scarring 
(grade S1) there is a further sub-categorisation into S1a-S1c. This sub-categorisation of 
grade S1 was included as the TS (Trachomatous Scarring) study involved participants with 
mild-moderate scarring and therefore a finer grading at this end of the spectrum was 
desirable.  
 
Table 7: New grading system for trachomatous conjunctival scarring11 
Grade Definition* 
S0 No visible scarring of the upper lid 
S1 Scarring occupying <⅓ of the upper lid 
S1a One or more pinpoint scars and/or a single line of 
scarring less than 2mm in length# 
S1b Multiples lines of scarring less than 2mm in length 
S1c One or more lines/patches of scarring each 2mm or 
more in length/maximal dimension 
S2 Scarring occupying ≥ ⅓ but < ⅔ of the upper lid 
S3 Scarring occupying ≥ ⅔ of the upper lid 
 
*   ”upper lid” refers to zones 2 and 3 of the everted lid. 
#  2mm was chosen as this is the approximate width of the lower lid margin, which is 
therefore readily available for comparison. 
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Figure 3: Example images for the new conjunctival scarring grading system 
  
  
  
 
 
This novel grading system was used in both of the main case-control studies using 2.5× 
loupes and a bright torch for the field grading. Digital photographs were also taken (D200, 
Nikon, Tokyo).  
 
To assess inter-observer variation of the novel grading system for trachomatous conjunctival 
scarring grading was performed on 51 subjects with a range of scarring. Photographs were 
graded at 5× magnification by two independant observers (VH and MB) masked to the 
clinical status.  A kappa score of 0.68 (linear weighting, p<0.0001) or 0.83 (quadratic 
weighting, p<0.0001) was obtained. 
 
 
  
S0 S1a 
S1b S1c 
S2 S3 
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Table 8:  Interobserver variation for the new conjunctival scarring grading system 
  
Grader MB  
 
 
 
VH 
Grade 0 S1a S1b S1c S2 S3 Total 
0 7 0 1 0 0 0 8 
S1a 3 0 1 0 0 0 4 
S1b 1 1 3 1 1 0 7 
S1c 2 1 0 5 6 1 15 
S2 0 0 0 1 6 0 7 
S3 0 0 0 0 3 7 10 
 Total 13 2 5 7 16 8 51 
 
 
We have found this grading system straightforward to apply both in the field and for 
photographic grading of scarring. We have used it in both of the major case-control studies 
and plan to use it in futures studies. It has shown good correlation with in vivo confocal 
microscopy analysis of scarring and also been applied to the microbiological and gene 
expression analyses with good results. 
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 Chapter 6 
The problem, overall aims  
and study summaries 
 
 
 
 
Linking material summarising a statement of the problem, 
the central research focus, specific objectives and 
hypotheses, and outlines of the main studies 
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Statement of the problem 
 
A major challenge in the development and assessment of strategies to control blinding 
trachoma is that the progression from active trachoma in childhood to the development of 
scarring and blinding complications in later life occurs very slowly over many years. 
Therefore, prospective clinical trials and epidemiological studies conducted to investigate 
whether control measures prevent the development and progression of scarring and 
blindness would be prohibitively long. Moreover, it is important in the context of the 
worldwide effort to control blinding trachoma by the year 2020 to know as soon as possible 
whether progressive scarring disease can be prevented by the current control measures 
 
It has been assumed that by controlling Chlamydia trachomatis infection through antibiotic 
distribution, face washing and environmental improvements that the progression to blinding 
disease will be halted. This assumption is likely to be correct for people who have not 
previously been infected by C. trachomatis, for example, children born after effective control 
measures were introduced. However, it is not known whether older children and adults who 
have previously been infected by C. trachomatis will be prevented from developing 
progressive scarring disease and blinding complications in future years. The answer to this 
question has major ophthalmic public health implications for blindness control programmes 
in trachoma endemic countries such as Tanzania. 
 
There are also grounds for concern that the disease could still progress following a reduction 
in the prevalence of C. trachomatis infection. Firstly, clinically visible conjunctival 
inflammation is frequently found to persist in communities following the introduction of high 
coverage levels of mass antibiotic distribution.1-4 This is likely to be much more pronounced 
in operational programmes where coverage levels may be disappointing. Such inflammation 
has been linked in long term epidemiological studies with scarring later in life.5-9 Secondly, in 
countries where the prevalence of C.trachomatis infection is thought to have been low for 
some time new cases of trichiasis and corneal blindness continue to develop.8 Relatively 
little is known about the pathogenesis of blinding trachoma. Whilst it is widely accepted that 
the process is initiated by recurrent chlamydial infection in childhood, it is probable that other 
poorly understood factors are important, which are not addressed by the current trachoma 
control strategies. 
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Central research focus 
 
The main aim of this work was to identify the principal immuno-fibrogenic processes 
associated with trachomatous scarring. I set out to describe various correlates of 
trachomatous conjunctival scarring, including microbiological, immunological, fibrogenic and 
in vivo confocal microscopic. The purpose of this was improve our understanding of the 
pathogenesis of trachomatous scarring thereby aiding the development of future control 
strategies such as anti-scarring treatments and an anti-chlamydial vaccine, and also to help 
identify biomarkers for progressive scarring disease.  
 
Specific objectives 
 
1. To describe the microbiological, immunological, fibrogenic and confocal microscopic 
correlates of trachomatous conjunctival scarring, and how these differ from normal 
controls. 
 
2. To describe in detail the histopathological appearance of conjunctival scarring in 
individuals with trachomatous trichiasis compared with normal control subjects, and 
relate this to the observations made with confocal microscopy.   
 
Hypotheses 
 
The following hypotheses were examined: 
 
1. Clinically visible conjunctival inflammation and scarring in trachomatous subjects is 
correlated with differences seen using in vivo confocal microscopy, and this 
corresponds to the histological appearance. 
 
2. Trachomatous scarring is driven by several factors, in addition to infection with C. 
trachomatis, such as non-chlamydial bacterial infection. 
 
3. Trachomatous scarring is associated with a TH2 cytokine response (particularly IL-
13) and pro-fibrogenic mediators, such as MMP-9. 
 
4. Trachomatous scarring is associated with evidence of innate immune responses. 
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Outline of the main studies 
 
The data for this PhD are drawn from two main case-control studies. The first (TS) study is 
of trachomatous conjunctival scarring in which the cases had relatively mild scarring. Any 
participants which had progressed to trichiasis were excluded from this study. Chapters 8, 9, 
11 and 12 utilise data from this TS study. The second (TT) study is of trachomatous 
conjunctival scarring in which the cases all had trichiasis and generally had severe scarring. 
Chapters 10 and 13 utilise data from this TT study. 
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Chapter 7 
Survey of trachomatous scarring 
 
 
 
 
 
Linking material describing an enumeration and screening 
operation in the Kilimanjaro region to identify cases for the 
Trachomatous Scarring (TS) case-control study 
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Introduction 
 
For the TS (Trachomatous Scaring) case-control study we planned to recruit around 400 
cases with trachomatous conjunctival scarring (without trichiasis) and 400 control subjects 
(without clinically visible scarring). A trachoma-endemic area was therefore identified. 
Assistance for this was provided by Paul Courtright at the Kilimanjaro Centre for Community 
Ophthalmology which had performed trachoma surveys in the Kilimanjaro Region of northern 
Tanzania. In order to identify suitable participants we conducted an enumeration and 
screening survey in the chosen area. 
 
Methods 
 
The enumeration and screening programme was carried out in three villages in Siha district: 
Mawasiliano, Magadini and Wiri. Adults (18 years or older) were enumerated with the 
assistance of the village leaders and balozi (leaders in charge of 10-20 families). House to 
house visits were made and available adults were examined  by an ophthalmologist (VH) 
and a senior trachoma grader (Patrick Massase) using ×2.5 loupes after obtaining verbal 
consent. Conjunctival scarring was recorded as being present if any of grades C1-C3 of the 
1981 WHO Trachoma Grading system were present, Table 11 Demographic information was 
also recorded, including name, age and sex. A repeat visit was also made in an attempt to 
examine those initially absent. These three villages historically and geographically form a 
single unit, having been sub-divided for administrative purposes only two years before the 
study started. 
 
Table 1:  1981 WHO Trachoma Grading system for conjunctival scarring1 
Grade Description 
 
C 0 No scarring on the conjunctiva 
C 1 Mild: fine scattered scars on the upper tarsal conjunctiva, or scars on 
other parts of the conjunctiva. 
C 2 Moderate: more severe scarring but without shortening or distortion of the 
upper tarsus. 
C 3 
 
Severe: scarring with distortion of the upper tarsus. 
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 Figure 1:  Map of Tanzania showing the study area 
 
	  
 
Results 
 
Adults in the three villages of Mawasiliano, Magadini and Wiri were screened for 
trachomatous conjunctival scarring in December 2008 and January 2009. The total 
population of the three villages was 3626 people at the time of the census. Of these, 2418 
(67%) were examined. Of the 1208 individuals not seen: 711 (59%) were absent at the time 
of the census, despite 2 visits to their homes; 347 (29%) were temporarily resident 
elsewhere; and 150 (12%) refused examination. 
 
Of those examined, 983 (41%) were found to have conjunctival scarring. The distribution of 
TS by age and sex is shown Table 2. The prevalence of scarring increased with age for both 
males and females. The age-specific prevalence of scarring between the sexes was broadly 
similar. The proportion of people found to have scarring is high, this is at least partly 
because people were included as cases if they had any scarring, even if this scarring was 
minimal. Also, a bright torch under standard lighting conditions was used for the clinical 
examination. 
 
 
 
Study	  area	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 Table 2:  Proportion of trachomatous conjunctival scarring in the study area by age and sex 
 
Age (years) TS present Males with TS present Females with TS 
 n/N   (%) n/N   (%) n/N   (%) 
18 - 25 134 / 572   (23.4) 35 / 176 (19.9) 99 / 396 (25.0) 
 25 - 35 188 / 578 (32.5) 69 / 194 (35.6) 119 / 384 (31.0) 
35 - 45 205 / 506 (40.5) 82 / 207 (39.6) 123 / 299 (41.1) 
45 - 55 166 / 315 (52.7) 63 / 125 (50.4) 103 / 190 (54.2) 
55 - 65 118 / 188 (62.8) 49 / 79 (62.0) 69 / 109 (63.3) 
> 65 170 / 252 (67.5) 80 / 125 (64.0) 89 / 126 (70.6) 
       
Total 981 / 2411* (40.1) 378 / 906 (41.7) 602 / 1504 (40.0) 
 
*Some data points missing leading to reduced overall number for inclusion in the table 
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 Chapter 8 
In vivo confocal microscopy of 
trachoma in relation to normal tarsal 
conjunctiva 
 
 
 
 
Research paper comparing in vivo confocal microscopy 
findings in trachomatous cases with controls and a 
description of grading systems for confocal analysis 
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In Vivo Confocal Microscopy of Trachoma
in Relation to Normal Tarsal Conjunctiva
Victor H. Hu, MB, BCh, MRCOphth,1,2 Patrick Massae, DCEH,2 Helen A. Weiss, PhD,3
Ian A. Cree, PhD, FRCPath,4 Paul Courtright, DrPh,2 David C. W. Mabey, DM, FRCP,5
Robin L. Bailey, FRCP, PhD,5 Matthew J. Burton, FRCOphth, PhD1,2
Objective: To describe the in vivo confocal microscopy (IVCM) appearances of the tarsal conjunctiva in
trachoma compared with the appearance of healthy conjunctiva and to develop grading systems for IVCM
examination of the tarsal conjunctiva for use in future studies on trachoma and other conjunctival diseases.
Design: Prospective observational study.
Participants: In vivo confocal microscopy examination was performed on 302 clinically normal adults, 16
clinically normal children, 750 adults with trachomatous conjunctival scarring, and 25 children with active
trachoma.
Methods: Clinical evaluation was performed with 2.5 loupes, and IVCM examination of the upper tarsal
conjunctiva was carried out with a Heidelberg Retina Tomograph 3 with the Rostock Cornea Module (Heidelberg
Engineering GmbH, Dossenheim, Germany).
Main Outcome Measures: In vivo confocal microscopy images were analyzed for cellular and tissue
changes associated with trachomatous inflammation and scarring compared with healthy subjects.
Results: Trachomatous subjects with follicular and papillary inflammation had an increased inflammatory
cellular infiltrate, including dendritiform cells, discrete follicular and papillary structures, and cystic lacunae
suggestive of tissue edema. Trachomatous conjunctival scarring was seen with IVCM as organization of the
subepithelial connective tissue into bands/sheets. Grading systems for inflammatory changes and scarring were
developed, with the system for scarring showing good interobserver agreement with an intraclass coefficient of
0.88.
Conclusions: In vivo confocal microscopy provides a powerful tool for examining the ocular surface.
Numerous cellular and tissue changes were observed in subjects with trachoma, the first time IVCM has been
applied to this disease. These changes both complement and add to previous histologic analyses. In vivo
confocal microscopy promises to provide new insights into the pathogenesis of trachoma and other conjunctival
diseases.
Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed
in this article. Ophthalmology 2011;118:747–754 © 2011 by the American Academy of Ophthalmology.
Trachoma is caused by recurrent infection with Chlamydia
trachomatis. The infection is most commonly found in
children who develop a chronic follicular conjunctivitis
with papillary hypertrophy, referred to as “active tra-
choma.” Later in life, such individuals are at risk of devel-
oping conjunctival scarring, entropion, trichiasis, and even-
tually blinding corneal opacification. Trachoma is an
ancient disease that was previously endemic in Europe and
North America but is now largely found in poor rural
communities in the developing world. Trachoma remains
the most common infectious cause of blindness globally
with more than 1.3 million people blind from the disease,
8.2 million with trichiasis, and 40 million with active
disease.1,2
In vivo confocal microscopy (IVCM) is a noninvasive
means of obtaining high-resolution tissue images down to
the cellular level. The illumination and observation systems
are focused on the same focal point, giving rise to the term
“confocal,” so that any light originating from outside the
focal plane is highly suppressed. This allows a magnifica-
tion of up to 800 with an optical resolution of 1 to 2 m.
This relatively new technique has shown promise in the
study of ocular surface disease, including corneal dystro-
phies, changes after refractive surgery, drug toxicity, and
dendritic cell changes in inflammatory disease.3–5 The tech-
nique’s application to the study of ocular infections has
shown that it is able to differentiate among bacterial, fungal,
and protozoan agents.6 Although much of the work done so
far has been concentrated on the cornea, several studies
have reported interesting results on the conjunctiva, includ-
ing changes in atopic keratoconjunctivitis, filtration blebs
after glaucoma surgery, and inflammatory changes in re-
sponse to bacterial lipopolysaccharide.3,7–11
In vivo confocal microscopy has several advantages over
alternative methods of studying cellular events in the con-
junctiva. Histopathology of biopsy specimens, the “gold
747© 2011 by the American Academy of Ophthalmology ISSN 0161-6420/11/$–see front matter
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standard,” allows exceptional detail to be seen, but it is an
invasive procedure in which usually only a small amount of
tissue can be investigated and sequential examination over
time is not feasible. In addition, there can be artefact
changes in the tissue introduced during processing. Impres-
sion cytology can be useful; however, cells are probably
collected from only the most superficial layers of the epi-
thelium, and no information about the structure of the tissue
is provided. In vivo confocal microscopy has not been
associated with any adverse events, can be used repeatedly
all over the ocular surface, and provides high-resolution
images.
The pathogenesis of trachoma is poorly understood. The
infection itself is believed to be limited to a small minority
of the superficial conjunctival epithelial cells. It is generally
accepted that much of the tissue damage in this disease is
the result of a pathologic immune response.12–17 A limited
serovar-specific protective immunity probably develops.
However, it remains unclear why some individuals develop
blinding sequelae and others do not (with a similar infection
exposure), and what factors are important in the progression
of scarring. In vivo confocal microscopy has the potential to
provide useful insights into this disease process at the tissue
level. Specifically, IVCM can reveal the morphology and
distribution of fibrotic tissue within the palpebral conjunc-
tiva. In addition, inflammatory cell infiltrates can be exam-
ined and related to the clinical phenotype.
This article presents descriptive findings from IVCM of
the different clinical stages of trachoma and compares these
with normal tarsal conjunctiva. We also propose a grading
system for IVCM findings in subjects with trachoma to
facilitate formal image analysis in ongoing studies. It is
anticipated that this grading system will also have rele-
vance for other immuno-fibrogenic diseases of the con-
junctiva, such as mucous membrane pemphigoid and
atopic keratoconjunctivitis.
Patients and Methods
Ethical Permission
The observations presented were made during the course of studies
approved jointly by the London School of Hygiene and Tropical
Medicine Ethics Committee, the Kilimanjaro Christian Medical
Centre Ethics Committee, and the National Ethics Committee of
the Tanzanian National Institute of Medical Research. Informed
consent was obtained before enrollment of each subject.
Clinical Assessment
These studies were conducted in trachoma endemic communities
in Siha District, Kilimanjaro Region, Northern Tanzania. Subjects
were examined in a dark room or tent with 2.5 loupes and a
bright torch. Signs of trachoma were graded using the 1981 de-
tailed World Health Organization grading system, which assesses
the upper palpebral conjunctiva for follicles, papillae, and scarring,
and grades entropion/trichiasis and corneal opacity.18 A portable
slit lamp was used if a more magnified view was needed, partic-
ularly to rule out subtle conjunctival scarring in normal controls.
High-resolution digital photographs were taken of the upper tarsal
conjunctiva.
The protocols for the ongoing related studies involved the
recruitment of 800 adults with trachomatous conjunctival scarring
and 360 adults without scarring. We attempted IVCM examina-
tions on all consenting individuals. In a previously untreated
village that was about to receive mass drug administration with
azithromycin for trachoma control, we also performed IVCM
examinations on children who could comfortably tolerate the
procedure.
Confocal Microscopy Assessment
In vivo confocal microscopy was performed using the Heidelberg
Retina Tomograph 3 (HRT3) in combination with the Rostock
Cornea Module (RCM) (Heidelberg Engineering GmbH, Dossen-
heim, Germany). This uses a 670-nm diode laser as a light source
with a 63 water-contact objective (Olympus Europa GmbH,
Hamburg, Germany) covered with a sterile single-use polymeth-
ylmethacrylate (PMMA) cap (Tomocap, Heidelberg Engineering).
A small amount of carbomer gel (GelTears, Chauvin Pharmaeuti-
cals Ltd., Surrey, UK) was used as a coupling agent between the
RCM lens and the cap. The device scans an area of 400400 m
with a magnification of 800 and a lateral resolution of 1 m.
The related study protocols required confocal examination of
the upper tarsal conjunctiva in the left eye in adults and the right
eye in children. Topical anesthesia was applied to the conjunctival
sac (proxymetacaine 0.5%, Chauvin Pharmaceuticals Ltd., Surrey,
UK), and the upper eyelid was everted. Additional coupling gel
was not needed for the examination of the conjunctiva. The posi-
tion of the HRT3/RCM unit was adjusted to bring the surface of
the device into contact with the tarsal portion of the palpebral
conjunctiva, with the assistance of a live-view side video camera.
Scans were taken using the “volume” setting in which 40 coronal
images are taken in rapid succession at 2.1-m intervals from
superficial to deep. Scans started at the conjunctival epithelial
surface, and the final scan was at a depth of 85 m. It was
generally found that the quality of the image became impaired
beyond 85 m with little structural detail visible. The brightness
control was set on automatic. Ten volume scans were taken per
patient from random locations across the tarsal conjunctiva. The
total examination time was approximately 5 minutes. In selected
patients, scans of the marginal portion of the palpebral conjunctiva
were also obtained in a manner similar to those of the tarsal
conjunctiva. None of the IVCM images shown in this article have
had any adjustments made (e.g., in contrast or brightness) after
being exported from the HRT3/RCM unit.
Results
Study Subjects
All IVCM examinations were performed as part of studies per-
formed in a trachoma endemic area in Siha District of northern
Tanzania. The descriptions of normal and diseased conjunctiva and
the proposed grading systems are based on experience gained from
IVCM examinations of 302 clinically normal adults (18 years),
16 clinically normal children (mean age 9.4 years, range 5–15
years), 750 adults with a wide range of trachomatous conjunctival
scarring, and 25 children with active trachoma (mean 6.8 years,
range 3–17 years).
Normal Palpebral Conjunctiva
In the tarsal portion of the healthy palpebral conjunctiva, round
grey bodies can be seen at the surface, which probably represent
epithelial cell nuclei (Fig 1A; further images of normal conjunctiva
Ophthalmology Volume 118, Number 4, April 2011
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can also be seen in Fig 2, available at http://aaojournal.org).
These are not always readily seen, and it is difficult to determine
how many layers there are with IVCM. Scattered among the
epithelial cells and extending beneath them are bright bodies (Fig
1B), which have been described as inflammatory cell nuclei. These
are heterogeneous in size and shape, with some being circular and
others multi-lobulated. These scattered presumed inflammatory
cells are present to a depth of approximately 20 m. Dendritiform
cells (DCs) are sometimes seen near the surface of the conjunctiva
(Fig 1C). These appear as bright structures with cell bodies and
multiple processes. In clinically normal conjunctiva, these pro-
cesses are relatively short and there is usually no interdigitation
with those of other DCs.
Round black spaces are often seen in the superficial conjunc-
tiva, previously described as “microcysts” (Fig 2F, available at
http://aaojournal.org). Sequential scanning shows these to be tu-
bular in shape. The spaces contain highly reflective material, often
in the form of discrete, round particles or cells. There is also often
a bright reflection around their edge, suggestive of encapsulation.
Approximately 20 to 30 m below the surface, a fine network of
small blood vessels is usually seen (Fig 1D). These are surrounded
by brightly reflective fibrous material that is probably supportive
connective tissue. Beneath the small blood vessels, there is loose
connective tissue within which few, if any, cells are seen (see
Conjunctival Scarring section below). Deep blood vessels, which
are much broader than the more superficial network, can be seen at
variable depths with blood flowing inside (Fig 2H, available at
http://aaojournal.org). Sometimes an oblique view is obtained (as
opposed to the usual en face), as a result of unequal apposition of
the PMMA cap on the conjunctival surface, which gives some
appreciation of the various strata in the tissue (Fig 2I, available at
http://aaojournal.org).
If confocal microscopy is performed on the marginal portion of
the palpebral conjunctiva, next to the lid margin, then adenoid
structures can be seen, which probably represent meibomian gland
ducts or acinar units (Fig 2J, available at http://aaojournal.org).
The IVCM appearance of palpebral conjunctiva in children and
young adults is similar to that of older adults. One feature observed
in the conjunctiva of approximately 20% of children (both clini-
cally normal and inflamed) was fine blood vessels seen in cross-
section (Fig 2K, available at http://aaojournal.org). Unlike the
other small vessels mentioned above, which are parallel to the
conjunctival surface, these vessels are perpendicular. They ex-
tended from a very superficial level to around the level of the usual
vascular network at 20 m and were surrounded with highly
reflective connective tissue.
Figure 1. Normal tarsal conjunctiva. Images are 400400 m with the bar representing 50 m. A, Superficial epithelial cell nuclei. B, Inflammatory cell
nuclei; note heterogeneity in size and shape (arrow). C, Dendritic cells (arrow). D, Superficial blood vessels.
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Active Trachoma in Children
All of the children with active trachoma examined by IVCM were
grade F2 or P2 on the World Health Organization grading system
(i.e., having a significant number of follicles or papillary inflam-
mation). Follicular structures occasionally were found (Fig 3A,
available at http://aaojournal.org), which were formed of discrete
collections of moderate to highly reflective round cell nuclei. They
began at approximately 10 m below the surface and were roughly
spherical with an estimated maximum diameter of approximately
0.5 to 1 mm.
Approximately half of the children with active disease had
black, “cystic” spaces or lacunae near the conjunctival surface,
which may reflect areas of tissue edema (Fig 3B, available at
http://aaojournal.org; corresponding image from an adult is shown
in Fig 4D). These lacunae were generally larger and more irregular
in outline than the microcystic spaces seen in normal conjunctiva,
and they did not have the surrounding bright edge, suggestive of
encapsulation. These spaces were largely acellular with no flow
seen, which suggests that they are not blood vessels. Approxi-
mately half of the children also had a network or honeycomb of
interconnecting bands (Fig 3C, available at http://aaojournal.org).
This network was seen near the surface and extended into the
tissue for a variable distance. Small vessels were often seen near
the surface in the central areas of this network, and it is likely that
this appearance represents tiny papillae. Dendritiform cells were
seen more frequently in children with active disease and, when
present, were more numerous and had longer dendritic processes
that often interdigitated (Fig 3D, available at http://aaojournal.org).
Trachomatous Inflammation in Adults with
Conjunctival Scarring
Clinical inflammation is often seen in adults with trachomatous
scarring. In adults with clinical inflammation and scarring, IVCM
often reveals an increase in the inflammatory cell infiltrate that was
more marked than in children with active disease (Fig 4A; further
images of conjunctiva from adults with inflammation and scarring
can also be seen in Fig 5, available at http://aaojournal.org). This
increased cellularity is most prominent in the superficial conjunc-
tiva, rarely extending beyond 20 m. Papilliform structures, com-
posed of discrete conjunctival elevations with central vessels were
seen with IVCM (Fig 5B, available at http://aaojournal.org). Fol-
licular structures (0.5 mm) were also observed in some subjects
(Fig 4B), although follicles were rarely seen clinically. Cystic
lacunae and DCs were also seen in adults (Fig 4C, D). The
honeycomb of interconnecting bands was rarely seen.
Figure 4. Active disease in adults with conjunctival scarring. Images are 400400m with the bar representing 50 m. A, Increased inflammatory cell
infiltrate. B, Follicular structure. C, Activated DCs. D, Cystic lacunae. DC  dendritiform cells.
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For the evaluation of markers of inflammatory activity, we
propose the grading scheme shown in Table 1. There was some
variation in the inflammatory cell count density between images
taken from different areas of the same conjunctival surface. For 30
subjects, we measured the cell count in the full 10 volume scans
taken for each subject. From the variation in these estimates from
the same lid, we found that the average cell count score of 3
random images provided sufficient precision.
Conjunctival Scarring
The appearance of the subepithelial connective tissue (starting at
30 m from the surface) in individuals with clinically visible
trachomatous conjunctival scarring varied widely. At the mild end
of the spectrum, the appearance was similar to that seen in normal
controls: mostly moderately reflective, amorphous tissue with a
few fine, wispy strands randomly arranged. With increasing sever-
ity of clinically visible scarring, increasingly marked changes were
found in the deeper subepithelial connective tissue. In the more
severe cases, we observed broad bands of highly reflective con-
nective tissue that were often arranged in parallel, with a striated
“texture.” We interpret this appearance as organized bands of scar
tissue. By reviewing these images, we developed a 4-point grad-
ing system for the degree of subepithelial connective tissue
organization/scarring: normal to grade 3. Definitions and charac-
teristic examples are provided in Figures 6 and 7 (available at
http://aaojournal.org).
An overall IVCM connective tissue organization/scarring grade
can be calculated with this grading system. Each volume scan is
given a score of 0 (normal), 1 (grade 1), 2 (grade 2), or 3 (grade
3). If the grade varies between the individual images of the volume
Figure 6. Conjunctival connective tissue organization/scarring grading
system for IVCM. Images are 400400 m. A, Normal: homogenous,
amorphous appearance with occasional fine, wispy strand. B, Grade 1:
Heterogeneous appearance with poorly defined clumps or bands present.
C, Grade 2: clearly defined bands of tissue that constitute 50% of the
area of the scan. D, Grade 3: clearly defined bands or sheets of tissue that
constitute50% of the area of the scan and in which striations are visible.
If different grades of scarring are seen within a particular volume scan,
then the highest grade is recorded. The connective tissue that is graded
needs to be separate from that associated with the vascular tissue; if this is
not possible then the scan is considered ungradable. IVCM  in vivo
confocal microscopy.
Table 1. Conjunctival Inflammation Grading System for In
Vivo Confocal Microscopy
Feature Grading Description
Inflammatory
infiltrate
Mean inflammatory cell density of 3 randomly
selected volume scans*
DCs Present or absent: to be present, the mean number of
DCs per volume scan needs to be 1†
Tissue edema Present or absent: present if seen in any volume scan
Papillae Present or absent: present if seen in any volume scan
DC  dendritiform cells.
*Cell density is measured with the RCM software, for which it is suggested
that a minimum of 50 cells is counted per field. See text for explanation
of why 3 scans are selected. The individual scan with the largest density of
cells from within the volume scan is used to calculate the density.
†The largest number of DCs in any individual scan in a particular volume
scan is used.
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scan, then the highest grade is used. The mean score for that
patient is then calculated by dividing the sum of the volume scan
scores by the number of volume scans read. At least 3 gradable
volume scans need to be available to generate a mean score. The
minimum score possible is therefore 0 and the maximum is 3 (if
each volume scan score was 0 or 3, respectively).
Interobserver agreement was assessed by calculating the intra-
class correlation coefficient on the mean scores of 50 patients.
These were graded independently by VH and MB, who were also
masked to the clinical appearance. The intraclass correlation co-
efficient showed a high agreement of 0.88, that is, 88% of the total
variance was due to between individual variation (rather than
between observer variation).
As described in the methodology, up to 10 sets of volume scans
were taken from each subject. We found that the scarring grade
generally showed little variation between the multiple images
taken from different areas of the same tarsal conjunctiva. Analysis
of the image grading of 50 randomly selected subjects with con-
junctival scarring showed that all the separate volume scans of
74% of individuals had a difference of 1 (i.e., all scores were
within 1 grade of each other). Only 1 individual had a range of 3.
Meibomian glands were not systematically imaged as part of
the study protocols. However, acinar units at the marginal epithe-
lium were seen in a few subjects with trachomatous scarring. In a
limited number of scans, the lumen of these acinar units was seen
to contain low reflectivity material, possibly scar tissue (Fig 8A,
available at http://aaojournal.org). The walls of the units were also
poorly defined, in contrast with those from normal subjects. In
subjects with more advanced scarring, concretions were also a
frequent finding (Fig 8B, available at http://aaojournal.org).
Discussion
The pathogenesis of trachoma has been studied from vari-
ous angles, but these have tended not to show what is
happening at a tissue or cellular level.19–22 A number of
studies have used histopathology and immunohistochemis-
try. However, these involve an invasive biopsy procedure
and analysis is restricted to a tiny amount of tissue.23 We
have carried out a large number of IVCM examinations in
both trachomatous and clinically non-scarred subjects to
gain insights into the pathophysiology of progressive con-
junctival scarring in trachoma. To the best of our knowl-
edge, this is the first time IVCM has been reported from
individuals with trachoma or from children.
Follicular and papillary inflammation are the key fea-
tures of active trachoma. Follicular structures can be seen
with IVCM in the subepithelial tissue, probably composed
of the nuclei of inflammatory cells and corresponding to
follicles seen clinically. Histologic analysis has shown these
to be composed mainly of B cells with some macrophages
and T cells.23,24 Follicles in adults may be seen on histology
without being a prominent clinical feature, and these folli-
cles seem to be morphologically distinct from those in
children in that they lack germinal centers.25
Papillae are composed of engorged blood vessels with an
edematous/inflamed overlying epithelium that varies in size.
Adults with inflammation commonly had papillae seen with
IVCM. These have been noted in the palpebral conjunctiva
of patients with atopic keratoconjunctivitis.10 These papillae
were not commonly seen among children with active dis-
ease. Children did, however, often have structures corre-
sponding to tiny, or micro, papillae: (1) a honeycomb ap-
pearance of the tissue with small blood vessels within the
cells of the honeycomb and (2) small, superficial vessels
perpendicular to the conjunctival surface with prominent
surrounding connective tissue. The latter were seen in chil-
dren with and without clinically apparent inflammation. We
suggest that these vessels formed during papillary inflam-
mation and slowly recede once the inflammation has re-
solved. We would not, therefore, expect this appearance to
be found in a population of children from a non-trachoma
endemic area.
Another morphologic change seen in active trachoma is
the appearance of what has been described as “inflammatory
lacunae.”26 A feature of active trachoma is thickening of the
upper tarsal conjunctiva probably due to edema,27 and this
probably corresponds to the IVCM finding of these lacunar
spaces. This edema has not been observed in histologic
studies. However, the processing of histopathology speci-
mens may cause disruption with loss of the spaces.
Changes in cell populations were seen in both children
and adults with clinical inflammation. The brightly reflec-
tive nuclei seen within and below the epithelium probably
belong to inflammatory cells, such as neutrophils or lym-
phocytes.7,10,11,28 This inflammatory infiltrate has been
found to be elevated in patients with atopic keratoconjunc-
tivitis compared with controls.26 In addition, subconjuncti-
val injection of lipopolysaccharide in rabbit eyes resulted in
a significant increase in the infiltrate.11 Histopathologic
analysis shows a marked inflammatory infiltrate in trachoma
of mixed cell types,23,25,29 and IVCM shows that this in-
flammatory infiltrate is generally limited to the superficial
20 m.
Dendritiform cells have been found with ocular surface
IVCM, and studies have been done on their density and
distribution in the cornea.5,30 We found DCs to be increased
in children and adults with inflammation and that they had
longer dendritic processes that frequently interdigitated. In
addition to being the only antigen-presenting cells that are
able to induce primary immune responses, dendritic cells
are also important in the regulation of the type of T-cell
response and the development of immunologic toler-
ance.31,32 The type of immune response (e.g., a type 1 vs
type 2 T-helper response) seems to be important in tra-
choma in determining whether infection is resolved rapidly
or a chronic inflammatory reaction develops.20,33,34 The
study of dendritic cells in trachoma is also important be-
cause their role is likely to be important in the design of any
chlamydial vaccine.35 However, although IVCM studies
have generally labeled DCs as being Langerhans or den-
dritic cells, immunohistochemistry is needed because other
cell types may also have a dendritic morphology.
We are aware of 2 previously published IVCM images of
conjunctival scarring. The first of these was from patients
with atopic keratoconjunctivitis with an appearance similar
to that found in trachoma with organized bands of connec-
tive tissue.10 The second report shows an unusual honey-
comb type appearance that we have not observed else-
where.8 The subepithelial tissue of nonfunctioning blebs
shows dense connective tissue with few or no clear spaces,
similar to that observed in scarred subjects. Histologic stud-
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ies of trachomatous scarring have shown the conjunctival
stroma to be replaced with compact, largely avascular scar
tissue.36,37 The tissue organization that we observed with
IVCM probably shows collagen fibrils that, in keeping with
the histology, may be haphazardly arranged or, in more
advanced cases, parallel to each other.
In addition to studying subjects with trachoma, we also
examined the palpebral conjunctiva of a larger number of
healthy subjects than has previously been done. The appear-
ance of the tarsal conjunctiva in healthy children is largely
similar to that of adults. Images of epithelial cells of the
tarsal conjunctiva in an oblique view have been published,
which are similar to those we found.7 It has been reported,
using IVCM, that the palpebral conjunctival epithelium is
organized in 6 to 7 cell layers.28 However, this was also
based on an oblique view that may have overestimated the
number of layers, which was significantly more than we or
previous histologic studies found.38 Another published im-
age of the palpebral conjunctival epithelium probably shows
images from the marginal portion of the palpebral conjunc-
tiva,39 shown from one of our study subjects in Figure 9
(available at http://aaojournal.org).
The “microcystic” spaces that we found in normal pal-
pebral conjunctival epithelium have been observed by other
investigators.8,39 It is only speculative whether these spaces
are actually cystic because it is unknown whether they are
lined by epithelium. It is also unknown what these spaces
and the debris seen within them represent. It has been
suggested that they are occluded goblet cells,39 although
they seem too large for this and to extend too deep into the
tissue. They may represent mucous crypts, which are tubu-
lar structures consisting of clusters of goblet cells arranged
around a central lumen with an overall diameter of 50 m.38
Kessing40 states that there may be stagnation of mucin in
these crypts leading to the formation of cysts. Goblet cells
are not visible perhaps because they are of a similar reflec-
tivity to the surrounding tissue in the palpebral conjunctiva
and the HRT3/RCM is unable to differentiate them.
In vivo confocal microscopy offers a unique opportunity
of studying tissue morphology and cellular activity in nor-
mal and diseased states. It is not invasive or harmful and can
be used repeatedly. A high level of resolution is gained,
almost comparable to histologic analysis. Once proficiency
with the HRT3/RCM is achieved, images can be obtained
within a few minutes, and we have found the machine to be
robust and portable. There are, however, some limitations
with the technique. The RCM requires contact with the
tissue surface, which is not always well tolerated despite
topical anesthesia. It can be difficult to satisfactorily posi-
tion the everted upper lid, especially if the subject has
limited mobility. The PMMA cap is currently relatively
large and can impede good positioning on the conjunctival
surface. The combination of the large cap and very small
image area precludes identification of the exact location
being imaged. The exact same area cannot, therefore, be
imaged sequentially to observe temporal changes. In vivo
confocal microscopy in its current state cannot be used in
conjunction with tissue/cellular staining, an integral part of
histologic-immunohistochemical analysis that yields much
valuable information. In vivo confocal microscopy is a
relatively new technique, and histologic confirmation of
these appearances is needed. We are currently in the process
of conducting a case-control study of subjects with tracho-
matous trichiasis who are undergoing conjunctival biopsies
at the time of trichiasis surgery. This will enable a system-
atic comparison of IVCM and histologic findings.
In conclusion, this article presents descriptive IVCM
findings gained from examining a large number of subjects
with trachoma compared with healthy control subjects, in-
cluding children. We also present grading systems for ana-
lyzing conjunctival images. We are currently applying this
grading system to a large case-control study of trachoma-
tous scarring in which we are correlating confocal micros-
copy findings with clinical grading. We hope the descrip-
tions presented will be of help in the interpretation of
images from patients with a range of conjunctival diseases
and further our understanding of trachomatous inflamma-
tion, scarring, and blindness.
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Figure 2. Normal tarsal conjunctiva. Images are 400×400µm with the bar representing 
50µm. A-B, Superficial epithelial cell nuclei. C, Deep epithelial cell nuclei with some brightly 
reflective inflammatory cell nuclei also visible (arrows).  D, Inflammatory cell nuclei, note 
heterogeneity in size and shape (arrow). E, Dendritic cells (arrow). F, Microcyst (arrow). G, 
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Superficial blood vessels. H, Deep blood vessel. I, Oblique view. J, Meibomian gland acinar 
units. K, Superficial blood vessels perpendicular to the surface with brightly reflective 
surrounding connective tissue. L, Clinical photograph of normal palpebral conjunctiva. 
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Figure 3. Active disease in children. Images are 400×400µm with the bar representing 
50µm. A, Follicle at a depth of 20µm. B, Cystic lacunae (arrows). The tissue at the edges of 
this image has some resemblance to early lymphocyte cell aggregates, but no cellularity is 
seen on further sections at different depths. C, Honeycomb with central blood vessels. D, 
Numerous, inter-digitating dendritiform cells. E, Clinical photograph of the subject shown in 
A, note numerous follicles. 
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Figure 5. Active disease in adults with conjunctival scarring. Images are 400×400µm with 
the bar representing 50µm. A, Increased inflammatory cell infiltrate. B, Papillae with central 
vessels (arrow). C-E, Follicles at various depths. F, activated dendritiform cells. G, Cystic 
lacunae. H, Clinical photograph of the subject shown in A, note bands of scarring and 
papillary inflammation with obscuration of deep vessels. I, clinical photograph of the subject 
shown in C, note bands of scarring but lack of prominent follicles. 
 
 
 
 
 
 
 
 
 
Victor Hu   PhD thesis   124
Normal: Homogeneous, amorphous appearance, with occasional fine, wispy strands. 
   
Grade 1:   Heterogeneous appearance with poorly defined clumps or bands present. 
   
Grade 2: Clearly defined bands of tissue which constitute less than 50% of the area of the 
scan. 
  
Grade 3: Clearly defined bands or sheets of tissue which constitute 50% or more of the 
area of the scan and in which striations are visible. 
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Figure 7.  Conjunctival connective tissue organization/scarring grading system for in vivo 
confocal microscopy. Images are 400×400µm. If different grades of scarring are seen within 
a particular volume scan then the highest grade is recorded. The connective tissue which is 
graded needs to be separate from that associated with the vascular tissue, if this is not 
possible then the scan is considered ungradable. 
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Figure 8. Meibomian gland scarring and concretions in trachoma. Images are 400×400µm 
with the bar representing 50µm. A, Scar tissue in the lumen of meibomian gland acinar units. 
B, concretions. C, clinical photograph of the subject shown in B, note concretions. 
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Figure 9. Lid margin epithelium. Images are 400×400µm with the bar representing 50µm.  
A, superficial epithelium. B, deeper epithelium. 
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In Vivo Confocal Microscopy in
Scarring Trachoma
Victor H. Hu, MBBCh, MRCOphth,1,2 Helen A. Weiss, PhD,3 Patrick Massae, DCEH,2
Paul Courtright, DrPH,2 William Makupa, MMED David C. W. Mabey, DM, FRCP,4
Robin L. Bailey, PhD, FRCP,4 Matthew J. Burton, PhD, FRCOphth1,2
Objective: To characterize the tissue and cellular changes found in trachomatous scarring (TS) and inflam-
mation using in vivo confocal microscopy (IVCM).
Design: Two complimentary case-control studies.
Participants: The first study included 363 cases with TS (without trichiasis), of whom 328 had IVCM
assessment, and 363 control subjects, of whom 319 had IVCM assessment. The second study included 34 cases
with trachomatous trichiasis (TT), of whom 28 had IVCM assessment, and 33 control subjects, of whom 26 had
IVCM assessment.
Methods: All participants were examined with 2.5 loupes. The IVCM examination of the upper tarsal
conjunctiva was carried out with a Heidelberg Retina Tomograph 3 with the Rostock Cornea Module (Heidelberg
Engineering GmbH, Dossenheim, Germany).
Main OutcomeMeasures: The IVCM images were graded in a masked manner using a previously published
grading system evaluating the inflammatory infiltrate density; the presence or absence of dendritiform cells (DCs),
tissue edema, and papillae; and the level of subepithelial connective tissue organization.
Results: Subjects with clinical scarring had a characteristic appearance on IVCM of well-defined bands and
sheets of scar tissue visible. Similar changes were also seen in some clinically normal subjects consistent with
subclinical scarring. Scarred subjects had more DCs and an elevated inflammatory infiltrate, even after adjusting
for other factors, including the level of clinical inflammation. Cellular activity was usually seen only in or just below
the epithelium, rarely being seen deeper than 30 m from the surface. The presence of tissue edema was
strongly associated with the level of clinical inflammation.
Conclusions: In vivo confocal microscopy can be quantitatively used to study inflammatory and scarring
changes in the conjunctiva. Dendritic cells seem to be closely associated with the scarring process in trachoma
and are likely to be an important target in antifibrotic therapies or the development of a chlamydial vaccine. The
increased number of inflammatory cells seen in scarred subjects is consistent with the immunopathologic nature
of the disease. The localization of cellular activity close to the conjunctival surface supports the view that the
epithelium plays a central role in the pathogenesis of trachoma.
Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed
in this article. Ophthalmology 2011;xx:xxx © 2011 by the American Academy of Ophthalmology.
Trachoma is a chronic, cicatrizing keratoconjunctivitis and
is the most common infectious cause of blindness globally.1
Trachoma is caused by infection with Chlamydia tracho-
matis, serovars A–C. In endemic regions, chlamydial infec-
tion is most frequently found in children, who develop a
follicular and papillary conjunctivitis and sometimes cor-
neal pannus (vascular infiltration). After repeated episodes
of infection and inflammation, the scarring complications of
trachoma develop: conjunctival scarring, entropion, trichia-
sis, and corneal opacity. Although there has been an en-
couraging downward trend in the number of people with
active trachoma over the last 3 decades, this disease remains
a significant public health problem in 50 countries.2
Despite numerous studies on the pathogenesis of scarring
trachoma, the factors driving the late-stage scarring process
and the immunofibrogenic responses involved remain to be
elucidated.3 In vivo confocal microscopy (IVCM) is a new
technique that provides high-resolution images of the ocular
surface down to the cellular level. It has been used to study
a wide range of infectious, inflammatory, and metabolic
disease processes affecting the ocular surface.4–9 We have
previously reported a description of the main features of
trachoma seen with IVCM and a new grading system for the
quantitative assessment of these images.10 With the use of
IVCM, one can assess the type and density of inflammatory
cell infiltrates and the morphology and distribution of fi-
brotic tissue within the tarsal conjunctiva. In vivo confocal
microscopy is noninvasive, has no adverse effects, and can
be repeated in the same individual.
To better understand the disease process in scarring
trachoma, we conducted a case-control study comparing the
IVCM findings in individuals with trachomatous scarring
1© 2011 by the American Academy of Ophthalmology ISSN 0161-6420/11/$–see front matter
Published by Elsevier Inc. doi:10.1016/j.ophtha.2011.04.014
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(TS) and normal controls. It is anticipated that this technol-
ogy can be used to support the detailed assessment of
progressive scarring in the study of both current and future
interventions in trachoma control.
Patients and Methods
Ethical Permission and Subject Recruitment
This study was approved by ethics committees in Tanzania and the
United Kingdom; written, informed consent was obtained from
each subject. The first study, on TS, was conducted in the Siha
District of the Kilimanjaro Region of Northern Tanzania, in what
was historically a single village. Two years before the study, this
village was subdivided into 3 administrative units that form a
single continuous geographic entity. Previous surveys of children
in this village found a moderate level of active trachoma (18%
follicular trachoma in children aged 1–9 years). After an initial
census, adults with conjunctival scarring (grade S1b or worse, see
below) were recruited as cases. An equal number of control sub-
jects without scarring, frequency matched by ethnicity, were re-
cruited. Individuals with trichiasis or previous eyelid surgery were
excluded from this study.
Most of the cases in the TS study had relatively mild
conjunctival scarring. Therefore, to characterize the full range
of the scarring phenotype, a second case-control study was
conducted in which all the cases were individuals with tracho-
matous trichiasis (TT), who generally had more severe conjunc-
tival scarring. The cases in the TT study were recruited from
patients undergoing trichiasis surgery in the Kilimanjaro Re-
gion. Control subjects were recruited from patients undergoing
cataract or retinal detachment surgery at Kilimanjaro Christian
Medical Centre.
Clinical Assessment
All subjects were examined by an ophthalmologist (VH) using
2.5 loupes and a bright torch. Examinations were carried out in
a darkened tent or room. The 1981 World Health Organization
(FPC) trachoma grading system was used to grade conjunctival
follicles and papillae, entropion, trichiasis, and corneal opacity.11
We developed a more detailed grading system for conjunctival
scarring (Table 1 and Fig 1, available at http://aaojournal.org). A
slit lamp was used to rule out subtle conjunctival scarring in
normal controls.
Confocal Microscopy Assessment
The IVCM examination of the upper tarsal conjunctiva was
performed using the Heidelberg Retina Tomograph 3 in com-
bination with the Rostock Corneal Module (Heidelberg Engi-
neering GmbH, Dossenheim, Germany) using a previously de-
scribed protocol.10 For the TS study, all IVCM assessments
were done on the left eye, whereas for the TT study a mixture
of right and left eyes were examined. Ten “volume” scans were
taken from random locations across the tarsal conjunctiva, each
of which consisted of 40 coronal scans taken in rapid succession
at 2.1-m intervals, starting at the conjunctival surface, moving
from superficial to deep.
The IVCM images were graded for inflammatory features (Fig
2) and the degree of subepithelial connective tissue organization
(Fig 3).10 All IVCM grading was performed by a single observer
(VH) who was masked to the clinical status of the patient, with the
exception of the cell counts for the inflammatory infiltrate in the
TS study, which was done by a single trained observer. For every
subject, each volume scan was assessed and scored: 0 (normal), 1
(grade 1), 2 (grade 2), or 3 (grade 3) for the connective tissue
organization grading. The overall connective tissue organization
score for that subject was calculated by dividing the sum of these
separate volume scan scores by the number of volume scans
graded. Individuals with fewer than 3 gradable volume scans were
excluded from the analysis. We have previously reported good
interobserver agreement (intraclass coefficient of 0.88).10
Sample Size and Data Analysis
These studies are part of a series of related studies on the patho-
genesis of TS with the sample size calculated to encompass these
other components. For example, the sample of 363 cases and 363
controls has 85% power to detect an association of a factor with
an odds ratio (OR) of 2 when the factor is present in 10% of
control subjects.
Data were entered into Access 2007 (Microsoft Corp, Red-
mond, WA) and analyzed using STATA 11.0 (StataCorp LP,
College Station, TX). Logistic regression models were developed
for clinical scarring to estimate ORs and 95% confidence intervals
(CIs) for association with demographic and categoric IVCM char-
acteristics. In view of the differences in ages between cases and
controls in the TS study and the known association of TS with age,
all ORs were age-adjusted. Linear regression (age-adjusted for the
TS study) was used to estimate the strength of associations be-
tween clinical scarring and continuous IVCM variables (inflam-
matory infiltrate and connective tissue organization score). The TS
study had a larger number of participants, so a more detailed
analysis is also presented for this study. Multivariable logistic
regression models (for categoric outcomes) and multivariable lin-
ear regression models (for continuous outcomes) were fitted to
assess whether IVCM characteristics were independently associ-
ated with the presence of scarring, the level of scarring, and the
level of clinical inflammation after adjusting for potential con-
founding factors. Likelihood ratio tests were used to assess the
strength of association of factors with scarring. Tests for nonlin-
earity were conducted to assess whether fitting factors on a linear
scale provided an adequate fit to the data. Tests for trend were used
to examine the association of IVCM parameters with the ordered
categories of clinical scarring and inflammation severity using the
Wald test.
Results
Study Participants
The TS study village had an adult population of 3626, of whom
2418 (67%) were seen. Of the 1208 individuals not seen, the
majority (58.9%) were absent during the census, despite 2
visits; 9.6% were temporarily resident elsewhere; and 4.1%
refused examination. Of the 2418 participants seen, we ex-
cluded 36 (1.5%) because of the presence of trichiasis, previous
eyelid surgery, or inability to give informed consent. Of the
remaining 2382 participants, 862 (36.2%) had clinically appar-
ent TS and 1520 (63.8%) did not have visible scarring. We
recruited 363 TS cases and 363 controls. Demographic and
clinical characteristics are shown in Table 2. Cases were sig-
nificantly older than controls (P  0.001), so subsequent anal-
yses were adjusted for age. The majority of cases and controls
were of Maasai ethnicity (77% of both groups) followed by
Chagga ethnicity (11% of both groups).
We recruited 34 TT cases and 33 controls for the TT study
(Table 3). There was no significant difference between the ages of
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TT cases and controls. The majority of the cases (85%) were
Maasai, whereas the controls were more evenly divided between
different ethnic groups (the largest groups were Chagga, 42%, and
Pare, 24%).
Analysis Based on Case-Control Status
The clinical scarring was mostly mild to moderate in the TS study
and severe in the TT study (Tables 2 and 3). Most of the cases were
clinically inflamed; in contrast, most controls were not. In the TT
study most cases had severe clinical scarring (70% with S3), in
contrast with the TS study (3.6% with S3).
In all participants, most of the cellularity detected by IVCM
was found within the most superficial 20 –30 m of the con-
junctiva, with cells not usually seen below this level. There
were more inflammatory cells in cases than controls, signifi-
cantly so in the larger TS study (Table 4). Cases were also more
likely than controls to have dendritiform cells (DCs) and tissue
edema present, but there was no association with the presence
of papillae (Table 4).
The mean IVCM connective tissue organization score was
higher in cases than in controls in both studies, but particularly
in the TT study in which the cases had more severe clinical
scarring (TT cases 2.29 vs. controls 0.59; P  0.001; Table 4).
The tissue organization score was similar in the control groups
of both studies (TT study controls 0.59 vs. TS study controls
0.77). The IVCM connective tissue organization score was
categorized into 3 groups (0 –1, 1–2, and 2–3). In both
studies, the majority of controls had a score of 1 (79% in the
TS study and 92% in the TT study), compared with the cases
(26% in the TS study and 8% in the TT study). Most of the
cases in the TS study (63/81; 78%) with an IVCM score in the
lowest 0 –1 category had the mildest degree of clinical
scarring, S1b. There were no controls in either study with the
Figure 2. In vivo confocal microscopy grading system of inflammatory features. Images are 400400 m. A, Inflammatory infiltrate: seen as multiple
bright white nuclei. The mean inflammatory cell density of 3 randomly selected volume scans is calculated. The individual scan with the highest
density of cells from within the volume scan is used. B, Dendritiform cells: graded as present or absent. To be present, the mean number of DCs
per volume scan needs to be 1. The largest number of DCs in any individual scan in a volume scan is used for measurement. A mean number
of 1 is used to differentiate occasional DCs seen in scans of otherwise normal subjects. C, Tissue edema: seen as multiple black empty spaces.
Graded as present or absent in any volume scan. D, Papillae: seen as elevations with a central vascular network. Graded as present or absent in
any volume scan.
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highest IVCM connective tissue organization category (2–3),
which is characterized by clearly defined bands or sheets of
tissue.
A multivariable logistic regression model of the TS study
showed that after controlling for age and clinical inflammation,
clinical scarring remained associated with the presence of DCs
(OR 4.27, 95% CI, 1.39 –13.09, P0.008, Table 5, available at
http://aaojournal.org). The corresponding adjusted association
is even stronger for the TT study (OR 25.36, 95% CI, 1.69 –
380.00, P  0.02). Tissue edema was not significantly associ-
Figure 3. In vivo confocal microscopy grading system for conjunctival connective tissue organization. Images are 400400 m. If different grades of
scarring are seen within a particular volume scan, then the highest grade is recorded. The connective tissue that is graded needs to be separate from that
associated with the vascular tissue; if this is not possible, then the scan is considered ungradable.
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ated with scarring after adjusting for age and clinical
inflammation.
Analysis Based on Clinical Scarring Grade (TS
Study Only)
The IVCM inflammatory infiltrate, connective tissue organization
score, presence of DCs, and presence of tissue edema all increased
with the clinical scarring grade (Table 6, available at http://aao-
journal.org). Regression models were used to analyze the associ-
ation of each of these factors adjusting for age, sex, and the clinical
inflammation grade. For modeling purposes, clinical scarring
grades S2 and S3 were combined, because there were few indi-
viduals in clinical scarring grade S3 in the TS study. For each unit
increase in the clinical scarring grade, there was an independent
increase of 87 cells/mm2 in the inflammatory infiltrate (95% CI,
45–130; P  0.001) and of 0.36 in the organization score (95% CI,
0.29–0.43; P  0.001). Similarly, the OR for the presence of DCs
increased by 1.68 (95% CI, 1.14–2.47, P  0.008) for each
increase in clinical scarring grade. The presence of tissue edema
was not significantly associated with increasing clinical scarring
grade (OR  0.83, 95% CI, 0.43–1.61).
For reference, the mean connective tissue organization score
for clinical scarring grade S3 in the TT study was 2.65 (95% CI,
Table 2. Demographic and Clinical Characteristics of the Trachomatous Scarring Study Participants and Age-Adjusted Associations
with Conjunctival Scarring
Parameter
Cases
N  363
Controls
N  363 Age-Adjusted Association with Scarring
n (%) n (%) OR 95% CI P Value
Demographic Characteristics
Sex
Female 222 (61.2) 242 (66.7) 1.00 –
Male 141 (38.8) 121 (33.3) 1.19 0.83–1.71 0.34
Age (year groups) 2.20* 1.94–2.50 0.001
18–25 29 (8.0) 117 (32.2)
25–35 53 (14.6) 114 (31.4)
35–45 65 (17.9) 87 (24.0)
45–55 81 (22.3) 28 (7.7)
55–65 58 (16.0) 9 (2.5)
 65 77 (21.2) 8 (2.2)
Age (yrs) [median, IQR] 49.7 36.7–62.7 29.2 22.2–39.2
Formal education† 0.001
None 250 (69.4) 166 (46.1) 1.00 – –
1–7 yrs 106 (29.4) 177 (49.2) 0.57 0.40–0.81
 7 yrs 4 (1.1) 17 (4.7) 0.25 0.07–0.88
BMI‡ 0.48
Underweight 55 (15.3) 30 (8.4) 1.39 0.79–2.44
Normal 259 (72.0) 287 (80.2) 1.00 – –
Overweight/obese 46 (12.8) 41 (11.5) 1.14 0.68–1.92
Clinical Characteristics
Scarring grade§
S0 – – 363 (100)
S1a 0 0 – –
S1b 188 (51.8) – –
S1c 128 (35.3)  
S2 34 (9.4) – –
S3 13 (3.6)  
Papillary inflammation grade
P0 81 (22.3) 346 (95.3)
P1 189 (52.1) 17 (4.7)
P2 85 (23.4) 0 (0.0)
P3 8 (2.2) 0 (0.0)
Follicles grade
F0 358 (98.6) 358 (99.7)
F1 2 (0.6) 1 (0.3)
F2 1 (0.3) 0 (0.0)
F3 2 (0.6) 0 (0.0)
BMI  body mass index; CI  confidence interval; IQR  interquartile range; OR  odds ratio.
*The result shown is the increase in the OR with each increase in age group category.
†Primary schooling in Tanzania is completed after 7 years.
‡Categories from the National Institutes of Health.
§All of the controls had no scarring (grade 0), and all of the cases had scarring grade S1b.
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2.36–2.94). Of these severely scarred cases, 13 of 16 (81%) were
in the highest IVCM organization grade 2–3, and 3 of 16 (19%)
were in the intermediate grade 1–2.
Analysis Based on Clinical Inflammation Grade
(TS Study Only)
The IVCM inflammatory infiltrate, connective tissue organization
score, presence of DCs, and presence of tissue edema all tended to
increase with the clinical inflammation grade (Table 7, available at
http://aaojournal.org). Regression models were used to analyze the
association of each of these factors, adjusting for age, sex, and
clinical scarring grade, in a similar manner to that above. For each
unit increase in the clinical inflammation grade, there was a small
increase in the inflammatory infiltrate, but this was of only bor-
derline statistical significance (P  0.06). After adjusting for the
other factors, the organization score no longer remained signifi-
cantly associated with the level of clinical inflammation. The
presence of DCs did remain associated with the level of clinical
inflammation (P0.03), especially for the highest grade of inflam-
mation (OR 12.1, 95% CI, 2.1–69.2). With each increase in
clinical inflammation grade, there was an increase of 5.12 in the
OR for the presence of tissue edema (95% CI, 2.69–9.76,
P0.001).
Discussion
In this study, IVCM was used to examine tissue changes in
a large number of people with trachomatous conjunctival
scarring and compared with controls. Previously developed
grading systems were used to formally evaluate tissue mor-
phology and cellular appearances.
Previous studies have shown that the cellular infiltrate is
probably composed of inflammatory cells, such as neutro-
phils or lymphocytes, and is increased in patients with
atopic keratoconjunctivitis.8,12-15 In vivo confocal micros-
Table 3. Demographic and Clinical Characteristics of the Trachomatous Trichiasis Study Participants and Associations with
Conjunctival Scarring
Cases N  34 Controls N  33 Association with Scarring
Parameter n (%) n (%) OR 95% CI P Value
Demographic Characteristics
Sex
Female 23 (67.7) 15 (45.5) 1.00 –
Male 11 (32.3) 18 (54.5) 2.61 0.93–7.34 0.06
Age (year groups) 1.62* 0.90–2.95 0.11
18–25 0 (0.0) 0 (0.0)
25–35 0 (0.0) 0 (0.0)
35–45 1 (6.9) 2 (6.1)
45–55 1 (20.7) 7 (21.2)
55–65 10 (20.7) 6 (18.2)
 65 22 (51.7) 18 (54.6)
Age (yrs) [median, IQR] 68.5 61.0–80.0 70.0 53.1–78.1
Formal education† 0.001
None 28 (87.5) 4 (13.3) 1.00 – –
1–7 yrs 4 (12.5) 18 (60.0) 0.02 0.00–0.12
7 yrs 0 (0.0) 8 (26.7) 0.02 0.00–0.18
BMI Data not collected
Clinical Characteristics
Scarring grade‡
S0 – – 33 (100)
S1a 0 0 – –
S1b 0 0 – –
S1c 6 (17.7) – –
S2 4 (11.8) – –
S3 24 (70.6) – –
Papillary inflammation grade
P0 4 (11.8) 31 (93.9)
P1 5 (14.7) 1 (3.0)
P2 17 (50.0) 1 (3.0)
P3 8 (23.5) 0 (0.0)
Follicles grade
F0 34 (100.0) 33 (100.0)
F1 0 (0.0) 0 (0.0)
F2 0 (0.0) 0 (0.0)
F3 0 (0.0) 0 (0.0)
BMI  body mass index; CI  confidence interval; IQR  interquartile range; OR  odds ratio.
*The result shown is the increase in the OR with each increase in age group category.
†Primary schooling in Tanzania is completed after 7 years.
‡All of the controls had no scarring (grade 0), and all of the cases had scarring grade S1c.
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copy assessment of the inflammatory cell density also has
shown good correlation with assessment by brush cytol-
ogy.15 Some attempt can be made to differentiate these cells
on the basis of nuclear detail, for example, segmentation
suggesting polymorphs, but definitive identification would
require biopsy. We found that the inflammatory cell density
increased with increasing clinical scores for both conjunc-
tival inflammation and scarring. The association with scar-
ring was greater than with inflammation and remained
strongly significant even after adjusting for the level of
clinical inflammation. This suggests that the increased cel-
lularity may be more closely related to the scarring process
than clinically visible “inflammation,” which is character-
ized by erythema and edema.
Dendritiform cells were found to be independently asso-
ciated with TS. These cells have invariably been labeled as
dendritic cells in previous studies of the ocular surface using
IVCM, although there has not been definitive histologic
confirmation of this finding.7,16 Dendritic cells play a cen-
tral role in determining the type of immune response that
develops to response to infection, which is of particular
relevance in trachoma because the tissue damage is immune
mediated.17-21 The view that dendritic cells are likely to
play an important role in the design of any chlamydial
vaccine gains some support from our study.22
Of note, most of the cells seen in these adults with TS
were within the superficial 30 m of the surface. This
distribution suggests close interaction between these cells
and the epithelium and lends support to the cellular para-
digm of chlamydia pathogenesis. The cellular paradigm
suggests that non-immune host cells, particularly epithelial
cells, release proinflammatory cytokines and chemokines in
response to chlamydial and other bacterial infection, which
induces an inflammatory response leading to tissue dam-
age.3,23,24 This is in contrast with the immunologic para-
digm, which argues that the damage is primarily driven by
an acquired cell-mediated immune response that is impor-
tant for defense against infection but also leads to collateral
tissue damage.22
Some attempt has been made at grading the density of
conjunctival subepithelial connective tissue in relation to
blebs after trabeculectomy surgery.25 However, no clear
definitions were provided for this grading system, nor was
there any evaluation of interobserver variation. In this arti-
Table 4. In Vivo Confocal Microscopy Findings from the Trachomatous Scarring and Trachomatous Trichiasis Studies and
Associations with Conjunctival Scarring
Parameter
Cases Controls Association with Scarring†
n (%) n (%) OR 95% CI P Value
N  328* N  319*
TS Study
Mean inflammatory infiltrate (cells/mm2)
[mean, 95% CI]
875 832–919 674 640–707 154‡ 90–217 0.001
DCs present 50 (15.2) 7 (2.2) 4.10 1.71–9.85 0.002
Tissue edema present 22 (6.7) 9 (2.8) 3.77 1.53–9.26 0.004
Papillae present 110 (33.5) 129 (40.4) 1.14 0.78–1.66 0.49
N  314 N  302
Connective tissue organization grade 0.001
0–1 81 (25.8) 238 (78.8) 1.00 –
1–2 178 (56.7) 64 (21.2) 6.2 4.1–9.4
2–3 55 (17.5) 0 (0.0) 107.4§ 14.2–813.7
Mean connective tissue organization
score (mean, 95% CI)
1.48 1.41–1.56 0.77 0.71–0.82 0.59‡ 0.48–0.69 0.001
TT Study
N  28 N  26
Mean inflammatory infiltrate (cells/mm2)
[mean, 95% CI]
1572 1174–1972 1252 1037–1467 0.11
DCs present 16 (61.5) 1 (3.6) 43.20 5.05–369.6 0.001
Tissue edema present 10 (38.5) 0 (0.0) 16.9‡ 1.97–144.4 0.01
Papillae present 0 (0.0) 3 (10.7) 0.33‡ 0.03–3.43 0.36
N  26 N  25
Connective tissue organization grade 0.001
0–1 2 (8.0) 24 (92.3) 1.00 –
1–2 6 (24.0) 2 (7.7) 72.0 5.6–933.0
2–3 17 (68.0) 0 (0.0) 204.0§ 17.1–2434.9
Mean connective tissue organization
score (mean, 95% CI)
2.29 1.94–2.64 0.59 0.41–0.77 0.001
CI  confidence interval; OR  odds ratio; TS  trachomatous scarring; TT  trachomatous trichiasis.
*There are different numbers because not all subjects had images that could be graded.
†Age-adjusted for the TS study.
‡Age-adjusted difference between cases and controls.
§If a cell contained 0, then a participant was moved up a category to be able to generate a representative OR.
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cle, we have applied the use of a grading system that has
clear definitions and good interobserver agreement with the
graders masked to the clinical findings.10 This study showed
that scarring of the conjunctiva has a characteristic appear-
ance on IVCM with well-defined bands or sheets of scarring
seen. These probably represent collagen fibers. The IVCM
organization score tended to show an increase with the
clinical scarring grade. Most of the cases in the TT study
had severe scarring, and most were also scored as being in
the highest IVCM connective tissue organization grade,
showing good agreement between clinical and IVCM as-
sessment. Not all cases had an IVCM appearance suggestive
of scarring, with some having a homogenous appearance
similar to control subjects. However, most of these had very
mild clinical scarring.
Some control subjects also had a more organized appear-
ance of the connective tissue. This may represent limitations
in the grading system or the quality of the images gained by
the microscope. However, we have also performed tarsal
conjunctival IVCM with a similar protocol on 30 healthy
volunteer subjects from a variety of non-trachoma endemic
areas (mean age 36.7 years, range 22–85 years). These
scans were graded in a masked manner (mixed with scans
from cases with scarring so that the grader, VH, did not
know the clinical status), and the mean IVCM connective
tissue organization score was 0.40 (95% CI, 0.27–0.54)
with all individuals graded as being in the lowest IVCM
organization grade. Although this may reflect differences
based on ethnicity, an alternative explanation is that the
confocal microscope is able to detect subclinical scarring.
Many of the control subjects in both case-control studies
presented were probably exposed to chlamydial infection as
children. There is likely to be a spectrum of scarring sever-
ity seen in the population, some of which may not be visible
clinically but can be detected with the confocal microscope.
This may be represented by the 20% of clinically normal
subjects in the TS study with an intermediate grade of
IVCM organization. This is supported by the observation
that in people from non-trachoma endemic areas, the mean
IVCM organization score was lower than that of the con-
trols in both case-control studies, and that the entire group
had only the lowest grade of IVCM organization.
Study Limitations
There are a number of limitations to these studies. In the TS
study, cases tended to be older than controls. However, we
adjusted for this in the analysis. The age distribution was
similar between cases and controls in the TT study. Also,
not all potential study participants were able to tolerate
confocal microscopy. However, we think it is unlikely that
any systematic bias was introduced that would have affected
the results. We are currently comparing IVCM findings with
paired histology specimens to further validate the interpre-
tation of these observations. These studies were conducted
in a district previously found to be endemic for trachoma,
and results may differ in other areas/countries, for example,
where levels of infection are hyperendemic. Although the
cases and controls in the TS study were recruited from the
same community, the controls in the TT study were from a
mixture of urban and rural areas.
In conclusion, these studies have used IVCM to ex-
plore the cellular and tissue changes occurring in tracho-
matous conjunctival scarring and inflammation. A robust
grading system has been used, and new insights have
been gained into the pathologic mechanisms at work. We
hope the grading system may be of relevance in the study
of other immunofibrogenic diseases of the conjunctiva,
such as mucous membrane pemphigoid and atopic
keratoconjunctivitis.
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Table 1:  Clinical Scarring Grading System for the tarsal conjunctiva.  
 
Grade Definition* 
S1  Scarring occupying <⅓ of the upper lid 
 S1a One or more pinpoint scars and/or a single line of 
scarring less than 2mm in length† 
 S1b Multiples lines of scarring less than 2mm in length 
 S1c One or more lines/patches of scarring each 2mm or 
more in length/maximal dimension 
S2  Patches of scarring occupying in surface area ≥ ⅓ but < ⅔ 
of the upper lid 
S3  Patches of scarring occupying in surface area ≥ ⅔ of the 
upper lid 
 
*   ”upper lid” refers to zones 2 and 3 of the everted lid.29  
†  2mm was chosen as this is the approximate width of the lower lid margin, which is readily 
available for comparison. 
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Table 5:  Multivariable logistic regression model for the presence of conjunctival scarring 
(Trachomatous Scarring Study subjects only)               
 
Risk factor Odds Ratio 95% CI p-value 
Age group* 2.26 1.86-2.75 <0.001 
Presence of any clinical inflammation 72.45 38-138 <0.001 
Dendritiform cells present 
 
4.27 1.39-13.04 0.008 
 
* The result shows the increase in the OR with each increasing age group (10 year) 
category.  
 
CI = Confidence intervals 
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 Chapter 10 
In vivo confocal microscopy and 
histopathology of the conjunctiva in 
healthy and trachomatous conjunctiva: 
a systematic comparison 
 
 
 
 
 
 
Research paper comparing in vivo confocal microscopy 
and immunohistological analyses of tarsal conjunctiva in 
trachomatous scarring and control subjects 
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  Abstract: 
 
Objective: To compare the in vivo confocal microscopy (IVCM) analysis of tissue and 
cellular changes with corresponding immunohistological analysis in normal and diseased 
conjunctiva. 
 
Design: Comparative study of IVCM and immunohistological analyses of tarsal conjunctiva. 
 
Participants:  A total of 67 participants, 34 of whom had severe trachomatous conjunctival 
scarring and were undergoing trichiasis surgery, and 33 of whom were normal controls 
undergoing cataract or retinal detachment surgery. Many of the scarred cases also had 
significant clinical inflammation.  
 
Methods: Participants underwent a clinical examination and IVCM of the tarsal conjunctiva 
was performed using the Heidelberg Retina Tomograph 3 with the Rostock Cornea Module. 
At the time of surgery a 3mm conjunctival biopsy was taken which was initially placed in 
buffered formalin, then embedded into paraffin wax and subsequently stained with 
hematoxylin and eosin and other tinctorial stains, and by immunohistochemistry for CD45 
and CD83.  
 
Main outcome measures:  IVCM connective tissue scarring, inflammatory cell density and 
presence of dendritiform cells were quantitatively assessed using established protocols and 
masked grading. Immunohistological assessment for comparative analysis including the 
masked grading of: scarring using cross polarised light to visualise collagen fibres; the 
inflammatory cell infiltrate seen with hematoxylin and eosin staining; and the presence of 
CD83+ cells, and CD45+ cells with a dendritic morphology, as markers of mature dendritic 
cells. 
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  Results:  The IVCM connective tissue scarring score was closely correlated with the 
histological grading of scarring (p<0.001). There was a moderate association of the IVCM 
inflammatory cell infiltrate and the histological inflammatory cell grade (p=0.05). We did not 
find any evidence that dendritiform cells seen with IVCM are mature, conventional dendritic 
cells. 
 
Conclusions:  The IVCM analysis of scarring in the tarsal conjunctiva is able to show good 
agreement with histological grading. The inflammatory cell infiltrate on IVCM has a weaker 
agreement with histological assessment. The discordance between IVCM dendritiform cells 
and immunohistochemical dendritic cells may be result of study limitations or may be 
because these dendritiform structures represent fibroblasts rather than dendritic cells. 
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  Introduction 
 
In vivo confocal microscopy (IVCM) provides high-resolution tissue images of living subjects 
in a non-invasive manner. It relies on the optical principle of confocality of the illumination 
and observation systems, i.e., the two systems are focused on the same focal points.1, 2 
Light outside of the focal plane is highly suppressed, thereby markedly increasing the 
resolution. This is in contrast to light biomicroscopy, for example with a slit lamp, where there 
is a large amount of scattered light that limits the maximum resolution which can be attained. 
The confocal field of view is very small and so to the microscope rapidly scans the focal 
point across the tissue and reconstructs an image. The image obtained is parallel to the 
surface being examined. 
 
IVCM is increasingly being used in several medical disciplines, including dermatology and 
gastroenterology, where it has been used to examine for malignant changes.3, 4 In 
ophthalmology there has been a stream of reports on IVCM as a research tool for examining 
the ocular surface and it is being used increasingly in clinical practice. Used include the 
diagnosis and monitoring of microbial keratitis, where it may help to identify acanthamoeba 
cysts and filamentary fungi; assessment of potentially malignant lesions; and examination of 
the ocular surface after glaucoma and other forms of surgery.5-8  
 
Trachoma is a chronic, scarring keratoconjunctivitis initiated by recurrent infection with 
Chlamydia trachomatis in childhood.9 The scarring complications of the disease, usually 
seen in adulthood, include tarsal conjunctival scarring, entropion and corneal opacity. We 
have previously used IVCM to quantify both inflammatory and scarring changes in the tarsal 
conjunctiva in cicatricial trachoma.10, 11 However, interpreting IVCM images can be 
challenging. In this relatively new field of imaging the structures and morphology observed 
need to be carefully evaluated to prevent misinterpretation. This is especially true for IVCM 
of the conjunctiva, underlying tarsal/bulbar tissue and lid margin. This part of the ocular 
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  surface contains a highly specialised mucosal surface, which in contrast to the cornea, is 
vascular and contains many different structures and cell types including goblet cells, 
meibomian glands, lymphoid tissue and pseudoglands of Henle.  
 
To validate the interpretation of IVCM images of the tarsal conjunctiva, including those from 
our previous studies on trachomatous scarring, we conducted a case-control study to 
systematically compare IVCM with the histological / immunohistological appearance of the 
tarsal conjunctival surface. Histological analysis of biopsy samples permits greater cellular 
phenotypic resolution and sub-cellular structures to be identified. Participants with 
trachomatous conjunctival scarring (many of whom also had a marked inflammation) and 
controls with healthy conjunctiva were compared. We examined the hypotheses that the 
IVCM scarring score and inflammatory cell count would show significant agreement with the 
grading of corresponding immunohistological parameters, and that the presence of IVCM 
dendritiform cells would be associated with the immunohistological presence of dendritic 
cells. There have been limited attempts previously to compare IVCM and histological 
findings, which have been purely descriptive and employed only impression cytology 
specimens.12, 13 
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  Patients and Methods 
 
Ethical permission & Subject recruitment 
This study adhered to the tenets of the Declaration of Helsinki. It was approved by the 
Tanzanian National Institute of Medical Research Ethics Committee, the Kilimanjaro 
Christian Medical Centre Ethics Committee and the London School of Hygiene and Tropical 
Medicine Ethics Committee. The study was explained to potential study subjects and 
informed consent was obtained before enrolment and recorded. Individuals with 
trachomatous trichiasis (TT) were recruited from those undergoing trichiasis surgery in the 
Kilimanjaro Region. Control participants were recruited from patients undergoing cataract or 
retinal detachment surgery at Kilimanjaro Christian Medical Centre who had healthy tarsal 
conjunctiva. 
 
Clinical assessment 
All subjects were examined by an ophthalmologist using ×2.5 loupes and a bright torch. The 
1981 World Health Organization (FPC) trachoma grading system was used to grade 
conjunctival follicles and papillae, entropion, trichiasis and corneal opacity.14 A more detailed 
grading system was used for conjunctival scarring as previously described.11, 15 
 
Confocal microscopy assessment 
IVCM examination of the upper tarsal conjunctiva was performed using the Heidelberg 
Retina Tomograph 3 (HRT3) in combination with the Rostock Corneal Module (RCM) 
(Heidelberg Engineering GmbH, Dossenheim, Germany) using previously described 
examination and image grading protocols.10, 11 IVCM images were graded for inflammatory 
features including the inflammatory cell density and the presence of dendritiform cells (DFC), 
and also for sub-epithelial connective tissue organisation/scarring (Figures 1 and 2). 
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  Biopsy samples and staining 
The eyelid was anaesthetized with an injection of 2% lignocaine (Vital Healthcare, India) and 
the eye cleaned with 5% povidone iodine. A biopsy sample was taken using a 3mm trephine 
from the tarsal conjunctiva, 2mm from the lid margin, at the junction of the medial ⅔ and 
lateral ⅓ of the everted lid. Samples were immediately placed in 10% neutral buffered 
formalin and subsequently embeded in paraffin wax. Sections, 4 µm thick, were cut 
perpendicular to the conjunctival surface and stained with hematoxylin and eosion (H&E) 
and stained by immunohistochemistry for CD45 as a marker of nucleated hematopoietic 
cells (mouse monoclonal antibody, Dako, UK, Clones 2B11+PD7/26, 1:800) and for CD83 
as a marker of mature dendritic cells (mouse monoclonal antibody, Abd Serotec, UK, Clone 
HB1e, 1:75). Prior to immunohistochemical staining sections were dewaxed and pressure-
cooked for 4 minutes in de-ionized water with antigen retrieval solution (Vector Lab, UK). 
After incubation at room temperature for 30 minutes with the primary antibody, sections were 
incubated with a biotinylated secondary antibody, followed by streptavadin-conjugated 
horseradish peroxidase (Dako, UK), and finally 3,3’-diaminobenzidine (Dako, UK) was used 
as the chromogen. Endogenous peroxidase was inhibited using Real Endogenous 
Peroxidase Block (Dako, UK). The slides were counterstained with Harris hematoxylin. All 
staining procedures were performed using the Dako autostainer (Dako, UK). Positive control 
samples were provided by human tonsil sections and omission of primary antibody controls 
were used throughout. 
 
Microscopic examination of biopsy samples 
Grading was performed by ocular pathologists who were masked to the clinical status of the 
patients. The grading was performed on the sub-epithelial tissue (lamina propria and stroma 
unless stated otherwise) using the parameters shown below. These were chosen to enable 
comparison with the IVCM scarring score, inflammatory infiltrate and presence of DFC. 
• The degree of scarring was assessed using cross polarised light for both the 
subepithelium and the tarsus. Initial comparison of the examination of picrosirus red 
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  and other tinctorial stains under cross polarised light showed that the organization of 
collagen bundles was apparent with a variety of staining methods. For assessment 
purposes we used elastin/Van Gieson stained preparations as these sections 
contained all of the samples available.. In healthy subepithelial tissue short 
connective tissue fibres running parallel to the surface in an ordered manner could be 
seen. In healthy tarsus long connective tissue fibres passing between the meibomian 
glands could be seen, perpendicular to the surface, which terminated in shorter fibres 
running parallel to the surface, giving rise to a “T” appearance, Figure 4. Tissue 
appearing healthy was graded as 0 and grades 1-3 used for progressive disorder of 
the normal appearance Figures 3-4.   
• The inflammatory cell density was assessed using the H&E stained slides using an 
ordinal scale of 0-3 where 0=scattered cells; 1=few cells; 2=moderate cells; 
3=abundant/confluent cells, Figure 5 
• Cellular staining with the CD83 antibody as an indicator of dendritic cells (DC). An 
ordinal scale of 0-3 was used where 0=no/very few cells; 1=occasional cells; 
2=moderate cells; 3=abundant/confluent cells, Figure 6. 
• To further characterize the presence of DC we counted the number CD45+ cells with 
dendritic morphology, where the dendritic processes ≥ twice the width of the nucleus 
(in order to exclude CD45+ cells which are not DC), Figure 7. The field with the 
greatest density of cells using ×400 magnification was used for counting, and cells 
were counted in the epithelium and subepithelium. 
 
Data analysis 
Data were entered into Access 2007 (Microsoft) and analysed using STATA 11.0 (StataCorp 
LP, TX). The Kruskal-Wallis one-way analysis of variance was used to compare the 
respective scarring and inflammatory cell measurements gained by IVCM and histology. The 
Wilcoxon rank sum test was used to compare the IVCM inflammatory cell infiltrate by a 
binary histological inflammatory cell score (grades 0 and 1 combined vs. grades 2 and 3 
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  combined). A non-parametric test for trend was used to look at the IVCM scarring score by 
the histological tarsal connective tissue scarring grade. Fisher’s exact tests were used to 
determine the strength of association between IVCM DFC and immunohistochemical CD83 
staining. The Wilcoxon rank sum test was used to test for a difference in the number of 
CD45+ cells with a dendritic morphology on immunohistochemistry according to the 
presence of IVCM DFC.  
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  Results 
 
Study participants, IVCM and immunohistological findings 
Demographic and clinical characteristics of the participants are shown in Table 1.  A little 
over half of the participants were female, ages ranged from 35 to 91 years and the most 
common ethnic group was Maasai followed by Chagga. There were 34 patients with 
trachomatous trichiasis and marked conjunctival scarring and 33 control participants without 
scarring. Demographic, clinical and IVCM characteristics according to the presence of 
trachomatous scarring has been previously presented.11 The overall IVCM and 
immunohistological findings are shown in Tables 2 and 3 respectively. 
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  Table 1: Demographic and clinical characteristics 
 n (%) 
 N=67 
Demographic characteristics   
Female 37 (55.2) 
Age (years)   
34-45 3 (4.5) 
45-55 8 (11.9) 
55-65 16 (23.9) 
65-75 18 (26.9) 
75-85 16 (23.9) 
85-95 6 (9.0) 
Ethnic group   
Maasai 28 (41.8) 
Chagga 18 (26.9) 
Pare 8 (11.9) 
Other 13 (19.4) 
Clinical characteristics   
Trichiasis present* 34 (50.7) 
Scarring grade   
S0 33 (49.3) 
S1a 0 (0.0) 
S1b 0 (0.0) 
S1c 6 (9.0) 
S2 5 (7.4) 
S3 23 (34.3) 
Papillary inflammation grade   
P0 35 (52.2) 
P1 6 (9.0) 
P2 19 (28.4) 
P3 7 (10.4) 
 
* Either one or more lashes constantly touching the globe or evidence of recent epilation with 
a suggestive history. 
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  Table 2: In vivo confocal microscopy findings 
Mean connective tissue scarring score (95%CI)] N=51* 
 1.41 (1.11-1.71) 
Connective tissue scarring grade [n (%)] N=51* 
0-1 26 (51.0) 
>1-2 9 (17.6) 
>2-3 16 (31.4) 
Mean inflammatory cell infiltrate(95%CI)] N=50* 
 1390 (1194-1586) 
Dendritiform cells present [n (%)] N=54* 
 17 (31.5) 
 
* It was possible to perform in vivo confocal microscopy on 54 out of the 67 participants, and 
a small number of these scans were not suitable for connective tissue scarring grading or 
inflammatory cell counting. 
CI=confidence interval 
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  Table 3: Immunohistological findings 
Subepithelial connective tissue 
scarring grade [n (%)] 
N=60* 
0 29 (48.3) 
1 18 (30.0) 
2 12 (20.0) 
3 1 (1.7) 
Tarsal connective tissue scarring 
grade [n (%)] 
N=45* 
0 31 (68.9) 
1 5 (11.1) 
2 7 (15.6) 
3 2 (4.4) 
Inflammatory cell infiltrate on 
H&E stain [n (%)] 
N=65* 
0 16 (24.6) 
1 29 (44.6) 
2 11 (16.9) 
3 9 (13.9) 
Cellular CD83 staining  
[n (%)] 
N=65* 
0 14 (21.5) 
1 32 (49.2) 
2 18 (27.7) 
3 1 (1.5) 
Mean number of CD45+ cells with 
dendritic morphology (95%CI) 
N=67* 
6.72 (5.15-8.28) 
 
* Some samples did not yield gradable sections and several sections did not have adequate 
tarsal tissue for grading of the connective tissue scarring. 
H&E = Hematoxylin & eosin 
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  Comparison of histological and IVCM connective tissue scarring assessments 
The mean IVCM connective tissue scarring score according to the histological subepithelial 
and tarsal connective tissue scarring grades are shown in Table 4. It can be seen that the 
higher histological scarring grades are associated with greater IVCM scarring scores. A clear 
pattern is especially apparent for IVCM scarring score by tarsal histological scarring grade, 
Figure 5 (non-parametric test for trend <0.001).  
 
 
Table 4: Comparison of histological and in vivo confocal microscopy connective tissue 
scarring assessments 
Mean IVCM scarring score by histological subepithelial scarring grade 
     
Histological scarring grade Mean IVCM scarring score (95%CI) N p-value* 
0 0.74 (0.362-1.11) 21 0.0008 
1 2.01 (1.56-2.46) 15  
2 2.29 (1.63-2.94) 7  
3 2.00 (-) 1  
Mean IVCM scarring score by histological tarsal scarring grade 
     
Histological scarring grade Mean IVCM scarring score (95%CI) N p-value* 
0 0.59 (0.35-0.83) 26 0.0024 
1 1.63 (0.93-2.32) 3  
2 1.99 (1.45-2.53) 5  
3 2.5 (1.64-3.53) 2  
 
IVCM = in vivo confocal microscopy 
* Kruskal-Wallis analysis of variance. 
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  Comparison of histological and IVCM inflammatory cell density assessments 
The mean IVCM inflammatory cell density according to the histological inflammatory cell 
grade on H&E staining is shown in Table 5. There is some evidence of a difference between 
the histological grades, but no clear pattern is apparent. However, if the power is increased 
by combining the bottom two and the top two histological grades, then the top two combined 
grades have significantly more IVCM inflammatory cells than the bottom two combined 
grades (mean 1834 [95%CI 1420-2248] vs 1245 [95%CI 1027-1465] cells/mm2, p=0.01 with 
the Wilcoxon rank sum test). 
 
 
Table 5: Comparison of histological and in vivo confocal microscopy inflammatory cell 
density assessments 
Histological inflammatory 
infiltrate grade 
Mean IVCM inflammatory cell 
density, cells/mm2 (95%CI) 
N p-value* 
0 1342 (999-1684) 15 0.05 
1 1181 (898-1463) 22  
2 1958 (1487-2570) 7  
3 1660 (1097-2180) 5  
 
* Kruskal-Wallis analysis of variance 
IVCM = in vivo confocal microscopy 
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  Comparison of immunohistological dendritic cell parameters and IVCM dendritiform cells 
The presence of IVCM DFC showed no significant association with the presence of CD83+ 
cells (Table 7). The mean number of CD45+ cells which had a dendritic morphology per field 
was higher if IVCM DFC had been identified, but this was not statistically significant (Table 
6). 
 
 
Table 6: Comparison of immunohistological dendritic cell parameters and the presence of in 
vivo confocal microscopy dendritiform cells 
 
 DFC present DFC absent p-value 
Cellular CD83 staining [n (%)] N=17 N=35 0.50* 
0 3 (17.7) 7 (20.0)  
1 11 (64.7) 17 (48.6)  
2 3 (17.7) 11 (31.4)  
3 0 (0.0) 0 (0.0)  
Mean number of CD45+ cells 
with dendritic morphology per 
field (95%CI) 
N=17 N=37 0.32† 
9.5 (6.3-
12.7) 
5.8 (3.7-8.0)  
 
* Chi-squared test 
† Wilcoxon rank sum test 
DFC = dendritiform cells on IVCM 
CI = Confidence interval 
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  Discussion 
In this study we have used defined grading systems to systematically compare IVCM of the 
tarsal conjunctival surface with immunohistological findings in order to validate our 
interpretation of confocal microscopy. The IVCM connective tissue scarring score was 
strongly correlated with the histological assessment of scarring. The histological 
quantification of scarring has not been well-defined, particularly in the tarsal conjunctival 
surface. We developed a novel system for grading the amount of scarring present using 
polarised light to directly visualise connective tissue fibres. This grading also shows a very 
close association with the presence of clinical scarring (paper in preparation). We have 
previously shown the IVCM scarring assessment to also be strongly associated with clinical 
scarring.11 Overall, these studies suggest that scarring can be reliably assessed with IVCM. 
Previous descriptions of conjunctival scarring using IVCM have been very limited.16-18 
 
The presence of small, round, hyper-reflective bodies has been widely reported in IVCM 
studies of the conjunctival surface and these are generally accepted as representing the 
nuclei of inflammatory cells.  We did find some evidence of an association between this 
apparent IVCM cell infiltrate and inflammatory cells seen histologically. Leucocytes are the 
most likely explanation as the cell type responsible for these hyper-reflective bodies seen on 
IVCM with few plausible alternative explanations. Previous studies have found a similar 
IVCM appearance to be associated with clinical inflammation in vernal keratoconjunctivitis 
and to show a rapid increase in rabbit conjunctiva after the injection of lipopolysaccharide.19, 
20 
 
We found no association between the presence of IVCM DFC and the histological 
identification of DC. This may be a result of limitations of this study. To maximise the number 
of histological sections available they were cut perpendicular to the conjunctival surface. 
This may limit the detection of DC as the dendritic processes appear to spread out parallel to 
the surface and so may be more easily identified by IVCM where the image obtained is 
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  parallel to the surface. Multiple IVCM images were obtained from all over the tarsal 
conjunctiva for analysis which were compared to a single biopsy specimen. Additionally, 
dendritic cell immunophenotyping is complex and requires a combination of staining intensity 
coupled with positive and negative markers in order to confidently identify different types.21-23 
We had insufficient tissue to exhaustively type this cell population and selected markers 
which we expected would best indicate a number of cell types including DC. The IVCM 
grading identified DFC with well developed dendritic processes, suggesting mature DC, 
which would usually stain with CD83.24, 25 The use of cellular CD45 staining and dendritic 
morphology should also have identified mature DC.  
 
An alternative explanation for the discordance between the IVCM and histology is that the 
DFC seen on IVCM are not actually DCs. One possibility is that these dendritiform structures 
are fibroblasts, which can have marked dendritic extensions.26, 27 IVCM studies have shown 
similar DFC to be increased in microbial infection, vernal keratoconjunctivitis, contact lens 
wear, immune-mediated inflammation and pterygium.20, 28-31 Many of these conditions are 
associated with scarring and fibroblasts would be expected to be present. The cornea 
contains numerous keratocytes and these can transform into activated corneal fibroblasts in 
response to injury.32, 33 The comprehensive identification of these conjunctival DFCs requires 
further study. 
 
We chose to use an ordinal scale for the immunohistological grading of inflammatory cells 
and cellular CD83 staining, with the observer masked to the clinical status. Alternative forms 
of analysis include cell counts on representative fields. However, this is open to bias unless 
the fields selected are chosen at random which is difficult if the infiltrate is not evenly 
distributed within the tissue, and it also restricts the amount of tissue used for the 
assessment. 
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  This is the first time that IVCM analysis has been objectively and quantitatively compared to 
immunohistological findings. The comparison was performed using masked observers and 
defined grading systems on a large number of participants thereby allowing significance 
testing to be performed. We have shown found that the grading of scarring in the tarsal 
conjunctiva with IVCM can show very good correlation with histological grading of scarring. 
However, we found only a moderate association between the amount of presumed 
inflammatory cell infiltrate on IVCM and that reported with histology. We did not find 
evidence to support the interpretation that DFC seen with IVCM are mature, conventional, 
immune DC. This may be a result of study limitations, but may also indicate that these 
dendritiform structures represent something else, such as fibroblasts.  
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  Figure 1: In vivo confocal microscopy grading system of inflammatory features. Images are 
400×400µm. A, Inflammatory infiltrate: seen as multiple bright white nuclei. The mean 
inflammatory cell density of 3 randomly selected volume scans is calculated. The individual 
scan with the highest density of cells from within the volume scan is used. B, Dendritiform 
cells: graded as present or absent. To be present, the mean number of DCs per volume 
scan needs to be ≥1. The largest number of dendritiform cells in any individual scan in a 
volume scan is used for measurement. A mean number of ≥1 is used to differentiate 
occasional dendritiform cells seen in scans of otherwise normal subjects. C, Tissue edema: 
seen as multiple black empty spaces. Graded as present or absent in any volume scan. D, 
Papillae: seen as elevations with a central vascular network. Graded as present or absent in 
any volume scan. 
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  Figure 2: In vivo confocal microscopy grading system for conjunctival connective tissue 
organization. Images are 400×400µm. (A) Normal: homogenous, amorphous appearance, 
with occasional, fine, wispy strands. (B) Grade 1: heterogenous appearance with poorly 
defined clumps or bands present. (C) Grade 2: clearly defined bands of tissue which 
constitute less than 50% of the area of the scan. (D) Grade 3: clearly defined bands or 
sheets of tissue which constitute 50% or more of the area of the scan and in which striations 
are present. If different grades of scarring are seen within a particular volume scan then the 
highest grade is recorded. The connective tissue which is graded needs to be separate from 
that associated with the vascular tissue, if this is not possible then the scan is considered 
ungradable. 
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  Figure 3:  Example grading photos for the histological grading of connective tissue scarring 
in the conjunctival subepithelial tissue using cross polarized light. The top images shows 
collagen fibres parallel with the surface found in normal tissue (arrows) and is graded 0. 
Subsequent images show progressive disorganisation of this appearance, grades 1-3. 
Original magnification ×100. 
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  Figure 4: Example grading photos for the histological grading of connective tissue scarring 
in the tarsal tissue using cross polarized light. The top image shows long collagen fibres 
between the meibomian glands which join shorter fibres next to the stroma forming a “T” sign 
in normal tissue (arrow), which is graded 0. Subsequent images show progressive 
disorganisation of this appearance, grades 1-3. Original magnification ×100. 
 
 
Grade	  3	  
Grade	  2	  
Grade	  0	  
Grade	  1	  
 
 
Victor Hu   PhD thesis   172
	  Figure 5: Example grading photos for the inflammatory cell infiltrate on the heamtoxylin and 
eosin stain in the sub-epithelium (arrows). Original magnification ×200. 
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  Figure 6: Example grading photos for the CD83+ cells in the sub-epithelium (stained brown). 
Original magnification ×200. 
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  Figure 7: CD45+ cells with a dendritic morphology (stained brown, arrows). Original 
magnification ×400. 
 
 
 
 
 
 
Victor Hu   PhD thesis   175
	  Figure 8: Mean IVCM connective tissue scarring score by histological tarsal connective 
tissue scarring grade 
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Bacterial Infection in Scarring Trachoma
Victor H. Hu,1,2 Patrick Massae,2 Helen A. Weiss,3 Caroline Chevallier,4,5
Jecinta J. Onyango,5 Isaac A. Afwamba,5 David C. W. Mabey,6 Robin L. Bailey,6
and Matthew J. Burton1,2
PURPOSE. To assess whether non-chlamydial bacterial infection
is associated with trachomatous scarring in adults.
METHODS. This was a case–control study of 360 cases with
trachomatous scarring but without trichiasis, and 360 controls
without scarring. All participants underwent clinical examina-
tion, and a swab was taken from the inferior conjunctival
fornix. Samples were inoculated onto blood and chocolate agar
later that day.
RESULTS. Bacterial isolates were identified in 54.0% of cases
compared with 34.6% of controls (P  0.001). A multivariate
logistic regression model adjusted for age and lack of education
showed that scarring was associated with the presence of
commensal organisms (odds ratio [OR], 1.46; 95% confidence
interval [CI], 1.01–2.09) and was strongly associated with the
presence of pathogenic organisms (OR, 4.08; 95% CI, 1.59–
10.45). There was an increasing prevalence of all bacterial
isolates with increasing severity of scarring (Ptrend  0.001).
CONCLUSIONS. Trachomatous scarring is strongly associated with
non-chlamydial bacterial infection compared with controls.
The role of such infection with regard to scarring progression
should be investigated and may have important implications
for trachoma control strategies and prevention of blindness.
(Invest Ophthalmol Vis Sci. 2011;52:2181–2186) DOI:
10.1167/iovs.10-5829
Trachoma is the leading infectious cause of blindness world-wide. It is caused by infection with Chlamydia trachoma-
tis and is characterized by inflammatory changes in the con-
junctiva in children with subsequent conjunctival scarring,
trichiasis, and blinding corneal opacity in adults. It is estimated
that more than 1.3 million people are blind from the disease,
8.2 million have trichiasis, and 40 million have active dis-
ease.1,2
Over the past 30 years, because of improved living stan-
dards and the implementation of trachoma control strategies,
there has been an encouraging downward trend in the global
prevalence of people with active trachoma.2–5 However, tra-
choma is still a public health problem in more than 50 coun-
tries with high levels of active disease where children are at
future risk of scarring and blindness.5 The number of people
estimated to have trichiasis has shown little decline since 1991,
suggesting that progressive conjunctival scarring can occur
even when there has been a marked reduction in active disease
and C. trachomatis infection and that those who already have
conjunctival scarring are at risk of going on to blinding corneal
opacity caused by trachoma.
While nearly all children in hyperendemic areas suffer
repeated infection with C. trachomatis, it is unclear which
factors drive the scarring process in the conjunctiva, why
only a proportion of scarred subjects subsequently have
trichiasis, and why only a proportion of these become blind.
Severe inflammation and prolonged chlamydial infection ap-
pear to put children at increased risk of future scarring.6,7
However, infection with Chlamydia trachomatis is only
rarely found in adults, suggesting that this is not necessarily
the only factor driving progressive scarring.8 –11 While the
onset of trichiasis may be associated with chlamydial infec-
tion,12 incident trichiasis has also been found to develop in
a significant proportion of eyes in a cohort where the chla-
mydial infection rate was 1%.12,13
Chronic conjunctival inflammation is probably a key factor
in the development of blinding trachoma.6,7,13–15 An important
element in maintaining this inflammatory state may be non-
chlamydial bacterial infection. Previous studies have shown
that (non-chlamydial) bacterial infection is found more fre-
quently in patients with trichiasis and is associated with trichi-
asis recurrence after surgery.8,10,15 Patients with trachomatous
conjunctival scarring without trichiasis were also found to
have an increased frequency of bacterial infection compared
with controls, although this was not statistically significant,
probably due to a limited sample size.10 A recent study exam-
ining trichiasis patients 1 year after surgery found that, after
adjustment for other factors, bacterial infection was signifi-
cantly associated with elevated levels of interleukin-1, matrix
metalloproteinase-9, and the ratio of matrix metalloproteinase-
1/tissue inhibitor metalloproteinase-1.16 This finding suggests that
bacterial infection may promote a proinflammatory and tissue
remodelling response in the conjunctiva, possibly through innate
immune mechanisms, which may be an important factor in the
pathogenesis of trachomatous scarring and blindness.
The purpose of this study was to compare the frequency
and type of non-chlamydial bacterial conjunctival infection
between subjects with trachomatous scarring and controls. A
strengthened understanding of the pathophysiology of tracho-
matous scarring and its progression will help in the assessment
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of current blindness prevention strategies and assist in the
development of new interventions.
METHODS
Ethical Approval
This study adhered to the tenets of the Declaration of Helsinki. It was
approved by the Tanzanian National Institute of Medical Research
Ethics Committee, the Kilimanjaro Christian Medical Centre Ethics
Committee and the London School of Hygiene and Tropical Medicine
Ethics Committee. The study was explained to potential study subjects
and written, informed consent was obtained before enrollment.
Subject Recruitment
This study was conducted in the Siha district of the Kilimanjaro region
of northern Tanzania, in what was historically a single village. Two
years before the study the area was divided into three administrative
units, but these still form a single continuous geographic entity. Pre-
vious surveys of children in this village showed a moderate level of
active trachoma. A survey conducted 6 months before the start of this
study found a follicular trachoma (TF) prevalence rate of 18% among 1-
to 9-year-olds. However, no children of the 43 randomly selected
individuals from this village were positive for chlamydia infection by
PCR (Amplicor; Roche Molecular Diagnostics, Mannheim, Germany)
(Courtright P, personal communication, October 2010). A two-stage
process was undertaken to identify suitable candidates for a case-
control study. Initially, a census was made of the resident adult pop-
ulation (18 years or older). At the time of the enumeration, door-to-
door visits were conducted, and available adults were screened for the
presence of trachomatous conjunctival scarring. After participants
with trichiasis or previous eyelid surgery were excluded, individuals
with scarring were invited to join a related cohort study. Only those
with more than minimal scarring (grade S1b or worse, see below) were
included in the analysis of this case-control study. An equal number of
village residents without scarring were invited to join as control sub-
jects, frequency matched by ethnicity.
Clinical Examination
All subjects were examined by an ophthalmologist (VH) using 2.5
loupes and a bright torch. Examinations were performed in a dark tent,
ensuring standard conditions. The 1981 World Health Organization
trachoma grading system3 was used with some modification. The WHO
system for grading conjunctival scarring does not have very objective
definitions for “mild” or “moderate” scarring. Therefore, we developed
a modified system for classifying tarsal conjunctival scarring (Table 1;
example photographs shown in Supplementary Fig. S1, http://www.
iovs.org/lookup/suppl/doi:10.1167/iovs.10-5829/-/DCSupplemental).
Microbiology Samples and Analysis
The conjunctiva was anesthetized with preservative-free proxymeta-
caine 0.5% eye drops (Minims; Chauvin Pharmaceuticals, Montpellier,
France). A rayon-tipped swab sample was collected from the inferior
fornix and placed immediately into Amies charcoal transport medium
(Sterilin, Caerphilly, UK) and kept at ambient temperature. Samples
were inoculated onto blood and chocolate agar later the same day
(rarely 6 hours, usually 5 hours from collection time) and incu-
bated at 37°C for 48 hours. Culture isolates were identified by standard
microbiologic techniques.
Sample Size and Data Analysis
This study was part of a larger series of related studies on the patho-
genesis of trachomatous scarring with the sample size calculated to
encompass these other components. The sample of 360 cases and 360
controls has90% power to detect an association with non-chlamydial
bacterial infection with an odds ratio of 2.5 when such infection is
present in 6%10 of control subjects.
Data were entered into a database (Access 2007; Microsoft, Red-
mond, WA) and analyzed (Stata 10.0; StataCorp LP, College Station,
TX). The 2 test was used to determine strength of association for
individual bacterial isolates or groups of isolates (commensal or patho-
genic organisms) according to case-control status. A nonparametric
test for trend was used to look at prevalence of bacterial culture by the
ordered categories of scarring severity. Given the known association of
trachomatous scarring with age, logistic regression models were used
to estimate single-factor, age-adjusted, odds ratios (ORs) and 95% con-
fidence intervals (CIs) for factors associated with the presence of
scarring and inflammation. A multivariable logistic regression model
was fitted, including age as an a priori factor, and other factors, if they
were associated with scarring in the age-adjusted analysis and indepen-
dently associated in the multivariable model (P 0.1). Likelihood ratio
tests were used to assess the strength of association of each factor with
the outcome, and tests for nonlinearity were conducted to assess
whether fitting age as a continuous variable provided an adequate fit to
the data.
RESULTS
This village had an adult population of 3626 people at the time
of the census, of whom 2418 (67%) were seen. Of those not
seen, 711 (19.6%) were absent at the time of the census,
despite two visits; 347 (9.6%) were temporarily resident else-
where; and 150 (4.1%) refused examination. We excluded 36
(1.0%) due to the presence of trichiasis, previous eyelid sur-
gery, or an inability to give informed consent. Of the remain-
ing, 862 (23.8%) had trachomatous conjunctival scarring, and
1520 (41.9%) did not have scarring.
We recruited 360 cases with trachomatous conjunctival
scarring and 360 control subjects without scarring. Baseline
demographic characteristics are shown in Table 2. The major-
ity of cases and controls were of Maasai ethnicity (77% of both
groups) followed by Chagga ethnicity (11% of both groups).
The controls were younger than the entire census population
(mean age, 31.9 vs. 37.4 years; P 0.001), which may cause an
overestimation of the association of scarring with age in the
study population. Odds of trachomatous scarring increased
twofold with each 10-year increase in age (P  0.001). After
adjustment for age, lack of education was strongly associated
with scarring.
Clinical findings are shown in Table 2. The scarring was
mostly mild to moderate. Conjunctival inflammation (grades P2
and P3) was present in 25.5% of cases and in none of the
controls. Follicles were found very infrequently in both cases
(1.5%) and controls (0.3%).
Bacterial isolates were identified in 54% of cases, compared
with 34% of controls (P  0.001; Table 3). Coagulase negative
TABLE 1. Tarsal Conjunctival Scarring Grading System
Grade Definition*
S1 Scarring occupying 1/3 of the upper lid
S1a One or more pinpoint scars and/or a single line of scarring
less than 2 mm in length†
S1b Multiples lines of scarring less than 2 mm in length
S1c One or more lines/patches of scarring each 2 mm or more
in length/maximal dimension
S2 Patches of scarring occupying in surface area 1/3 but
2/3 of the upper lid
3 Patches of scarring occupying in surface area 2/3 of the
upper lid
* Upper lid, zones 2 and 3 of the everted upper lid.3
† 2 mm was chosen, as this is the approximate width of the lower
lid margin, which is readily available for comparison.
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staphylococci (CNS), Corynebacterium spp., Streptococcus
viridans, and Bacillus spp. were designated as commensal
organisms for the purposes of this analysis. Both pathogenic
and commensal organisms were more prevalent in cases versus
controls (pathogenic: 6.7% vs. 1.9%; OR, 4.90; 95% CI, 2.06–
11.65; P  0.001; commensal: 47.4% vs. 32.6%; OR, 2.09; 95%
CI, 1.54–2.84; P  0.001). There was an increasing prevalence
of bacterial isolates (both commensal and pathogenic), with
increasing severity of scarring (Ptrend  0.001, Table 4).
To assess the association between papillary inflammation
and bacterial isolates among those with scarring, the cases
were subdivided into either inflamed (P2 or P3) or nonin-
flamed (P0 or P1). There were 92 (25.6%) inflamed cases and
268 (74.4%) noninflamed cases. A bacterial isolate (commensal
or pathogenic) was cultured in 60 (65.2%) of the inflamed
cases compared with 135 (50.4%) of the noninflamed cases
(OR, 1.86; 95% CI, 1.14–3.04; P  0.01). Commensal organ-
isms were not significantly associated with inflammation, being
found in 45 (48.9%) of the inflamed cases and 126 (47.0%) of
the noninflamed ones (OR, 1.48; 95% CI, 0.89–2.48; P 0.13).
There was no evidence that individual commensal organisms
were associated with inflammation. The presence of patho-
genic organisms, however, was strongly associated with in-
flammation. They were detected in 15 (16.3%) of 92 of in-
flamed cases and 9 (3.4%) of 268 of the noninflamed (OR, 6.93;
95% CI, 2.79–17.24; P  0.001).
Multivariable analyses showed that trachomatous scarring
was independently associated with increasing age and lack of
education (Table 5). Scarring was also associated with the
presence of commensal organisms (adjusted OR, 1.47; 95% CI,
1.03–2.12) and was strongly associated with pathogenic organ-
isms (adjusted OR, 4.08; 95% CI, 1.60–10.43).
DISCUSSION
This study showed, for the first time, that trachomatous scar-
ring without trichiasis is strongly associated with non-chlamyd-
ial bacterial infection in cases compared with controls. Chla-
mydial infection itself is only rarely found in adults with
scarring, and repeated infectious episodes with other bacteria
may contribute to progressive scarring.
Several studies from The Gambia have examined the role of
bacterial infection and inflammation in cicatricial trachoma,
although most of these have been in patients with trichiasis.
Bacterial infection was found before surgery in 30% of patients
undergoing trichiasis surgery. Recurrent trichiasis at 12 months
was associated with conjunctival inflammation and bacterial
TABLE 2. Demographic and Clinical Characteristics of the Study Participants and Age-Adjusted Associations with Scarring
Cases (n  360) Controls (n  360) Age-Adjusted Association with Scarring
Parameter n (%) n (%) OR 95% CI P
Age groups, y 0.001
18–25 29 (8.1) 117 (32.5) 1
25–35 53 (14.7) 113 (31.4) 1.88 1.11–3.16
35–45 65 (18.1) 85 (23.6) 3.13 1.87–5.26
45–55 80 (22.2) 28 (7.8) 11.53 6.38–20.84
55–65 57 (15.8) 9 (2.5) 28.75 12.36–66.87
65 76 (21.1) 8 (2.2) 34.07 15.28–75.95
Age in years, mean (95% CI) 50.2 (48.3–2.0) 31.9 (30.7–3.1) Trend 2.19* (1.92–2.49) 0.001
Sex 0.40
Female 219 (60.8) 241 (66.9) 1.00 —
Male 141 (39.2) 119 (33.1) 1.17 0.81–1.68
Formal education† 0.001
None 250 (69.4) 166 (46.1) 1.00 —
1–7 y 106 (29.4) 177 (49.2) 0.61 0.42–0.87
7 y 4 (1.1) 17 (4.7) 0.24 0.06–0.86
BMI‡ 0.55
Underweight 55 (15.4) 30 (8.5) 1.35 0.77–2.39
Normal 257 (72.0) 284 (80.0) 1.00 —
Overweight/obese 45 (12.6) 41 (11.6) 1.12 0.66–1.89
Scarring grade§
0 — — 360 (100)
1a 0 (0.0) — —
1b 187 (51.9) — —
1c 127 (35.3) — —
2 33 (9.2) — —
3 13 (3.6) — —
Papillary inflammation grade
P0 80 (22.2) 343 (95.3)
P1 188 (52.2) 17 (4.7)
P2 84 (23.3) 0 (0.0)
P3 8 (2.2) 0 (0.0)
Follicles
F0 355 (98.6) 359 (99.7)
F1 2 (0.6) 1 (0.3)
F2 1 (0.3) 0 (0.0)
F3 2 (0.6) 0 (0.0)
* The result shown is the increase in the OR with each increase in age group category.
† Primary schooling in Tanzania is completed after 7 years.
‡ Categories from the National Institutes of Health.
§ All controls had no scarring (grade 0), and all cases had scarring grade 1b or higher.
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infection at 12 months.8 Postoperative bacterial infection and
conjunctival inflammation were also associated with recurrent
trichiasis in another study in which examined patients were
examined 3.5 years after surgery.8,15 Bacterial infection and
inflammation were found to be associated with major trichiasis
(five or more lashes touching the globe) in a cohort study of
Gambian patients with trichiasis who declined surgery; how-
ever, neither was significantly associated with progression in
trichiasis after adjustment for other factors.13 Finally, the first
of two related case-control studies found that patients with
trichiasis had an increased bacterial infection rate compared
with controls and that infection was more common with in-
creasing trichiasis severity.10 In the second case-control study,
while there was an increased infection rate in those with
trachomatous scarring without trichiasis, this did not reach
statistical significance (OR, 2.2; 95% CI 0.79–6.33; P  0.144),
probably because of a limited sample size. The current study,
which has greater power, showed that scarring is associated
with bacterial infection. Several clinical trials have investigated
the effect of single-dose oral azithromycin after trichiasis sur-
gery on TT recurrence. These have reported variable impact on
the subsequent recurrence rate. It is plausible that at least part
of the benefit of this intervention is attributable to the effect of
this antibiotic on Gram-positive infection rather than on chla-
mydial infection alone.8,17,18
The results of studies on patients with trichiasis cannot
necessarily be extrapolated to those with scarring alone, as the
two groups are notably different. Trichiasis denotes lashes
rubbing against the globe, causing mechanical damage and a
persistent foreign body on the ocular surface. This effect pro-
vides a nidus for infection that may itself lead to an increased
risk of infection and inflammation rather than the other way
around. In this study we found that scarring without trichiasis
is also associated with bacterial infection and inflammation.
While cause and effect cannot be established with this study,
we are currently observing a cohort of scarred subjects who
are being assessed at regular intervals for infection and scarring
progression.
Earlier studies have also examined bacterial culture rates in
active trachoma, especially in relation to seasonal epidemics of
TABLE 4. Bacterial Culture Rates by Scarring Grade
Conjunctival Scarring Grade
Test for
Trend
P
0 (n  360) 1b (n  187) 1c (n  127) 2 (n  33) 3 (n  13)
n (%) n (%) n (%) n (%) n (%)
Any isolate cultured 124 (34.4) 84 (44.9) 78 (61.4) 23 (69.7) 10 (76.9) 0.001
Type of isolate cultured
None 236 (65.6) 103 (55.1) 49 (38.6) 10 (30.3) 3 (23.1)
Commensal only 117 (32.5) 76 (40.6) 68 (53.5) 18 (54.6) 9 (69.2) 0.001
Pathogenic / commensal 7 (1.9) 8 (4.3) 10 (7.9) 5 (15.2) 1 (7.7) 0.001
TABLE 3. Bacterial Culture Results by Case-Control Status
Cases (n  360) Controls (n  360)
n (%) n (%) 2 test
Any isolate cultured 195 (54.2) 124 (34.4) 0.001
Number of organisms cultured
0 165 (45.8) 236 (65.6) —
1 125 (34.7) 96 (26.7) 0.001
2 66 (18.3) 24 (6.7) 0.001
3 4 (1.1) 4 (1.1) 0.62
Type of isolate cultured*
None 165 (45.8) 236 (65.6) —
Commensal only 171 (47.5) 117 (32.5) 0.001
Pathogenic / commensal 24 (6.7) 7 (1.9) 0.001
Organisms
CNS 110 (30.6) 69 (19.2) 0.001
Corynebacterium spp. 89 (24.7) 42 (11.7) 0.001
Viridans group streptococci 35 (9.7) 32 (8.9) 0.70
Bacillus spp. 8 (2.2) 8 (2.2) 1.0
Haemophilus influenzae, B 9 (2.5) 0 (0.0) 0.003
Streptococcus pneumoniae 7 (1.9) 1 (0.3) 0.03
Escherichia coli 3 (0.8) 0 (0.0) 0.08
Neisseria spp. 3 (0.8) 0 (0.0) 0.08
Staphylococcus aureus 2 (0.6) 0 (0.0) 0.16
Aeromonas hydrophilia 0 (0.0) 2 (0.6) 0.16
Fungus, mould 0 (0.0) 2 (0.6) 0.16
Gram negative rods (other) 1 (0.3) 1 (0.3) 1.0
Actinomyces 1 (0.3) 0 (0.0) 0.32
Enterobacter cloacae 1 (0.3) 0 (0.0) 0.32
Gram-negative rods, non-Lactose fermenting 1 (0.3) 0 (0.0) 0.32
Klebsiella spp. 0 (0.0) 1 (0.3) 0.32
* Commensal organisms include CNS, Corynebacterium spp., and Viridans group streptococci.
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bacterial conjunctivitis.19–25 However, most of these studies
were in children without cicatricial stages of trachoma, did not
contain control groups, and used older trachoma grading sys-
tems that are difficult to compare with those currently used.
The two studies that did compare groups with and without
trachoma showed little difference in the bacterial isolation
rates between the two groups; however, these findings relate
only to children with active disease.24,25
Monkey models of trachoma have also sought to elucidate
the relationship between trachoma and bacterial infection.
These have shown that bacterial co-infection in active disease
did not result in more severe disease.26 However, when bac-
teria were introduced into eyes with conjunctival scarring, a
more marked and prolonged inflammatory reaction was pro-
duced compared with control animals.26
Another interesting question that our study raises is the role
and definition of commensal organisms. Such organisms can
act as part of the defensive mechanism of the ocular surface by
preventing colonization and infection by more pathogenic bac-
teria.27 However, deciding which organisms to categorize as a
commensal can be a moot point. Previous studies have gone
some way toward identifying organisms commonly found on
the ocular surface of healthy eyes which generally behave in a
non-pathogenic manner. These include CNS and Corynebacte-
ria.28–32 However, findings depend on various factors. Poly-
merase chain reaction with DNA sequencing, for example,
detects a much broader range and higher frequency of organ-
isms than does conventional bacterial culture.31 The popula-
tion being sampled is important, as many studies performed so
far have been on subjects from developed areas. A recent
survey from Sierra Leone of healthy eyes found a much higher
proportion of isolates of bacteria usually thought of as patho-
genic than previous studies, as well as fungi, the significance of
which remains unknown.32
We found that one third of our control subjects had an
organism cultured. This is on the lower end of the range
compared with results of previous studies on the conjunctival
flora, which showed culture rates of between 34% and
100%.28–32 This discrepancy may be partly because our study
was conducted in a remote, rural community and there was a
short delay in getting the samples to the laboratory. However,
the sample handling was identical between cases and controls,
and we do not believe that any systematic bias resulted. We
considered any increase in detection rates that may be
achieved with plating the swabs directly onto culture media in
the field would have been outweighed by higher contamina-
tion rates.
We included Streptococcus viridans and Bacillus as com-
mensal organisms as well as CNS and Corynebacteria. S. viri-
dans is a common oral commensal which is also frequently
found in the ocular flora in trachoma endemic areas and does
not appear to act in a pathogenic manner.20,23,24 Poor dental
hygiene in these areas may facilitate spread of the organism
from the oral cavity to the eye, which are joined by a contin-
uous mucosal surface. Bacillus was also included as a commen-
sal organism, as a number of factors indicated that it was acting
in a nonpathogenic manner. It was found equally in cases and
controls; on all the occasions on which it was cultured, there
was only mild growth and there was usually co-culture with
other organisms; and it did not cause any clinically significant
inflammation.
In our study, pathogens were significantly associated with
inflammation while commensals (both individually and overall)
were not. This result suggests that the scarred surface is more
easily colonized by commensal organisms with little adverse
effect, although a subclinical effect cannot be ruled out. The
scarred surface also appears to be more prone to infection with
pathogens that do cause inflammation and, perhaps, scarring
progression.
Our study benefited from a prospective approach with
standard clinical grading. There was minimal delay between
taking the swabs and inoculating samples onto the culture
medium. We also identified and adjusted for potential con-
founding factors. A potential confounder was the difference in
age between cases and controls; however, bacterial infection
remained significantly associated with scarring even after ad-
justment for age in a logistic regression model. Limitations of
the study include not having a specific culture for fungi, which
may have led to underestimation of their role. This study was
conducted in an area mesoendemic for trachoma, and the level
of scarring in the cases reflected this, being relatively mild,
with most of the cases having less than one third of the upper
lid scarred. This study, therefore, is applicable to the many
other areas with a moderate level of trachoma. We found that
the infection rate tended to increase with the level of scarring,
suggesting that more bacterial infection would be found in
communities with more severe scarring.
Chlamydial infection data are not available for this group of
subjects. However, in this setting, we would expect the prev-
alence of infection with C. trachomatis in adults to be low,
previous studies having suggested it the would probably be
between 0% and 10%.8–13
In summary, trachomatous conjunctival scarring is associ-
ated with increased bacterial infection, the role of which war-
rants further investigation, especially with regard to scarring
progression and the risk of blindness.
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  Abstract 
 
Trachoma is the most common infectious cause of blindness and a major public health 
problem in many developing countries. It is caused by recurrent ocular infection with 
Chlamydia trachomatis in childhood, with conjunctival scarring seen later in life. The 
pathogenesis of trachomatous scarring, however, is poorly understood and this study was 
carried out to investigate the immuno-fibrogenic correlates of trachomatous conjunctival 
scarring. A case-control study of 363 cases with conjunctival scarring and 363 control 
participants was conducted. Investigations included in vivo confocal microscopy (IVCM) 
assessment, quantitative real-time PCR gene expression, C. trachomatis detection and non-
chlamydial bacterial culture. Trachomatous scarring was found to be strongly associated 
with a pro-inflammatory, innate immune response with increased expression of: psoriasin; 
interleukin-1β; tumour necrosis factor-α; defensin-β4A; chemokine (CXC) ligand 5; and 
serum amyloid A1. There was also differential expression of various modifiers of the extra-
cellular matrix including: metalloproteinases 7, 9, 10 and 12; tissue inhibitor of matrix 
metalloproteinase 1; and secreted protein acidic cystein-rich-like 1. The expression of many 
of these genes was also significantly associated with the presence of non-chlamydial 
bacterial infection. These infections had a marked effect on conjunctival immune processes 
including an increased inflammatory infiltrate and edema seen with IVCM. This study 
supports the possibility that the immuno-fibrogenic response in scarring trachoma is partly 
stimulated by non-chlamydial bacterial infection which is characterised by the expression of 
innate factors.  
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  Trachoma is a major cause of blindness, especially in developing countries. Children suffer 
recurrent episodes of ocular infection with Chlamydia trachomatis which stimulate a 
follicularand papillary conjunctivitis. These children are subsequently at risk of developing 
conjunctival scarring which can progress to entropion (in-turning of the eyelid) and trichiasis 
(eyelashes rubbing against the eyeball). Corneal opacity and blindness can result, as well as 
severe and persistent discomfort. Trachoma is the most common infectious cause of 
blindness, with at least 1.3 million people estimated to be blind from the disease, 8.2 million 
to have trichiasis and 40 million to have active disease. (40, 52) 
 
The pathogenesis of trachoma, and especially of the scarring process, is poorly understood. 
Histological studies of conjunctival biopsies from scarred individuals show a chronic 
inflammatory cell infiltrate, especially in the substantia propria, with large numbers of 
lymphocytes. (1, 4, 25, 51) T cells, both CD4+ and CD8+, tend to outnumber B cells. The 
conjunctival stroma is replaced by thick, mostly avascular scar tissue. Earlier studies 
examining lymphoproliferative responses to chlamydial antigens in trachomatous subjects 
were consistent with findings from animal models of infection, which suggested that a strong 
Th1 response with production of IFNγ was important in clearing chlamydial infection and 
may be protective against the development of scarring.(5, 27, 28) These studies also 
provided limited evidence that Th2 responses were associated with conjunctival fibrosis, 
which may have parallels with other infectious disease, such as schistosomiasis.(59) 
However, recent studies using microarray analysis of conjunctival swab samples from 
subjects with trachomatous trichiasis have not found evidence of Th1/Th2 polarisation. 
Instead, pro-inflammatory mediators, particularly suggestive of innate immune responses 
and factors affecting extra-cellular matrix (ECM) remodelling, were prominent.(14, 29) A 
number of studies have also provided compelling evidence supporting the importance of 
conjunctival inflammation in the development of scarring and blinding complications.(11, 18, 
43, 55, 57)  
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  Two models have been proposed to account for the pathogenesis of C. trachomatis induced 
scarring in the eye or genital tract:  the “immunological” and the “cellular” paradigms, which 
are not necessarily mutually exclusive.(7, 16, 53) The immunological paradigm argues that 
cellular immune responses, especially those involving T-cells, against specific chlamydial 
antigens are important in causing disease. The cellular paradigm proposes that host 
epithelial cells act as a key innate responder cell and are central in driving tissue damage.  
 
In this case-control study we investigated the pathophysiology of trachomatous conjunctival 
scarring by measuring conjunctival gene expression. We examined the hypotheses that 
conjunctival scarring is associated with: (1) a predominantly Th2 (IL-13 mediated) rather 
than Th1 response, (2) various pro-fibrotic mediators such as matrix metalloproteinases, and 
(3) markers of innate immunity. In addition, we investigate the relationship between the 
expression of these various factors and both C. trachomatis and other bacterial infections. 
Finally, we relate the gene expression profile to the microscopic tissue morphology changes 
and inflammatory cell infiltrate observed by in vivo confocal microscopy (IVCM). IVCM is a 
relatively new technique to examine the ocular surface, which provides high-resolution 
images down to the cellular level.(31, 32)  
  
MATERIAL AND METHODS 
 
Ethical approval 
This study adhered to the tenets of the Declaration of Helsinki. It was approved by the ethics 
committees of the Tanzanian National Institute for Medical Research, the Kilimanjaro 
Christian Medical Centre and the London School of Hygiene and Tropical Medicine. The 
study was explained to potential study subjects and written, informed consent was obtained 
before enrolment. 
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  Participant recruitment 
The recruitment of participants into this population-based study has been previously 
described.(30, 32) Briefly, adults with trachomatous conjunctival scarring, but without 
trichiasis, were recruited from a trachoma endemic area in Siha district of northern Tanzania. 
Control subjects without scarring from the same community, frequency matched for ethnicity, 
were also recruited.  
 
Clinical examination and sample collection 
All participants were examined clinically, as previously described, using the 1981 World 
Health Organization trachoma grading system with some modifications including a more 
detailed grading for conjunctival scarring.(17, 30, 32) The left conjunctiva was anaesthetised 
with preservative-free proxymetacaine 0.5% eye drops (Minims®, Chauvin Pharmaceuticals) 
and a swab collected for microbiological analysis from the inferior fornix. Two upper tarsal 
conjunctival swabs were also collected (Dacron polyester-tipped, Hardwood Products 
Company, Guildford, ME). The first was for RNA isolation (described later) and was placed 
directly into a tube containing 0.2 ml RNA stabilizer (RNAlater, Life technologies, UK). The 
second was for C. trachomatis detection and put into a dry tube. Samples were kept on ice 
packs until frozen later the same day at -80°C. 
 
Confocal microscopy assessment 
IVCM examination of the upper tarsal conjunctiva was performed using the Heidelberg 
Retina Tomograph 3 (HRT3) in combination with the Rostock Corneal Module (RCM) 
(Heidelberg Engineering GmbH, Dossenheim, Germany) using previously described 
examination and image grading protocols.(31) IVCM images were graded for inflammatory 
features sub-epithelial connective tissue organisation/scarring (Figures 1 and 2). 
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  Quantitative RT-PCR 
Twenty-three different gene transcripts were selected for quantitation by real time RT-PCR 
including  interferon gamma (IFNG);  indoleamine-2,3-dioxygenase (INDO); tumour necrosis 
factor, alpha (TNFα); interleukin 1, beta (IL1B); interleukin 10 (IL10);  interleukin 12, beta 
(IL12B);  interleukin 13 (IL13); interleukin 13 receptor, alpha 2 (IL13RA2); S100 calcium 
binding protein A7 (S100A7); defensin, beta 4A (DEFB4A); chemokine (C-X-C motif) ligand 
5 (CXCL5); serum amyloid A1 (SAA1); argninase, liver (ARG1); nitric oxide synthase 2, 
inducible (NOS2); matrix metalloproteinase 1 (MMP1); matrix metalloproteinase 7 (MMP7); 
matrix metalloproteinase 9 (MMP9); matrix metalloproteinase 10 (MMP10); matrix 
metalloproteinase 12 (MMP12); TIMP (tissue inhibitor of matrix metalloproteinase) matrix 
metalloproteinase inhibitor 1 (TIMP1); SPARC (secreted protein, acidic, cystein-rich)-like 1 
(hevin) (SPARCL1); complement factor H (CFH); and CD83 molecule (CD83). 
 
Genes were chosen to investigate the specific hypotheses outlined above. Specifically, 
IFNG, IL12B, IL13 and IL13RA2 expression to investigate a Th1/Th2 predominance; the 
expression of matrix metalloproteinases, TIMP1 and SPARCL1 as potentially important 
regulators of  extra-cellular matrix; and IL1B, TNFA, S100A7, DEFB4A, CXCL5 and SAA1 
expression as evidence of a pro-inflammatory and/or innate immune response. We were 
also interested in examining evidence of differential macrophage activity (ARG1 and NOS2), 
mature dendritic cells (CD83) and complement regulation (CFH).  The selection of these 
genes was informed by previous studies including a conjunctival microarray transcriptome 
analysis.(6, 9, 14, 15, 22, 27, 28, 42, 45, 47-49) The microarray data have been deposited in 
NCBI's Gene Expression Omnibus under accession numbers GSE23705 (Ethiopia) and 
GSE24383 (Tanzania).  
 
Total RNA was extracted from the swab sample using RNeasy Micro Kit (Qiagen, Hilden, 
Germany) and reverse transcribed to cDNA using the QuantiTect Reverse Transcription Kit 
(Qiagen) according to the manufacturer’s instructions. Multiplex real-time quantitative PCR 
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  was performed on a Rotor-Gene 6000 (Corbett Research, Cambridge, UK) using the 
QuantiTect Multiplex NoROX Kit (Qiagen) according to the manufacturer’s instructions. 
Probes and primers for multiplex assays, which included up to four separate targets 
(including HPRT-1, which was used as a reference gene), were designed and synthesised 
by Sigma Life Science (www.sigma.com/designmyprobe, available on request). The samples 
were tested in duplicate, in a total reaction volume of 25µl, which contained 2 µl of sample or 
standard. The thermal cycle protocol used the following conditions: 95°C for 15 minutes, 
followed by 45 - 50 cycles of (1) denaturation at 94°C for 30 seconds, (2) annealing and 
extension at 60°C for 30 seconds. Fluorescence data was acquired at the end of each cycle. 
The relative efficiency of the component reactions was assessed using standards containing 
all targets in a sequence of tenfold serial dilutions. 
 
Microbiology samples and analysis 
C. trachomatis DNA was detected using a PCR-based assay (Amplicor CT/NG Test; Roche) 
with previously described modifications.(12) Samples for culture were inoculated onto blood 
and chocolate agar later on the day of collection (rarely more than 6 hours) and incubated at 
37°C for 48 hours. Culture isolates were identified by standard microbiological techniques.  
 
Data analysis 
Data were entered into Access 2007 (Microsoft) and analysed using STATA 11.0 (StataCorp 
LP, TX). The transcript abundances for the genes of interest were standardised relative to 
that of HPRT1 in the same reaction using the ΔΔCT method and were normalised by log10 
transformation.(37) Linear regression models were used to estimate fold changes (age and 
sex adjusted) in the level of gene expression in those with clinically visible scarring 
compared to controls, subdivided into those with no/minimal inflammation - TS (inflammation 
grades P0 and P1); and those with inflammation - TSI (inflammation grades P2 and P3),  
where P0=no inflammation; P1=minimal inflammation with individual papillae prominent; 
P2=moderate inflammation in which normal vessels appear hazy; P3=pronounced 
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  inflammation in which normal vessels on the tarsus are hidden over more than half the 
surface).(17) Similar fold changes were estimated for the presence of clinically significant 
inflammation (P2 or P3), adjusted for the level of clinical scarring as well as age and sex. 
Age and sex adjusted fold changes in gene expression by grade of IVCM connective tissue 
organization/scarring, and for the presence of dendritiform cells were also estimated. 
Correlation coefficients were estimated between the increase in gene expression (log10 
transformed) and the IVCM inflammatory infiltrate, with the significance tested using age/sex 
adjusted linear regression models. Likelihood ratio tests were used to assess the strength of 
association of each factor with gene expression fold change. P-values for all associations 
are shown in the results section. For reference, the P-values for the critical significance 
thresholds determined by a Bonferroni correction for multiple comparisons are shown in 
table footnotes. However, the choice of targets for gene expression were not selected at 
random, as is assumed by the Bonferroni method, but contain related groups of genes which 
might be expected to act in a similar manner. In addition, using such a conservative 
correction increases the likelihood of a Type 2 error. 
 
RESULTS 
 
Study participants 
We recruited 363 cases with trachomatous conjunctival scarring and 363 control participants 
without scarring. The demographic, clinical, IVCM and non-chlamydial bacterial infection 
data have previously been reported in detail.(30, 32) In summary, controls were younger 
than the cases (mean 31.9 vs 50.3 years, p<0.001) and all analyses were age and sex 
adjusted. Conjunctival scarring in the cases was mostly mild to moderate and cases had 
significantly more clinical inflammation than controls. IVCM analysis showed that cases had 
more inflammatory cells and a higher connective tissue scarring score. Non-chlamydial 
pathogenic organisms were cultured more frequently from cases (25 [6.9%]) than controls (7 
[1.9%], p-value 0.002). The most frequently cultured pathogenic organisms were 
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  Haemphilus influenze type b and Streptococcus pneumoniae while Coagulase negative 
staphylococci, Corynebacterium spp., Streptococcus viridans and Bacillus spp. were 
designated as commensal organisms in this analysis. Five (1.4%) of the cases and none of 
the controls had C. trachomatis infection detected. 
 
Conjunctival gene expression 
Quantitative, real-time RT-PCR was performed for 23 gene expression targets for all 363 
cases and 363 controls. There was inadequate sample for detection in 4 samples (3 cases 
and 1 control) and amplification failed in a number of experiments for technical reasons 
related to laboratory power supply problems. The number of samples successfully detected 
for each target ranged from 313 to 359 for cases and 316 to 362 for controls.  
  
Gene expression levels in relation to clinical findings 
Cases with scarring had enriched gene expression compared to controls for the majority of 
transcripts measured, even after adjusting for age and sex (Table 1). This tended to be more 
marked in those cases with inflammation (increased: INDO, TNFA, IL1B, S100A7, DEFB4A, 
CXCL5, SAA1, ARG, NOS2, MMP7, MMP9, MMP12, TIMP1 and CD83; decreased: 
MMP10, CFH and SPARCL1). There was also some evidence, but with less robust P-
values, that the expression of INFG and IL13RA2 were increased in cases with scarring.  
 
After adjusting for age, sex and the level of clinical scarring a number of genes were also 
differentially expressed in those with clinical inflammation compared to those without 
inflammation (increased: INDO, IL1B, DEFB4A, CXCL5, MMP7, MMP9, MMP12 and CD83; 
decreased: MMP10, SPARCL1 and CFH). 
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  TABLE 1. Conjunctival gene expression in relation to clinical phenotype. 
 
Gene TSI vs Ca TS vs Ca Inflamed vs non-
inflamedb 
 FC pc FC pc FC pc 
S100A7 5.54 <0.0001 3.2 <0.0001 1.3 0.11 
SAA1 4.99 <0.0001 2.11 <0.0001 1.6 0.04 
DEFB4A 4.72 <0.0001 1.42 0.01 2.46 <0.0001 
CXCL5 3.89 <0.0001 1.18 0.43 3.4 <0.0001 
MMP12 3.55 <0.0001 1.74 <0.0001 1.62 0.0002 
INDO 3.29 <0.0001 1.5 <0.0001 1.96 <0.0001 
MMP9 3.06 <0.0001 1.76 <0.0001 1.67 <0.0001 
IL1B 2.57 <0.0001 1.59 <0.0001 1.48 0.0003 
NOS2 2.16 <0.0001 1.27 0.005 1.38 0.007 
MMP7 2.14 <0.0001 1.23 0.003 1.51 <0.0001 
CD83 1.9 <0.0001 1.4 <0.0001 1.31 0.0004 
IL13RA2 1.62 0.006 1.38 0.008 1.08 0.65 
IL12B 1.52 0.02 1.29 0.04 1.22 0.23 
TNFA 1.47 <0.0001 1.14 0.008 1.23 0.003 
IL10 1.46 0.2 0.64 0.03 1.27 0.42 
TIMP1 1.46 <0.0001 1.4 <0.0001 0.93 0.3 
IFNG 1.42 0.001 1.06 0.4 1.41 0.002 
ARG1 1.3 0.01 1.25 0.0003 1.04 0.64 
IL13 1.22 0.3 1.17 0.19 1.09 0.64 
CFH 0.75 <0.0001 1.13 0.005 0.68 <0.0001 
MMP1 0.58 0.009 1.28 0.05 0.63 0.02 
MMP10 0.38 <0.0001 0.86 0.02 0.54 <0.0001 
SPARCL1 0.06 <0.0001 0.51 <0.0001 0.19 <0.0001 
 
a Adjusted for age and sex  
b Adjusted for age, sex and level of clinical scarring 
c Using a Bonferroni correction for 69 comparisons then a P-value of <0.0007 would be 
considered significant, see text for discussion. 
TSI = trachomatous scarring with inflammation; TS = trachomatous scarring without 
inflammation; FC = fold change; S100A7 = S100 calcium binding protein A7; SAA1 = serum 
amyloid A1; DEFB4A = defensin, beta 4A; CXCL5 = chemokine (C-X-C motif) ligand 5; 
MMP12 = matrix metalloproteinase 12; INDO = indoleamine-2,3-dioxygenase; MMP9 = 
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  matrix metalloproteinase 9; IL1B = interleukin 1; NOS2 = nitric oxide synthase 2, inducible; 
MMP7 = matrix metalloproteinase 7; CD83 = CD83 molecule; IL13RA2 = interleukin 13 
receptor, alpha 2;  IL12B = interleukin 12, beta; TNFα = tumour necrosis factor, alpha; beta; 
IL10 = interleukin 10; TIMP1 = TIMP (tissue inhibitor of matrix metalloproteinase) matrix 
metalloproteinase inhibitor 1; IFNG = interferon gamma; ARG1 = argninase, liver; IL13 = 
interleukin 13; CFH = complement factor H; MMP1 = matrix metalloproteinase 1; MMP10 = 
matrix metalloproteinase 10; SPARCL1 = SPARC (secreted protein, acidic, cystein-rich)-like 
1 (hevin).  
  
 
 
Victor Hu   PhD thesis   199
	  Gene expression in relation to IVCM findings 
The relationship between the gene expression results and the IVCM findings are presented 
in Table 2. Increasing IVCM connective tissue grade was associated with increased 
expression of S100A7, which also had the largest fold changes, TIMP1 and CFH; and with 
decreased expression of SPARCL1. There was also some evidence, but with less robust P-
values, that the connective tissue grade was associated with increased levels of INDO, IL1B, 
SAA1, ARG1, MMP12 and CD83. 
 
The expression of a number of genes were correlated with the IVCM inflammatory infiltrate 
density: the correlation coefficient for IL1B, S100A7 and DEFB4 was greater than +0.40 
(Figure 3); for SAA1, MMP9, and MMP12 it was between +0.25 and +0.35; and for MMP10 
and SPARCL1 it was between -0.20 and -0.30. The presence of DFCs was associated with 
increased expression of INDO and S100A7; and with decreased expression of SPARCL1.  
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  TABLE 2. Gene expression levels in relation to in vivo confocal microscopy findings  
 
Gene Fold change in gene expression 
with increasing connective tissue 
gradea 
IVCM infiltrate Fold change in 
gene expression if 
dendritiform cells 
presenta 
 Grade FC p-valueb correlation 
coefficient 
p-valueab FC pb 
        
S100A7 1 1.00 <0.0001 0.43 <0.0001 2.03 0.0004 
 2 1.64      
 3 3.76      
SAA1 1 1.00 0.002 0.28 <0.0001 1.80 0.03 
 2 1.18      
 3 2.74      
DEFB4A 1 1.00 0.01 0.42 <0.0001 1.74 0.01 
 2 0.84      
 3 1.60      
CXCL5 1 1.00 0.50 0.08 0.01 1.51 0.22 
 2 1.25      
 3 1.40      
MMP12 1 1.00 0.004 0.31 <0.0001 1.36 0.05 
 2 1.23      
 3 1.69      
INDO 1 1.00 0.004 0.16 <0.0001 1.71 0.0001 
 2 1.17      
 3 1.60      
MMP9 1 1.00 0.01 0.28 <0.0001 1.19 0.19 
 2 1.26      
 3 1.33      
IL1B 1 1.00 0.008 0.49 <0.0001 1.15 0.27 
 2 1.18      
 3 1.45      
NOS2 1 1.00 0.14 0.15 0.02 1.28 0.07 
 2 1.01      
 3 1.33      
MMP7 1 1.00 0.65 0.08 0.14 1.06 0.62 
 2 1.02      
 3 1.12      
CD83 1 1.00 0.003 0.10 0.03 1.11 0.25 
 2 1.21      
 3 1.13      
IL13RA2 1 1.00 0.79 0.14 0.005 0.92 0.65 
 2 0.98      
 3 1.11      
IL12B 1 1.00 0.87 -0.09 0.01 0.90 0.59 
 2 1.06      
 3 1.07      
TNFA 1 1.00 0.39 0.12 0.009 1.05 0.54 
 2 1.07      
 3 1.04      
IL10 1 1.00 0.15 0.13 0.0003 1.11 0.77 
 2 0.86      
 3 0.49      
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  TIMP1 1 1.00 <0.0001 0.19 0.0005 1.09 0.27 
 2 1.18      
 3 1.46      
IFNG 1 1.00 0.43 -0.12 0.0003 1.05 0.71 
 2 0.91      
 3 0.89      
ARG 1 1.00 0.003 0.14 0.002 1.09 0.42 
 2 1.24      
 3 1.17      
IL13 1 1.00 0.13 0.001 0.98 0.92 0.27 
 2 1.24      
 3 0.94      
CFH 1 1.00 0.0004 -0.09 0.004 0.93 0.30 
 2 1.15      
 3 1.24      
MMP1 1 1.00 0.32 0.02 0.88 0.97 0.87 
 2 1.06      
 3 1.40      
MMP10 1 1.00 0.02 -0.22 <0.0001 0.76 0.01 
 2 1.14      
 3 0.85      
SPARCL1 1 1.00 <0.0001 -0.27 <0.0001 0.30 <0.0001 
 2 0.87      
 3 0.67      
 
a Adjusted for age and sex. 
b Using a Bonferroni correction for 69 comparisons then a P-value of <0.0007 would be 
considered significant, see text for discussion. 
IVCM = in vivo confocal microscopy. FC = fold change. See Table 1 for gene abbreviations. 
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  Gene expression levels in relation to microbiology findings 
Infection with C. trachomatis was associated with up-regulated IFNG, INDO and NOS2; and 
with down-regulated MMP10 and SPARCL1, Table 3 (note that only 5 participants had 
detectable C. trachomatis DNA). There was also some evidence, but with less robust P-
values, that C. trachomatis infection was associated with increased IL12B, MMP1, MMP7 
and MMP10. Non-chlamydial bacterial infection was associated with increased expression of 
INDO, S100A7, DEFB4A and MMP12 and with decreased expression of MMP10, SPARCL1 
and CFH (Table 3). There was also some evidence that non-chlamydial bacterial infection 
was associated with increased IL1B, IL10, CXCL5, SAA1, MMP7 and MMP9. 
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  TABLE 3. Gene expression in relation to microbiological infection status 
 
Gene Chlamydial infectiona Non-chlamydial bacterial infectiona 
 FC p FCb p 
S100A7 4.21 0.04 2.59 0.0006 
SAA1 8.06 0.01 2.47 0.008 
DEFB4A 4.82 0.02 3.56 <0.0001 
CXCL5 8.2 0.07 4.15 0.002 
MMP12 1.84 0.21 2.21 <0.0001 
INDO 6.78 <0.0001 2.74 <0.0001 
MMP9 1.57 0.28 1.73 0.002 
IL1B 1.49 0.32 1.72 0.001 
NOS2 4.5 0.0003 1.40 0.06 
MMP7 3.01 0.002 1.52 0.003 
CD83 1.30 0.34 1.27 0.05 
IL13RA2 0.81 0.72 0.98 0.94 
IL12B 3.10 0.05 1.16 0.56 
TNFA  1.60 0.06 1.14 0.20 
IL10 1.29 0.81 3.30 0.005 
TIMP1 0.98 0.94 1.09 0.36 
IFNG 4.2 <0.0001 1.12 0.46 
ARG 0.71 0.27 0.92 0.56 
IL13 0.26 0.02 0.66 0.13 
CFH 0.64 0.03 0.67 <0.0001 
MMP1 0.14 0.004 0.59 0.06 
MMP10 0.34 0.002 0.46 <0.0001 
SPARCL1 0.02 <0.0001 0.09 <0.0001 
 
a Adjusted for age and sex. Using a Bonferroni correction for 46 comparisons then a P-value 
of <0.001 would be considered significant, see text for further discussion. 
b Compared to no organism cultured. 
FC = fold change. See Table 1 for gene abbreviations. 
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  IVCM findings in relation to non-chlamydial bacterial infection status 
A new combined analysis of previously published IVCM and microbiology data found that 
pathogenic organisms were associated with significantly more inflammatory cells (P<0.0006) 
and with the presence of tissue edema (P=0.02), Table 4.(30, 32) 
 
 
TABLE 4. In vivo confocal microscopy parameters by non-chlamydial bacterial infection 
status 
IVCM parameter No organism Pathogenic organism   
 Mean 95% CI Mean 95% CI Adjusted 
increasea 
p-value 
Inflammatory infiltrate 
(cells/mm2)  
731 (694-769) 972 (841-1102) 230 0.0006 
Connective tissue 
organization score 
1.04 (0.97-1.11) 1.31 (1.06-1.56) 0.12 0.40 
 n % n % Adjusted 
ORa 
p-value 
Dendritiform cells 
present 
22 (6.0) 4 (14.3) 1.89 0.33 
Tissue edema present 13 (3.6) 3 (10.7) 5.4 0.02 
 
a Compared to no growth and adjusted for age and sex. 
 
CI = Confidence intervals; OR = Odds ratio. 
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  DISCUSSION 
Previous studies have used gene expression measurement of conjunctival swab samples to 
study the pathogenesis of trachoma.(6, 9, 14, 21, 22, 29, 46)   However, this is the first study 
to systematically compare a large number of cases with trachomatous scarring and control 
subjects in which the scarring had not yet progressed to trichiasis. Cases with trichiasis are 
quite distinct from cases with scarring alone as they have a persistent foreign body abrading 
the globe stimulating inflammation and facilitating secondary infection.(13) In this study we 
have shown that scarring without trichiasis is associated with large fold changes in gene 
expression of various cytokines, chemokines and other immuno-fibrogenic mediators, even 
though the scarring was generally mild-moderate.  
 
We found that mild to moderate trachomatous scarring is strongly associated with a pro-
inflammatory, innate immune response which has marked anti-microbial properties, with 
increased expression of S100A7, DEFB4A, CXCL5, IL1B, TNFA and SAA1. This is 
consistent with a transcriptome microarray study of end-stage scarring trachoma with 
trichiasis from Ethiopia.(14) In both studies the expression of S100A7 (psoriasin) showed the 
greatest fold increase between cases and controls. Psoriasin was initially identified as being 
upregulated in epithelial cells from psoriatic lesions.(38) It is an antimicrobial peptide (AMP) 
and therefore an important component of innate immune defence.(56) Psoriasin is 
chemotactic for neutrophils and regulates neutrophil function by inducing the production of 
several cytokines, chemokines and reactive oxygen species.(34, 61) It has been shown to 
reduce Escherichia coli survival, the mechanism of which may be either through zinc 
sequestration or direct adherence with the bacteria.(24, 36) It has more recently been shown 
to be upregulated at the ocular surface in response to Staphylococcus aureus and 
Haemophilis influenzae.(23) Binding of E. Coli flagellin by the Toll-like receptor 5 on 
keratinocytes is important in psoriasin induction, supporting its role as an innate immune 
molecule.(2) The defensins are another group of AMPs found at the ocular surface with β-
defensins released by leucocytes and epithelial cells.(26, 41)  CXCL5 is a potent chemotaxin 
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  involved in neutrophil activation which is produced by epithelial cells.(33, 56) TNFα and IL1β 
are pro-inflammatory mediators which play a central role in mediating an innate immune 
response and have previously been found to be associated with active and scarring 
trachoma.(3, 6, 9, 15, 22, 47). Serum amyloid A, of which SAA1 is a main isoform, is an 
acute phase protein which is raised in inflammatory diseases and has been shown to have 
anti-bacterial effects.(19, 39)  
 
The upregulation of these various pro-inflammatory, chemotactic and antimicrobial mediators 
suggests an important role for the innate immune response in trachomatous scarring. This is 
consistent with the cellular paradigm of Chlamydia trachomatis pathogenesis. While there 
was some evidence of Th1 response in scarring (increased IFNG and INDO expression), 
there was no significant difference in IL13 expression, which might have suggested a Th2 
response. There was some evidence that the expression of IL13RA2, which appears to act 
as a decoy receptor for IL13 and oppose its function, was increased in cases compared to 
controls.(60) 
 
Many of the measured transcripts were upregulated in the presence of clinical inflammation. 
When scarred cases were compared to controls without scarring, the additional presence of 
inflammation in the cases tended to lead to more marked increases in gene expression. 
These observations are consistent with the hypothesis that episodes of inflammation are 
important in the pathogenesis of scarring and blindness. It is also interesting to note that a 
number of genes, for example, S100A7, IL1B, SAA1 and MMP12 showed large fold changes 
in gene expression even in relatively non-inflamed cases with scarring compared to controls.  
These genes also showed a clearly progressive increase in expression with increasing IVCM 
connective tissue organization grade. 
 
We found infection with C. trachomatis to be infrequent in these adults with conjunctival 
scarring, with a similar detection rate to previous studies of trachomatous trichiasis.(8, 11, 
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  13) While caution is needed in interpreting these data because of the small numbers, 
individuals infected with C. trachomatis had gene expression profiles characteristic of C. 
trachomatis infection in children.(9, 46) There was a typical Th1 dominated response with 
upregulated IFNG and IL12B (p=0.05) and also INDO and NOS2 (both IFNγ-regulated) and 
some acute phase reactants. Infection with other bacteria was more frequent, and many of 
the above genes involved in innate immunity showed moderate-large increases in 
expression if a pathogenic organism was present. A previous study found that the presence 
of bacterial infection was associated with increased expression of IL1B, TNFα, MMP1, 
MMP9 and TIMP2 after trichiasis surgery.(10) In the current study bacterial infection was 
also found to be associated with an increased inflammatory infiltrate and tissue edema. 
Overall, these studies support the hypothesis that non-chlamydial bacterial infection is 
important in driving the scarring process. 
 
Matrix metalloproteinases are capable of degrading the protein components of the ECM and 
also have wide-ranging effects on inflammatory and immune responses.(58) (50) Previous 
studies have implicated MMPs in the pathogenesis of trachomatous scarring and this was 
further confirmed in this study in a separate population.(9, 10, 14, 20, 29, 44)  MMP7, 9, 12 
and TIMP1 were upregulated in scarring and inflammation, while MMP10 and SPARCL1 
were downregulated. SPARCL1 is a matricellular protein which regulates the synthesis and 
turnover of the ECM.(35, 54) The gene expression levels by clinical scarring grade were 
broadly consistent with the levels by IVCM connective tissue grade, and the expression 
levels by clinical inflammation were consistent with the IVCM inflammatory infiltrate 
correlation. The differential gene expression of these ECM modifiers was closely related to 
bacterial infection status as discussed above. 
 
Strengths of this population-based study were that we studied a large number of cases with 
early scarring trachoma to analyse gene expression changes in relation to clinical, IVCM and 
microbiological status. There are, however, a number of limitations. Gene expression levels 
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  do not necessarily reflect the level of functional protein, exemplified by TFGβ, which has 
significant post-transcriptional regulation. Conjunctival swabs obtain material from the tissue 
surface and so have a tendency to limit the observations to events in or near the epithelium. 
To address these two issues we are currently comparing gene expression with 
immunohistochemical analysis of conjunctival biopsy tissue.  
 
This study showed that mild-moderate trachomatous scarring is strongly associated with a 
pro-inflammatory, innate immune response, and with differential expression of various 
modifiers of the ECM. We found no evidence for an active role for IL-13 / Th2 responses at 
this stage of the disease. This is consistent with the findings from a microarray transcriptome 
study from Ethiopia on advanced trachomatous scarring.(14) We were also able to use 
IVCM to show differential transcript levels according to connective tissue morphology and 
inflammatory cell infiltrate. A key determinant in the expression of many of these genes 
appears to be the presence of non-chlamydial bacterial infection which, as well as causing 
inflammation, may contribute to the scarring process.  
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  Figure 1: In vivo confocal microscopy grading system of inflammatory features. Images are 
400×400µm. A, Inflammatory infiltrate: seen as multiple bright white nuclei. The mean 
inflammatory cell density of 3 randomly selected volume scans is calculated. The individual 
scan with the highest density of cells from within the volume scan is used. B, Dendritiform 
cells: graded as present or absent. To be present, the mean number of DCs per volume 
scan needs to be ≥1. The largest number of dendritiform cells in any individual scan in a 
volume scan is used for measurement. A mean number of ≥1 is used to differentiate 
occasional dendritiform cells seen in scans of otherwise normal subjects. C, Tissue edema: 
seen as multiple black empty spaces. Graded as present or absent in any volume scan. D, 
Papillae: seen as elevations with a central vascular network. Graded as present or absent in 
any volume scan. 
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  Figure 2: In vivo confocal microscopy grading system for conjunctival connective tissue 
organization. Images are 400×400µm. (A) Normal: homogenous, amorphous appearance, 
with occasional, fine, wispy strands. (B) Grade 1: heterogenous appearance with poorly 
defined clumps or bands present. (C) Grade 2: clearly defined bands of tissue which 
constitute less than 50% of the area of the scan. (D) Grade 3: clearly defined bands or 
sheets of tissue which constitute 50% or more of the area of the scan and in which striations 
are present. If different grades of scarring are seen within a particular volume scan then the 
highest grade is recorded. The connective tissue which is graded needs to be separate from 
that associated with the vascular tissue, if this is not possible then the scan is considered 
ungradable. 
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  Figure 3.  Gene expression levels relative to HPRT1 of S100A7, DEFB4A and IL1B by in 
vivo confocal microscopy inflammatory cell infiltrate. 
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Immunohistological analysis of 
trachomatous scarring reveals increased 
CD8+ cells and an infiltrate of CD45 
negative inflammatory cells 
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Abstract 
 
Purpose.  To assess the tissue morphology and cellular infiltrates found in trachomatous 
scarring. 
 
Methods.   Case-control study of 34 cases with severe trachomatous scarring undergoing 
trichiasis surgery and 33 control subjects without scarring undergoing cataract or retinal 
detachment surgery. Participants were examined clinically and conjunctival biopsy samples 
were taken which were fixed in buffered formalin and processed into paraffin wax. 
Hematoxylin and eosin (H&E) staining was performed for assessment of the inflammatory 
cell infiltrate. Immunohistochemical processing was performed to identify cells staining with 
CD3 (T-cells), CD4 (helper T-cells), CD8 (suppressor/cytotoxic T-cells and Natural Killer 
cells), CD20 (B-cells), CD45 (nucleated hematopoietic cells), CD56 (Natural Killer cells), 
CD68 (macrophages/monocytes) and CD83 (mature dendritic cells). The degree of scarring 
was assessed histologically using cross polarised light to visualise collagen fibres. 
 
Results.  Scarring was associated with increased inflammatory cell infiltrates on H&E and 
CD45 staining. Scarring was also associated with increased CD8+ and CD56+ cells, but not 
CD3+ cells, indicating a Natural Killer cell infiltrate.  There was some increase of CD20+ 
cells, but no evidence for increased CD4+, CD68+ or CD83+ cells. Numerous CD45 
negative cells were also seen in scarred conjunctiva. Clinically scarred conjunctiva was 
strongly associated with disorganization of the normal collagen architecture.  
 
Conclusion.  Scarred conjunctiva appears to be infiltrated with Natural Killer cells and 
further investigation is warranted on the role these cells may play in the pathogenesis of 
trachoma. Further work is also required on the identification of an unexpected infiltrate of 
CD45 negative cells in scarring. 
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Introduction 
 
Trachoma starts in childhood with repeated conjunctival infection by the gram-negative 
bacterium Chlamydia trachomatis. The infection provokes a marked inflammatory response, 
which can lead to cicatricial sequelae in later life: conjunctival scarring, entriopion, trichiasis, 
corneal opacity and, eventually, blindness. Trachoma is still a major problem world-wide; the 
World Health Organization (WHO) currently estimates that about 84 million people (mostly 
children) have active inflammatory trachoma, and about 8 million (mostly adults) are either 
blind or visually impaired.1 There has been an encouraging reduction in the number of 
children with active disease over the last few decades, which is probably attributable to 
improved living standards and trachoma control programmes.2 However, even in areas 
where the prevalence of C. trachomatis infection has been low for some time scarring 
complications still appear to develop and progress. Therefore, it is important to better 
understand the cicatricial disease process. 
 
The pathophysiology of scarring complications of C. trachomatis infection, both in the eye 
and genital tract, remains unclear and various models have been proposed. The 
“immunological” paradigm suggests that disease is the result of a cell-mediated immune 
process, particularly involving T-cells responses, against specific C. trachomatis antigens.3, 4 
The “cellular” paradigm argues that infected epithelial cells are central in causing tissue 
damage through the release of pro-inflammatory cytokines, chemokines and growth factors, 
although this may also subsequently involve adaptive responses.5, 6 Recent studies have 
supported the role of innate immunity in the development of scarring complications and the 
epithelium may be important in driving these innate processes.7-10 
 
Histological examination of trachomatous tissue gives a valuable opportunity to study the 
disease. Several previous studies have examined the histopathology of conjunctival biopsy 
specimens from individuals with trachoma.11-21 However, these studies have tended to have 
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relatively small sample sizes and either lacked or had very few control samples for 
comparison. In the present study we have analysed conjunctival biopsies from a sizeable 
number of patients with trachomatous trichiasis and control subjects recruited from the same 
region. We characterised in detail the morphological and cellular changes using masked 
observers and defined grading systems with robust analytical techniques. We examined the 
hypotheses that conjunctiva with trachomatous scarring is characterised by connective 
tissue changes that can be seen histologically and with an increased inflammatory cell 
infiltrate. We also wanted to examine the nature of the cellular infiltrate found in scarred 
trachoma. 
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Methods 
 
Ethical permission & Subject recruitment 
This study adhered to the tenets of the Declaration of Helsinki. It was approved by the 
Tanzanian National Institute of Medical Research Ethics Committee, the Kilimanjaro 
Christian Medical Centre Ethics Committee and the London School of Hygiene and Tropical 
Medicine Ethics Committee. The study was explained to potential study subjects and written, 
informed consent was obtained before enrolment. 
 
Clinical assessment and swab sample collection 
All subjects were examined by an ophthalmologist using ×2.5 loupes and a bright torch. The 
1981 World Health Organization (FPC) trachoma grading system was used to grade 
conjunctival follicles and papillae, entropion, trichiasis and corneal opacity.22 A more detailed 
grading system was used for conjunctival scarring as previously described.23, 24 The 
conjunctiva was anaesthetised with preservative-free proxymetacaine 0.5% eye drops 
(Minims®, Chauvin Pharmaceuticals). An upper tarsal conjunctival swab was collected 
(Dacron polyester-tipped, Hardwood Products Company, Guildford, ME) for C. trachomatis 
detection and put into a dry tube. Samples were kept on ice packs until frozen later the same 
day at -80°C. 
 
Biopsy samples and staining 
The eyelid was injected with 2% lignocaine (Vital Healthcare, India) and the eye cleaned with 
5% povidone iodine. A biopsy sample was taken using a 3mm trephine from the tarsal 
conjunctiva, 2mm from the lid margin, at the junction of the medial ⅔ and lateral ⅓ of the 
everted lid. Samples were immediately placed in 10% neutral buffered formalin and 
subsequently embedded in paraffin wax. Sections, 4 µm thick, were cut perpendicular to the 
conjunctival surface and stained with hematoxylin and eosion (H&E) and for 
immunohistochemistry with the antibodies shown in Table 2. Prior to immunohistochemical 
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staining, sections were dewaxed and pressure-cooked for 4 minutes in de-ionized water with 
antigen retrieval solution (Vector Lab, UK). After incubation at room temperature with the 
primary antibody sections were incubated with a biotinylated secondary antibody, followed 
by streptavadin-conjugated horseradish peroxidase (Dako, UK), and finally 3,3’-
diaminobenzidine (Dako, UK) was used as the chromogen. Endogenous peroxidase was 
inhibited using Real Endogenous Peroxidase Block (Dako, UK). The slides were 
counterstained with Harris hematoxylin. All staining procedures were performed using the 
Dako autostainer (Dako, UK). Positive control samples were provided by human tonsil 
sections and omission of primary antibody controls were used throughout. 
 
Table 2: Summary of primary antibody targets  
 
Antigen Specificity Dilution Source and type 
CD3 T-cells* 1:400 Dako. polyclonal, rabbit. Code no. A.0452. 
CD4 Helper T-cells 1:50 Dako. Monoclonal, mouse. Clone 4B12. 
CD8 Cytotoxic/suppressor  T-cells* 1:100 Dako. Monoclonal, mouse. Clone C8/144B. 
CD20 B-cells 1:600 Dako. Monoclonal, mouse. Clone L26. 
CD45 Nucleated hematopoietic cells 1:800 Dako. Monoclonal, mouse. Clones 2B11+PD7/26. 
CD56 Natural killer cells 1:100 Dako. Monoclonal, mouse. Clone 123C. 
CD68 Macrophages/monocytes 1:100 Dako. Monoclonal, mouse. Clone KP1. 
CD83 Mature dendritic cells 1:75 Serotec AbD. Monoclonal, mouse. Clone HB15e. 
 
Incubation times were 30 minutes for all antibodies 
* Natural killer cell lines can also be identified. 
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Microscopic examination of biopsy samples 
Grading was performed by ophthalmic pathologists who were masked to the clinical status of 
the patients. The grading was performed on the subepithelial tissue (lamina propria and 
stroma unless otherwise stated), on the parameters below, with examples pictures shown in 
Figures 1-11 (see end of manuscript). 
• The degree of scarring was assessed using cross polarised light for both the 
subepithelium and the tarsus. Initial comparison of the examination of picrosirus red 
and other tinctorial stains under cross polarised light showed that the organization of 
collagen bundles was apparent with a variety of staining methods. For assessment 
purposes we used elastin/Van Gieson stained preparations as these sections 
contained all of the samples available. Tissue appearing healthy was graded as 0 
and grades 1-3 used for progressive disorder of the normal appearance.   
• The inflammatory cell density was assessed using the H&E stained slides using an 
ordinal scale of 0-3 where 0=scattered cells; 1=few cells; 2=moderate cells; 
3=abundant/confluent cells. 
• Cellular staining was performed with the antibodies listed in Table 1. The whole of 
the available section was examined and an ordinal scale of 0-3 was used where 
0=no/very few cells; 1=few cells; 2=moderate cells; 3=abundant/confluent cells. 
 
Data analysis 
Data were entered into Access 2007 (Microsoft) and analysed using STATA 11.0 (StataCorp 
LP, TX). Fisher’s exact tests were used to determine the strength of association for the 
parameters graded according to case-control status. 
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Results 
 
Study participants 
Demographic and clinical characteristics of the participants are shown in Table 3. All of the 
cases had trichiasis, defined as at least one lash rubbing against the globe or evidence of 
recent epilation with a suggestive history. The majority of the cases were of Maasai ethnicity, 
while the controls were more evenly divided between different ethnic groups. Clinically 
visible conjunctival inflammation was very strongly associated with the presence of scarring. 
Lymphoid follicles, which are the clinical hallmark of active disease in children, were not 
seen in any of the participants. Infection with C. trachomatis was not detected in any of the 
participants. Surgery was performed on the right eye of 14 (40%) of the cases and 19 (58%) 
of the controls.  
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Table 3: Demographic and clinical characteristics 
Parameter Cases 
N = 34 
Controls 
N = 33 
p-value* 
Demographic Characteristics    
Female [n (%)]  22 (64.7) 15 (45.5) 0.09 
Age in years [ū (95%CI)] 69.6 (65.6-73.6) 67.1 (62.1-72.1) 0.52 
Ethnicity [n (%)]      <0.001 
Maasai 28 (82.3) 0 (0.0)  
Chagga 4 (11.8) 14 (42.4)  
Pare 0 (0.0) 8 (24.2)  
Other 2 (5.9) 11 (33.3)  
Any education [n (%)] 4 (12.5) 26 (86.7) <0.001 
      
Clinical Characteristics     
Scarring grade [n (%)]      
S0 - - 33 (100)  
S1a 0 0 - -  
S1b 0 0 - -  
S1c 6 (17.7) - -  
S2 5 (14.7) - -  
S3 23 (68.6) - -  
Papillary inflammation grade [n (%)]    <0.001 
P0 4 (11.8) 31 (93.9)  
P1 5 (14.7) 1 (3.0)  
P2 18 (52.9) 1 (3.0)  
P3 7 (20.6) 0 (0.0)  
 
* Using the Fisher’s exact test, and the Wilcoxon ranked sum test for age. 
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Histological scarring 
In healthy subepithelial tissue there could be seen short connective fibres running parallel to 
the surface in an ordered manner. In healthy tarsal tissue long connective tissue fibres 
passing between the meibomian glands could be seen, perpendicular to the surface, which 
terminated in shorter fibres running parallel to the surface, giving rise to a “T” appearance. 
On examination with cross polarised light all of the samples from control participants except 
for one had the “T-sign” visible in the tarsal connective tissue while all of the cases had 
some disorganisation of this appearance (Table 4). A similar pattern, although with slightly 
less well marked differentiation between cases and controls, was seen in the subepithelial 
connective tissue. 
 
Table 4: Connective tissue scarring grade using polarised light 
Scarring grade Cases Controls p-value* 
n  (% ) n (%)  
Subepithelial tissue N = 29 N = 31 <0.001 
0 3 (10.3) 26 (83.9)  
1 13 (44.8) 5 (16.1)  
2 12 (41.4) 0 (0.0)  
3 1 (3.5) 0 (0.0)  
Tarsal tissue N=13† N=32 <0.001 
0 0 (0.0) 31   
1 5 (38.5) 0 (0.0)  
2 6 (46.1) 1 (3.1)  
3 2 (15.4) 0 (0.0)  
 
* Using Fishers’ exact test. 
† Insufficient tarsal tissue limited the number available for grading. 
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Inflammatory cells 
Cases had significantly more inflammatory cells than controls, assessed both with the H&E 
and CD45 stains. Table 5. A number of sections were noted to have a marked inflammatory 
cell infiltrate in which a large proportion of the cells were CD45 negative, Figure 12. The 
inflammatory cell infiltrate was analysed in relation to the presence of clinical inflammation 
(with significant inflammation defined as grades P2/3 and non significant inflammation as 
grades P0/1). This was restricted to cases only, as clinical inflammation was very strongly 
associated with case-control status. There was no significant difference for the H&E infiltrate 
(p=0.59) or the CD45 infiltrate (p=0.38) in inflamed vs non-inflamed cases, although the 
number of non-inflamed cases was small (n=9). The inflammatory infiltrates were more 
severe in non-inflamed cases compared to non-inflamed controls, for both the H&E infiltrate 
(p=0.005) and CD45 infiltrate (p=0.001). 
 
Table 5: Inflammatory cell infiltrates 
Parameter Cases Controls p-value* 
n  (% ) n (%)  
H&E inflammatory infiltrate N=32 N=33 <0.001 
0 0 (0.0) 16 (48.5)  
1 15 (46.9) 14 (42.4)  
2 8 (25.0) 3 (9.1)  
3 9 (28.1)   0 (0.0)  
Cellular CD45 staining N=34 N=33 <0.001 
0 6 (17.7) 21 (63.6)  
1 11 (32.3) 11 (33.3)  
2 9 (26.5) 0 (0.0)  
3 8 (23.5) 1 (3.0)  
 
* Using Fisher’s exact test. 
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Specific immunohistochemical cell staining 
Cases had significantly more CD8+, CD56+ and CD20+ cells than controls (Table 6). More 
than half of the cases had grade 2 for CD8+ cells compared to very few of the controls 
(p=0.001, none of the sections graded as 3). Almost a third of the cases were grade 2 for 
CD56+ cells compared to none of the controls (p=0.001), none of the sections were grade 
3).   Almost half of the cases had grades 2 or 3 for CD20+ cells compared to very few of the 
controls (p=0.03). Of borderline statistical significance, cases had marginally more CD3+ 
cells than controls. There was a significant association between the presence of CD8+ and 
CD56+ cells (Table 6). Neutrophils (which are generally easily apparent on histological 
sections without specific immunohistochemical staining) were very infrequent in either cases 
or controls and therefore no formal grading was undertaken. 
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Table 6: Specific cellular stains 
Cellular stain Cases Controls p-value* 
n  (% ) n (%)  
CD3 N=33 N=33 0.06 
0 16 (48.5) 20 (60.6)  
1 12 (36.4) 13 (39.4)  
2 5 (15.1) 0 (0.0)  
3 0 (0.0) 0 (0.0)  
CD4 N=33 N=32 0.36 
0 10 (30.3) 6 (18.8)  
1 19 (57.6) 24 (75.0)  
2 4 (12.1) 2 (6.2)  
3 0 (0.0) 0 (0.0)  
CD8 N=33 N=32 0.001 
0 0 (0.0) 1 (3.1)  
1 14 (42.4) 27 (84.4)  
2 19 (57.6) 4 (12.5)  
3 0 (0.0) 0 (0.0)  
CD20 N=32 N=33 0.03 
0 8 (25.0) 13 (39.4)  
1 10 (31.3) 16 (48.5)  
2 10 (31.3) 4 (12.1)  
3 4 (12.5) 0   
CD56 N=20† N=31 0.001 
0 8 (40.0) 10 (32.3)  
1 6 (30.0) 21 (67.7)  
2 6 (30.0) 0 (0.0)  
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3 1 (4.2) 2 (6.7)  
CD68 N=33 N=33 0.33 
0 23 (69.7) 23 (69.7)  
1 10 (30.3) 8 (24.2)  
2 0 (0.0) 2 (6.1)  
3 0 (0.0) 1 (0.0)  
CD83 N=32 N=33 0.68 
0 6 (18.8) 8 (24.2)  
1 16 (50.0) 16 (48.5)  
2 10 (31.2) 8 (24.2)  
3 0 (0.0) 1 (3.0)  
 
* Using Fisher’s exact test. 
† A number of the sections were no longer available for CD56 staining owing to limited 
sample.  
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Discussion 
 
In this study we have characterised in detail the morphological and cellular changes found in 
trachomatous scarring. Scarring was found to be associated with marked infiltrates of CD8+ 
and CD56+ cells compared to controls. CD56 is a maker for natural killer (NK) cells, 
although usually in combination with other phenotypic markers of cell lineage.25-27 The CD8 
antigen can be expressed by both T-cells and NK cells.26 If the identified cells were CD8+ T-
cells they would be expected to co-express CD3. However, there was a marked lack of 
CD3+ cells relative to CD8+ cells. This suggests that the increased CD8+ cells found in 
scarred conjunctiva may be NK cells. There was a significant association between CD8+ 
and CD56+ infiltrates, Table 7 (p=0.03 with Fisher’s exact test). These results overall 
support the finding that scarred conjunctiva in trachoma contains a prominent NK cell 
infiltrate. The CD8 and CD56 stains were done on sections from different ends of the biopsy 
sample which might explain their association not being stronger. 
 
 
Table 7: Comparison of CD8 and CD56 cellular grading 
   CD56   
  0 1 2 Total 
 0 1 0 0 1 
CD8 1 12 20 1 33 
 2 5 7 5 17 
 Total 18 27 6 51 
 
Fisher’s exact test = 0.03 
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NK cells represent around 10-15% of circulating lymphocytes and were historically identified 
as granular lymphocytes that can lyse target cells without previous sensitisation.25, 27 They 
are generally considered to be part of the innate immune response as they lack the fine 
antigen specificity of T and B-cells and respond rapidly to bacterial, viral and parasitic 
infections through a variety of pattern recognition receptors.28 They can also have a 
regulatory role on both innate and adaptive immunity through the production of cytokines 
and pro-inflammatory mediators, notably interferon gamma (IFNү). More recently, a form of 
NK cell adaptive memory to diverse antigens has been described.29 NK cells lack a single 
defining genetic or phenotypic characteristic and share considerable overlap with cytotoxic 
CD8+ T-cells.26 While NK cells are usually described as being CD3 negative, CD3 subunit 
chains may be identified with immunohistochemistry. 
 
Until recently NK cells had received relatively little attention in trachoma research. However, 
a microarray study of active disease in children found extensive evidence for enrichment of 
genes in pathways that regulate NK cell activation and cytoxicity.9 NK cells have been found 
to be a major source of IFNү, a key cytokine in the immune response to C. trachomatis 
infection, in trachomatous patients.30 Infection of epithelial cell lines with C. trachomatis 
render them susceptible to NK cell lysis and a murine model of C. trachomatis infection 
found NK cell depletion to exacerbate the course of infection.31-33 While the results of the 
present study require confirmation they indicate that NK cells may be important in the 
development of scarring complications. Repeated C. trachomatis infection may cause a 
pathological NK cell response resulting in tissue damage either through a direct cytolytic 
effect or through the production of cytokines and related molecules. This would be consistent 
with recent studies pointing towards the importance of innate immune responses in the 
pathogenesis of trachoma and warrants further investigation into the role of NK cells.7, 9, 10 
 
Some of the findings in our study contrast with two previous immunohistological studies on 
biopsy samples from subjects with trachomatous scarring. Both found increased T-cell 
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populations in scarred tissue and suggested that in inflamed cases these were 
predominantly CD4+ T-cells and in non-inflamed cases predominantly CD8+ T-cells.12, 14 
However, these studies had a number of methodological and analytical differences which 
may explain the discrepancy with our conclusions. The first study recruited only three control 
participants whose demographic details were not presented; the grading system used was 
not defined; only limited data was presented and no significance testing was performed.12 
The second study appears to have been performed in a non-trachoma endemic region; it 
also utilised only three control samples which were collected post-mortem after various 
causes of death; cases were divided into inflamed or non-inflamed on the basis of the 
number of immunohistochemically stained cells present in relation to control samples (rather 
than clinical status); and limited data was presented since statistical tests for significance 
were not presented and would not have been appropriate with such a limited sample size.14 
Other studies looking at cell populations in trachomatous scarring have not included control 
tissue or presented quantitative data.11, 19 
 
We also found evidence that trachomatous scarring is associated with increased numbers of 
CD20+ B-cells. Anti-chlamydial antibodies have been found in tears and sera of both 
children with active disease and adults with scarring. Whether these are protective, or simply 
markers of previous infection, is not known.34-37 Animal models of genital tract infection have 
supported the role of humoral immunity in protection against re-infection.38-40  
 
We found no evidence suggestive of increased T-helper cells (CD4+), macrophages 
(CD68+) or neutrophils in scarring. The presence of neutrophils tends to be short-lived, 
however, and it is possible that a significant neutrophil presence may not have been 
detected by our analysis.  There was also no difference in the levels of cells expressing 
CD83+, a marker of mature dendritic cells. However, dendritic cell immunophenotyping is 
complex. This normally requires a combination of staining intensity coupled with positive and 
negative markers in order to confidently identify specific DC phenotypes. This was beyond 
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the scope of this study due to the limited amount of biopsy tissue and the total number of 
immunohistochemical markers used. A marked inflammatory cell infiltrate was seen in 
biopsies from individuals with scarring which could was not accounted for by the specific 
stains and increased numbers of  CD8+, CD56+ and CD20+ cells.  It was also notable that 
in a number of cases there were numerous CD45 negative inflammatory/immune cells 
present. We had not anticipated this finding based on previous studies as we had expected 
most or all of the inflammatory cells present to be positive for CD45 which is expressed on 
nearly all nucleated cells of hematopoietic origin.41 The identity of these CD45 negative cells 
infiltrating scarred tissue remains an enigma. However, one of several potential explanations 
might be the induction of  follicular dendritic cells, which are non-hematopoietic in origin and 
associated with lymphoid follicle formation.42, 43  
 
Conjunctival inflammation is probably on the causal pathway to the development and 
progression of scarring complications in trachoma and we found the presence of scarring to 
be very strongly associated with clinical inflammation.44-48 Of interest, our data showed that 
cases with more clinical inflammation did not have increased histological cellular infiltrates 
compared to less inflamed cases. Non-inflamed cases did, however, have increased 
infiltrates compared to non-inflamed controls. While there were small numbers involved in 
these comparisons, they do suggest that the scarring itself is associated with 
inflammatory/immune cell infiltration, rather than simply being part of a general inflammatory 
response. 
 
This study benefitted from including a sizeable number of control participants who were well 
matched for age. The socio-demographic background of the controls was probably different 
to the cases, as reflected in the different educational levels. However, many of the controls 
were identified through outreach programmes in rural areas where trachoma is typically 
found and most had had the cost of their surgery subsidised. Identifying control subjects with 
a completely identical background to scarred trachoma cases is challenging as often the 
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majority of older adults have some scarring in a trachoma-endemic area. The inclusion of 
control participants has allowed us to compare the normal pattern of conjunctival immune 
cells to that found in scarring trachoma. This comparison is essential for interpretation of 
diseased tissue, especially in the regions where trachoma is found as these tend to have a 
relatively high prevalence of conjunctival bacterial infection.23, 49 Studies of normal 
conjunctival cell populations have found various inflammatory/immune cells are normally 
present with T cells most commonly found, but also B-cells, macrophages, NK cells, 
neutrophils and dendritic cells.50-53 Varying proportions of CD4+:CD8+ cells have been found 
depending on the study and conjunctival location, but with overall roughly equal numbers, or 
a slight predominance of CD8+ cells, in the tarsal stroma.50-53 In this study we found a 
predominance of CD8+ cells over CD4+ cells in controls.    
 
Quantification of tarsal conjunctival scarring is not straight-forward with a paucity of robust 
grading systems in the literature. In this study we developed a novel system for grading both 
the sup-epithelial and tarsal connective tissue using cross polarised light. This allowed us to 
directly visualise collagen fibres and the grading closely corresponded to the clinical status. 
The association was particularly strong for grading the tarsal connective tissue where the 
fibres were longer and could be more easily visualised.  
 
We chose to use an ordinal scale for grading of the sections with the observer masked to the 
clinical status. A commonly employed alternative form of analysis involves cell counts on 
representative fields. However, the choice of fields is open to bias unless done in a random 
manner, and this method also restricts the amount of tissue analysed.  
 
In conclusion, our study found evidence of a NK cell infiltrate in scarring trachoma and lends 
further support to studies implicating innate immune responses in the pathogenesis of 
trachoma. Scarred tissue was also infiltrated by large numbers of CD45 negative cells and 
further work is required to characterise these cells.  
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Figure 1:  Example grading photos for the histological grading of connective tissue scarring in 
the conjunctival subepithelial tissue using cross polarized light. The top images shows collagen 
fibres parallel with the surface found in normal tissue (arrows) and is graded 0. Subsequent 
images show progressive disorganisation of this appearance, grades 1-3. Original magnification 
×100. 
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Figure 2: Example grading photos for the histological grading of connective tissue scarring in 
the tarsal tissue using cross polarized light. The top image shows long collagen fibres between 
the meibomian glands which join shorter fibres next to the stroma forming a “T” sign in normal 
tissue (arrow), which is graded 0. Subsequent images show progressive disorganisation of this 
appearance, grades 1-3. Original magnification ×100. 
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Figure 3: Example grading photos for the inflammatory cell infiltrate on the heamtoxylin and 
eosin stain in the sub-epithelium (arrows). Original magnification ×200. 
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Figure 4: Example grading photos for CD45+ cells in the sub-epithelium (stained brown). 
Original magnification ×200. 
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Figure 5: Example grading photos for the CD3+ cells in the sub-epithelium (stained brown). No 
section was given a grade 3. A proportion of the inflammatory/immune cells present are CD3 
negative and do not stain with the brown chromagen (arrows). Original magnification ×200. 
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Figure 6: Example grading photos for the CD4+ cells in the sub-epithelium (stained brown, 
arrows). No section was given a grade 3. Original magnification ×200. 
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Figure 7: Example grading photos for the CD8+ cells in the sub-epithelium (stained brown). No 
section was given a grade 3. Original magnification ×200. 
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Figure 8: Example grading photos for the CD20+ cells in the sub-epithelium (stained brown). 
Original magnification ×200. 
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 The sections stained for CD20+ cells also showed focal collections of cells. The below is an 
example of a focal collection of cells given a grade 3. Original magnification ×200. 
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Figure 9: Example grading photos for the CD56+ cells in the sub-epithelium (stained brown). 
No section was given a grade 3. Original magnification ×200. 
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Figure 10: Example grading photos for the CD68+ cells in the sub-epithelium (stained brown). 
No section was given a grade 3. Original magnification ×200. 
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Figure 11: Example grading photos for the CD83+ cells in the sub-epithelium (stained brown). 
Original magnification ×200. 
 
 
Grade	  0	  
Grade	  1	  
Grade	  	  2	  
Grade	  3	  
 
 
Victor Hu   PhD thesis   253
Figure 12: CD45 negative inflammatory/immune cells. (CD45 negative cells indicated by 
arrows; CD45+ cells staining brown indicated by broken arrows). Original magnification ×400. 
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 Chapter 14 
Overall conclusions and future work 
 
 
 
 
General discussion drawn from all of the contributing work 
including details of ongoing projects and potential future 
studies 
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Trachoma remains a major public health problem worldwide. Using data from 2002 the WHO 
estimated that 1.3 million people were blind from trachoma.1 However, there was an even 
larger number blind from “corneal opacities”, much of which may be attributed to trachoma. 
Many more people suffer from serious visual impairment as a result of trachoma including 
those with constant ocular discomfort from trichiatic lashes abrading the cornea. There does 
appear to have been encouraging reductions in the number of children with active disease 
over the last few decades. However, there are still estimated to be 40 million affected at any 
one time and these children are at risk of future cicatricial complications. There has not been 
a corresponding reduction in the numbers estimated to have trichiasis. Trachoma is still very 
prevalent in poor, under-resourced areas such as Ethiopia and Sudan. The aim of this work 
was to further our understanding of the pathogenesis of trachomatous scarring with the 
objective of informing current trachoma control strategies and aiding in the development of 
future interventions to reduce blindness. 
 
Innate immune responses 
Both of the case-control studies employed in this work found evidence that innate immune 
responses are associated with trachomatous scarring. Gene expression data from the 
Trachomatous Scarring (TS) study found that cases had increased expression of the innate 
molecules S100A7, DEFB4A and CXCL5 and the pro-inflammatory mediators TNFα and 
IL1B. The Trachomatous Trichiasis (TT) biopsy study indicated that scarred conjunctiva 
contains a greater infiltrate of Natural Killer (NK) cells than control tissue. NK cells respond 
to pathogens through pattern recognition receptors and are generally considered to be part 
of the innate immune response. These findings are consistent with recent transcriptome 
studies from The Gambia and Ethiopia, in children and adults, which found enrichment of 
innate pathways including NK cell related transcripts.2, 3 Animal models of ocular and genital 
C. trachomatis infection and in vitro studies have also indicated that innate immune 
responses play an important role in tissue damage and the development of fibrotic 
complications.4-7 The role of NK cells in the development and progression of scarring 
requires further investigation. The function of these cells is still being studied but range from 
direct lysis of infected cells as an early reponse to the release of mediators that shape T and 
B cell responses. The possibility of an NK cell-based adaptive immunity which is 
independent of the recombination-activating gene (RAG) associated antigen receptors seen 
in T and B cells has challenged the way we think about immune memory. NK cells are a 
major source of IFNү in response to C. trachomatis elementary bodies and it is likely that 
they are activated as part of the initial, innate response to infection. Our work suggests that 
they are also involved in mediating tissue damage. The LSHTM Trachoma Study Group is 
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planning further work including in vitro examination of NK cells responses to C. trachomatis 
elementary bodies in relation to trachomatous scarring phenotype. 
 
There is good evidence that clearance of C. trachomatis infection relies on a Th1 response 
involving IFNү. We were interested in examining the hypothesis that a predominantly Th2 
response is associated with scarring, one that has gained some support in the literature. 
However, scarring was not associated with increased IL13 expression, but there was 
actually evidence of increased Th1 activity.  This is consistent with a lack of Th2 polarisation 
in microarray studies.2, 3  
 
Understanding the immunopathology of trachoma is important in the rational development of 
a vaccine. A safe and effective vaccine would help prevent future children being infected and 
may help to reduce re-infection in those previously infected, thereby having beneficial effects 
on scarring progression. It could also have potential benefit in the control of genital tract 
infection, also a very major public health problem. Trachoma vaccine studies using 
inactivated whole elementary bodies gave protection little better than natural immunity and 
may have resulted in more severe disease. Understanding the immunobiology of the disease 
will help in the choice of antigen or antigen combination and the adjuvant used, and also in 
the detection of immunopathological responses. 
 
Modification of the extra-cellular matrix (ECM) 
Strong evidence was found for differential expression of various modifiers of the ECM in 
trachomatous scarring including matrix metalloproteinases (MMPs) and SPARCL. The 
expression of SPARCL showed the greatest fold change of all of the genes examined, being 
found 16× less in scarred cases with inflammation, and half as much in scarred cases 
without inflammation, compared to controls. These findings are consistent with previous 
gene expression and polymorphism studies.2, 8-11 A potential avenue of investigation is to 
alter the pro-fibrotic environment found in trachoma with the aim of reducing progression of 
the scarring process. Anti-fibrotic agents after glaucoma surgery have included the use of 
MMP inhibitors.12 An agent such as doxycycline, which can inhibit MMP function and is also 
anti-chlamydial, might be a realistic agent for use in trachoma studies, such as the effect on 
recurrence after trichiasis surgery. 
 
C. trachomatis and non-chlamydial bacterial infection 
C. trachomatis was rarely detected in these studies on scarring trachoma. Five (1.4%) of the 
cases in the TS study and none of the participants in the TT study were positive with 
Amplicor testing. A number of studies have confirmed that infection with C. trachomatis is 
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infrequently found in adults with trachomatous scarring. This is probably partly a result of the 
shortened duration of infection in adults compared to children, thereby making it more 
difficult to detect infection.13, 14 However, even taking this into account, it seems likely that 
other factors are also important in driving the scarring process. One of the hypotheses we 
tested was that non-chlamydial bacterial infection is found more frequently in scarring, and a 
significant association was indeed found. Furthermore, such infection was strongly 
associated with marked fold changes in expression of a number of genes, particularly innate, 
anti-bacterial mediators and ECM modifiers. Non-chlamydial bacterial infection has also 
been found more frequently in children with active disease, and this was also associated 
with differential expression of a number of genes.15, 16 It would appear that the conjunctiva of 
individuals previously exposed to ocular C. trachomatis infection is more vulnerable to 
harbouring both commensal and pathogenic organisms, and the latter, in particular, provoke 
an inflammatory response. This could well be an important factor leading to the development 
and/or progression of scarring complications. This could conceivably be mediated by NK 
cells, initially activated by C. trachomatis infection, being further stimulated by the presence 
of these additional bacteria into an uncontrolled, pathological response. 
 
Future work on a cohort study of progressive scarring 
While the studies in this current work have helped to establish factors associated with the 
presence of trachomatous scarring, it is of interest to analyse whether these factors are also 
associated with the progression of scarring. This would help to provide evidence of a causal 
relationship in the pathogenesis of scarring. To this end I have been leading/conducting the 
field work of a cohort study of 800 individuals with trachomatous scarring who have been 
examined every 6 months for 2 years (a total of 5 examination points). This cohort (which 
includes the cases from the TS Study) have been examined clinically and had high 
resolution digital photographs taken at each examination. Conjunctival swabs for gene 
expression, bacteriology and detection of C. trachomatis were taken at 0, 6, 12 and 18 
months. In vivo confocal microscopy (IVCM) was performed at baseline and at the final 
examination which was completed mid-2011. We are in the process of performing the qPCR 
for this study and analysing the large amount of data generated. Being able to identify 
factors causing progression of scarring will help to focus the development of future 
interventions aimed at reducing blindness. Identification of biomarkers for progressive 
disease can also be used to evaluate the effect of mass antibiotic distribution, a core 
element of the WHO endorsed SAFE strategy.   
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Future work involving immunohistochemical staining of conjunctival biopsies 
A limited amount of tissue is remaining for analysis from the conjunctival biopsies taken as 
part of the TT study. Important points which need addressing are confirmation of the identity 
of the CD8+ and CD45- cell infiltrates seen in scarring. Double staining of a number of 
samples with CD8 and CD56 would provide further confirmation that the CD8+ cells are 
Natural Killer cells. Identification of the infiltrate of CD45 negative cells may require 
extensive further work. Follicular dendritic cells, for example, lack specific cellular markers 
and are difficult to work with.  
 
The biopsies have already been stained for various cytokines and other mediators including 
IL1β, IL13, IL17, S100A7, CXCL5, TGFβ, MMP7 and MMP9. It is anticipated that the grading 
of these sections and the subsequent analysis will help to validate the gene expression 
results from swab samples, and also give information on their origin and tissue distribution. 
 
Microscopic examination of trachomatous scarring 
Scarred and control tissue was examined both with IVCM and with light microscopy on 
histological sections. Novel grading systems were developed for the assessment of scarring 
with both techniques which showed good correlation with clinical examination and with each 
other.  
 
Histological and IVCM analyses found that scarring was associated with increased 
inflammatory cells. This inflammatory cell infiltrate appeared to be more strongly associated 
with scarring than with clinical inflammation.  
 
The fold changes in gene expression seen with clinical scarring in the TS study tended to 
show corresponding fold changes with IVCM scarring. The fold changes were not so marked 
with IVCM, but this may have been because of differences in the types of analysis. Clinical 
scarring could be defined on a binary basis, while the IVCM scarring measurement was 
defined as a categorical variable, analysis of which will reduce the fold changes found. The 
use of IVCM has allowed some novel observations to be made about the pathophysiology of 
trachomatous scarring. Comparison of scans taken from different locations on the tarsal 
conjunctiva showed that the IVCM scarring grade tended to show little variation. If highly 
organised bands or sheets of organised connective tissue were seen in one scan, then the 
other scans usually showed a similar appearance. This indicates that the scarring process 
affects the whole of the conjunctival surface rather than focal areas, as might be concluded 
from clinical examination where bands of scar tissue are often seen. IVCM ma also be able 
to detect sub-clinical scarring. Most of the cellular activity seen with IVCM was very close to 
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the conjunctival surface and this was confirmed on examination of the histological sections. 
This is consistent with the cellular paradigm of pathogenesis which proposes that the release 
of mediators by the epithelium is central in driving pathological responses. IVCM also 
identified dendritiform cells and found that these were very strongly associated with scarring. 
We did not find these structures to be associated with immunohistochemical markers of 
mature, conventional dendritic cells and further work is required to confirm what they are.  
 
Further work on the identification of IVCM dendritiform cells 
In order to identify what these cells are it would be helpful to cut histological sections in the 
same plane that the IVCM image is taken, i.e. en face. This will allow direct comparison of 
the images seen. If tissue can be identified which contains numerous dendritiform cells on 
IVCM, and removed for analysis (such as removal of a tumour with clear surgical margins), 
then sections could be cut en face and stained for a number of dendritic and fibroblast 
markers.  
  
Other potential areas of future work: innate immune responses 
To further investigate the contribution of the innate immune response to the pathogenesis of 
trachoma it would be worthwhile to examine polymorphisms in Killer-cell immunoglobulin-like 
receptors (regulatory cell surface proteins on NK cells) associated with scarring. This would 
provide further confirmation of the role of NK cells in the development of scarring. The 
identification of specific bacterial components provoking innate/scarring responses, either 
with the use of epithelial cell lines or animal models, could also be investigated. 
 
Final conclusion 
This work has potentially helped to change the way we think about the pathogenesis of 
trachoma by providing evidence that innate immune responses are involved, rather than a T-
helper cell type 2 response, and that non-chlamydial bacterial infection may be an important 
driver for this. This work has also shown that clinical, molecular and immunohistological 
features of scarring trachoma are associated with particular IVCM appearances. This 
imaging technique could also be applied to the study of active disease and the identification 
of factors associated with the development/progression of scarring. Infection with C. 
trachomatis appears to play a relatively minor role in driving trachomatous scarring and this 
has very important implications for future trachoma control measures. Even if C. trachomatis 
infection is effectively eliminated there will remain a very large number of people at risk of 
future blindness from trachoma. 
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Appendix 2a:  Information sheet for the TS Study (English) 
 
LSHTM / KCMC TRACHOMA PROJECT 
 
Pathophysiology of Progressive Trachomatous Conjunctival Scarring 
 
Information Sheet 
 
Kilimanjaro Christian Medical Centre, Moshi, Tanzania 
Kilimanjaro Regional Eye Care Programme, Moshi, Tanzania 
International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK 
 
What is this study about? 
 
Trachoma is one of the main causes of blindness in Tanzania. It starts in childhood when children get 
redness and soreness under their eyelids, caused by infection with a bacteria called Chlamydia. As people 
get older they may develop eyelid scarring causing the eyelashes to turn inwards and rub on the eyeball. 
This is called trichiasis. This can cause the clear part of the eye to become white leading to blindness and 
the trichiasis is often painful. Currently, this disease process is only poorly understood and the treatments for 
it are only partially effective. In order to try to understand this better we would like to follow-up a group of 
people with eyelid scarring every six months for 2 years to investigate why some people have progressive 
scarring disease and some do not. 
 
Whose help do we need? 
 
We need the help of people who have scarring of the eyelids from trachoma. 
 
What will we ask you to do?  
 
We will ask you several questions about your eyes. A small sponge or tube may be used to collect tears 
from the inner corner of the eye. Then your eyes will be examined and photographed, to confirm that you 
have scarring from trachoma. We will examine a surface of the eye with a microscope. Three swab samples 
will be collected by gently rubbing the swab on the eyelid. 
 
What benefits are there to taking part in the study? 
 
1. It is only poorly understood how this disease causes blindness. You will be helping us to answer this 
question. 
2. We will check the general health of your eyes and refer you to receive appropriate eye care if 
necessary. 
 
Are there any risks caused by taking part in the study? 
 
There is no known risk from the investigations we will do on your eyes. Collecting swabs samples has been 
done in many studies conducted in Tanzania and elsewhere. 
 
What tests will we do on the swab sample? 
The swab samples will be tested in various ways to try to help improve the understanding of trachoma. 
Samples will be tested in laboratories in Moshi and London. This will involve tests for bacterial and 
chlamydial infection. We will also study the human body’s response to the infection to try to understand 
better how it fights the infection and how the scarring problems develop. It is hoped that information from 
these studies will help in the development of new ways to fight the disease.  
 
 
 
 
What will happen to the records and photos we keep about your eye? 
 
All the information we collect will be kept confidential. It will be kept securely and only the people organising 
the trial will have access to it. 
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Do I have to take part in this study? 
 
You do not have to take part in this study. 
 
 
How many people are taking part in this study? 
 
We plan to recruit 1000 people with eyelid scarring to participate in this study.  
 
 
Who is doing this study? 
 
This project is collaboration between: 
Kilimanjaro Christian Medical Centre, Moshi, Tanzania. 
Kilimanjaro Regional Eye Care Programme, Moshi, Tanzania. 
International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK 
Institute of Ophthalmology, London, UK 
 
Study Organisers: 
Matthew Burton, LSHTM and KCMC 
Victor Hu, LSHTM and KCMC. 
 
If you have any questions please ask us: 
Telephone:  027 275 3240  (Victor Hu or Patrick Massae) 
              Email:  victor.hu@lshtm.ac.uk 
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Appendix 2b:  Information sheet for the TS Study (Kiswahili) 
 
MRADI WA TRACHOMA KCMC/LSHTM 
 
Mabadiliko ya kifuniko cha jicho baada ya kovu 
 
KARATASI YA MAELEZO 
 
Kilimanjaro Christian Medical Centre, Moshi, Tanzania 
Kilimanjaro Regional Eye Care Programme, Moshi, Tanzania 
International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK 
 
TRACHOMA(vikope) INAHUSU NINI? 
 
Trachoma ni mojawapo ya kisababishi cha upofu Tanzania. Inaanza kipindi cha utotoni wakati 
watoto wanapopata maambukizi  ya ugonjwa wa trachoma ndani ya kifuniko cha jicho  ambao 
unasababishwa na vimelea viitwavyo Chlamydia. Wakati watu wanapozidi kukua, kovu katika kifuniko cha 
jicho linazidi kukua na kusababisha kope kuingia ndani na kugusa jicho. Kitendo hiki kinaitwa KIKOPE. 
Kitendo hiki kinaweza kusababisha kioo cha jicho kuwa na kidonda na baadaye kovu na kusababisha upofu 
na maumivu. Kwa sasa, ugonjwa unaweza kuendelea katika hali isiyoeleweka na  matibabu yasiwe bora. Ili 
kuelewa vizuri kuhusu hili, tunatakiwa tuwafuatilie watu wenye kovu chini ya kifuniko cha jicho katika kila 
miezi sita, kwa muda wa miaka miwili ili kuchunguza kwa nini baadhi ya watu wana ugonjwa wa makovu 
yasiyoisha na wengine hawana. 
 
Tunahitaji msaada kwa watu gani? 
 
Tunahitaji msaada kwa watu ambao wana makovu chini ya vifuniko vya macho yao, yanayotokana na 
ugonjwa wa TRACHOMA (vikope). 
 
Tutakuomba ufanye nini? 
 
Tutakuuliza maswali mengi kuhusu macho yako. Pamba ndogo itatumika kukusanya machozi kutoka 
sehemu ya nje ya jicho. Baada ya hapo, macho yako yatafanyiwa uchunguzi na kupigwa picha ili 
kuhakikisha kuwa una kovu linalotokana na trachoma.Tutachunguza sehemu ya nje ya jicho lako kwa 
kutumia darubini. 
 
 
NI FAIDA GANI AMBAZO ZITASAIDIA SOMO HILI? 
1. Haieleweki vizuri ni jinsi gani ugonjwa huu unaweza kusababisha upofu. Utatusaidia kutupa majibu 
ya swali hili. 
2. Tutaangalia afya ya macho yako kwa ujumla na ikiwezekana macho yako yapate uangalifu wa hali 
ya juu. 
JE KUNA HATARI YOYOTE INAYOWEZA KUTOKEA KUTOKANA NA KUHUSIKA NA SOMO HILI? 
 
Hakuna hatari yoyote utakayoyapata kutokana na uchunguzi wa macho yako. Uchukuzi wa sampuli 
umeshafanyika katika masomo mengi  hapa Tanzania na sehemu nyinginezo. 
 
 
 
 
 
MAJARIBIO GANI YANAWEZA KUFANYIKA KWA KUTUMIA SAMPULI ILIYOTOKA KWENYE MACHO 
YAKO? 
 
Sampuli itafanyiwa majaribio kwa kutumia njia mbalimbali ili kukuza uelewa wa Trachoma(vikope). Sampuli 
zitajaribiwa maabara ya Moshi na Uingereza. Itahusisha majaribio ya vimelea na madhara yake.Tutasoma 
pia jinsi mwili unavyoweza kuhusika kutokana na madhara ili kujaribu kuelewa vizuri ni jinsi gani mwili 
unaweza kupambana na madhara na matatizo ya makovu kutokea. Inaaminika kuwa maelezo kutoka 
kwenye masomo haya yatasaidia kuendeleza njia mbadala za kupambana na ugonjwa. 
 
Kitatokea nini kwenye kumbukumbu na picha tunazohifadhi kuhusu jicho lako? 
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Tutakusanya maelezo yote kama siri. Itawekwa kwa usalama na ni kwa watu wale tu ambao wanaoendesha 
jaribio wanaweza kuipata. 
 
Je ni lazima kuhusika kwenye somo hili? 
Hulazimishwi ila ni hiyari yako kushiriki kwenye somo hili.  
 
Ni watu wangapi watashiriki kwenye somo hili? 
 
Tumepanga kuwatembelea  watu 1000 wenye kovu chini ya kifuniko cha jicho kushiriki kwenye somo hili. 
 
Nani anafanya somo hili? 
 
Mradi huu ni ushirikiano kati ya: 
 
Kilimanjaro Christian Medical Centre(KCMC), Moshi, Tanzania 
Kilimanjaro Regional Eye Care Programme, Moshi, Tanzania 
International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK. 
Institute of Ophthalmology,London,UK 
 
Wanaendeshaji wa somo: 
Matthew Burtton, KCMC na LSHTM 
Victor Hu, LSHTM na KCMC 
 
Kwa maswali yoyote tuulize kupitia: 
Barua pepe:victor.hu@lshtm.ac.uk 
Simu: 0272753240(Victor Hu au Patrick Massae) 
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Appendix 2c:  Information sheet for the TT Study (English) 
 
Pathology of Trachomatous Conjunctival Scarring: A Case-Control Study 
 
Kilimanjaro Christian Medical Centre, Moshi, Tanzania 
Kilimanjaro Center for Community Ophthalmology, Moshi, Tanzania 
Kilimanjaro Regional Eye Care Programme, Moshi, Tanzania 
International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK 
 
What is this study about? 
Trachoma is one of the main causes of blindness in Tanzania. It starts in childhood when children get 
redness and soreness under their eyelids, caused by infection with a bacteria called Chlamydia. As people 
get older they may develop eyelid scarring causing the eyelashes to turn inwards and rub on the eyeball. 
This is called trichiasis, and you will be having surgery to correct this. Trichiasis can cause the clear part of 
the eye to become white leading to blindness is often painful. Currently, this disease process is only poorly 
understood and the treatments for it are only partially effective. In order to try to understand this better we 
would like to examine a group of people with eyelid scarring. 
 
Whose help do we need? 
We need the help of people who have eye lid scarring from trachoma and people without scarring. 
 
What will we ask you to do? 
We will ask you several questions about your eyes. A small sponge or tube will be used to collect tears from 
the inner corner of the eye. Then your eyes will be examined and photographed, to confirm the prescence of 
trachoma scarring. We will examine the surface of the eye with a microscope. Anaesthetic drops will be put 
in the surface of the eye to make it numb. Three swab samples will be collected by gently rubbing the swab 
on the eyelid. We will take a very small (2mm by 2mm) piece of tissue from the inner surface of the upper lid, 
after turning the lid over. You will be offered a routine post-operative review about 1 to 2 weeks after the 
operation. 
 
What benefits are there to taking part in the study? 
1. Trachoma is a poorly understood disease. You will be helping us to learn new things which will 
hopefully help in the development of ways of preventing blindness.. 
2. Your eyes will receive a thorough examination for infection, inflammation or scarring. 
3. If you have signs of an active infection we would provide appropriate treatment for this. 
 
 
Are there any risks caused by taking part in the study? 
There is no known risk from taking swab or tear samples, and has been done in many studies conducted in 
Tanzania and elsewhere. Several studies have collected small biopsy samples from the inner surface of the 
upper lid, without any problems. There is a very low risk of infection following surgery; this risk will be 
minimized by the use of antibiotic ointment, which is standard practice after eye surgery. If you experience 
any unusual problems or pain after the operation, before or after your scheduled post-operative review, you 
are advised to contact us for assistance. You will be provided with written contact information on your 
discharge. 
 
 
What tests will we do on the swab sample? 
The samples will be tested in various ways to try to help improve the understanding of trachoma. Samples 
will be tested in laboratories in Moshi and England. This will involve tests for bacterial and chlamydial 
infection and examining the tissue for inflammation or scarring. We will also study the human body’s 
response to the infection to try to understand better how it fights the infection and how the scarring problems 
develop. The biopsy specimens will be examined at the Institute of Ophthalmology in London. We would like 
to archive the biopsy material indefinitely, so that in the future if new information about trachoma disease 
arises it will be possible to return the specimens to perform additional histopathological analysis. It is hoped 
that information from these studies will help in the development of new ways of preventing blindness from 
trachoma. 
What will happen to the records and photos we keep about your eye? 
All the information we collect will be kept confidential. It will be kept securely and only the people organising 
the trial will have access to it. 
 
Do I have to take part in this study? 
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You do not have to take part in this study. 
 
Who is doing this study? 
This project is a collaboration between: 
Kilimanjaro Christian Medical Centre, Moshi, Tanzania. 
Kilimanjaro Center for Community Ophthalmology, Moshi, Tanzania 
Kilimanjaro Regional Eye Care Programme, Moshi, Tanzania. 
International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK 
Institute of Ophthalmology, London, UK 
 
Study Organisers: 
William Makupa, Kilimanjaro Centre for Community Ophthalmology, KCMC, Moshi, Tanzania. 
Wahida Shangali, Mawenzi Regional Hospital, Moshi, Tanzania 
Matthew Burton, Kilimanjaro Centre for Community Ophthalmology, KCMC, Moshi, Tanzania. 
Victor Hu, Kilimanjaro Centre for Community Ophthalmology, KCMC, Moshi, Tanzania. 
 
If you have any questions please ask us: 
Telephone:  027 275 3547  (Victor Hu or Matthew Burton) 
Email:  victor.hu@lshtm.ac.uk 
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Appendix 2d:  Information sheet for the TT Study (Kiswahili) 
 
MRADI WA TRAKOMA KCMC/LSHTM 
MABADILIKO YA KIFUNIKO CHA JICHO BAADA YA KOVU 
KARATASI YA MAELEKEZO KWA WATU WENYE VIKOPE 
 
Kilimanjaro Christian Medical Centre, Moshi, Tanzania 
Kilimanjaro Regional Eye Care Programme, Moshi, Tanzania 
International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK 
 
Utafiti huu unahusu nini? 
Trachoma ni mojawapo ya kisababishi cha upofu Tanzania. Inaanza kipindi cha utotoni wakati watoto 
wanapopata maambukizi  ya ugonjwa na kusababisha wekundu na uvimbe ndani ya kifuniko cha jicho  
ambao unasababishwa na wadudu wanaoitwa Chlamydia. Wakati watu wanapozidi kukua, kovu katika 
kifuniko cha jicho linazidi kukua na kusababisha kope kuingia ndani na kukwaruza jicho. Kitendo hiki 
kinaitwa KIKOPE na inawezekana kurekebishwa kwa kufanyiwa upasuaji. Kitendo hiki kinaweza kusababisha 
sehemu nyeupe ya jicho kuwa na ukungu   baadaye kovu na kusababisha upofu na maumivu ya mara kwa 
mara.Mpaka sasa hali ya ugonjwa huu haieleweki na kufanya matibabu yake yasiwe kamilifu. Ili kujaribu  
kuelewa vizuri kuhusu hili, tungependa kulinganisha idadi ya watu wenye makovu katika kifuniko cha jicho 
na idadi ileile ya watu ambao hawajaathirika.  
 
Tunahitaji msaada kwa watu gani? 
Tunahitaji msaada kwa watu ambao wana makovu chini ya vifuniko vya macho yao yatokanayo na vikope. 
 
 Tutakuomba ufanye nini? 
Tutakuuliza maswali mbalimbali kuhusu macho yako. Tutatumia pamba ndogo au kichupa kidogo 
kukusanya machozi kutoka sehemu ya kona ya ndani ya jicho. Kisha, macho yako yatafanyiwa uchunguzi na 
kupigwa picha ili kuhakikisha kama una kovu linalotokana na trakoma.Tutachunguza sehemu ya jicho lako 
kwa kutumia darubini. Tutakuweka dawa kidogo ya kuondoa maumivu ndani ya jicho ambayo itakupa 
ganzi.Tutachukua kipande kidogo cha nyama sehemu ya kifuniko cha jicho.Utapewa taarifa ya mara kwa 
mara baada ya upasuaji husika kufanyika katika muda wa wiki moja hadi  mbili. 
 
Kuna faida zipi ukishiriki kwenye utafiti huu? 
3. Trakoma ni ugonjwa ambao haujaeleweka. Unaweza kutusaidia sisi kufahamu njia mpya ambazo 
natumaini zitatusaidia kukuza njia za kuepuka au za kuondokana na upofu. 
4. Macho yako yatafanyiwa uchunguzi wa kina ili kujua kama una maambukizi,uvimbe au upofu. 
5. Kama una dalili za maambukizi,tungependa kukupa matibabu sahihi ya ugonjwa huu 
Je kuna athari zozote zinaweza kutokea kutokana na utafiti huu? 
 
Hakuna athari yoyote utakayoyapata kutokana na uchunguzi wa macho yako. Uchukuzi wa sampuli 
umeshafanyika katika tafiti nyingi  hapa Tanzania na sehemu nyinginezo.Katika tafiti nyingi tulikusanya 
sampuli kidogo kutoka ndani,(chini ya kifuniko) cha jicho bila matatizo.Baada ya upasuaji,kuna uwezekano 
wa kupata madhara kidogo sana utakayoyapata,na madhara hayo yanaisha baada ya kupewa dawa ya 
macho,ambayo ni ya kuua vijidudu(antibiotic) ambapo ni kawaida baada ya  upasuaji.Kama utaendelea 
kupata matatizo au maumivu baada ya upasuaji,utatakiwa kuwasiliana na sisi kwa uangalizi,pia utatakiwa 
kutupa namna ya mawasiliano na sisi wakati wa kupewa ruhusa. 
 
Je,ni majaribio gani yatafanyika kwa kutumia sampuli tuliyopata kwenye macho yako? 
Sampuli zitafanyiwa majaribio mbalimbali ili kupata uelewa zaidi wa ugonjwa wa Vikope. Sampuli 
zitafanyiwa majaribio kwenye maabara ya Moshi (KCMC) na Uingereza. Hii itahusisha majaribio ya 
maambukizi ya vijidudu vya vijidudu vya bacteria wa Chlamydia. Pia kupima kijinyama kilichotolewa 
kwenye kovu lililopo chini ya kifuniko cha jicho.Tutajifunza jinsi mwili wa binadamu unavyojikinga na 
mashambulizi ya vijidudu na jinsi kovu linavyotokea. Kijinyama kitachunguzwa katika chuo cha 
macho,Uingereza (Institute of ophthalmology London).Tungependa kupokea sampuli hizi wakati wowote 
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na kuhifadhi ili hata baadaye ikihitajika irudishwe kwa uchunguzi zaidi.Tunategemea uchunguzi kama huu 
utatusaidia kupata njia mpya za kuzuia upofu utokanao na vikope.  
 
Ni nini kitatokea kwenye kumbukumbu na picha tutakazotunza kuhusu macho yako? 
Maelezo yote yanayokusanywa yatahifadhiwa kwa siri.  Yatatunzwa kwa usalama na ni kwa wale tu ambao 
wanafanya utafiti huu ndio wanaweza kuzipata. 
 
Je ni lazima kushiriki kwenye utafiti huu? 
Hakuna ulazima wowote wakushuriki kwenye utafiti huu. 
 
Je ni watu wangapi watachukuliwa kushiri kwenye utafiti huu? 
Tumepanga kuwashirikisha watu mia mbili (200) ambao wana kovu kwenye kifuniko cha jicho ili kushiriki 
katika utafiti huu. 
 
Je ni nani anafanya utafiti huu? 
Mradi huu ni ushirikiano kati ya:- 
Kilimanjaro Christian Medical Centre, Moshi Tanzania. 
Kilimanjaro Center for Community Ophthalmology, Moshi Tanzania. 
Kilimanjaro Regional Eye Care Programme, Moshi Tanzania. 
International Centre Eye Health, London School of Hygiene & Tropical Medicine, UK 
Institute of Ophthalmology, London, UK. 
 
Waendeshaji wa utafiti:- 
William Makupa, Kilimanjaro Centre for Community Ophthalmology, KCMC, Moshi, Tanzania. 
Wahida Shangai, Mawenzi Regional Hospital, Moshi Tanzania. 
Matthew Burton, Kilimanjaro Centre for Community Ophthalmology, KCMC, Moshi Tanzania. 
Victor Hu, Kilimanjaro Centre for Community Ophthalmology, KCMC, Moshi Tanzania. 
 
Kwa maswali zaidi tafadhali wasiliana nasi kwa: 
Simu:  027 275 3547 (Victor Hu, and Matthew Burton) 
Barua pepe:  victor.hu@lshtm.ac.uk 
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Appendix 3a:  Consent form for the TS Study (English) 
 
LSHTM / KCMC TRACHOMA PROJECT 
Pathophysiology of Progressive Trachomatous Conjunctival Scarring 
Consent Form 
 
Kilimanjaro Christian Medical Centre, Moshi, Tanzania 
Kilimanjaro Regional Eye Care Programme, Moshi, Tanzania 
International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK 
 
 
 
Name: ……………………………………………………………………. 
 
Subject reference  number: 
     
I have read / had explained to me the information about the research study. I understand what will be 
involved in taking part in the study.  
 
 
 
……………………..........................................  has answered all my questions about the study. 
 
I agree to take part in this study. 
 
 
 
 
Signed / Thumbprint………………………………..       Date…………………….. 
 
I have explained the purpose of the study to the above subject and I am satisfied that he/she willingly agrees 
to participate 
 
 
 
Signed……………………………………..       Date…………………….. 
 
Name:………………………………. 
 
In the event that the patient cannot read the above information, an additional witness is required: 
I have witnessed the explanation and informed consent to this study of above named patient 
 
 
 
Signed……………………………………..       Date…………………….. 
 
Name:………………………………. 
 
Study Organisers: 
Matthew Burton, Kilimanjaro Centre for Community Ophthalmology, KCMC, Moshi, Tanzania. 
Victor Hu, Kilimanjaro Centre for Community Ophthalmology, KCMC, Moshi, Tanzania.  
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Appendix 3b:  Consent form for the TS Study (Kiswahili) 
 
FOMU YA RIDHAA 
 
Kilimanjaro Christian Medical Centre, Moshi, Tanzania 
Kilimanjaro Regional Eye Care Programme, Moshi, Tanzania 
International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK 
 
 
 
Jina: ……………………………………………………………………. 
 
Subject reference  number:
     
 
Nimesoma/nimeelezewa maelezo kuhusu somo la utafiti.Nimeelewa nini kitahusika katika sehemu ya somo 
hili 
 
 
 
……………………..........................................  amejibu maswali yote kuhusu somo hili. 
 
Nimekubali kuwa sehemu ya somo hili 
 
 
 
 
Imesainiwa na/ kidole gumba………………………………..       Tarehe…………………….. 
 
Nimeelezea lengo la somo hapo juu na nimeridhika me/ke yupo tayari na amekubali kushiriki 
 
 
 
 
Imesainiwa na……………………………………..       Tarehe…………………….. 
 
Jina:………………………………. 
 
 
Katika tukio ambalo mgonjwa hawezi kusoma maelezo hapo juu,shahidi wa ziada anatakiwa: 
 
Nimetoa ushahidi na maelezo ya ridhaa ya somo hili kwa mgonjwa hapo juu. 
 
 
 
Imesainiwa na ……………………………………..       Tarehe…………………….. 
 
Jina:………………………………. 
 
Washiriki wa somo: 
Matthew Burton, Kilimanjaro Centre for Community Ophthalmology, KCMC, Moshi, Tanzania. 
Victor Hu, Kilimanjaro Centre for Community Ophthalmology, KCMC, Moshi, Tanzania. 
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Appendix 3c:  Consent form for the TT Study (English) 
Pathology of Trachomatous Conjunctival Scarring: A Case-Control Study 
Consent form 
 
Kilimanjaro Christian Medical Centre, Moshi, Tanzania 
Kilimanjaro Center for Community Ophthalmology, Moshi, Tanzania 
Kilimanjaro Regional Eye Care Programme, Moshi, Tanzania 
International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK 
 
 
 
Name: ……………………………………………………………………. 
 
Study Reference Number:      
 
 
I have read / had explained to me the information about the research study. I understand what will be 
involved in taking part in the study.  
 
 
……………………..  has answered all my questions about the study. 
 
 
I agree to take part in this study. 
 
 
 
Signed / Thumbprint………………………………..       Date…………………….. 
 
 
 
I have explained the purpose of the study to the above subject and I am satisfied that he/she willingly agrees 
to participate 
 
 
 
Signed……………………………………..       Date…………………….. 
 
Name:………………………………. 
 
 
In the event that the patient can not read the above information, an additional witness is required: 
 
I have witnessed the explanation and informed consent to this study of above named patient 
 
 
 
Signed……………………………………..       Date…………………….. 
 
Name:………………………………. 
 
 
 
Study Organisers: 
 
William Makupa, Kilimanjaro Christian Medical Center, KCMC, Moshi, Tanzania. 
Wahida Shangali, Mawenzi Regional Hospital, Moshi, Tanzania 
Matthew Burton, Kilimanjaro Centre for Community Ophthalmology, KCMC, Moshi, Tanzania. 
Victor Hu, Kilimanjaro Centre for Community Ophthalmology, KCMC, Moshi, Tanzania. 
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Appendix 3d:  Consent form for the TT Study (Kiswahili) 
FOMU YA RIDHAA 
MABADILIKO YA KIFUNIKO CHA JICHO BAADA YA KOVU 
 
Kilimanjaro Christian Medical Centre, Moshi, Tanzania 
Kilimanjaro Center for Community Ophthalmology, Moshi, Tanzania 
Kilimanjaro Regional Eye Care Programme, Moshi, Tanzania 
International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK 
 
Kilimanjaro Christian Medical Centre(KCMC), Moshi, Tanzania. 
Kilimanjaro Regional Eye Care Programme, Moshi, Tanzania. 
International Centre for Eye Health, London School of Hygiene & Tropical Medicine, UK. 
 
Jina: …………………………………………………………....................................................................…………. 
 
Kumbukumbu namba:     
     
 
Nimesoma/nimeelezewa maelezo kuhusu somo la utafiti.Nimeelewa nini kitahusika katika sehemu ya utafiti 
huu 
 
…………………….................................................................................  amejibu maswali yote kuhusu utafiti 
huu. 
 
Nimekubali kuwa sehemu ya utafiti huu 
 
 
 
Imesainiwa na/ Dole gumba……………......... Tarehe…………………….................. 
 
Nimeelezewa lengo la utafiti hapo juu na nimeridhika me/ke yupo tayari na amekubali kushiriki 
 
 
 
Imesainiwa na……………………….......... Tarehe…………….................……….. 
 
 
 
Jina: ………..................................................................................... 
 
Katika tukio ambalo mgonjwa hawezi kusoma maelezo hapo juu,shahidi wa ziada anatakiwa: 
 
Nimetoa ushahidi na maelezo ya ridhaa ya utafiti huu kwa mgonjwa hapo juu. 
 
 
Imesainiwa na …………….....………  Tarehe………...................………….. 
 
 
Jina: .......................................................................................... 
 
Washiriki wa utafiti:- 
 
William Makupa, Kilimanjaro Christian Medical Centre, KCMC,  Moshi, Tanzania. 
Wahida Shangali, Mawenzi Regional Hospital, Moshi, Tanzania 
Matthew Burton, Kilimanjaro Centre for Community Ophthalmology, KCMC, Moshi, Tanzania. 
Victor Hu, Kilimanjaro Centre for Community Ophthalmology, KCMC, Moshi, Tanzania. 
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Appendix 4a:  Data form for the TS Study 
Baseline subject examination form 
   
1. Demographic data 
 
Subject Number          
 
Study Number      
Date of the examination Day / Month / Year    
First name   
Middle name   
Last name   
Village name   
Sub-village name   
Balozi name   
Household head name   
Telephone number (if 
possible) 
 
 
Whose telephone is this?   
Sex 1 = Male 2 = Female  
Date of birth Date / Month / Year  
Is this an estimate only?    
0 = No         1 = Yes 
 
Ethnic group 1 = Maasai 2= Chagga 
3 = Meru 
4 = Mang’ati 
5 = Pare 
6 = Other (specify) 
 
Education Year of schooling attained  
Literacy 0 = Illiterate 1 = Able to read Kiswahili only 
2 = Able to read English only  
3 = Able to read other 
language only (specify) 
4 = Able to read more than 
language 
5 = Refused to answer 
 
 
 
2. General examination 
 
Height in cm 0 = Not performed  
Weight in kg 0 = Not performed  
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3. Ophthalmic Examination 
Number of medial globe lashes  R L 
Number of lateral globe lashes  R L 
Number of corneal lashes  R L 
Trichiasis grade T  0/1/2/3 R L 
Entropion grade E  0/1/2/3/4 R L 
Trichiasis / entropion photo 0 = Not performed 
1 = Performed R L 
Bacteriology swab 0 = Not performed 
1 = Performed  L 
Bacteriology swab number   E1     
Follicle grade F  0/1/2/3 R L 
Papillary grade PH  0/1/2/3/4/5/6 R L 
Conjunctival scarring S 1a/b/c/2/3 R L 
Lid margin conjunctivilisation 
grade CM  0/1/2/3 R L 
Tarsal plate photo 0 = Not performed 
1 = Performed R L 
Corneal scarring grade CC 1/2a/b/c/d/3/4 R L 
Corneal photo 1 = Performed 
2 = Not performed R L 
Tarsal plate confocal microscopy 0 = Not performed 
1 = Full protocol 
performed 
2 = Performed, but not 
full  
L 
RNA swab 0 = Not performed 
1 = Performed  L 
RNA swab number   F1     
DNA swab 0 = Not performed 
1 = Performed  L 
DNA swab number   G1     
 
 
 
 
I have recorded the demographic and general examination sections: 
 
Signature      Date 
 
 
 
I have recorded the ophthalmic examination findings: 
 
 
Signature       Date 
 
 
 
I have entered the data onto the database: 
 
Signature      Date 
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Appendix 4b:  Data form for the TT Study 
TT Biopsy Study 
   
1. Demographic data 
 
 
Study Number     
Case or Control 
0 = Control 
1 = Case 
 
Date of the examination Day / Month / Year    
First name   
Last name   
Village name   
Sub-village name   
Balozi name   
Telephone number   
Whose telephone is this?   
Sex 1 = Male 2 = Female  
Date of birth Date / Month / Year  
Is this an estimate only?    
0 = No         1 = Yes 
 
Ethnic group 
1 = Maasai 
2= Chagga 
3 = Meru 
4 = Mang’ati 
5 = Pare 
6 = Other (specify) 
 
Education Year of schooling attained  
 
 
 
2.  Study eye 
 
 
Side 
1 = Right 
2 = Left 
 
Had previous surgery? 
Y = Yes 
N = No R L 
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3. Ophthalmic Examination 
Number of medial globe lashes  R L 
Number of lateral globe lashes  R L 
Number of corneal lashes  R L 
Trichiasis grade  0/1/2/3 R L 
Entropion grade  0/1/2/3/4 R L 
Corneal scarring grade  0/1/2/3/4/5/6/7 R L 
Corneal photo number 0 = Not performed R L 
Trichiasis / entropion photo 
number 0 = Not performed R L 
Follicle grade  0/1/2/3 R L 
Papillary grade  0/1/2/3/4/5/6 R L 
Conjunctival scarring A, B, C, D, E R L 
Lid margin conjunctivilisation 
grade  0/1/2/3 R L 
Tarsal plate photo number 0 = Not performed R L 
Confocal microscopy 
0 = Not performed 
1 = Full protocol 
2 = Reduced protocol 
 
Bacteriology swab number  X    
RNA swab number  Y    
Biopsy number  Z    
 
 
 
I have recorded the data onto the form: 
 
Signature      Date 
 
 
 
 
 
 
I have entered the data onto the database: 
 
Signature     
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Appendix 5:  Clinical Examination Protocol 
 
Abbreviations 
TVH:  Victor Hu 
PaM:  Patrick Massae 
HM:  Henry  
AP:  Alex Pallangyo 
PhM: Phillipo Mollel T 
The clinical examination and photographs to be done on both eyes, the confocal microscopy and 
swabs only on the left eye for the TS Study and on the eye to be operated for the TT Study. VH to 
use a fresh pair of gloves between each subject. 
 
 
STEP 1 Trichiasis assessment (VH) 
 
- Assess eyelash position with the eye in the primary position (looking straight ahead). 
- Count the number of lashes making contact with the globe: 
o Medial to the cornea. 
o Lateral to the cornea. 
o Touching the cornea. 
- Determine the grade of trichiasis (cf FPC System T/E0-3) 
 
T0  No  trichiasis 
T1  Lashes deviated towards the eye, but not touching the globe. 
T2  Lashes touching the globe, but not rubbing on the cornea. 
T3  Lashes constantly rubbing on the cornea. 
 
STEP 2 Entropion assessment (VH) 
 
- Assess eyelash position with the eye in the primary position. 
- If necessary, gently raise the excess fold of upper lid skin, without disturbing the lid 
position. 
- Determine the grade of entropion: 
 
 
 
 
 
Degree of severity 
 
Area of entropion 
 
<50% of lid margin 
 
>50% of lid margin 
 
None 
 
E0 (none) 
 
Without corneal-lash base 
contact E1 (mild) E2 (moderate) 
With corneal-lash base 
contact E3 (severe) E4 (total) 
 
None ‘Normal’ lid margin (see glossary) visible 
Without corneal-lash base contact Definite inwards rotation of the lid margin such that 
the lid margin is no longer visible when viewed in the 
primary position.  
With corneal-lash base contact Inward rotation of the lid margin, with some or all of 
the lash bases touching the globe 
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STEP 3. Photograph trichiasis / entropion / (HM) 
 
- Photograph both eyes all the way through the protocol. 
- Use the Nikon D200 camera with a VR lens, commander unit and 2 ring flash units.  
- White balance to be set at the start and with any change in lighting conditions. 
- Digital images will be visualized directly, and then saved, on a laptop. 
- Trichiasis / entropion photo to be taken with the subject looking slightly upwards so that the 
lid margin can be visualised. 
 
 
STEP 4. Corneal scarring grading (VH)1 
 
CC1  Opacity not entering central 4mm 
CC2a  Opacity within central 4mm but not entering within the central 1mm of the cornea. 
The pupil margin is visible through the opacity. 
CC2b Opacity within central 4mm but not entering within the central 1mm of the cornea. 
The pupil margin is not visible through the opacity. 
CC2c Opacity within central 4mm and entering the central 1mm of the cornea. The pupil 
margin is visible through the opacity.  
CC2d Opacity within central 4mm and entering within the central 1mm of the cornea. The 
pupil margin is not visible through the opacity. 
CC3 Opacity large enough and dense enough to make whole pupil margin invisible.  
CC4 Phthisis 
 
If there is more than one corneal scar then grade as for the worst/most central scar.  
 
1. Rajak SN, Habtamu E, Weiss HA, et al. Epilation for Trachomatous Trichiasis and the Risk 
of Corneal Opacification. Ophthalmology 2011. 
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 STEP 5. Photography of the cornea (HM) 
 
If corneal scarring is present then the cornea will photographed in a similar manner to that of the 
conjunctiva. 
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STEP 6. Bacteriology swab (VH) 
 
- One drop of proxymetacaine to be instilled into the lower fornix (VH). 
- Use Amies Charcoal transport swabs. 
- Sweep horizontally in the inferior fornix, particularly in areas of discharge, while rotating the 
swab along its long axis 3 times (VH). Avoid as much as possible swab contact with skin 
and lashes at the lid margin. 
- Place swab into tube (opened and held by PaM) containing Amies media without touching 
any part of the swab that is in the tube. 
- Seal the tube (PaM) and attach the sample number label (HM) 
- Record the swab label number in the patient’s study record form (AP). 
- Record the patient number and the sample number on the lab form (HM). 
- The tube to be kept at room temperature. 
-   
STEP 7. Tarsal plate grading (VH) 
 
- The examiner to wear a fresh pair of non-sterile latex examination gloves (these will be 
changed between each examination to minimise the risk of cross contamination) and a pair 
of 2.5× binocular loupes and a bright hand-held torch). 
- The upper lid to be everted and the conjunctival surface examined and graded. (VH) 
- Zones 2 and 3 will be used for assessment in keeping with WHO guidelines. 
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Examine upper lid for follicles  
 
F 0  No follicles. F 1  1-4 follicles. 
  
 
F 2  5-10 follicles. 
 
F 3  >10 follicles. 
  
 
Examine upper lid for papillary hypertrophy 
 
- Determine whether papillary reaction is over less than or greater than 50% of the tarsal 
area. 
 <50% of tarsal area 
affected 
>50% of tarsal area 
affected 
None PH 0  PH 0  
Mild PH 1  PH 2 
Moderate PH 3 PH 4 
Severe PH 5 PH 6 
 
Mild  Individual vascular tufts (papillae) prominent, but deep sub-conjunctival vessels on 
the tarsus are not obscured. 
Moderate More prominent papillae and normal vessels appear hazy, even when seen by the 
naked eye. 
Severe Conjunctiva thickened and opaque, normal vessels on the tarsus are hidden. 
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WHO grading: 
P 0 Absent: normal appearance P1 Minimal: individual vascular tufts 
(papillae) prominent, but deep sub-
conjunctival vessels on the tarsus are 
not obscured. 
  
P2 Moderate: more prominent papillae and 
normal vessels appear hazy, even when 
seen by the naked eye 
P3 Pronounced: conjunctiva thickened and 
opaque, normal vessels on the tarsus are 
hidden over more than half of the surface. 
  
-  
- To convert to traditional papillary grading system use this table: 
Degree of inflammation 
/’redness’ 
<50% of tarsal area 
inflamed 
>50% of tarsal area 
inflamed 
None  P0 P0 
Mild P1 P1 
Moderate P2 P2 
Severe P2 P3 
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Examine upper lid for Conjunctival scarring 
 
Grade 
 
Definition* 
S1 Scarring occupying <⅓ of the upper lid 
S1a One or more pinpoint scars and/or 
a single line of scarring less than 
2mm in length† 
 
S1b Multiples lines of scarring less 
than 2mm in length 
 
S1c One or more lines/patches of 
scarring each 2mm or more in 
length/maximal dimension 
S2 
 
Scarring occupying ≥ ⅓ but < ⅔ of the 
upper lid 
 
S3 
 
 
 
Scarring occupying ≥ ⅔ of the upper lid 
 
 
 
 
S1a   
 
S1b   
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S1c   
 
S2   
 
S3                        
                                                             
A portable slit-lamp to be used to rule out subtle scarring in potential control subjects. 
STEP 8. Upper lid margin conjunctivilisation grading (VH) 
 
- To be performed with the eyelid everted, so that the lid margin is visible. 
- Grading: 
CM 0 No conjunctivilisation of the lid margin with the meibomian gland orifices in a normal 
position. 
CM 1 The muco-cutaneous junction is located anterior to its normal position, but the whole 
line is still posterior to the line of Meibomian gland orifices. 
CM 2 The muco-cutaneous junction is located anterior to the line of the Meibomian gland 
orifices for less than 50% of the lid. 
CM 3 The muco-cutaneous junction is located anterior to the line of the Meibomian gland 
orifices for greater than 50% of the lid. 
STEP 9. Photography of the tarsal conjunctiva (HM) 
 
To be performed in a standard manner 
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 STEP 10. Confocal microscopy of the tarsal conjunctiva (VH) 
 
- Fresh sterile tomocap to be used for each examination. 
- Viscotears to be inserted between tomocap and laser probe. 
- A second drop of proxymetacaine to be instilled into the eye prior to the scan. 
- Subject details to be entered onto the CLSM (confocal laser scanning microscopy) laptop, 
including ID number, first and last names, date of birth. 
- HRT3 machine to be used with standard settings: 
o auto brightness 
o FV400 lens 
o Focus on +12 dioptres 
- Upper lid to be everted. PaM will help to keep the lid everted with the use of a sterile cotton 
bud holding the lashes. 
- When the end of the second bright reflection of the tomocap seen, the digital micrometer 
gauge to be set to zero. 
- The tomocap will be applanated onto the upper palpebral conjunctiva with digital images 
visualized directly on the laptop screen.  
- 10 volume scans, each of 40 individual scans, to be taken. The scans should be spaced 
out over zones 2 and 3.  
 
STEP 11. Conjunctival swab for Chlamydial RNA (VH) 
 
- Swabs to be taken in a standard manner similar to the bacteriology swab. 
- Evert upper lid. 
- Sweep swab horizontally four times with a quarter turn of swab after each pass. 
- Place swab into RNAlater tube.  
- Seal the tube. 
- Record the swab label number in the patient’s record. 
- Place tube in cool box. 
- Label the next tube in preparation. 
 
 
STEP 12. Conjunctival swab for Chlamydial DNA swab (VH) 
 
- To be taken in standard manner, as above. 
- Evert upper lid 
- Sweep swab horizontally four times with a quarter turn of swab after each pass. 
- Place swab into empty tube.  
- Seal and label tube. 
- Record the swab label number in the patient’s record. 
- Place tube in cool box 
- Label the next tube in preparation. 
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Appendix 6a:  Background methodology: Quantitative real-time reverse transcriptase polymerase 
chain reaction (qRT-PCR) 
 
 
RNA extraction 
In our study conjunctival swabs were placed in RNALater® to stablise the RNA and kept at -80˚C. 
Total RNA was subsequently extracted using the RNAeasy Mini Kit system (Qiagen, Crawley, UK) 
which is very effective in retrieving small amounts of RNA.  
 
Reverse transcription 
DNA polymerase can only act on DNA templates. Therefore, the RNA is reverse transcribed to 
cDNA using reverse transcriptase. Two-step PCR was performed in this study in which the reverse 
transcription was performed in a separate step to the PCR. The QuantiTect Multiplex NoROX Kit 
(Qiagen) was used in this study. 
 
Amplification of cDNA using PCR 
A combination of various components are added to the cDNA which include: 
• Two primers that are complementary to the 3’ ends of each of the sense and anti-sense 
strand of the cDNA target. 
• Heat stable DNA polymerase (e.g. Taq polymerase). 
• Dexoynucleoside triphophosphates (dNTPs) which form the building blocks from which new 
DNA strands are synthesized. 
• Buffer solution with cations provide an environment in which DNA amplification can occur. 
• Fluorescent reporter probes which detect DNA containing the probe sequence.  
The PCR was carried out in a reaction volume of 25µl in a thermal cycler (Rotor-Gene 6000 
Corbett Research, Cambridge, UK). This normally consist of around 40-45 repeated temperature 
change cycles (the specific temperature and length of time depend on factors such as the enzyme 
used for DNA synthesis, melting temperature of the primers and dNTPs used) : 
• Initialisation: heating to 95˚C for 15 minutes for heat activation of the DNA polymerase. 
• Denaturation: heating to 94˚C for 30 seconds to cause melting of the cDNA template by 
disrupting hydrogen bonds between complementary bases resulting in single-stranded 
DNA molecules. 
• Annealing and extension: the temperature is lowered to 60˚C for 30 seconds allowing 
annealing of specific primers that are complimentary to a site on each strand. Polymerase 
binds to the primer-template complex and extends the DNA from the primers to form two 
new cDNA strands 
• The denaturation and annealing/extension steps are repeated, doubling the number of 
cDNA strands with each cycle. After x cycles there are 2x times as many strands as there 
was to start with. The reaction reaches a plateau when the reagents are used up. 
 
 
 
Victor Hu   PhD thesis   289
Real Time PCR 
This allows quantification of the amount of the specific cDNA target initially present, even in small 
samples, as the reaction progresses. Real time quantification can utilize either fluorescent dyes 
that bind non-specifically to double-stranded DNA, such as SYBR Green, or fluorescent probes 
that are sequence specific and consist of labeled oligonucleotides. Fluorescent reporter probes 
detect only the DNA containing the probe sequence and help to increase specificity and have to be 
used in multiplex assays. Dual-labeled fluorescent reporter probes are single-stranded 
oligonucleotides labeled with a reporter dye at the 5’ end and a quencher molecule at the 3’ end. 
The quencher molecule inhibits the natural fluorescence of the reporter dye. During the annealing 
stage of the PCR both probe and primers anneal the DNA target. The polymerase starts 
polymerization at the primer, once it reaches the probe it breaks the reporter-quencher proximity 
allowing emission of fluorescence which can be detected after excitation with a laser. 
 
Quantification depends on analyzing the PCR reaction when the amount of cDNA, and therefore 
fluorescence, is increasing exponentially. Relative concentrations of DNA present during this 
phase are determined by plotting fluorescence against cycle number on a logarithmic scale (which 
will show a straight line during the exponential stage). A threshold for detection of fluorescence is 
selected, often between a third to half-way of the linear part. The cycle threshold, Ct, is the cycle at 
which the fluorescence from a sample crosses the threshold. During the exponential phase the 
amount of DNA doubles with each cycle (if the efficiency of the reaction is 100%). The numbers of 
copies of the cDNA target can be determined by comparison to a standard curve of serial dilutions 
of a known amount of DNA. The measured amount of target is usually divided by the amount of 
reference or housekeeping gene to normalize for variation in the amount and quality of RNA in 
different samples. The delta delta or comparative Ct method uses the difference in the Ct between 
the target of interest and housekeeping gene in cases or samples of interest, and compares this to 
the results from a control group. The amplification efficiencies of the target and housekeeping 
need to be approximately equal. 
 
Multiplex PCR 
Multiple primer sets within a single PCR reaction mixture are used to produce amplification 
products that are specific for different cDNA targets. Different reporter probes are also used, 
specific for each target, that have unique emission spectra. The amount of different cDNA targets 
can therefore be detected in the same reaction mixture, using a single sample, by detection of the 
different wavelengths of light emitted. This can help to maximize use of limited sample and is more 
time-efficient. 
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Figure 1: Amplifcation curves of samples from the TS study. A 100-well plate was used: 44 
samples (coloured lines), 5 standards (brown lines), water as a negative control (blue lines), all in 
duplicate. Four different channels are used for detection of different wavelengths of light, allowing 
4 different reporter probes to be used.  
 
 
Figure 2: Amplification curves of the standards. Five standards of known concentration of the 
target gene were used in duplicate. Concentrations ranged from 102 copies (amplified last) to 106 
copies (amplified first) of DNA. The higher the concentration the earlier the amplification occurs. 
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Figure 3:  Amplification curves of the standards during the linear phase. 
 
 
 
 
 
Figure 4:  Efficiency of the standard curves (98%). 
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Figure 5:  Amplification of all 100 wells during the linear phase. 
 
 
 
 
 
Figure 6:  Delta delta Ct calculation. 
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Appendix 6b:  Background methodology for histology and immunohistochemistry 
 
 
Fixation 
This is the process of preserving the tissue architecture from degradation so that the cellular and 
sub-cellular components can be examined. Buffered 10% formalin, which contains 4% 
formaldehyde, or a similar agent, is commonly used for light microscopy. These irreversibly cross-
link proteins and may reduce the biological functionality of enzymes. Some antigens may not 
survive this fixation process and for these tissues frozen sections could be cut with the use of a 
cryostat.  
 
Embedding 
Paraffin is the most commonly used medium for embedding specimens. Infiltration of the tissue 
with paraffin allows thin sections to be cut. Before this can be done water needs to be removed 
from the tissue which is done by moving the sample through increasingly concentrated ethanol. 
This is followed by a hydrophobic clearing agent such as xylene to remove the alcohol. Molten 
paraffin wax then replaces the xylene. A microtome is used to cut thin sections. 
 
Tinctorial stains 
Special chemical agents are used to stain specific targets in the tissue. Hematoxylin and eosin is 
commonly used. Hematoxylin is a basic dye that stains nuclei blue and eosin is an acidic dye that 
stains cytoplasm pink. 
 
Immunohistochemistry 
This uses antibody binding to specific antigens. Antigen retrieval refers to the initial process of 
unmasking antigens and improving their detection by breaking the cross-links between proteins 
formed by formalin fixation. This can be done either by exposure to heat, such as with a pressure 
cooker, or with a proteolytic enzyme method, usually after deparaffinisation.  
 
Reporter molecules are used in order to detect the antibody. Common techniques utilize enzymes 
for chromogenic detection or fluorophores for fluorescence detection. Horseradish peroxidase is a 
commonly used enzyme which uses diaminobenzadine as a substrate resulting in a brown stain. 
Antigen detection may involve the direct method where a single antibody is used which binds the 
antigen and is itself labeled with the reporter molecule. While quick and specific this generates little 
signal amplification and indirect methods are more commonly used. These involve an unlabeled 
primary antibody which binds the antigen. A labeled secondary antibody is then used which binds 
the primary antibody. Several secondary antibodies can bind to different antigenic sites on the 
primary antibody resulting in signal amplification. Further amplification can be achieved through 
the use of biotin which can be conjugated to the secondary antibody. The secondary antibody can 
be conjugated to several molecules of biotin. Streptavadin has a high affinity for biotin and can 
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also be conjugated to horse-radish peroxidase. Addition of diaminobenzadine results in the 
chromogenic reaction and identification of the antigen location in the tissue with microscopy. 
 
After the immunohistochemical stain a counter-stain may be used to help show cellular 
compartments such as hematoxylin. Background staining may result from the antibody binding to 
non-specific or reactive sites, or the presence of endogenous biotin or reporter enzymes such as 
peroxidase. To prevent antibodies binding to non-specific or reactive sites a buffer may be used 
which blocks these reactive sites and enzymes. 
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Appendix 7d:  In vivo confocal microscopy in scarring trachoma 
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